Pharmacology and Chemical Probe Development of the K-26 Family of Natural Product Angiotensin-I Converting Enzyme Inhibitors by Kramer, Glenna Jean
 PHARMACOLOGY AND CHEMICAL PROBE DEVELOPMENT OF THE K-26 FAMILY 
OF NATURAL PRODUCT ANGIOTENSIN-I CONVERTING ENZYME INHIBITORS 
 
By 
Glenna J. Kramer 
 
Dissertation 
Submitted to the Faculty of the 
Graduate School of Vanderbilt University 
in partial fulfillment of the requirements 
for the degree of 
DOCTOR OF PHILOSOPHY 
in 
Chemistry 
December, 2014 
Nashville, Tennessee 
 
Approved: 
Professor Brian O. Bachmann, Ph.D. 
Professor Lawrence Marnett, Ph.D. 
Professor Gary A. Sulikowski, Ph.D. 
Professor Borden Lacy, Ph.D. 
ii 
 
TABLE OF CONTENTS 
 
Page 
 
DEDICATION .................................................................................................................. v 
 
ACKNOWLEDGEMENTS ............................................................................................... vi 
 
LIST OF TABLES ............................................................................................................ x 
 
LIST OF FIGURES .......................................................................................................... xi 
 
LIST OF SCHEMES ....................................................................................................... xii 
 
LIST OF ABBREVIATIONS ........................................................................................... xiv 
 
Chapter 
 
I. INTRODUCTION ............................................................................................. 1 
 
Unmodified peptides as ACE inhibitors ........................................................... 3 
Fungal and plant ACE inhibitors ...................................................................... 4 
Microbially produced ACE inhibitors ................................................................ 5 
K-26 family of natural products ...................................................................... 11 
Angiotensin converting enzymes domain and functions ................................ 16 
Early ACE inhibitors ...................................................................................... 21 
Domain selective ACE inhibitors ................................................................... 22 
ACE as an evolutionary conserved enzyme .................................................. 23 
Dissertation statement .................................................................................. 28 
 
II. INTERKINGDOM PHARMACOLOGY OF K-26 ............................................ 30 
 
Introduction ................................................................................................... 30 
Results .......................................................................................................... 32 
          Synthesis of K-26 family natural products ........................................... 32 
          ACE inhibitory activity of the K-26 family ............................................. 34 
          Co-crystal structures of K-26 with N-domain and C-domain ACE ....... 36 
          Overexpression and characterization of dicarboxypeptidases ............ 39 
Discussion ..................................................................................................... 44 
Materials and methods .................................................................................. 49 
          Synthesis of K-26 family natural products ........................................... 49 
          Co-crystallization of K-26 and ACE ..................................................... 71 
          Assays for ACE inhibition .................................................................... 74 
          Expression and purification of bacterial DCPs .................................... 75                    
Acknowledgements ....................................................................................... 78 
 
iii 
 
III. ACE INHIBITORY ACTIVITY OF A LIBRARY OF K-26 VARIANTS ............. 79 
 
Introduction ................................................................................................... 79 
Results .......................................................................................................... 80 
          Rosetta prediction of K-26 variant binding ........................................... 80 
          Selection of K-26 variants for further study ......................................... 83 
          Synthesis of K-26 variants ................................................................... 87 
          Inhibitory activity of K-26 variants ........................................................ 90 
          Correlation between Rosetta prediction and activity measurements ... 90 
Discussion ..................................................................................................... 92 
Materials and methods .................................................................................. 96 
          Rosetta prediction of binding energy for K-26 variants ........................ 96 
          Chemical synthesis of K-26 variants ................................................... 97 
          Assay for ACE inhibition .................................................................... 126 
Acknowledgements ..................................................................................... 126 
 
IV. K-26 CHEMICAL PROBE DEVELOPMENT ................................................ 127 
 
Introduction ................................................................................................. 127 
Results ........................................................................................................ 130 
          Probe design and synthesis .............................................................. 130 
          Biotin-K-26 probe evaluation ............................................................. 132 
          General pull down schematic ............................................................ 134 
          Mutually exclusive binding of biotin-K-26 .......................................... 135 
          Pull down of heterologously expressed ACE with sepharose-K-26 ... 137 
          Application of sepharose-K-26 in preliminary target ID ..................... 142 
Discussion ................................................................................................... 144 
Materials and methods ................................................................................ 147 
          Chemical synthesis ........................................................................... 147 
          Analysis of biotin-K-26 probe ............................................................ 151 
          Pull downs with chemical probe ........................................................ 153 
Acknowledgements ..................................................................................... 156 
 
V. SUMMARY AND FUTURE DIRECTIONS ................................................... 158 
 
REFERENCES ............................................................................................................ 163 
 
APPENDIX 
 
A. NMR Spectra of Synthetic Intermediates from Chapter II ................................. 180 
 
NMR spectra of K-4 and synthetic intermediates.............................................. 181 
NMR spectra of 15-B-2 and synthetic intermediates ........................................ 188 
NMR spectra of SF2513B and synthetic intermediates .................................... 195 
NMR spectra of SF2513C and synthetic intermediates .................................... 202 
NMR spectra of SF2514D and synthetic intermediates .................................... 209 
iv 
 
B. Graphs used in IC50 and Ki Calculations from Chapter II .................................. 218 
 
IC50 curves for inhibition of somatic ACE by the K-26 family ............................ 219 
IC50 curves for inhibition of C-domain ACE by the K-26 family ......................... 220 
IC50 curves for inhibition of N-domain ACE by the K-26 family ......................... 221 
Dixon plots to determine the Ki of inhibition of C-domain ACE ......................... 222 
Dixon plots to determine the Ki of inhibition of N-domain ACE ......................... 223 
IC50 curves for inhibition of ACE-like enzymes by K-26 and captopril .............. 224 
 
C. Rosetta Predicted Binding Conformations of Variants from Chapter III ............ 225 
 
D. NMR Spectra of Synthetic Intermediates from Chapter III ................................ 229 
 
NMR spectra of Ac-Ile-Trp-AHEP and synthetic intermediates......................... 230 
NMR spectra of Ac-Ile-Ser-AHEP and synthetic intermediates ........................ 237 
NMR spectra of Ac-Ile-His-AHEP and synthetic intermediates ......................... 245 
NMR spectra of Ac-His-Trp-AHEP and synthetic intermediates ....................... 252 
NMR spectra of Ac-Leu-Tyr-AHEP and synthetic intermediates....................... 257 
NMR spectra of Ac-Leu-Ile-AHEP and synthetic intermediates ........................ 264 
NMR spectra of Ac-Tyr-Ile-AHEP and synthetic intermediates ......................... 271 
NMR spectra of Ac-Pro-Ile-AHEP and synthetic intermediates ........................ 279 
 
E. Graphs used in IC50 Calculations from Chapter III ............................................ 286 
 
IC50 curves for inhibition of somatic ACE by the K-26 variant ........................... 287 
 
F. NMR Spectra of Biotin Probe from Chapter IV ................................................. 289 
 
1H NMR spectrum of biotin-K-26 probe ............................................................ 290 
 
 
 
 
  
v 
 
 
 
 
 
 
 
 
To my family, for all of your love. 
 
 
 
 
 
 
 
 
 
 
 
 
 
“You don't even have to understand the desert: all you have to do is contemplate a 
simple grain of sand, and you will see in it all the marvels of creation.” 
 
-Paulo Coelho, The Alchemist 
 
 
 
 
 
 
  
vi 
 
ACKNOWLEDGEMENTS 
 
First and foremost, I would like to thank the Vanderbilt chemistry department for 
giving me the opportunity to follow my dream to pursue a PhD in chemistry.  Without the 
guidance, encouragement and support of all faculty, staff and students in the 
department my pursuit would have been much more difficult.  Specifically, I would like to 
thank Dr. Stone and Dr. Rizzo for working to accommodating me when I followed the 
not traditional path of having a baby in graduate school.  The demands of a career in 
science are notoriously not conducive to raising a family, so I deeply appreciate that 
they have tried to make this department friendly to graduate students with children.  I 
must thank Sandra Ford for patiently answering all of my questions ranging from class 
registration to defense scheduling and the storeroom and front office personnel for 
helping me order any chemical or reagent that I needed and for getting my packages 
shipped on time.  Your assistance has been invaluable.   
I would especially like to thank those that I have worked with on teaching 
assignments throughout the years.  I have enjoyed working under Dr. Phillips and Dr. 
Todd throughout my graduate school career.  I truly appreciate all of the light-hearted 
conversations and the reminders that there is more to science than my research project.  
I have learned much about myself as an educator in science from working with them.  
Also, I must say thank you for all of the pizza for compensation for the long days spent 
proctoring and grading general chemistry exams.  I may have complained about grading 
days, but to be truthful, I enjoyed the opportunity to get to know the other graduate 
students in the department.   
vii 
 
Secondly, I would like to thank the people that have been more directly involved 
in my research.  To my thesis committee, thank you for all of the insight and input along 
the way.  From committee meetings to informal one-on-one conversations about 
research you have always provided me with a fresh new perspective on my project.  I 
have also had the opportunity to work with fantastic and enthusiastic collaborators 
throughout my time at Vanderbilt including scientists from the laboratories of Dr. E.D. 
Sturrock at University of Cape Town, Dr. Ravi Acharya at Bath and Dr. Jens Meiler at 
Vanderbilt.  It has been a pleasure to share excitement with this group of scientists 
about ongoing research and their scientific insight has been invaluable.  I would like to 
thank Dr. Sturrock specifically for welcoming me into his lab for a period of time for 
research collaboration and to the members of his lab for making me feel at home when I 
was so far away from home.   
I also would like to thank my advisor, Brian Bachmann for his guidance both with 
regard to my project and with regards to life.  Throughout my graduate school career, he 
has shared his excitement about science with me, and this excitement has helped me 
push to complete challenging experiments.  Ever since my first day in his lab, I was 
captivated by the multi-disciplinary perspective that Brian takes on science, a trait that I 
continuously aspire to develop further,  for pushing me to accomplish more than I 
thought possible and for helping me grow in to a more confident person.  Also, I would 
like to thank Brian for the sometimes brutally honest perspective on balancing a career 
as a scientist and a family.   Most of all, I look up to Brian for being able to balance a 
career as successful scientist, while being dedicated to his wife and children.      
viii 
 
I also must thank my co-workers and lab mates.  I consider myself lucky to have 
spent the last few years surrounded by such a great group of people.  Thank you 
especially for all of the lab lunches, trips to get coffee, games of where’s Waldo and 
politically incorrect debates.  I will certainly miss all of you.  A special thanks to David 
Nanneman and Vanessa Phelan for making me feel at home in the lab while introducing 
me to the wonders of Fantasy Pizza.  I truly looked up to you as a younger student in 
the lab.  Also, thank you to Kasia, Emilianne McCranie and Will Birmingham for your 
friendship and for making my last few years fun.   
Lastly, I must thank my friends and family for their love and support.  Kerri Grove 
and Gongping Chen, thank you for your friendship over our journey as graduate 
students together, for all those morning workouts, and for always listening and cheering 
me up.  Thank you also to Kevin Perzynski for all of the music recommendations that 
have kept my lab playlist fresh and for providing a listening ear when I have needed a 
break.  To Vanessa Phelan, thank you for being so positive and encouraging and for 
your honest perspective on being a female in science.  I cannot express how I value 
your friendship.  And to my flood friends, the honey badgers, who have been my 
adopted family for the last four years.  Thank you for all of the holiday celebrations, 
random Thursday night fireworks, trivia, group dinners, bourbon and just general 
ridiculousness and debauchery.  When I had been most frustrated with my lab work and 
graduate school career you helped me keep the situation in perspective and 
encouraged me to see the end goal.  I might be leaving Nashville, but you are not 
getting rid of me. 
ix 
 
To my parents, I think at times you may have not understood why I wished to 
pursue a career as a scientist, but you have stood behind me as my biggest 
cheerleaders every step of the way.  Ever since I was young you have encouraged me 
to have a curiosity in the world around me, to work hard and to follow my dreams.  
Thank you for all of your dedication, support, and love, for without your guidance I would 
not be here today.   
Thank you also to my husband, Brandon, who has been my rock during the 
process of graduate school.  In many ways you have saved me from myself by 
reminding me that there is more to life than my lab work.  You have been my friend, 
partner in crime, soul-mate and have given me one of the best gifts, our handsome son.  
Thank you for your love and encouragement. I am so lucky to have you and I look 
forward to our future adventures.     
Lastly, to my little man, Jude, you have filled a void in my life that I didn’t even 
realize was there.  I am so proud of you and I love you so much.  Thank you for all of 
the smiles, laughs and bringing me so much joy over the last year.           
   
 
  
x 
 
LIST OF TABLES 
 
Table     ..................................................................................................................... Page 
II-1. IC50 values calculated for least active (S)- diastereomers of the K-26 family ......... 35 
II-2. ACE inhibitory activity of synthesized K-26 variants............................................... 36 
II-3. Hydrogen bond interactions of C- and N- domains of ACE with K-26. ................... 37 
II-4. Sequence coverage and identity for ACE-like enzymes ......................................... 40 
II-5. Inhibition of overexpressed bacterial dicarboxypeptidases by K-26 ....................... 44 
II-6. Refinement statistics for crystal structures of K-26 in both domains of ACE .......... 73 
II-7. PCR primers used for the cloning of EcDCP and MR1DCP ................................... 76 
III-1. Somatic ACE inhibition by both diastereomers of the K-26 variants synthesized . 90 
III-2. Measured IC50 values for each synthetic K-26 variant with somatic ACE and the  
        corresponding ∆∆Gpredicted and ∆∆Gmeaured values .................................................. 91 
 
IV-1. Summary of proteomics hits for K-26 and lisinopril probe with overexpressed ACE  
         in media .............................................................................................................. 140 
 
IV-2. Hits from pull-down with sepharose-K-26 in E.coli cell free extract ..................... 143 
 
IV-3. Summary of proteomics hits for sepharose-K-26 probe applied for target       
        identification with actinomycete K-26 cell free extract ......................................... 144 
 
 
 
 
  
xi 
 
LIST OF FIGURES 
 
Figure     .................................................................................................................... Page 
I-1. Schematic of the renin angiotensin system ............................................................... 2 
I-2. Structure of K-26 ....................................................................................................... 3 
I-3. ACE inhibitory compounds from fungal and plant species ........................................ 5 
I-4. Non-peptidic ACE inhibitory natural products from Streptomyces ............................. 6 
I-5. Peptidic ACE inhibitory natural products from Streptomyces .................................... 8 
I-6. The Muracins, a series of ACE inhibitory glycopeptides ........................................... 9 
I-7. Peptidic ACE inhibitory natural products with terminal tyrosine-like moiety ............ 10 
I-8. The K-26 family of natural products ........................................................................ 13 
I-9. C-P bond formation by PEP mutase ....................................................................... 15 
I-10. ACE isoforms present in mammals ....................................................................... 17 
I-11. Substrate and structural differences between N- and C-domain ACE ................... 19 
I-12. Crystal structures of N- and C- domain of ACE ..................................................... 20 
I-13. Binding motifs of ACE inhibitors ............................................................................ 23 
I-14. Sequence identity of ACE-like enzymes from different kingdoms ......................... 26 
I-15. Co-crystal structure of K-26 and captopril in AnCE ............................................... 27 
II-1. K-26 analogs of interest ......................................................................................... 31 
II-2. K-26 binding in both domains of ACE .................................................................... 38 
II-3. Binding motifs of K-26, RXPA380, and captopril in the active site of ACE ............. 39 
II-4. Boxshade sequence alignment for ACE and ACE-like enzymes in this study ........ 41 
II-5. Phylogenetic tree comparing ACE and related bacterial dicarboxypeptidases  ..... 42 
xii 
 
II-6. Ligand plot of K-26 bound in both domains of ACE................................................ 45 
II-7. Sequence homology between human tACE and N-ACE and MR1DCP  ................ 48 
III-1. K-26 and modifications for our computational study  ............................................. 82 
III-2. Comparison of the low binding energy structures predicted by Rosetta and the       
        crystal structure ..................................................................................................... 83 
 
III-3. Heat maps showing the Rosetta predicted ΔΔG of binding for the set of 400  
        K-26 variants analyzed in this study ...................................................................... 84 
 
III-4. K-26 variants selected for further study ................................................................. 87 
 
III-5. Correlation plot of ∆∆Gpredicted and ∆∆Gmeasured ...................................................... 92 
 
IV-1. Important structural features of K-26 and analogs for ACE inhibition ................. 129 
 
IV-2. Inhibitors and probes of interest in this study ...................................................... 131 
 
IV-3. IC50 curves for inhibition of ACE by the biotin-K-26 probe .................................. 133 
 
IV-4. HABA colorimetric assay evaluating the ability of biotin and biotin-K-26 to bind  
         to soluble avidin .................................................................................................. 134 
 
IV-5. General pull-down experimental design .............................................................. 135 
 
IV-6. ACE activity when incubated with biotin-K-26 and avidin, biotin-K-26, K-26  
        and avidin or K-26 alone ..................................................................................... 136 
 
IV-7. Western blots of preliminary pull downs with tACE ............................................. 138 
 
IV-8. Western blots of pull downs of tACE with sepharose-K-26 probe ....................... 139 
 
IV-9. Depletion of activity of ACE by the addition of the sepharose-K-26 probe .......... 142 
 
 
  
xiii 
 
LIST OF SCHEMES 
 
Scheme     ................................................................................................................. Page 
II-1. Chemical synthesis of K-4, 15-B-2. SF 2513B and SF 2513C  .............................. 33 
II-2. Chemical synthesis of SF 2513D  .......................................................................... 34 
III-1. Chemical synthesis of K-26 variants ..................................................................... 89 
IV-1. Aqueous coupling of dAcK-26 to linker bound N-hydroxysuccinimide to yield  
        K-26 affinity resin ................................................................................................. 133 
 
IV-2. Synthesis of sepharose-K-26 .............................................................................. 151 
 
 
 
 
  
xiv 
 
LIST OF ABBREVIATIONS 
 
ACE     Angiotensin converting enzyme 
AHEP    (R)-1-amino-2-(4-hydroxyphenyl)ethylphosphonic acid 
AnCE     ACE homologue in Drosophila melanogaster 
Ang I    Angiotensin I 
Ang II    Angiotensin II 
CDC    Center for Disease Control 
C-ACE   C-domain ACE 
C-dom   C-domain 
dAcK-26    Des-acetyl-K-26 
DCM    Dichloromethane 
DCP    Dicarboxypeptidase 
DIPCl    Diisopropylcarbodiimide 
DMF    Dimethylformamide 
EcDCP   E. coli dicarboxypeptidase 
EDC    1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
FAPGG   Furylacryloyl-phenylalanyl-glycyl-glycine 
HABA    4'-hydroxyazobenzene-2-carboxylic acid 
HHL    Histadyl-histadyl-leucine 
HOBT    Hydroxybenzotriazole 
HPLC    High-performance liquid chromatography 
IC50     Half maximal inhibitory concentration 
xv 
 
I-TMSi   Iodotrimethylsilane 
K26DCP   Actinomycete K-26 DCP 
Ki    Inhibitory constant 
LB     Luria broth 
LC     Liquid chromatography 
MS     Mass spectrometry 
MR1DCP   Schwanella DCP 
N-ACE   N-domain ACE 
N-dom   N-domain 
NHS    N-hydroxysuccinimide 
NMR     Nuclear magnetic resonance 
PCR    Polymerase chain reaction 
Pd/C    Palladium on carbon 
PEG    Polyethylene glycol 
PEP     Phosphoenolpyruvate 
RAS    Renin angiotensin system 
sACE    Somatic ACE 
SDS-PAGE    Sodium dodecylsulfide polyacrylamide gel electrophoresis 
TAEA    Tris(2-aminoethyl)amine 
tACE    Testicular ACE 
TEA    Triethylamine 
TFA    Trifluoroacetic acid 
TLC     Thin layer chromatography 
xvi 
 
TtACE   T. tessulatum ACE 
tRNA     Transfer ribonucleic acid 
WHO    World Health Organization 
XcACE   Xanthamonas ACE-like enzyme     
 
  
1 
 
CHAPTER I 
 
INTRODUCTION 
 
Natural products and natural product derived structures have been a source of many 
new drug leads for the treatment of human diseases.1  One pharmacological target 
which has been employed in natural product bioactivity screens with is angiotensin-I 
converting enzyme (ACE), EC 3.5.15.1, an enzyme best known for its role in blood 
pressure modulation in mammals.2  As part of the renin-angiotensin system (RAS), ACE 
is responsible for the hydrolysis of the vasodilator bradykinin to inactive peptides, and 
for cleaving the inactive decapeptide angiotensin I (ang I) to the vasoconstrictor 
angiotensin II (ang II) (Figure I-1).  Ang II not only raises blood pressure directly, it 
activates the release of the hormone aldosterone from the adrenal cortex, which 
increases the absorption of sodium and water, thereby increasing blood volume and 
raising blood pressure.  As hypertension is a widespread health concern that is 
estimated by the Center for Disease Control to effect 1 in 3 adults in the US and 
believed by the World Health Organization to affect one billion people worldwide and 
claim nine million lives annually, effectively modulating the function of this enzyme is 
beneficial to human health.3-4   
2 
 
 
Figure I-1. Schematic of the renin angiotensin aldosterone system emphasizing the role of ACE in blood 
pressure regulation. 
 
 
ACE inhibitors have been developed as a means of treatment for hypertension, a 
condition that is a risk factor for cardiovascular disease including heart attack, heart 
disease and stroke.  However, recent literature has focused on biological functions of 
ACE outside of the realm of blood pressure regulation, shedding light on why current 
ACE inhibitor pharmaceuticals are not without side effects, such as angioedema and a 
dry cough, attributed both to off target effects of these inhibitors and poor modulation of 
other biological functions of ACE.2, 5  Despite the relevance of this enzyme to human 
health, the question of ACE inhibition has not yet been fully answered.   
  
 
ACE 
Angiotensin I 
Angiotensin II 
(Vasoconstrictor) 
Inactive Peptides 
Bradykinin 
(Vasodilator) 
Renin 
Angiotensinogen 
Increase in  
Blood Pressure Aldosterone 
(Water retention) 
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A search of the dictionary of natural products reveals a cohort of over 50 known natural 
products that have been noted for their inhibitory activity towards ACE.6  These 
bioactive natural products have been isolated from a variety of sources including 
bacteria, fungi, plants and animals.  Of these isolated ACE inhibitors, many are peptides 
or peptide derivatives, including our potent ACE inhibitor and molecule central to this 
study, K-26 (I-1) (Figure I-2).7  However, a handful of these natural products that have 
been noted for their potent ACE inhibitory activity contain other scaffolds.  In the 
following paragraphs, ACE inhibitory natural products and their sources will be 
discussed.   
 
 
 
Figure I-2: Structure of the potent ACE inhibitory natural product, K-26 (I-1). 
 
 
Unmodified peptides as ACE inhibitors 
 ACE inhibitory peptides have been isolated and characterized from a broad array 
of sources including animals, fungi and food products.  Tryptic digests of human serum 
albumen have revealed several ACE inhibitory peptides including Acein I, Acein II, and 
Albutensin I.8-10  ACE inhibitory peptides have been isolated from the digestive system 
of the bonito fish and tuna.11-14 Viper venom from the species Bothrops jararaca , Vipera 
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aspis, and Agkistrodon halys blomhof, has also been noted for its ACE inhibiting 
peptides.15-17  Fungal sources of peptidic natural products with ACE inhibitory activity 
include the Asian medicinal mushroom Tricholoma giganteum and the edible mushroom 
Pleurotus cornucopiae.18-19  Furthermore, milk, fish, and meat have also been 
discovered as a source of many bioactive ACE inhibitory peptides.20-21  Generally, 
isolated ACE inhibitory peptides range from 3 amino acids to just under 20 amino acids 
in length and have reported IC50s which fall in the low- to mid- micromolar range.  
Perhaps the wide array of diverse peptides which have exhibited micromolar inhibitory 
concentrations towards ACE is a testament to the promiscuity of the enzyme.   
 
Fungal and plant ACE inhibitors 
Only a handful of non-peptidic ACE inhibitory natural products have been isolated from 
fungal and plant sources (Figure I-3).  Study of the Chinese medicinal mushroom, 
Ganoderma lucidum, a species known as a rich source of bioactive natural products, 
have revealed a series of ACE inhibitory triterpenoids.22  These natural products are 
variants of Ganolucidic acid A (I-2) and Ganderol B (I-3).23  Also, an iridoid-type 
metabolite, oleacein (I-4), was isolated from the olive species Olea europaea and Olea 
lancea, and the jasmine species, Jasminium azoricum and Jasminus grandiflorum and 
noted for its ACE inhibitory activity.24-25  Natural product screening of the jasmine 
species yielded an additional three bioactive iridoid compounds, sambacein I, II and III 
(I-5, I-6, I-7), with an IC50 for ACE of 26-36 µM.
24
 The most potent ACE-inhibitor isolated 
from a fungal species is a modified peptide with a C-terminal tyrosine, WF 10129. (I-8)   
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This metabolite is produced by Doratomyces putredinis, and is reported to have an IC50 
of 14 nM.26-27  
 
 
 
Figure I-3. ACE inhibitory compounds isolated from fungal and plant species.  
     
 
Microbially produced ACE inhibitors 
Microbially produced ACE inhibitory natural products have more structural diversity than 
those isolated from animal, plant or fungal sources.  Although most of these natural 
products are modified peptides, two scaffolds of non-peptidic natural products have 
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been isolated for their ACE inhibitory activity, both from Streptomyces (Figure I-4).  The 
first is a tricyclic natural product produced by Streptomyces tanashiensis-
zaomyceticus with a phenazine scaffold.  This natural product, phenacein (I-9), inhibits 
ACE with a Ki of 580 nM.
28-29  The second class consists of A58365A (I-10) and 
A58365B (I-11), two 3-pyridinyl propanoic acid containing natural products which have 
been isolated from the organism Streptomyces chromofuscus.30 The discovery of the 
A58365 series of compounds was particularly interesting due to the structural similarity 
with captopril (I-12), a benchmark ACE inhibitor (IC50 = 7.7 nM) developed for the 
treatment of hypertension and one of the first pharmacological successes of ligand 
based drug design.31 
 
 
Figure I-4. Non-peptidic natural products isolated from Streptomyces. The commonly prescribed ACE 
inhibitor, captopril (I-12), is shown to highlight structural similarities with the A 58365 series of compounds 
(I-10, I-11).   
 
 
 
 Several peptidic natural products have been isolated from Streptomyces strains 
(Figure I-5).  Foroxymithine (I-13) has been isolated from both Streptomyces 
nitrosporeus and Streptomyces zaomyceticus and has an IC50 of 200 µM.
32  L 681176 
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(I-14), isolated from Streptomyces sp. MA5143a has an IC50 of 3.72 µM.33-34  Also, the 
siderophore Tsukubachelin (I-15) is reported as an ACE inhibitor isolated from 
Streptomyces sp. TM-34.35  Other peptidic ACE inhibitors include Ancovenin (I-16), a 
16-amino acid containing tricyclic molecule.36-37  This ACE inhibitor, produced by 
Streptomyces sp. No. A647P-2 is unique due to the prevalence of dehydroalanine and 
sulfide containing amino acids.  This large peptide was discovered to inhibit ACE with 
an IC50 of 870 nM. 
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Figure I-5. Peptidic natural products with ACE inhibitory activity which have been isolated from 
Streptomyces. 
 
 
 Other peptidic ACE inhibitory natural products consist of a series of 
glycopeptides, which have been isolated from Nocardia orentalis (Figure I-6).  These 
muramyl peptides, contain three structural variants, muracein A (I-17), muracein B (I-
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18), and muracein C (I-19) with ranges in ACE inhibition from 280 nM to 170 µM.38-39  
Interestingly, the muraceins have been shown to exhibit selectivity for mammalian ACE 
as they do not inhibit carboxypeptidase A at concentrations of 150 µM.  
 
 
Figure I-6. The muracins, a series of ACE inhibitory glycopeptides. 
 
 
 
One structural feature common to many peptidic ACE inhibitors is a carboxy-terminal 
tyrosine (Figure I-7).  The microginin series of ACE inhibitors (I-20 to I-24), isolated from 
the bluegreen algae Microcystis aeruginosa, are noted not only for their low µM inhibiton 
of ACE, but also for their selectivity.40-45  The microginins were found not to inhibit other 
peptidases including trypsin, plasmin, chymotrypsin and, carboxypeptidase A.  The 
inhibitor K-13 (I-25) was isolated from Micromonospora halophytica subsp. exilisia K-
13.46-47 This inhibitor, with a Ki of 349 nM, was also reported to be selective for the 
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mammalian enzyme as it did not potently inhibit carboxypeptidase A or trypsin, among 
other proteases.  Lastly, there is K-26 (I-1), a representative of a family of 6 natural 
products characterized by a unique phosphonic acid analog of tyrosine.  K-26 (I-1) is of 
particular interest as, to the best of our knowledge, it is the most potent ACE inhibitory 
natural product discovered to date.7   
 
 
 
Figure I-7. Peptidic ACE inhibitory natural products that are terminated by a tyrosine-like moiety. 
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The K-26 family of natural products 
 The representative natural product from this family, K-26 (I-1) was initially 
discovered through bioactivity guided fractionation and determined to have an IC50 in 
the low nanomolar range (12.5 nM), comparable to the widely prescribed 
pharmaceutical, captopril (IC50 = 7.7 nM).
7 The tripeptidic structure was elucidated 
through NMR, mass spectrometry and degradation.48  Synthetic investigations 
confirmed that this tripeptide was comprised of N-acetylated isoleucine, tyrosine and the 
non-proteinogenic amino acid (R)-1-amino-2-(4-hydroxyphenyl)ethylphosphonic acid 
(AHEP) (I-26).49  Testing with the substrate HHL revealed K-26 (I-1) to be a non-
competitive inhibitor of ACE.  Furthermore, K-26 was reported as a specific inhibitor of 
ACE, as carboxypeptidase A was only slightly inhibited by K-26 (I-1) and all as other 
proteases tested showed no degree of inhibition.  When administered to a normotensive 
rat intravenously, K-26 (I-1) was able to inhibit the pressor response in a similar manner 
to captopril (I-12).  This potent inhibition of ACE was postulated to be the result of 
interactions  between the phosphonate of the AHEP (I-26) and the active site zinc.7   
Structure activity relationship studies of synthetic K-26 (I-1) and variants have revealed 
features necessary for potent ACE inhibition.50  Inverting the stereochemistry of (R)-
AHEP to (S)-AHEP yielded a K-26 (I-1) variant that was 10 fold less active than K-26 (I-
1).  Replacing (R)-AHEP (I-26) with L-tyrosine resulted in a 1500 fold decrease in 
activity and removal of the N-acetyl group afforded des-acetyl K-26 (dAcK-26) which 
displayed a 15 fold decrease in activity compared to K-26 (I-1).  The stereochemistry of 
AHEP (I-26), the presence of the phosphonate, and the N-acetyl functionality were 
12 
 
deemed to be important structural aspects for the potent inhibition of ACE by K-26 (I-1).  
Interestingly, AHEP (I-26) alone is not a potent inhibitor of ACE (IC50 > 10µM).    
  Although the production of the K-26 family of metabolites is low, 6 members of 
this family have been isolated and described from species of, presumably closely 
related, soil dwelling actinomycetes (Figure I-8).  K-26 (I-1) has been isolated from the 
actinomycete Astrosporangium hypotensionis (NRRL 12379) whereas SF2513 A (I-27), 
SF2513 B (I-28) and SF2513 C (I-29) were isolated from Streptosporangium 
nondiastaticum.51  K-4 (I-30) was isolated from  Actinomadura spiculosospora and 
Actinomadura sp. No. 937ZE-1 was found to produce both K-4 (I-29) and 15-B-2 (I-
31).52-53   
All 6 characterized K-26 family metabolites are all classified as tripeptidic natural 
products, with N-terminal modification and AHEP (I-26) as the terminal moiety.  
Furthermore, all of these described AHEP (I-26) containing natural products have been 
noted for their potent nanomolar inhibition of mammalian ACE (Figure I-8).  Despite the 
potent activity towards mammalian angiotensin-I converting enzyme, an unusual 
interkingdom target for a microbially produced metabolite, the endogenous target of the 
K-26 family of bacterial metabolites, if any, has not been identified leaving the native 
significance of these fascinating metabolites a mystery.   
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Figure I-8. The K-26 family of natural products.  AHEP (I-26) is highlighted in red.  The N-acetyl is 
highlighted in blue in and the N-methyl is highlighted green.  Initially reported activity is presented with the 
structure.   
 
 
The carbon-phosphorus (C-P) bond in K-26 family allows the classification of these 
tripeptides with a diverse group of C-P bond containing natural products.  Many C-P 
bond containing natural products are bioactive and have broad utility ranging from 
antibacterial compounds to herbicides.54-58  Recently there have been insights into the 
biosynthesis of several phosphonate containing natural products revealing a common 
biosynthetic route for the formation of the C-P bond.59  Central to this process is 
phosphonenolpyruvate mutase (PEP mutase), an enzyme responsible for the 
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intramolecular rearrangement of phosphoenolpyruvate (I-32) to phosphonopyruvate (I-
33) (Figure I-9A).59  This enzyme is responsible for a phosphono-transfer, which is 
hypothesized to occur via two possible mechanisms allowing for the conservation of 
stereochemistry at both the phosphorus and the C3 carbon.  In the first proposed 
mechanism, a nucleophilic residue in the active site of the PEP mutase would 
participate in forming a phosphoenzyme intermediate (I-34) (Figure I-9B).60-61  This 
intermediate is then attacked by the pyruvate enolate (I-35) to yield the product.  In the 
second proposed mechanism, dissociated metaphosphate (I-36) would be held in place 
by enzymatic active site residues while a C1-C2 bond rotation occurs in the pyruvate 
enolate (I-35) (Figure I-9C).62  This would allow for attack of the pyruvate enolate C3 on 
the metaphosphate (I-36) with the appropriate retention of stereochemistry.  Despite 
insights and advances into the biosynthesis of phosphorus containing natural products, 
little is known about the biosynthesis of natural products from the K-26 family, in 
particular the AHEP (I-26) moiety.   
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Figure I-9. C-P bond formation by PEP mutase A. Intramolecular rearrangement carried out by PEP 
mutase to give phosphonopyruvate. B. Mechanism proposed via nucleophilic attack by an enzymatic 
active site residue. C. Mechanism proposed via dissociation of metaphosphate.  Hydrogens and oxygens 
are colored to highlight the retention of stereochemistry in this transformation.  
 
 
Some information has been gleaned about the biosynthesis of K-26 (I-1) and AHEP (I-
26) using precursor incorporation studies.  Feeding studies with isotopically labeled 
tyrosine has suggested that AHEP (I-26) is a discrete biosynthetic intermediate for K-26 
(I-1) that is derived from tyrosine or a closely related metabolite.49, 63  The nitrogen, the 
hydrogens on both the aromatic ring and the β-carbon of tyrosine were all incorporated 
into AHEP (I-26) moiety of K-26 (I-1) isolated from Astrosporangium hypotensionis.49  
Synthetic AHEP (I-26) was also incorporated directly into K-26 (I-1), whereas tyramine, 
the decarboxylated product of tyrosine, was not.63  These results suggest that in the 
biosynthesis of AHEP (I-26), a tyrosine-like AHEP (I-26) precursor must undergo 
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phosphonylation without the formation of an elimination intermediate.  Although all 
previously investigated carbon-phosphorus bond containing natural products have a 
biosynthetic route incorporating PEP mutase, it is difficult to rationalize a possible 
biosynthetic pathway utilizing phosphonopyruvate to generate AHEP (I-26) due to the 
placement of the aromatic ring, a hypothesis that is supported by the feeding studies.  
This supports the notion that a PEP mutase or an analogous enzyme may not be 
responsible for the biosynthesis of AHEP (I-26).  Presently, the biosynthesis of AHEP (I-
26) is not well understood and the gene cluster has not been identified.  As a result, the 
biosynthesis of K-26 (I-1) still remains cryptic leaving many unanswered questions 
about the origin of the unique carbon-phosphorus bond in this interesting bioactive 
molecule.      
 
Angiotensin converting enzyme domains and function 
Somatic ACE (sACE) was originally discovered by Leonard T. Skeggs Jr. in the mid 
1950’s as the last of the “”traditional components” of the RAS.64-65  Once this membrane 
bound protein was successfully cloned from human endothelial cells and mouse kidney, 
it was determined to contain two homologous domains, a phenomenon believed to be 
the result of gene duplication.66-67  This approximately 1300 amino acid protein was 
unexpectedly discovered to have two internal areas of homology, which for human ACE, 
is 612 amino acids in length.  These internal regions of homology have 60% of both the 
DNA and amino acid sequence in common with 89% homology being apparent in the 
region comprised of amino acids making up the active site.67  Within each of these two 
catalytic domains, there is a conserved HEXXH zinc binding motif.   The two histidines 
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in that motif, along with a glutamate found in its own characteristic EXIXD motif to the C-
terminal side of the HEXXH motif, are responsible for coordinating zinc in the active site.  
Each of these areas of homology and corresponding active sites on the somatic ACE 
have been termed N-domain (N-dom) ACE and C-domain (C-dom) ACE (Figure I-10A).   
A second tissue specific ACE isoform was discovered in 1971, testes ACE (tACE) 
(Figure I-10B).68  This ACE variant was found to be about half the size of somatic ACE, 
and to contain only one active site and be nearly identical to C-domain of sACE.69 
 
 
Figure I-10. ACE isoforms present in mammals.  The N-domain is colored orange and the C-domain is 
colored blue. A. Somatic ACE (sACE) tethered to the cell membrane through a C-terminal linker region.  
B. tACE tethered to the cell membrane through a C-terminal linker region. C. sACE after being cleaved off 
of the cell membrane. 
 
 
 
 ACE is tethered to the cell membrane through a C-terminal amino acid 
sequence, however this enzyme is found in plasma, suggesting that ACE is cleaved off 
of the cell membrane and released into the bloodstream as an active form of the 
enzyme (Figure I-10C).70-71  It is believed that there is an enzymatic factor responsible 
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for cleaving ACE off of the cell membrane through hydrolysis of the C-terminal amino 
acid stalk.72  This factor, which has not been identified with certainty, is referred to ACE 
sheddase, a hypothesized membrane associated enzyme.73-75  
Although the physiological role of ACE is the regulation of blood pressure through the 
degradation of bradykinin and the hydrolysis of ang I to ang II is well established, this 
promiscuous enzyme is believed to play a role in many other physiological processes.2, 
76-78  As both N-dom and C-dom ACE have been shown to have different substrate 
preferences, it suggests that these two domains also have different functions in vivo 
(Figure I-11).   
The N-dom of ACE is believed to be more efficient at cleaving the β amyloid peptide 
suggesting a possible role for ACE in Alzheimer’s disease, a disease characterized by 
an accumulation of amyloid plaques in the brain.79  However mouse studies and the 
clinical analysis of a large body of elderly patients concluded that pharmacological 
treatment with an ACE inhibitor did not encourage the accumulation of plaques in the 
brain.80-81  Furthermore, the peptide Ac-Ser-Asp-Lys-Pro (AcSDKP) is also preferentially 
cleaved by the N-domain with a kcat 40 times higher than that of the C-domain.
82  
AcSDKP is a peptide that is believed to be a natural regulator of hematopoietic stem cell 
proliferation, and has also been recently discovered to have a role in inflammation and 
fibrosis of the pulmonary system through its role in preventing the proliferation of 
fibroblasts.83-86  N-dom ACE is believed to be the primary means of degrading this 
peptide in vivo.77  
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Figure I-11. Substrate and structural differences between N-dom and C-dom ACE.   
 
 
 
C-dom ACE has been shown to be 3 times more efficient at catalyzing the hydrolysis of 
the decapaptide Ang I into the vasoconstrictor Ang II, highlighting the role of this domain 
in blood pressure regulation.87  Furthermore, the C-dom ACE, including the tissue 
specific tACE, has been shown to be absolutely necessary for fertility as male C-dom 
ACE knockout mice were shown to be sterile.88   
Despite the pharmacological interest in this enzyme the heavy glycosylation of this 
enzyme, with 10 glycosylation sites in the N-domain and 7 sites in the C-domain, has 
contributed to the difficulties in expression and crystallization.89-91  However, tACE and 
the N-domain of ACE have been successfully crystalized in 2003 and 2006, 
respectively, through the use of minimally glycosylated ACE mutants.92-93  These crystal 
structures show that both tACE and C-dom structures are comprised of α-helices which 
surround a zinc binding motif and active site buried in the interior of the enzyme (Figure 
I-12).  C-domain ACE requires substantially more chloride for activity than the N-dom 
N-domain ACE 
Cleaves AsSKDP and 
β-amyloid 
10 glycosylation sites 
1 chloride binding site 
Role in inflammation, 
stem cell proliferation 
and fibrosis 
Both Domains 
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mechanisms 
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structure  
HEXXH zinc binding 
domain 
C-domain ACE 
(tACE) 
Cleaves Angiotensin I 
7 glycosylation sites 
2 chloride binding 
sites 
Primary domain for 
blood pressure 
regulation and role in 
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ACE, a characteristic explainable by the two chloride ions apparent in the crystal 
structure near the active site in tACE versus the one chloride ion in N-dom ACE.87  As 
expected the crystal structures revealed differences in the amino acid residues present 
in the binding pocket, which likely contribute to the substrate and inhibitor preference of 
these two individual ACE domains. 
   
 
 
Figure I-12. Crystal structures of N-dom (purple) and C-dom (blue) ACE. Zinc present in the active site is 
colored grey and chloride is colored green.  Active site residues which coordinate zinc as part of the 
HEXXH motif are colored orange.  A. N-domain ACE. B. C-domain (tACE). C. Lisinopril bound in the 
active site of N-dom ACE.  D. Lisinopril bound in the active site of C-dom ACE (tACE). 
 
 
 
 
 
 
 
A B 
C D 
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Early ACE inhibitors  
 The first ACE inhibitor developed was captopril, in 1975 by Miguel Ondetti, 
Bernard Rubin and David Cushman who were working for the drug company Squibb.94-
95  The development of this inhibitor was one of the first successful drug designs using 
the revolutionary ligand-based approach.  The initial inspiration for this ACE inhibitor 
came from natural product peptides from the pit viper venom, Bothrops jararaca.96  This 
deadly venom, which was purposed as arrowhead poison by an indigenous Brazilian 
tribe, would cause a sudden drop in blood pressure causing the victim to collapse.    
 ACE inhibitor design is rationalized using a subsite notation.  The catalytic zinc is 
at the center of the binding pocket, with the prime subsites, S1’ and S2’, extending off to 
one side and the non-prime binding sites, S1 and S2, extending off to the other side.  
Studying inhibitor functionality at these ACE subsites was important in the design of 
inhibitors, in particular domain selective inhibitors, prior to the successful 
crystallography of ACE.  The first generation of ACE inhibitor pharmaceuticals, including 
captopril (I-12), lisinopril (I-37), and enalprilat (I-38) (administered as the esterified 
prodrug, enalapril) did not show significant preference for either ACE domain.97  
However, these initial inhibitors relied on a sulfhydryl (captopril (I-12)) or carboxyl 
(lisinopril (I-37) and enalprilat (I-38)) functionalities to coordinate the zinc and inhibit the 
enzyme by occupying the S1’, S2’ and in the case of some inhibitors, the S1 subsite 
(Figure I-13A).92-93, 97-98   
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Domain selective ACE inhibitors 
The first domain selective inhibitors, which were not developed until the late 1990s, 
made use of phosphinic moiety to coordinate the catalytic zinc and explored the S2 
subsite for its potential in domain selective inhibitor development, leading to the design 
of RXP 407 (I-39) and RXPA 380 (I-40).99-101 
RXP 407 (I-39) was the first N-domain selective inhibitor discovered, through a process 
of screening a phosphinic peptide library.99 (Figure I-13B).  This peptide was able to 
inhibit N-dom ACE with a Ki of 7 nM and a 1000 fold preference for the N-domain.  The 
potent and selective inhibiton of N-dom ACE by this peptide was attributed to the C-
terminal carboxamide along with the N-acetyl group and presence of an aspartic acid 
side chain at the S2 subsite.102 
The first C-dom inhibitor, RXPA 380 (I-40), was designed based on the observation that 
inhibitors containing a proline which would bind in the S1’ position had a binding 
preference for the C-dom (Figure I-13C).100   RXPA 380 was found to have Ki of 3 nM 
and a 3000 fold preference for the C-domain, with the pseudo-proline in the S1’ position 
and a tryptophan in the S2’ position necessary structural aspects of the inhibitor for 
potent and selective C-dom inhibition.103         
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Figure I-13. Structures of ACE inhibitors and their binding subsites. Zinc binding region of the inhibitor is 
highlighted in red.  A. Common ACE pharmaceuticals captopril (I-12), lisinopril (I-37) and enalaprilat (I-
38). B. N-dom selective inhibitor RXP 407 (I-39) C. C-dom selective inhibitor. RXPA 380 (I-40) 
 
 
 Domain selective ACE inhibition is enticing from a pharmacological standpoint as 
each ACE domain has a different biological function.  Not only will domain selective 
inhibitors provide the ability to study the biological functions of the two domains in vivo, 
but they may be more appropriate when treating patients when only the inhibition of one 
ACE active site is necessary.76  It is possible that a domain selective ACE inhibitor could 
reduce the occurrence of side effects which are attributed with the current general ACE 
inhibitors on the market.5  
 
ACE as an evolutionarily conserved enzyme 
The role of ACE in the mammalian cardiovascular system is well established with the 
other roles of this enzyme in mammalian physiology being more obscure.  Supporting 
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the notion that ACE has a broad role in physiology is the evolutionary analysis of this 
enzyme.  Due to the increase of the availability of DNA characterization of many 
species, primary sequence analysis has revealed that there are many variants of ACE 
in nature.76, 104  These ACE-like enzymes, which are widely distributed through various 
classes of organisms, are noted for their high sequence similarity with the human ACE 
isoforms.  Searching available databases for proteins with sequence similarities to 
human ACE, single domain ACE-like enzymes are found in an enormous number of 
species ranging from mammals, insects and invertebrates and even in protozoa and 
bacteria.105-112  Interestingly, many of these orthologs are present in prokaryotic 
organisms suggesting that this zinc dependent enzyme became necessary at a point in 
evolution long before its modern function in the role of blood pressure regulation.76 
Human ACE is characterized as an M2 metallopeptidase.  This enzyme falls into the 
broad classification of zincin due to the HEXXH residues that are responsible for binding 
the catalytic zinc.113  An additional glutamate residue, found 29 residues towards the C-
terminal side of the HEXXH motif is believed to be responsible for coordinating the zinc 
in the active site of ACE further classifying this enzyme as a distinct member of its own 
family, the angiotensin converting enzyme family.  Other families of zincins include the 
closely related enzymes in the thermolysin family, the neurotoxin family, the 
endopeptidase-24.11 family and the endopeptidase 24.15 family.114  Each one of these 
families have an additional glutamate residue outside the HEXXH motif which 
coordinates the zinc in the active site, however they differ due to the proximity of this 
glutamate residue to the HEXXH motif in the primary enzyme sequence. 
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A handful of ACE-like enzymes have been purified and biochemically characterized in 
vitro demonstrating that these enzymes retain their ability to hydrolyze angiotensin I, 
among other ACE substrates, and are inhibited by pharmacologically relevant ACE 
inhibitors.  Particularly well characterized ACE-like enzymes include the Drosophila 
melanogaster homologs AnCE and Acer, an ACE-like enzyme from Leishmania 
(LdDCP), the ACE2 homolog from humans, an ACE homolog from the leech 
Theromyzon tessulatum (TtACE), and the bacterial ACE-like enzymes from Escherichia 
coli (EcDCP) and Xanthamonas citri (XcACE)106-112, 115 Based on sequence similarities 
with human ACE, most of these enzymes fall into the M2 metalopeptidase family with 
ACE, with the exception of LdDCP and EcDCP, which are characterized as M3 
metallopeptidases.  BLAST and ClustalW analysis of the sequences of these ACE-like 
enzymes show a high degree of coverage and identity despite their presence in 
organisms from different kingdoms (Figure I-14).116-117  Regardless of the high 
sequence similarity and shared substrates between these ACE orthologs and 
mammalian ACE, in most cases the function of these evolutionarily conserved enzymes 
is unknown or poorly understood.76   
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 N-ACE  C-ACE  ACE2  AnCE  Acer  EcDCP  XcACE  LdDCP  
TtDCP  96% 
(48%)  
98% 
(48%)  
74% 
(41%)  
96% 
(41%)  
92% 
(39%)  
7% 
(37%)  
88% 
(35%)  
34% 
(24%)  
LdDCP  18% 
(33%)  
17% 
(38%)  
13% 
(36%)  
20% 
(32%)  
26% 
(24%)  
99% 
(45%)  
13% 
(38%)  
 
XcACE  91% 
(38%)  
97% 
(38%)  
73% 
(33%)  
95% 
(31%)  
78% 
(35%)  
11% 
(41%)  
  
EcDCP  20% 
(26%)  
15% 
(44%)  
8% 
(35%)  
11% 
(32%)  
7% 
(32%)  
   
Acer 96% 
(39%)  
97% 
(41%)  
76% 
(36%)  
99% 
(50%)  
    
AnCE  95% 
(42%)  
99% 
(45%)  
97% 
(36%) 
     
ACE2 96% 
(42%)  
99% 
(42%)  
      
C-ACE 96% 
(55%)  
       
 
Figure I-14.  Sequence identity and coverage (from BLAST) of biochemically characterized ACE-like 
enzymes and phylogenetic tree (from ClustalW) showing the relationship of ACE-like enzymes in nature.  
Shown in the table is percent identity (percent coverage).   
  
 
One particularly useful example of an ACE ortholog was discovered in the fruit 
fly, Drosophila melanogaster. This enzyme, AnCE, was first described in 1995 and has 
since been crystallized and used extensively in the study of ACE substrates and ACE 
inhibitors due to its similarity to C-dom ACE, along with its amenability to heterologous 
expression by the yeast strain Pichia pastoris as an unglycosylated, yet active 
enzyme.108, 110 This enzyme was shown to hydrolyze Ang I to Ang II (Km = 265 µM) and 
degrade bradykinin (Km = 22 µM), similar to mammalian ACE.  AnCE was also shown to 
be potently inhibited by the known ACE inhibitors captopril (I-12) (IC50 = 1.1 nM) and 
trandolaprilat (IC50 = 16 nM).  Furthermore, the crystal structure of this enzyme revealed 
a nearly identical tertiary structure when compared to human C-dom ACE.118  
Interestingly, despite the ability of AnCE to turnover substrates hydrolyzed by 
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mammalian ACE, none of these substrates are relevant in Drosophilia leaving the 
question of the physiological function of this ACE ortholog unanswered.76   
Co-crystal structures of AnCE with known ACE inhibitors on the pharmaceutical market 
show a preference of binding for the S2’ and S1’ subsites.119  These inhibitors also 
showed preference for the prime subsites in mammalian ACE, as shown by later crystal 
structures.93, 97-98  However, the co-crystalization of our inhibitor of interest, K-26 (I-1), in 
AnCE showed that this small molecule adopts a novel conformation in the binding 
pocket of AnCE, occupying only the non-prime subsites (Figure I-15).120  As K-26 (I-1) is 
the only known inhibitor to solely fill the non-prime binding pockets, it sets the stage for 
ACE inhibitor development focusing on the unique phosphonic acid moiety and the 
underexplored non-prime binding pockets.         
   
     
Figure I-15. Co-crystal structure of K-26 (I-1), captopril (I-12) and AnCE.  K-26 (I-1) is shown in dark 
green.  Captopril is shown in purple.  The active site zinc is colored orange.  Binding subsites are labeled 
on the diagram and structures of the inhibitors are shown with the zinc binding region highlighted in red. 
 
 
 
 
  
 
 
S1 
S2 
S2’ 
S1’ 
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Dissertation statement 
K-26 (I-1) has been established as one of the most potent natural product inhibitors of 
the pharmacological target ACE.  The structural features responsible for this bioactivity 
by the K-26 family of natural products have not been fully studied.   The potential for 
domain selective inhibition by these natural products has not been evaluated, especially 
in the context of the unique binding conformation that K-26 (I-1) has been shown to 
adopt in AnCE.  Also, questions remain unanswered regarding the biosynthesis of these 
AHEP containing compounds.  Furthermore, the native target of these microbially 
produced peptides is unknown.  In this thesis, we strive to glean insight into the 
pharmacology of the K-26 family of natural products with both mammalian ACE and 
bacterial ACE orthologs and progress towards the development of tools that may be 
applicable in unraveling the biosynthesis and in target identification of this fascinating 
metabolite.  
 
Chapter II describes the pharmacology of K-26 (I-1) and other related AHEP containing 
natural products with both mammalian and bacterial ACE. 
Chapter III describes the application of the computational tool Rosetta in structural 
activity relationship studies on an extensive set of K-26 variants and the experimental 
validation of the Rosetta predictions.   
Chapter IV describes the design of a chemical probe using K-26 (I-1) and initial 
applications for target and biosynthetic enzyme identification.  
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Chapter V describes the possible future studies and directions with regards to structural 
activity relationships of potent ACE inhibition by K-26 family of natural products and K-
26 target identification.   
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CHAPTER II 
 
INTERKINGDOM PHARMACOLOGY OF K-26 
 
Introduction 
  A significant number of secondary metabolites produced by bacteria are potent 
and selective inhibitors of enzymes and receptor targets in organisms classified in other 
kingdoms.121 Whether these activities are the result of adaptive evolutionary pressures 
or coincidence is unknown, but increasing evidence is accumulating that microbial 
secondary metabolites play central roles in interkingdom chemical ecological 
relationships.122 The significance of this interkingdom pharmacology is also evident in 
the role of bacterial natural products in clinically approved therapies. A striking example 
of such interkingdom activity are the microbial natural products, K-26, (II-1) and related 
compounds (II-2 – II-7) which are produced by actinomycetes isolated from soil-based 
ecosystems51, 123-125 (Figure II-1). These tripeptides contain a conserved terminal 
phosphonic acid analog of tyrosine, (R)-1-amino-2-(4-hydroxyphenyl) ethylphosphonic 
acid ((R)-AHEP,II-8). This non-proteinogenic amino acid, unique to this family, is the 
zinc-binding pharmacophore that renders these compounds among the most potent 
reported natural product inhibitors of the two domain human enzymatic target, ACE.  
The potency of the K-26 family against ACE, produced by a soil microbe for unknown 
purposes, raises questions pertaining to the structural origin of the potency and 
selectivity within the K-26 family and the chemical ecological roles of these compounds 
across kingdoms.  
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Figure II-1. K-26 analogs of interest. K-26 (II-1), K-4 (II-2), 15-B-2 (II-3), SF2513 B (II-4), SF2513 C (II-5), 
and SF2513 A (II-6) have been isolated from actinomycete cultures and noted for their potent ACE 
inhibitory activity. SF2513 D (II-7) was a synthetic analog used as a replacement for SF2513A in this 
study. All analogs are characterized by a non-proteogenic phosphonate analog of tyrosine, 1-amino-2-(4-
hydroxyphenyl)-ethylphosphonic acid, (AHEP) (II-8). This figure has been adapted from Kramer et. al.
126
 
and is used with permission. 
   
 
 
  Here we investigate the structural basis for K-26 inhibition of human ACE and the 
domain selectivity within the K-26 family of secondary metabolites. Chemical synthesis 
of five naturally produced structural variants of K-26 and analysis of their domain-
selective inhibition properties facilitates the determination of the structure-activity 
relationships within the natural product family. The co-crystallization of the most potent 
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member K-26, in both N- and C-domains, provides the first structural data of a natural 
product inhibitor in human ACE, and reveals a new mode of inhibitor binding. To 
investigate interkingdom structure-activity relationships, we also explore the activity of 
K-26 and synthetic ACE inhibitors against a panel of bacterial zinc metalloenzyme 
analogs of human ACE. Structural departures from the K-26/hACE inhibitor complex, 
engendered either within the inhibitor or the enzyme, resulted in significantly decreased 
binding affinity, confirming previous studies.127 Understanding the biochemical and 
structural basis for K-26 inhibition provides an avenue for the future development of 
domain-selective inhibitors for improved ACE-targeting therapies and the groundwork 
for future studies to elucidate the biological mechanism for the selectivity of K-26 for a 
mammalian enzyme.  
 
Results 
Synthesis of K-26 family natural products 
  With the exception of A. hypotensionis, the producing organisms are not 
publically available, and as K-26 metabolites are generated at very low production 
levels their total synthesis was necessary for study.  The full complement of the six 
known naturally occurring K-26 variants were synthesized, with the exception of the 
compound SF2513 A (II-6) (Scheme II-1), which was not readily accessible to us using 
an array of standard peptide coupling conditions.  Despite the usage of a variety of 
peptide coupling reagents including HATU, PyBrop, EDC, and acid chloride generation, 
bases including collidine and triethylamine, glutamate protecting group schemes, 
reaction times and conditions including microwave, the coupling of the N-Ac-isoleucine 
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to the N-methyl glutamate-AHEP did not result in the desired peptide.  Instead, either 
the original starting peptides were recovered or a peptide containing a cyclization 
product of the glutamate side chain resulted.  Therefore, a close structural analog of 
SF2513 A (II-6) was generated lacking methylation on the penultimate amide nitrogen, 
and designated SF2513 D (II-7) (Scheme II-2). Both synthetic schemes yielded the 
desired K-26 analogs as mixtures of two major diastereomers, which were separated by 
preparative C18-HPLC. Comparison of 
1H- and 13C-NMR acquired from synthetic 
(natural diastereomeric) natural products were consistent with extant literature spectral 
data, confirming the originally proposed structures and stereochemistries of these 
natural compounds.  Details of the synthesis are given in the methods section.   
 
 
Scheme II-1. Chemical Synthesis of K-4, 15-B-2, SF2513 B and SF2513 C.  Reagents and Conditions: 
(a) method A; HOBt, EDC, 2,4,6-trimethylpyridine, DMF, 0
o
C for 1 hr, then rt overnight. (b) method B; 3% 
NaCO3 in H2O, CH3CN, rt overnight. (c) method C; 10% Pd/C, H2, MeOH, rt overnight (d) method D; I-
TMSi, thioanisole, CH3CN, 0
o
C, 3 hours. K-4 II-2: R1=Me, R2=Cbz, R3=Val, R4=Phe, R5=Phe. 15-B-2 II-3: 
R1=Me, R2=Cbz, R3=Val, R4=Tyr(OBn), R5=Tyr. SF2513B II-4: R1=Ac, R2=H, R3=Ile, R4=Leu, R5=Leu. 
SF513C 5: R1=Ac, R2=H, R3=Ile, R4=Phe, R5=Phe. This figure has been adapted from Kramer et. al.
126
 
and is used with permission. 
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Scheme III-2. Chemical Synthesis of SF2513 D (II-7).  Reagents and conditions: (a) method A; HOBt, 
EDC, 2,4,6-trimethylpyridine, DMF, 0
o
C for 1 hr, then rt overnight. (b) method E; TAEA, DCM, rt, 20 min. 
(c) method A;  N-Ac-Ile, HOBt, EDC, 2,4,6-trimethylpyridine, DMF, 0
o
C for 1 hr, then rt overnight. (d) 
method C; 10% Pd/C, H2, MeOH, rt overnight. (e) method F; TFA, DCM, rt, 30 min. (f) method D; I-TMSi, 
thioanisole, CH3CN, 0
o
C, 3 hours. This figure has been adapted from Kramer et. al.
126
 and is used with 
permission. 
 
 
 
ACE inhibitory activity of the K-26 family 
  Chemically synthesized K-26 family phosponotripeptides were initially assayed 
for mammalian ACE inhibition using the benchmark chromogenic substrate furylacryloyl-
phenylalanyl-glycyl-glycine (FAPGG) and rabbit lung somatic ACE extract.127-128  
Consistent with previous data from K-26 SAR studies, diastereomers terminated by the 
naturally occurring (R)-AHEP amino acid were 10- to 400-fold more potent than the 
those terminated by (S)-AHEP (Table II-1, Table II-2).  
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(S)-diastereomer IC50 (M) 
K-4 (II-2) 4.2 x10
-6
 
15-B-2 (II-3) 5.4 x 10
-5
 
SF2513 B (II-4) 1.7 x 10
-6
 
SF2513 C (II-5) 2.4 x 10
-6
 
 
Table II-1. IC50 values calculated for least active (S)- diastereomers of the K-26 family of natural products 
using the substrate FAPGG with somatic ACE.  This figure has been adapted from Kramer et. al.
126
 and is 
used with permission. 
 
 
  With the exception of SF2513 D (II-7) (desmethyl SF2513 A), all synthesized 
natural products were potent nanomolar inhibitors of somatic rabbit lung ACE. SF2513 A 
(II-6) was previously reported to be a nanomolar inhibitor of ACE, with initial structure of 
SF2513 A (II-6) being elucidated using 1H NMR, 13C NMR and chemical degradation.51 
With these results in mind, if the originally published structure of SF2513 A (II-6) is 
correct, the N-methyl substituent must have an important role in promoting binding of 
SF2513 A (II-6) in the active site of ACE. In general, N-acetylated family members were 
markedly more potent than their respective N-methylated congeners using the substrate 
FAPGG. Of the N-acetylated variants, K-26 was found to be the most potent inhibitor of 
rabbit lung somatic ACE, with an IC50 of 25 nM, followed by SF2513 C (II-5) then 
SF2513 B (II-4). 
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IC50 Data (nM) Ki Data (nM) 
Compound sACE
a
 C-dom
b
 N-dom
b
 C-dom
b
 N-dom
b
 
K-26 (II-1) 25
d 
11
d
 110
e 
11
f 
75
d
 
K-4 (II-2) 370
e 
590
d
 220
c 
NT
g
 NT 
15-B-2 (II-3) 140
e
 54
e
 52
 c
 NT NT 
SF2513 B (II-4) 100
e
 12
d
 76
 c
 21
e
 33
d
 
SF2513 C (II-5) 35
e
 7
e
 88
e
 12
f
 170
d
 
SF2513 D (II-7) 5200
d
 NT NT NT NT 
      
Table II-2. ACE inhibitory activity of synthesized K-26 variants.  
a
Rabbit lung sACE was tested for 
inhibition with the substrate FAPGG. 
b
Z-FHL was used as a substrate with purified N- and C- domain ACE 
constructs.  Standard deviations, reported in supporting information on S89-S93, are 
c
1-10%, 
d
10-25%, 
e
25-50% or 
f
50-75%, of the mean. 
g
NT is not tested. This figure has been adapted from Kramer et. al.
126
 
and is used with permission. 
 
 
 
 Each of the synthesized natural products that exhibited nanomolar somatic ACE 
inhibition were also tested for domain selectivity by measuring the IC50 of inhibition 
using the substrate Cbz-Phe-His-Leu-OH (Z-FHL) (Table II-2)129-131 with purified N-
domain and C-domain human ACE constructs. Analogs showing promising domain 
selectivity were reevaluated via measurement of the inhibition constant Ki. The N-
methylated analogs, K-4 (II-2) and 15-B-2 (II-3), did not exhibit a large degree of 
domain-selectivity and SF2513 B only showed a slight preference for the C-domain, 
whereas N-acetylated analogs K-26 (II-1) and SF2513 C (II-5), showed approximately 
7- and 15-fold higher affinities for the C-domain, respectively. 
 
Co-crystal structures of K-26 with N-domain and C-domain ACE 
  To further understand the structural basis for inhibition of human ACE by the 
most potent member of this family of bacterial natural products, K-26 (II-1) was 
separately co-crystalized in the N-domain and the C-domain. As shown in the resulting 
crystal structures, K-26 (II-1) adopts a similar conformation in both domains (Figure II-
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2), conserving nearly identical potential hydrogen bond networks between the two 
domains (Table II-3). K-26 (II-1) has a unique binding motif as it occupies the “non-
prime” binding pockets of this mammalian ACE construct (Figure II-3). The phosphonate 
coordinates the zinc, the side chain of the AHEP (II-8) sits in the S1 binding pocket, the 
tyrosine side chain fills the S2 binding pocket and the N-acetyl isoleucine occupies a S3 
binding pocket. Other known inhibitors of the enzyme, including the synthetic phosphinic 
inhibitor RXPA380 (II-14), and the clinically relevant captopril (II-15) and lisinopril, and 
fill the ‘prime’ binding pockets.103, 132-133 The binding pattern of K-26 in human ACE is 
almost identical to that adopted by K-26 in the active site of Drosophila ACE (AnCE).120 
 
Ligand 
atom 
Interacting 
atom from the 
C-domain 
sACE 
Distance (Å) 
Ligand 
atom 
Interacting 
atom from the 
N-domain 
sACE 
Distance (Å) 
OAG Zinc ion 2.3 OAG Zinc ion 2.1 
OAJ Zinc ion 2.3 OAJ Zinc ion 2.5 
OAG Y523 OH 2.5 OAG Y501 OH 2.5 
OAJ H387 NE2 3.3 OAJ H365 NE2 3.0 
OAJ H383 NE2 3.2 OAJ H361 NE2 3.3 
OAD D358 N 2.8 OAD D336 N 2.8 
N A356 O 3.1 N A334 O 3.1 
O A356 N 2.9 O A334 N 2.8 
 
Table II-3.  Hydrogen bond interactions of C- and N- domains of ACE with K-26. Used with permission 
from Kramer et al.
126
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Figure II-2. K-26 binding in both domains of ACE. A. K-26 (green) bound in the N-domain of ACE. B. K-26 
(cyan) bound in the C-domain of ACE. Residues involved in K-26 interactions are shown as grey sticks. 
The zinc ion is shown as an orange sphere and water molecules in red. Potential hydrogen interactions 
and water mediated ones are presented with black and red dashed lines, respectively. Omit maps for K-
26 bound to N- and C-domain are shown at 1 contour level. Used with permission from Kramer et al.
126
 
 
 
39 
 
 
 
Figure II-3. Binding motifs of K-26 (II-1), RXPA380 (II-14) and captopril (II-15) in the active site of ACE. 
K-26 is shown in cyan, captopril (PDB 1UZF) in green and RXPA380 in pink (PDB 2OC2). Zinc is shown 
as an orange sphere. Binding pockets of the enzymes are labeled within the surface-rendered catalytic 
channel of C-domain ACE. Adapted from Kramer et al.
126
 Used with permission. 
 
 
 
Overexpression and characterization of dicarboxypeptidases 
  As K-26 family natural products are of microbial origin, and likely have not 
evolved to specifically inhibit human ACE, we endeavored to assay their interkingdom 
ACE-like activity. Biochemical characterization of several bacterial dicarboxypeptidases 
shows remarkable similarities in substrate and inhibitor preferences in comparison to 
mammalian ACE.107, 134 In support of these observations, sequence alignment of several 
bacterial dicarboxypeptidases reveals a high degree of sequence homology between 
mammalian ACE and bacterial dicarboxypeptidases (Table II-4, Figure II-4). This 
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encouraged us to explore the potential of the known potent mammalian ACE inhibitor, 
K-26, as an inhibitor of bacterial analogs of ACE. In order to explore the scope of 
interkingdom activity of K-26, we have recombinantly expressed, purified, and assayed 
a panel of ACE-like enzymes represented by phylogenetically distinct, bacterial zinc-
dependent dicarboxypeptidases for inhibition by captopril (II-15) and K-26 (Figure II-5).  
 
 N-domain tACE AnCE ACE2 K26DCP EcDCP 
MR1DCP 95%, 43% 97%, 43% 95%, 38% 74%, 38% 11%, 35% 18%, 45% 
EcDCP 20%, 41% 15%, 56% 11%, 55% 10%, 38% 99%, 46% 
K26DCP 17%, 83% 16%, 56% 12%, 33% 11%, 33% 
ACE2 73%, 42% 73%, 42% 77%, 41% 
AnCE 95%, 42% 99%, 45% 
tACE 96%, 55% 
  
Table II-4. Sequence coverage and identity for ACE-like enzymes.  N-ACE, tACE and ACE2 are human 
enzymes.  AnCE is a Drosophila homolog. K-26, E.coli and MR-1 are dicarboxypeptidases from the 
respective bacteria.  Adapted from Kramer et al.
126
 Used with permission. 
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MR1DCP      1 AQLSIEANRAEWIYSNFITEDTAALSAAVGEKVSAASVKFATEAAKYANVELDPAN--ARKLNILRSALVLPAPLDPAKN 
XcACE       1 KAAYPETTAAQWLSSTYINGDSQLLAAKANERSLAQLDRWIEQSKQYAGTPMSADS--ARALQLLKLMSALPAPRDPAKL 
NACE        1 EQVLFQSVAASWAHDTNITAENARRQEEAALLSQEFAEAWGQKAKELYEPIWQNFTDPQLRRIIGAVRTLGSANLPLAKR 
tACE        1 QVVWNEYAEANWNYNTNITTETSKILLQKNMQIANHTLKYGTQARKFDVNQLQNTT---IKRIIKKVQDLERAALPAQEL 
AnCE        1 AKRTNVETEAAWAYGSNITDENEKKKNEISAELAKFMKEVASDTTKFQWRSYQSED---LKRQFKALTKLGYAALPEDDY 
ACE2        1 EDLFYQSSLASWNYNTNITEENVQNMNNAGDKWSAFLKEQSTLAQMYPLQEIQNLT---VKLQLQALQQNGSSVLSEDKS 
EcDCP       1 QMPDFNNTILALEQSGELLTRVTSVFFAMTAAHTNDELQRLDEQFSAELAELANDIY-LNGELFARVDAVWQRRESLGLD 
K26DCP      1 EAPTFDNTVAALERSGQVLTRVSAVFFNQSSSDTNPTVQEIQKQIIPKLTQHGDAIH-LNRPLFARIKQISPD----GLD 
 
MR1DCP     79 AELAQISSELNGLYGKGKYCFADG---KCMTQP-ELSSLMAESRDPAKLLEAWKGWREIA-KPMRPLFQREVELANEGAK 
XcACE      79 AELTRIAAKMEGDYGAGSYCVGEGEQRRCRQLG-ELEQVLASSRDYNEQLDAWQGWHSTA-QPMRKDYQRFVELANEGAR 
NACE       81 QQYNALLSNMSRIYSTAKVCLPNK-TATCWSLDPDLTNILASSRSYAMLLFAWEGWHNAAGIPLKPLYEDFTALSNEAYK 
tACE       78 EEYNKILLDMETTYSVATVCHP---NGSCLQLEPDLTNVMATSRKYEDLLWAWEGWRDKAGRAILQFYPKYVELINQAAR 
AnCE       78 AELLDTLSAMESNFAKVKVCDYKDSTKCDLALDPEIEEVISKSRDHEELAYYWREFYDKAGTAVRSQFERYVELNTKAAK 
ACE2       78 KRLNTILNTMSTIYSTGKVCNPDN-PQECLLLEPGLNEIMANSLDYNERLWAWESWRSEVGKQLRPLYEEYVVLKNEMAR 
EcDCP      80 SESIRLVEVIHQRFVLAGAKLAQADKAKLKVLNTEAATLTSQFNQRLLAANKSGGLVVNDIAQLAGMSEQEIALAAEAAR 
K26DCP     76 AEQAWLLERYVTDFVRAGAELGAGDQERLKALNEELSTLSTRFEQNLLAHTNASAVIVDDVAQLDGLSDDSVKAAAETAK 
 
MR1DCP    154 DLGYANLSELWRSQYDMKP--------DEFSQELDRLWSQVKPLYESLHCYVRGELNKEYGDAIAPKTG-PIPAHLLGNM 
XcACE     157 GLGFADVGVLWRSGYDMPP--------AQLASETDRLWEQVKPLYAQLQCYARGKLDTQYGKDKGEVAGGLLPAHLMGNM 
NACE      160 QDGFTDTGAYWRSWYNSP----------TFEDDLEHLYQQLEPLYLNLHAFVRRALHRRYGDRYINLRG-PIPAHLLGDM 
tACE      155 LNGYVDAGDSWRSMYETP----------SLEQDLERLFQELQPLYLNLHAYVRRALHRHYGAQHINLEG-PIPAHLLGNM 
AnCE      158 LNNFTSGAEAWLDEYEDD----------TFEQQLEDIFADIRPLYQQIHGYVRFRLRKHYGDAVVSETG-PIPMHLLGNM 
ACE2      157 ANHYEDYGDYWRGDYEVNGVDGYDYSRGQLIEDVEHTFEEIKPLYEHLHAYVRAKLMNAY-PSYISPIG-CLPAHLLGDM 
EcDCP     160 EKGLDNKWLIPLLNTTQQPALAEMRDRATREKLFIAGWTRAEKNDANDTRAIIQRLVEIRAQQATLLGFPHYAAWKIADQ 
K26DCP    156 SRGLPGKYVIPLVLPTGQPGLAELTDRALRERIHRASIQRG----VPDNEELIVRIATLRAERAKLLGYPTHAAYVVADQ 
 
MR1DCP    225 WAQQWGNVYDLVAPENADPGYDVTELLAQKGYD------------------------------EHRMVKQAESFFTSLGF 
XcACE     229 WQQDWSNLWDLLQPYPGAGDLDITSALEKQYQGNLTAVLARNASGDGGAAARFNAEREAQLRTAKQMTERAQDFYTSLGM 
NACE      229 WAQSWENIYDMVVPFPDKPNLDVTSTMLQQGWN------------------------------ATHMFRVAEEFFTSLEL 
tACE      224 WAQTWSNIYDLVVPFPSAPSMDTTEAMLKQGWT------------------------------PRRMFKEADDFFTSLGL 
AnCE      227 WAQQWSEIADIVSPFPEKPLVDVSAEMEKQGYT------------------------------PLKMFQMGDDFFTSMNL 
ACE2      235 WGRFWTNLYSLTVPFGQKPNIDVTDAMVDQAWD------------------------------AQRIFKEAEKFFVSVGL 
EcDCP     240 MAKTPEAALNFMREIVPAARQRASDELASIQAV---------------------------IDKQQGGFSAQPWDWAFYAE 
K26DCP    232 TAPTTEAVTEMLGKLTPPAVANAHREADELR--------------------------------EQAGHDLEPWDWSFYAE 
 
MR1DCP    275 APLPDSFWSRSLFLQPKD-RDVVCHASAWDLDN--------LDDIRIKMCIQKTAEDFTVIHHELGHNFYQRAYKQQPFL 
XcACE     309 PKLPDTYWQRSQFIKPLD-RDVVCHASAWDMNMGGEASQNIGADVRTKMCIKPTEEDFTTIYHELGHIYYDLAYNPLPPL 
NACE      279 SPMPPEFWEGSMLEKPADGREVVCHASAWDFYNRK--------DFRIKQCTRVTMDQLSTVHHEMGHIQYYLQYKDLPVS 
tACE      274 LPVPPEFWNKSMLEKPTDGREVVCHASAWDFYNGK--------DFRIKQCTTVNLEDLVVAHHEMGHIQYFMQYKDLPVA 
AnCE      277 TKLPQDFWDKSIIEKPTDGRDLVCHASAWDFYLTD--------DVRIKQCTRVTQDQLFTVHHELGHIQYFLQYQHQPFV 
ACE2      285 PNMTQGFWENSMLTDPGNVQKAVCHPTAWDLGKG---------DFRILMCTKVTMDDFLTAHHEMGHIQYDMAYAAQPFL 
EcDCP     293 QVRREKFDLDEAQLKPYFELNTVLNEGVFWTANQLFG-----IKFVERFDIPVYHPDVRVWEIFDHNGVGLALFYGDFFA 
K26DCP    280 KVLKERYAIDGRQMRPYFELDRVLRDGVFHAATLLYG-----ITFTERPDLVGYHPDVRVFEVFNEDGSQLGLFLGDYYA 
 
MR1DCP    346 FKNSANDGFHEAIGDTIALSIT-PSYLKQIGLLE-EVPDASKDIG-LLLKQALDKIAFLPFGLMIDQWRWKVFSGEITP- 
XcACE     388 FQNGANDGFHEAIGDTIVLAMT-PKYLQSIGMVG-EQQTGRESLINSQMRMALSKVAFLPFGLMIDRWRWGVFDGSITP- 
NACE      351 LRRGANPGFHEAIGDVLALSVSTPEHLHKIGLLD-RVTNDTESDINYLLKMALEKIAFLPFGYLVDQWRWGVFSGRTPP- 
tACE      346 LREGANPGFHEAIGDVLALSVSTPKHLHSLNLLS-SEGGSDEHDINFLMKMALDKIAFIPFSYLVDQWRWRVFDGSITK- 
AnCE      349 YRTGANPGFHEAVGDVLSLSVSTPKHLEKIGLLK-DYVRDDEARINQLFLTALDKIVFLPFAFTMDKYRWSLFRGEVDK- 
ACE2      356 LRNGANEGFHEAVGEIMSLSAATPKHLKSIGLLSPDFQEDNETEINFLLKQALTIVGTLPFTYMLEKWRWMVFKGEIPK- 
EcDCP     368 RDSKSGGAWMGNFVEQSTLNKTHPVIYNVCNYQK--PAAGEPALLLWDDVITLFHEFGHTLHGLFARQRYATLSGTNTPR 
K26DCP    355 RPSKRGGAWMNSLVKQSTLEGTRPVVVNNLNIAK--PPAGEPTLMTFEEVNTMFHEFGHALHGLFSEVHYPRFSGTAVPR 
MR1DCP    422 ------AQYNQAWWELREKYQGVKAPTPRSETDFDPGAKYHVPG-----NVPYTRYFLAHILQFQFHKALCETAGDKG-- 
XcACE     465 ------EHYNQAWWELKAKYQGVAPVSARGEEFFDPGAKYHVPG-----NTPYTRYFLAHILQFQFYKGLCQAAGHQG-- 
NACE      429 ------SRYNFDWWYLRTKYQGICPPVTRNETHFDAGAKFHVPN-----VTPYIRYFVSFVLQFQFHEALCKEAGYEG-- 
tACE      424 ------ENYNQEWWSLRLKYQGLCPPVPRTQGDFDPGAKFHIPS-----SVPYIRYFVSFIIQFQFHEALCQAAGHTG-- 
AnCE      427 ------ANWNCAFWKLRDEYSGIEPPVVRSEKDFDAPAKYHISA-----DVEYLRYLVSFIIQFQFYKSACIKAGQYDPD 
ACE2      435 ------DQWMKKWWEMKREIVGVVEPVPHDETYCDPASLFHVSN-----DYSFIRYYTRTLYQFQFQEALCQAAKHEG-- 
EcDCP     446 DFVEFPSQINEHWATHPQVFARYARHYQSGAAMPDELQQKMRNASLFNKGYEMSELLSAALLDMRWHCLEENEAMQDVDD 
K26DCP    433 DFVEYPSQVNEMWAVWPSVLANYARHWQTGDPMPKDLLDRMLKSQKYNQGYKTVEYLAATLLDWSWHTFQTP--PENALT 
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MR1DCP    489 ----PVHRCSIYGNQAAGEKLNRMLELGSSQPWPMALKEVTGTETMDANAVLDYFAPLKTWLDEQNKAANR--------- 
XcACE     532 ----PLYECSFYGNKDAGQKFWSMLQRGSSQPWQTTLKELTGNDKLDAGPMLEYFAPMSDWLKQQNQGQ----------- 
NACE      496 ----PLHQCDIYRSTKAGAKLRKVLQAGSSRPWQEVLKDMVGLDALDAQPLLKYFQPVTQWLQEQNQQNGE--------- 
tACE      491 ----PLHKCDIYQSKEAGQRLATAMKLGFSRPWPEAMQLITGQPNMSASAMLSYFKPLLDWLRTENELHGE--------- 
AnCE      496 NVELPLDNCDIYGSAAAGAAFHNMLSMGASKPWPDALEAFNGERIMSGKAIAEYFEPLRVWLEAENIKNNV--------- 
ACE2      502 ----PLHKCDISNSTEAGQKLFNMLRLGKSEPWTLALENVVGAKNMNVRPLLNYFEPLFTWLKDQNKNSFVGWSTDWSPY 
EcDCP     526 FELRALVAENMDLPAIPPRYRSSYFAHIFGGGYAAGYYAYLWTQMLADDGYQWFVEQGGLTRENGLRFREAILS------ 
K26DCP    511 FEHEALTTAGVDLKLVPPRYRSTYFAHIWSSGYSAGYYSYIWSEVLDADTVDWFHENGGLLRENGDTFRQKLLS------ 
 
MR1DCP    556 -------------QCGW--------------------------------------------------------------- 
XcACE     597 -------------MCGWQATAAAPVTTKTAPAAAR--------------------------------------------- 
NACE      563 -------------VLGWPEYQWHPPLPDNYPEGID--------------------------------------------- 
tACE      558 -------------KLGWPQYNWTPNS------------------------------------------------------ 
AnCE      567 -------------HIGWTTSNKCVSS------------------------------------------------------ 
ACE2      578 ADQSIKVRISLKSALGDKAYEWNDNEMYLFRSSVAYAMRQYFLKVKNQMILFGEEDVRVANLKPRISFNFFVTAPKNVSD 
EcDCP     600 -------------RGNSEDLERLYRQWRGKAPKIMPMLQHRGLNI----------------------------------- 
K26DCP    585 -------------KGGSVDPMTAFQSFRGRTPRIEPLLDRRGLL------------------------------------ 
 
MR1DCP        -------------------------------------------------------------------------------- 
XcACE         -------------------------------------------------------------------------------- 
NACE          -------------------------------------------------------------------------------- 
tACE          -------------------------------------------------------------------------------- 
AnCE          -------------------------------------------------------------------------------- 
ACE2      658 IIPRTEVEKAIRMSRSRINDAFRLNDNSLEFLGIQPTLGPPNQPPVSIWLIVFGVVMGVIVVGIVILIFTGIRDRKKKNK 
EcDCP         -------------------------------------------------------------------------------- 
K26DCP        -------------------------------------------------------------------------------- 
 
MR1DCP        -------------------------------- 
XcACE         -------------------------------- 
NACE          -------------------------------- 
tACE          -------------------------------- 
AnCE          -------------------------------- 
ACE2      738 ARSGENPYASIDISKGENNPGFQNTDDVQTSF 
EcDCP         -------------------------------- 
K26DCP        -------------------------------- 
 
Figure II-4: Boxshade sequence alignment for ACE and ACE-like enzymes in this study.  The HEXXH 
zinc binding motif is highlighted in red. This figure has been adapted from Kramer et. al.
126
 and is used 
with permission.  
  
 
 
Figure II-5. Phylogenetic tree comparing ACE and related bacterial dicarboxypeptidases (DCP). 
Dicarboxypeptidases which have been overexpressed and purified in this study are shown in bold text. 
The optimal tree with the sum of branch length = 6.39523051 is shown. This figure has been adapted 
from Kramer et. al.
126
 and is used with permission. 
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  Three bacterial enzymes were chosen: dicarboxypeptidases from the K-26 
producing organism (K26DCP), from E.coli st. K-12 sbstr. MG1655 (EcDCP)134 and from 
Schwanella onedesis str. MR-1 (MR1DCP). K26DCP is the only putative zinc 
metallopeptidase present in the genome of the actinomycete Astrosporangium 
hypotensionis, the organism from which the tripeptide K-26 was originally isolated. 
MR1DCP was selected for the high similarity with human ACE as it has a 43% 
sequence identity with both the N- and C- domain of human ACE. All three enzymes 
contain the characteristic HEXXH zinc-binding domain, characteristic of the zincin family 
of zinc metalloproteases. The dicarboxypeptidases EcDCP and the K-26 producer 
K26DCP both are both classified specifically as a M3 zinc metalloproteases due to the 
presence of two additional glutamate residues, 30 and 37 amino acids C-terminal to the 
HEXXH zinc-binding domain that are believed to aid in coordinating the zinc in the 
active site of the enzyme.135 A glutamate residue present 29 residues downstream from 
the HEXXH zinc-binding domain, believed to be a ligand for zinc coordination in both 
MR1DCP and mammalian ACE, distinguishes these enzymes within the M2 subfamily of 
ACE zinc metalloproteases.  
  All three bacterial dicarboxypeptidases were found to efficiently hydrolyze the 
substrate FAPGG. Captopril (II-15) was shown to be a potent, low nanomolar inhibitor of 
all the purified overexpressed dicarboxypeptidases (Table III-5). However, K-26 (II-1) 
was found to be a potent inhibitor of the mammalian ACE, but a poor inhibitor of the 
bacterial ACE-like enzymes, including the dicarboxypeptidase encoded in the genome 
of the K-26 producer. 
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Dicarboxypeptidase Type 
Captopril IC50 
(M) 
K-26 IC50 
(M) 
Somatic ACE M3 7.7 x 10
-9 
2.5 x 10
-8 
K26DCP M2 5.2 x 10
-9
 4 x 10
-5 
EcDCP M2 1.6 x 10
-8 
1.5 x 10
-4 
MR1DCP M3 9.2 x 10
-9 
1.1 x 10
-5 
 
Table II-5. Inhibition of overexpressed bacterial dicarboxypeptidases by K-26. Adapted from Kramer et 
al.
126
 Used with permission. 
 
 
 
Discussion 
  The shared activity of K-26 family metabolites is largely determined by the 
terminal non-proteinogenic amino acid (R)-AHEP, which has been demonstrated to be 
an essential component for potent ACE inhibitory activity. On its own, AHEP (II-8) does 
not possess potent activity (IC50 > 1 µM), however, replacement of AHEP (II-8) by 
tyrosine causes a 1500-fold decrease in ACE inhibitory activity.127 Alteration of 
stereochemistry also decreases the activity 10 fold. The crystal structure reveals the 
importance of the phosphonate for potent binding as this is shown to coordinate with the 
zinc in the active site of the enzyme and form a hydrogen bond network with several 
conserved amino acids in both domains of ACE (Figure II-6). The AHEP (II-8) side chain 
fits into the S1 binding pocket, where the aromatic group of AHEP (II-8) may form 
hydrophobic interactions with Val 518 (Thr 496 in N-ACE). Furthermore, the high 
resolution of the crystallographic data allowed for the identification of several key water 
molecules which may have a role in inhibitor binding. The AHEP (II-8) seems to be 
stabilized at the active site by a network of water molecules anchoring K-26 (II-1) at S1 
in both crystal structures. Interestingly, additional water molecules interacting with K-26 
(II-1) were visible in the C-domain.  
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Figure II-6. Ligand plot of K-26 bound in both domains of ACE.  K-26 is shown in red and the zinc present 
in the active site is shown as a blue sphere.  A. K-26 bound in the C-domain of ACE B. K-26 bound in the 
N-domain of ACE 
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  In the S2 binding pocket, the tyrosine side chain may form conserved aromatic 
stacking interactions with His 387 and His 410 (His 365 and His 388 in N-domain) and 
hydrophobic interactions with Phe 391 (Tyr 369 in N-ACE). Interestingly, synthesis of a 
phosphinic inhibitor library analogous to the inhibitor RXPA380 (II-14) showed that a 
Phe or Tyr in the S2 position of the inhibitor encouraged the most ACE binding potency 
in both domains, suggesting the importance of these interactions.103 Hydrogen bonds 
between the backbone of the tyrosine in K-26 (II-1) with the backbone of Ala356 (Ala 
334 in N-ACE) are also evident. Additionally, the hydroxyl group of the tyrosine side 
chain makes water-mediated interactions with the backbone of Arg 402 and Gly 404 
(Figure II-2B). These two residues are conserved in both domains of ACE, however, Glu 
403 (C-domain) is occupied by Arg 381 in the N-domain. The long polar side chain of 
Arg 381 may thus prevent these water-mediated interactions in the N-domain, 
decreasing the binding affinity for K-26. 
  The remaining structural features of K-26 class of natural products are the third 
amino acid side chain and the N-terminal substitution, which occupies the S3 position. 
The N-terminal substitution has an effect on potency as shown with K-4 and 15-B-2, 
which have an N-terminal methyl group and inhibit somatic ACE with a 5 – 10 fold 
decrease in ACE inhibition, than the corresponding N-acetyl analogs. The origin of this 
activity difference likely derives from the ability of the N-acetyl carbonyl to form a 
hydrogen bond with backbone nitrogen of Asp 358 (Asp 336 in N-domain) and the OH 
from Tyr 369 in the N-domain. These hydrogen bonding interactions with the N-acetyl 
tail are likely important interactions for the increased potency of the N-acetylated 
analogs in comparison to cationic N-methylated congeners. 
47 
 
  Additionally in previous studies, in the insect homolog of ACE, AnCE (Drosophila 
melanogaster), captopril (II-15) has been shown to be a more potent inhibitor (Ki of 1.1 
nM) of the enzyme than K-26 (II-1) (Ki of 160 nM).
120, 136 Sequence alignment of human 
tACE with the most similar bacterial enzyme, MR1DCP, reveals five mutations in 
residues near the K-26 binding site (Figure II-7). In the binding pocket, Y360, F391, 
R402, G404 and F512 in tACE are mutated to D365, Q396, K407, S409, and Y515 
altering the polarity of the pocket. However, the difference in potency between the 
mammalian and bacterial enzyme likely arises from mutations which increases the net 
negative charge in the active site, and likely deleteriously effects binding of our 
negatively charged substrate, K-26 (II-1). 
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MR1DCP      1 AQLSIEANRAEWIYSNFITEDTAALSAAVGEKVSAASVKFATEAAKYANVELDPAN--ARKLNILRSALVLPAPLDPAKN 
NACE        1 EQVLFQSVAASWAHDTNITAENARRQEEAALLSQEFAEAWGQKAKELYEPIWQNFTDPQLRRIIGAVRTLGSANLPLAKR 
tACE        1 QVVWNEYAEANWNYNTNITTETSKILLQKNMQIANHTLKYGTQARKFDVNQLQNTT---IKRIIKKVQDLERAALPAQEL 
 
MR1DCP     79 AELAQISSELNGLYGKGKYCFADG---KCMTQP-ELSSLMAESRDPAKLLEAWKGWREIA-KPMRPLFQREVELANEGAK 
NACE       81 QQYNALLSNMSRIYSTAKVCLPNK-TATCWSLDPDLTNILASSRSYAMLLFAWEGWHNAAGIPLKPLYEDFTALSNEAYK 
tACE       78 EEYNKILLDMETTYSVATVCHP---NGSCLQLEPDLTNVMATSRKYEDLLWAWEGWRDKAGRAILQFYPKYVELINQAAR 
 
MR1DCP    154 DLGYANLSELWRSQYDMKP--------DEFSQELDRLWSQVKPLYESLHCYVRGELNKEYGDAIAPKTG-PIPAHLLGNM 
NACE      160 QDGFTDTGAYWRSWYNSP----------TFEDDLEHLYQQLEPLYLNLHAFVRRALHRRYGDRYINLRG-PIPAHLLGDM 
tACE      155 LNGYVDAGDSWRSMYETP----------SLEQDLERLFQELQPLYLNLHAYVRRALHRHYGAQHINLEG-PIPAHLLGNM 
 
MR1DCP    225 WAQQWGNVYDLVAPENADPGYDVTELLAQKGYD------------------------------EHRMVKQAESFFTSLGF 
NACE      229 WAQSWENIYDMVVPFPDKPNLDVTSTMLQQGWN------------------------------ATHMFRVAEEFFTSLEL 
tACE      224 WAQTWSNIYDLVVPFPSAPSMDTTEAMLKQGWT------------------------------PRRMFKEADDFFTSLGL 
 
MR1DCP    275 APLPDSFWSRSLFLQPKD-RDVVCHASAWDLDN--------LDDIRIKMCIQKTAEDFTVIHHELGHNFYQRAYKQQPFL 
NACE      279 SPMPPEFWEGSMLEKPADGREVVCHASAWDFYNRK--------DFRIKQCTRVTMDQLSTVHHEMGHIQYYLQYKDLPVS 
tACE      274 LPVPPEFWNKSMLEKPTDGREVVCHASAWDFYNGK--------DFRIKQCTTVNLEDLVVAHHEMGHIQYFMQYKDLPVA 
 
MR1DCP    346 FKNSANDGFHEAIGDTIALSIT-PSYLKQIGLLE-EVPDASKDIG-LLLKQALDKIAFLPFGLMIDQWRWKVFSGEITP- 
NACE      351 LRRGANPGFHEAIGDVLALSVSTPEHLHKIGLLD-RVTNDTESDINYLLKMALEKIAFLPFGYLVDQWRWGVFSGRTPP- 
tACE      346 LREGANPGFHEAIGDVLALSVSTPKHLHSLNLLS-SEGGSDEHDINFLMKMALDKIAFIPFSYLVDQWRWRVFDGSITK- 
 
MR1DCP    422 ------AQYNQAWWELREKYQGVKAPTPRSETDFDPGAKYHVPG-----NVPYTRYFLAHILQFQFHKALCETAGDKG-- 
NACE      429 ------SRYNFDWWYLRTKYQGICPPVTRNETHFDAGAKFHVPN-----VTPYIRYFVSFVLQFQFHEALCKEAGYEG-- 
tACE      424 ------ENYNQEWWSLRLKYQGLCPPVPRTQGDFDPGAKFHIPS-----SVPYIRYFVSFIIQFQFHEALCQAAGHTG-- 
 
MR1DCP    489 ----PVHRCSIYGNQAAGEKLNRMLELGSSQPWPMALKEVTGTETMDANAVLDYFAPLKTWLDEQNKAANR--------- 
NACE      496 ----PLHQCDIYRSTKAGAKLRKVLQAGSSRPWQEVLKDMVGLDALDAQPLLKYFQPVTQWLQEQNQQNGE--------- 
tACE      491 ----PLHKCDIYQSKEAGQRLATAMKLGFSRPWPEAMQLITGQPNMSASAMLSYFKPLLDWLRTENELHGE--------- 
 
MR1DCP    556 -------------QCGW--------------------------------------------------------------- 
NACE      563 -------------VLGWPEYQWHPPLPDNYPEGID--------------------------------------------- 
tACE      558 -------------KLGWPQYNWTPNS------------------------------------------------------ 
 
Figure II-7: Sequence homology between human tACE and N-ACE and MR1DCP.  Residues in proximity 
to K-26 (cyan) in the binding pocket of tACE that are mutated in MR1DCP are shown in magenta.  
Specific residue mutations between tACE, NACE and MR1DCP are shown in the table.  In the sequence 
alignment, the HEXXH binding motif is shown in red.  Residues directly interacting with captopril in the 
binding pocked are highlighted in green.  Residues in proximity to K-26 in the binding pocket are shown in 
orange.   Adapted from Kramer et al.
126
 Used with permission. 
 
tACE N-ACE MR1DCP 
Y360 Y338 D365 
F391 Y369 Q396 
R402 R380 K407 
G404 G382 S409 
F512 F490 Y515 
F512 
F391 
Y360 
R402 
G404 
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  In conclusion, we have illuminated the structure-activity relationships of the K-26 
family of natural products in mammalian ACE, the enzyme target that was originally 
used in screening for their discovery from Actinomycetes. These results provide 
structural insight that can be applied toward future development of potential domain-
selective inhibitors through improving binding in the unexplored non-prime pockets of 
ACE. The inhibition data from bacterial ACE-like dicarboxypeptidases, together with 
previous data from Drosophila ACE, emphasize that, among all known groups of ACE-
like dicarboxypeptidases, mammalian ACE seems uniquely inhibited by K-26 (II-1). 
Indeed, the combined enzyme and substrate structural activity data suggest that the 
natural target for K-26 (II-1) possesses an active-site architecture similar to mammalian 
ACE, prompting questions regarding potential interkingdom chemical ecological roles 
for natural target of K-26 (II-1). Future studies will investigate the potential for 
generation of improved domain selective analogs building from the AHEP (II-8) 
pharmacophore into the unique binding pose of this family of natural products, and work 
to identify potential chemical ecological targets for AHEP functional natural products. 
 
Materials and Methods 
Synthesis of K-26 family of natural products  
General Experimental 
  Reactions were carried out in oven or flame dried glassware.  All solvents were 
reagent grade.  Amino acids and peptide coupling agents were purchased from EMD or 
Bachem.  All reagents were commercially available and used without purification unless 
specified otherwise.  AHEP (II-8) and K-26 (II-1) were synthesized as previously 
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described.127 Silica gel (35-70 mm) from EM Science was used for column 
chromatography.  Silica gel 60 TLC plates were purchased from EMD and plates were 
visualized by UV.  HPLC purification was carried out using a Phenomonex C18 semi-
preparative HPLC column on a Waters instrument using a flow rate of 5 mL/min.  The 
purified analogs were tested for somatic ACE inhibitory activity using the substrate 
FAPGG. The most potent inhibitor was taken to be the desired (R)-diastereomer. All 
analogs were characterized by NMR and HRMS and quantitated, prior to inhibition 
studies, using an attenuated time delay proton NMR experiment (relaxation d1 = 15 s) 
with dioxane added as an internal standard.  NMR spectra were acquired on a Brucker 
DRX-400, AV-400, DRX-500, or AV-II-600 instrument.  NMR spectra of synthetic 
intermediates and analogs are available in Appendix A.  
 
Method A: Peptide Coupling125, 127, 137  
  The corresponding amino acids or peptides were dissolved in dimethylformamide 
(DMF) with N-hydroxybenzotriazole (HOBt) and the reaction mixture was cooled to 0 oC.  
Under inert atmosphere, 1-ethyl-3(3’-dimethylaminopropyl)carbodiimide hydrochloride 
(EDC) and 2,4,6-trimethylpyridine were added and the reaction was allowed to proceed 
for 1 hour at 0 oC and then overnight at room temperature.  Unless otherwise specified, 
the reaction was dissolved in ethyl acetate and washed with 1N HCl, 1N NaHCO3, and 
brine.  The organic layer was then dried over MgSO4, and then concentrated to give the 
desired product.   
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Method B: Saponification.127  
  The dipeptide methyl ester was dissolved in acetonitrile.  An aqueous solution of 
3% Na2CO3 was added and the reaction was stirred overnight at room temperature.  
The reaction was washed with hexane, acidified with 1 N HCl to pH = 3, then extracted 
with chloroform.  The combined chloroform fractions were washed with brine and dried 
over MgSO4, then concentrated to yield the product. 
 
Method C: Hydrogenation.125  
  The corresponding tripeptide and palladium on activated carbon (Pd/C) were 
combined in anhydrous methanol and allowed to stir overnight under 1atm hydrogen 
gas.  After filtering through Celite, the filtrate was evaporated to give the product.   
 
Method D: Phosphonate Deprotection.127, 138  
  The corresponding ethyl phosphonate was dissolved in anhydrous acetonitrile 
and thioanisole at 0 oC.  Iodotrimethyl silane (I-TMSi) was added dropwise, and the 
reaction was allowed to proceed for 3 hours at 0 oC, after which the solvent was 
removed under vacuum to give a brown oily residue of the phosphonate trimethylsilyl 
ester.  After hydrolysis of the trimethylsilyl ester, the solvent was evaporated and residue 
was redissolved in methanol ant the product was purified via preparative HPLC. 
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Method E: Fmoc Deprotection.139  
  The corresponding Fmoc protected dipeptide was dissolved in anhydrous DCM 
(5 mL) and under inert atmosphere tris(2-aminoethyl)amine (TAEA) (3.5 mL) was added 
dropwise.  The reaction was allowed to stir for 30 minutes at room temperature then 
was dissolved in additional DCM, washed with brine and phosphate buffer (pH 5.5).  
The aqueous portion was collected and back extracted with additional DCM.  The 
organic layers were combined, dried over MgSO4 and concentrated to give the product.   
 
Method F: t-Butyl Deprotection.140  
  The corresponding t-butyl protected peptide was dissolved in DCM (5 mL) and 
trifluoroacetic acid (TFA) (5 mL).  The reaction was stirred for 30 minutes at room 
temperature and the solvent was removed in vaccuo to give the product. 
 
N-benzyloxycarbonyl-N-methyl-L-valyl-L-phenylalanine methyl ester (II-2a). 
  Synthesized using N-benzyloxycarbonyl-N-methyl-L-valine II-9 (200 mg, 0.753 
mmol), L-phenylalanine methyl ester hydrochloride II-10 (156 mg, 0.791 mmol), HOBt 
(121 mg, 0.791 mmol), EDC (151 mg, 0.791 mmol) and 2,4,6-trimethylpyridine (200 L, 
1.51 mmol) in DMF (6 mL) using method A. Clear oil. Yield: 321 mg, 84.1%. Rotamers  
1H NMR (600 MHz, CDCl3) δ 7.42-7.03 (m, 10H),  5.18-5.12 (m, 2H), 4.90-4.85 (m, 1H), 
4.12 (d, J = 11.0 Hz, 0.8H), 3.97 (d, J = 10.7 Hz, 0.2H), 3.72 (s, 3H), 3.17-3.14 (m, 1H), 
2.96-2.92 (m, 1H), 2.80 (s, 0.7H), 2.71 (s, 2.3H), 2.25-2.20 (m, 1H), 0.96-0.88 (m, 3H), 
0.85--0.82 (m, 3H); 13C NMR (150 MHz, CDCl3) δ 171.68, 169.63, 157.30, 136.57, 
135.96, 129.11, 128.57, 128.10, 127.67, 126.95, 67.50, 54.93, 52.76, 52.31, 38.03, 
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29.53, 25.92, 19.50, 18.52; HRMS calculated for C24H31N2O5 (M+H
+) 427.2228 found 
427.2426. 
 
N-benzyloxycarbonyl-N-methyl-L-valyl-L-phenylalanine (II-2b).  
  Synthesized using N-benzyloxycarbonyl-N-methyl-L-valyl-L-phenylalanine methyl 
ester II-2a (702 mg, 1.64 mmol), acetonitrile (85 mL) and 3% Na2CO3 (130 mL) using 
method B. Clear oil. Yield: 522 mg, 77.2%. Rotamers. 1H NMR (600 MHz, CDCl3) δ 
7.45-6.90 (m, 10H), 5.20-5.15 (m, 2H), 4.93-4.89 (m, 1H), 4.20 (d, J = 11.2 Hz, 0.8H), 
4.01 (d, J = 10.4 Hz, 0.2H), 3.24 (dd, J = 14.0, 5.0 Hz, 1H), 2.89 (dd, J = 14.0, 8.2 Hz, 
1H), 2.78 (s, 0.7H), 2.71 (s, 2.3H), 2.26-2.19 (m, 1H). 0.92 (d, J = 6.5 Hz, 3H), 0.83 (d, J 
= 6.7 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 174.21, 169.75, 157.54, 136.29, 136.21, 
129.34, 128.70, 128.43, 128.32, 127.81, 126.91, 67.95, 64.88, 52.83, 37.83, 29.60, 
26.10, 19.44, 18.48; HRMS calculated for C23H29N2O5 (M+H
+) 413.2071 found 
413.2282. 
 
Diethyl N-(N-benzyloxycarbonyl-N-methyl-L-valyl-L-phenylalanyl)-1-amino-2-(4-
enzyloxyphenyl)ethyl phosphonate (II-2c).  
  Synthesized using N-benzyloxycarbonyl-N-methyl-L-valyl-L-phenylalanine II-2b 
(309 mg, 0.75 mmol), diethyl 1-amino-2-(4-benxyloxyphenyl)ethylphosphonate II-8 
(288.4 mg, 0.788 mmol), HOBt (120.6 mg, 0.788 mmol), EDC  (130 mg, 0.68 mmol) and 
2,4,6-trimethylpyridine (172 L, 1.30 mmol) in DMF (5 mL) using method A. The product 
was further purified by flash chromatography (4% methanol in DCM, Rf = 0.23) to give a 
mixture of diastereomers. Clear oil. Yield: 360 mg, 64.0%. 1H NMR (400 MHz, CDCl3) δ 
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7.43-6.82 (m, 19H), 5.19-5.06 (m, 2H), 5.03-4.93 (m, 2H), 4.81-4.70 (m, 2H), 4.17-4.01 
(m, 5H), 3.23-3.15 (m, 1H), 3.12-3.06 (m, 0.5H), 2.92-2.81 (m, 1.5H), 2.70-2.62 (m, 1H), 
2.59-2.55 (m, 3H), 2.17-2.12 (m, 1H), 1.37-1.25 (m, 6H), 0.87-0.74 (m, 6H); 13C NMR 
(150 MHz, CDCl3) δ170.84-170.54, 169.97, 169.50, 158.30-157.64, 157.36-157.14, 
137.15-136.98, 136.73-136.50, 130.36, 130.27, 129.24, 129.14, 129.11, 128.56, 128.40, 
128.20, 128.15, 127.92, 127.73, 127.68, 127.45, 126.92-126.59, 70.02, 69.91, 67.54, 
67.49, 64.95, 64.79, 62.95-62.41, 54.04-52.88, 47.34-45.74, 38.28, 37.99, 34.87, 29.74-
29.35, 25.85, 19.62,19.50, 18.43, 18.39, 16.59-16.29; 31P NMR (162 MHz,  CDCl3) δ 
24.92, 24.89. 24.82; HRMS calculated for C42H53N3O8P (M+H
+) 758.3565 found 
758.3983. 
 
Diethyl N-(N-methyl-L-valyl-L-phenylalanyl)-1-amino-2-(4-hydoxyphenyl)ethyl 
phosphonate (II-2d).  
  Synthesized using diethyl N-(N-benzyloxycarbonyl-N-methyl-L-valyl-L-
phenylalanyl)-1-amino-2-(4-benzyloxyphenyl)ethyl phosphonate II-2c (371 mg, 0.489 
mmol), Pd/C (10% Pd, 37 mg) in methanol (7 mL) using method C, to yield a mixture of 
diastereomers. White solid.  Yield: 206 mg, 78.9%. 1H NMR (600 MHz, CDCl3) δ 7.27-
6.98 (m, 7H), 6.74-6.67 (m, 2H), 4.73-4.64 (m, 2H), 4.16-4.01 (m, 4H), 3.18-3.07 (m, 
2H), 2.96-2.84 (m, 1H), 2.80-2.74 (m, 1H), 2.66 (dd, J=15.5. 4.5 Hz, 1H) 2.23 (s, 1.5H), 
2.10 (s, 1.5H), 1.92-1.83 (m, 1H), 1.33-1.25 (m, 6H), 0.83-0.56 (m, 6H); 13C NMR (150 
MHz, CDCl3) δ 174.37, 174.30, 171.39-171.19, 155.88, 155.79, 136.69, 136.62, 130.41, 
130.30, 129.34, 129.29, 128.63, 128.58, 127.45-127-21, 126.93, 115.61, 115.52, 70.87, 
70.48, 63.14-62.75, 53.98, 53.66, 47.32, 46.29, 37.77, 37.72, 36.05, 34.92, 34.86, 
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31.30, 31.14, 19.45, 19.42, 17.77, 17.48, 16.59-16.45;  31P NMR (162 MHz,  CDCl3) δ 
25.52, 25.39;  HRMS calculated for C27H41N3O6P (M+H
+) 534.2728 found 534.2973. 
 
K-4: N-(N-methyl-L-isoleucyl-L-phenylalanyl)-1-amino-2-(4-hydoxyphenyl)ethyl 
phosphonic acid (II-2).  
  Synthesized using diethyl N-(N-methyl-L-valyl-L-phenylalanyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate II-2d (30.1 mg, 0.0564 mmol), acetonitrile (6 mL), 
thioanisole (0.6 mL) and I-TMSi (3.0 mL) using method D.  The phosphonate 
trimethylsilyl ester was hydrolyzed by treatment with 8:2 methanol in water (30 mL). 
Purified by HPLC, using a gradient of 5% acetonitrile in water to 25% acetonitrile in 
water containing ammonium acetate (10 mM) over 30 minutes. White solid.  Yield: 3.45 
mg, 12.8%. 1H NMR (600 MHz, D2O pD = 11.9) δ 7.35-7.29 (m, 4H), 7.26 (t, J = 7.11, 
1H), 7.14 (d, J = 8.5 Hz, 2H), 6.70 (d, J = 8.5 Hz, 2H), 4.72 (m, 1H), 4.06 (m, 1H), 3.29 
(dd, J = 14.2, 3.5 Hz, 1H), 3.21 (dt, J = 14.2, 2.8 Hz, 1H), 2.73 (dd, J = 14.1, 11.9 Hz, 
1H), 2.64-2.57 (m, 2H), 1.68 (s, 3H), 1.64-1.57 (m, 1H), 0.74 (d, J = 6.8 Hz, 3H), 0.60 
(d, J = 6.8 Hz, 3H); 13C NMR (150 MHz, , D2O pD = 11.9) δ 174.68, 171.53, 171.49, 
154.89, 137.09, 130.61, 130.51, 130.32, 129.23, 128.53, 126.72, 115.42, 69.49, 54.09, 
51.99, 51.07, 37.76, 36.41, 32.85, 30.80, 18.30; 31P NMR (162 MHz, D2O pD = 11.9) δ 
15.15; HRMS calculated for C23H33N3O6P (M+H
+) 478.2102 found 478.2169. 
 
N-benzyloxycarbonyl-N-methyl-L-valyl-O-benzyl-L-tyrosine methyl ester (II-3a). 
  Synthesized using N-benzyloxycarbonyl-N-methyl-L-valine II-9 (200 mg, 0.753 
mmol), O-benzyl-L-tyrosine methyl ester hydrochloride II-11 (231 mg, 0.718 mmol), 
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HOBt (121 mg, 0.791 mmol), EDC (151 mg, 0.791 mmol) and 2,4,6-trimethylpyridine 
(200 L, 1.51 mmol) in DMF (6 mL) using method A. Clear oil. Yield: 321 mg, 84.1%. 
Rotamers. 1H NMR (600 MHz, CDCl3) δ 7.49-7.22 (m, 10H), 7.03-6.64 (m, 4H), 5.22-
5.12 (m, 2H), 5.03-4.90 (m, 2H)  4.89-4.79 (m, 1H), 4.20 (d, J = 11.2 Hz, 0.8H), 4.01 (d, 
J = 10.7 Hz, 0.2H), 3.70 (s, 3H), 3.13-3.07 (m, 1H), 2.94-2.87 (m, 1H), 2.85 (s, 0.7H), 
2.75 (s, 2.3H), 2.24 (m, 1H), 0.98-0.89 (m, 3H), 0.88-0.83 (m, 3H); 13C NMR (150 MHz, 
CDCl3) δ 171.61, 169.55, 157.66, 157.13, 136.87, 136.43, 130.03, 128.44, 128.38, 
128.11, 127.95, 127.74, 127.52, 127.24, 114.69, 69.66, 67.36, 64.70, 52.77, 52.10, 
37.06, 29.38, 26.87, 19.35, 18.44; HRMS calculated for C31H37N2O6 (M+H
+) 533.2647 
found 533.2981. 
 
N-benzyloxycarbonyl-N-methyl-L-valyl-O-benzyl-L-tyrosine (II-3b).  
  Synthesized using N-benzyloxycarbonyl-N-methyl-L-valyl-O-benzyl-L-tyrosine 
methyl ester II-3a (610 mg, 1.15 mmol), acetonitrile (67 mL) and 3% Na2CO3 (101 mL) 
using method B. Clear oil. Yield: 467 mg, 78.3%. Rotamers. 1H NMR (400 MHz, CDCl3) 
δ 7.43-7.29 (m, 10H), 7.02 (d, J = 7.9 Hz, 2H), 6.79 (d, J = 8.2 Hz, 2H), 5.19 (s, 2H), 
4.92-4.84 (m, 2H), 4.22 (d, J = 11.1 Hz, 0.8H), 4.02 (d, J = 10.3 Hz, 0.2H), 3.18 (dd, J = 
13.9, 4.62 Hz, 1H), 2.88-2.80 (m, 1H), 2.72 (s, 3H), 2.60 (s, 2H),  2.29-2.19 (m, 1H),  
0.93 (d, J = 6.2 Hz, 3H), 0.85 (d, J = 6.4 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ  174.08, 
169.75, 157.72, 157.47, 136.95, 136.16, 130.32, 128.62, 128.48, 128.24, 127.86, 
127.73, 127.39, 114.69, 69.77, 67.90, 64.81, 52.93, 36.93, 29.51, 26.02, 19.35, 18.43; 
HRMS calculated for C30H35N2O6 (M+H
+) 519.2490 found 519.2781. 
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Diethyl N-(N-benzyloxycarbonyl-N-methyl-L-valyl-O-benzyl-L-tyrosyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (II-3c).  
  Synthesized using N-benzyloxycarbonyl-N-methyl-L-valyl-L-tyrosine II-3b (315 
mg, 0.861 mmol), diethyl 1-amino-2-(4-benxyloxyphenyl)ethylphosphonate II-8 (131 mg, 
0.861 mmol), HOBt (132 mg, 0.861 mmol), EDC  (165 mg, 0.861 mmol) and 2,4,6-
trimethylpyridine (216 L, 1.64 mmol) in DMF (5 mL) using method A. The product was 
further purified by flash chromatography (4% methanol in DCM, Rf = 0.21) to give a 
mixture of diastereomers. Clear oil. Yield: 425 mg, 60.0%. 1H NMR (600 MHz, CDCl3) δ 
7.46-6.69 (m, 23H), 5.19-5.09 (m, 2H), 5.08-5.01 (m, 2H), 4.94-4.83 (m, 2H) 4.77-4.65 
(m, 2H), 4.18-4.00 (m, 5H), 3.20-3.13 (m, 1H), 3.03-2.97 (m, 1H), 2.90-2.83 (m, 1H), 
2.66-2.58 (m, 1H), 2.55 (s, 3H), 2.20-2.13 (m 1H), 1.36-1.24 (m, 6H), 0.87-0.75 (m, 6H); 
13C NMR (150 MHz, CDCl3) δ; 170.53, 170.50, 170.06,, 157.77, 157.64, 157.40, 157.30, 
137.07-136.97, 136.45, 130.34, 130.16, 128.79-128.60, 127.98, 127.81, 127.56, 
127.43, 114.80, 114.77, 69.93, 69.82, 67.68, 64.95, 62.88, 62.83, 62.70, 62.66, 53.84, 
46.66, 45.63, 37.03, 34.89, 29.78, 29.54, 25.82, 19.66, 18.51,  25.71, 19.56, 18.41, 
16.55-16.47; 31P NMR (162 MHz, CDCl3) δ 25.01, 24.95, 24.86; HRMS calculated for 
C49H59N3O9P (M+H
+) 864.3984 found 864.4500. 
 
Diethyl N-(N-methyl-L-valyl-L-tyrosyl)-1-amino-2-(4-hydoxyphenyl)ethyl phosphonate (II-
3d).  
  Synthesized using diethyl N-(N-benzyloxycarbonyl-N-methyl-L-valyl-O-benzyl-L-
tyrosyl)-1-amino-2-(4-benzyloxyphenyl)ethyl phosphonate II-3c (134 mg, 0.155 mmol), 
Pd/C (10% Pd, 14 mg) in methanol (3 mL) using method C, to yield a mixture of 
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diastereomers. White solid.  Yield: 69 mg, 81.0%. 1H NMR (600 MHz, MeOD) δ 6.97 (t, 
J = 8.5 Hz, 4H), 6.58 (dd, J = 15.4, 8.5 Hz, 4H), 4.61 (q, J = 7.5, 4.6 Hz, 1H), 4.45-4.39 
(m, 1H), 4.08-4.01 (m, 4H), 3.06-3.00 (m, 1H), 2.86 (dd, J = 14.0, 5.3 Hz, 1H), 2.71-2.64 
(m, 1H), 2.59 (dd, J = 14.0, 9.8 Hz, 1H),  2.52 (d, J = 6.8 Hz, 1H), 1.87 (s, 3H), 1.65-
1.59 (m, 1H), 1.20-1.14 (m, 6H), 0.71 (d, J = 6.8 Hz, 3H), 0.64 (d, J = 6.8 Hz, 3H); 13C 
NMR (150 MHz, MeOD) δ 175.37, 173.31, 173.29, 157.32, 157.29, 131.38, 131.05, 
128.86, 128.78, 116.25, 116.14, 71.45, 64.21-64.16, 55.16, 48.00, 39.03, 32.59, 19.63, 
19.20, 16.88-16.76; 31P NMR (162 MHz, MeOD) δ 25.57, 25.40; HRMS calculated for 
C27H41N3O7P (M+H
+) 550.2677 found 550.2920. 
 
15-B-2: N-(N-methyl-L-valyl-L-tyrosyl)-1-amino-2-(4-hydoxyphenyl)ethyl phosphonic 
acid (II-3).  
  Synthesized using diethyl N-(N-methyl-L-valyl-L-tyrosyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate II-3d (31.2 mg, 0.0599 mmol), acetonitrile (6 mL), 
thioanisole (0.6 mL) and I-TMSi (3.0 mL) using method D.  The phosphonate 
trimethylsilyl ester was hydrolyzed by treatment with 8:2 methanol in water (30 mL). 
Purified by HPLC, using a gradient of 5% acetonitrile in water to 25% acetonitrile in 
water containing ammonium acetate (10 mM) over 30 minutes. White solid.  Yield: 3.01 
mg, 10.2%.  1H NMR (600 MHz, D2O pD = 11.9) δ 7.13 (d, J = 7.9 Hz, 4H), 6.76 (d, J = 
8.5 Hz, 2H), 6.72 (d, J = 8.5 Hz, 2H),  4.65-4.61 (m, 1H),4.05-4.00 (m, 1H), 3.21-3.16 
(m, 2H), 2.65-2.56 (m, 3H), , 1.71 (s, 3H), 1.64-1.58 (m, 1H), 0.74 (d, J = 6.8 Hz, 3H), 
0.59 (d, J = 6.8 Hz, 3H); 13C NMR (150 MHz, , D2O pD = 11.9) δ 174.03, 171.61, 
171.57, 155.60, 153.92, 131.11, 130.52, 130.33, 128.03, 115.79, 115.10, 69.37, 54.21, 
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51.91, 50.99, 36.96, 36.37, 32.66, 30.71, 18.27, 18.19; 31P NMR (162 MHz, D2O pD = 
11.9) δ 16.47; HRMS calculated for C23H33N3O7P (M+H
+) 494.2039 found 494.2039. 
 
N-acetyl-L-isoleucyl-L-leucine methyl ester (II-4a).  
  Synthesized using N-acetyl-L-isoleucine II-12 (112 mg, 0.65 mmol), L-leucine 
methyl ester hydrochloride II-13 (99 mg, 0.68 mmol), HOBt (104 mg, 0.68 mmol), EDC 
(130 mg, 0.68 mmol) and 2,4,6-trimethylpyridine (172 L, 1.30 mmol) in DMF (5 mL) 
using method A. White solid. Yield: 130 mg, 69%.  1H NMR (600 MHz, CDCl3) δ 6.89 (d, 
J = 7.4 Hz, 1H), 6.60 (d,  J = 8.8 Hz, 1H) 4.57-4.52 (m, 1H), 4.40 (q, J = 0.8, 7.9 Hz, 
1H), 3.72 (s, 3H), 2.00 (s, 3H), 1.84-1.76 (m, 1H), 1.65-1.60 (m, 2H), 1.60-1.51 (m, 2H), 
1.19-1.09 (m, 1H), 0.96-0.85 (m, 12H); 13C NMR (150 MHz, CDCl3) δ 173.12, 171.66, 
170.17, 57.564, 52.27, 50.99, 41.11, 37.73, 25.10, 24.88, 23.25, 22.81, 21.96, 15.22, 
11.37; HRMS calculated for C15H29N2O4 (M+H
+) 301.2122 found 301.2284. 
 
N-acetyl-L-isoleucyl-L-leucine (II-4b).  
  Synthesized using N-acetyl-L-isoleucyl-L-leucine methyl ester II-4a (67.6 mg, 
0.225 mmol), acetonitrile (12 mL) and 3% Na2CO3 (20 mL) using method B. Clear oil. 
Yield: 51.0 mg, 79.1%. 1H NMR (600 MHz, DMSO-d6) δ 4.24-4.16 (m, 2H), 1.84 (s, 3H), 
1.71-1.66 (m, 1H), 1.65-1.57 (m, 1H), 1.57-1.51 (m, 1H), 1.50-1.45 (m, 1H), 1.45-1.38 
(m, 1H), 1.10-1.02 (m, 1H), 0.90-0.86 (m, 3H), 0.86-0.75 (m, 9H); 13C NMR (150 MHz, 
DMSO-d6) δ 173.93, 171.42, 171.34, 169.09, 169.01, 56.52-56.39, 50.22, 50.13, 39.84, 
36.81, 36.79, 24.33, 24.28, 22.86, 22.49, 22.44, 21.37, 15.28, 10.99; HRMS calculated 
for C14H27N2O4 (M+H
+) 287.1966 found 287.2097. 
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Diethyl N-(N-acetyl-L-isoleucyl-L-leucyl)-1-amino-2-(4-benzyloxyphenyl)ethyl 
phosphonate (II-4c).  
  Synthesized using N-acetyl-L-isoleucyl-L-leucine II-4b (80 mg, 0.28 mmol), 
diethyl 1-amino-2-(4-benxyloxyphenyl)ethylphosphonate II-8 (105 mg, 0.29 mmol), 
HOBt (44 mg, 0.29 mmol), EDC  (56 mg, 0.29 mmol) and 2,4,6-trimethylpyridine (74 L, 
0.56mmol) in DMF (3 mL) using method A. The product was further purified by flash 
chromatography (4% methanol in DCM, Rf = 0.15) to give a mixture of diastereomers. 
White solid. Yield: 112 mg, 63.3%.  1H NMR (600 MHz, CDCl3) δ 7.44-7.27 (m, 5H), 
7.17 (d, J = 8.58 Hz, 1H), 7.14 (d, J = 8.58 Hz, 1H), 6.87 (d, J = 8.64 Hz, 1H), 6.79 (d, J 
= 8.64 Hz, 1H), 5.01-4.97 (m, 1H), 4.94-4.88 (m, 1H), 4.87-4.82 (m, 0.5H), 4.71-4.56 (m, 
1.5H), 4.46-4.36 (m, 1H), 4.15-3.97 (m, 4H), 3.22 (dt, J= 14.2 Hz, 0.5H), 3.16-3.10 (m, 
0.5H), 2.93-2.81 (m, 1H), 2.05 (s, 1.5H), 1.98 (s, 1.5H), 1.79-1.71 (m, 1H), 1.71-1.58 (m, 
1H), 1.55-1.49 (m, 1.5H), 1.41-1.35 (m, 0.5H),  1.32-1.22 (m, 6H), 1.20-1.15 (m, 1H), 
1.14-1.06 (m, 1H), 1.04-0.96 (m, 0.5H), 0.91-0.79 (m, 9H), 0.74-0.66 (m, 3H);3C NMR 
(150 MHz, CDCl3) δ 172.02-1.71.99, 171.52, 171.28, 170.39, 170.28, 157.83, 157.65, 
137.06, 130.31, 130.13, 129.53-129.20, 128.66, 128.57, 128.05, 127.95, 127.55, 
127.44, 114.79, 114.76, 70.05, 69.86, 62.99, 62.94, 62.63-62.46, 57.78, 51.62, 51.35, 
47.29, 47.21, 46.26, 46.18, 42.61, 42.00, 37.84, 37.72, 34.86, 34.62, 29.78, 29.39, 
24.48, 24.47, 23.27, 23.05, 22.95, 22.84, 22.63, 22.17, 16.64-16.40, 15.34, 11.49, 
11.41; 31P NMR (162 MHz, CDCl3) δ 23.88, 23.69; HRMS calculated for C33H51N3O7P 
(M+H+) 632.3460 found 632.3539. 
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Diethyl N-(N-acetyl-L-isoleucyl-L-leucyl)-1-amino-2-(4-hydoxyphenyl)ethyl phosphonate 
(II-4d).  
  Synthesized diethyl N-(N-acetyl-L-isoleucyl-L-leucyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate II-4c (49 mg, 0.078 mmol Pd/C (10% Pd, 5 mg) in 
methanol (1 mL) using method C, to yield a mixture of diastereomers. White solid.  
Yield: 33 mg, 78.0%. 1H NMR (600 MHz, MeOD) δ 6.94 (dd, J = 8.5, 4.8 Hz, 2H), δ 6.59 
(dd, J = 11.6, 8.5 Hz, 2H) 4.48-4.40 (m, 1H), 4.38-4.32 (m, 0.5H), 4.28-4.24 (m, 0.5H), 
4.12-3.99 (m, 5H),   3.08-2.98 (m, 1H), 2.75-2.64 (m, 1H), 1.91 (s, 1.5H), 1.90 (s, 1.5H), 
1.75-1.64 (m 1H), 1.60-1.50 (m, 1H), 1.48-1.33 (m, 2H), 1.28-1.20 (m, 6H), 1.17-1.10 
(m, 2H), 0.89-0.76 (m, 9H), 0.75-0.68 (m, 3H); 13C NMR (150 MHz, MeOD) δ 174.36, 
174.04, 173.42-173.29, 158.21, 157.96, 131.13, 130.94, 128.51-128.15, 116.56, 116.52, 
64.16, 64.12, 59.41, 59.37, 52.73, 52.68, 47.85, 42.56, 42.17, 37.79, 37.71, 35.03, 
34.90, 26.07, 25.95, 25.55, 25.52, 23.40, 23.22, 22.41, 22.20, 21.94, 16.89-16.67, 
15.98, 15.93, 11.30, 11.24; 31P NMR (121 MHz, MeOD) δ25.94, 25.71; HRMS 
calculated for C26H45N3O7P (M+H
+) 542.2995 found 542.3144. 
 
SF2513 B: N-(N-acetyl-L-isoleucyl-L-leucyl)-1-amino-2-(4-hydoxyphenyl)ethyl 
phosphonic acid (II-4)  
  Synthesized using diethyl N-(N-acetyl-L-isoleucyl-L-leucyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate II-4d (34.1 mg, 0.063 mmol), acetonitrile (6 mL), 
thioanisole (0.6 mL) and I-TMSi (3.0 mL) using method D.  The phosphonate 
trimethylsilyl ester was hydrolyzed by treatment with 8:2 methanol in water (30 mL). 
Purified by HPLC, using a gradient of 5% acetonitrile in water to 25% acetonitrile in 
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water containing ammonium acetate (10 mM) over 30 minutes. White solid.  Yield: 4.85 
mg, 15.8%.  1H NMR (600 MHz, D2O) δ 7.15 (d, J = 8.5 Hz, 2H), 6.78 (2, J = 8.5 Hz, 
2H), 4.37 (dd, J = 10.6, 4.6 Hz, 1H), 4.18 (m, 1H), 3.98 (d, J = 8.6 Hz, 1H), 3.18 (dt, J = 
11.3, 3.1 Hz, 1H), 2.66 (td, J = 13.2 6.2 Hz, 1H), 2.02 (s, 3H), 1.73-1.65 (m, 1H), 1.60-
1.53 (m, 1H), 1.52-1.46 (m, 1H), 1.45-1.39 (m, 2H), 1.15-1.07 (m, 1H), 0.90 (d, J = 6.6 
Hz, 3H), 0.84 (m, 6H), 0.65 (d, J = 6.8 Hz, 3H); 13C NMR (150 MHz, D2O) δ 173.97 
173.12, 173.09, 172.79, 153.76, 130.30, 130.10, 130.00, 115.05, 58.47, 51.63, 50.54, 
49.57, 40.27, 35.81, 34.65, 24.61, 23.98, 21.46, 20.48, 14.52, 9.94; 31P NMR (162 MHz, 
D2O) δ 18.66; HRMS calculated for C22H37N3O7P (M+H
+) 486.2364 found 486.2533.   
 
N-acetyl-L-isoleucyl-L-phenylalanine methyl ester (II-5a).  
  Synthesized using N-acetyl-L-isoleucine II-12 (112 mg, 0.65 mmol), L-
phenylalanine methyl ester hydrochloride II-10 (104 mg, 0.68 mmol), HOBt (104 mg, 
0.68 mmol), EDC  (130 mg, 0.68 mmol) and 2,4,6-trimethylpyridine (172 L, 1.30 mmol) 
in DMF (5 mL) using method A. White solid. Yield: 153 mg, 73.7%. 1H NMR (400 MHz, 
CDCl3) δ 7.30-7.20 (m, 3H), 7.10 (d, J = 7.1 Hz, 2H), 6.62 (d,  J = 7.4 Hz, 1H), 6.33 (d, J 
= 8.5 Hz, 1H),  4.85 (q, J = 6.8 Hz, 1H), 4.32 (t, J = 8.2 Hz, 1H), 3.70 (s, 3H), 3.09 (ddd, 
J =19.8, 13.9, 6.2 Hz, 2H), 1.98 (s, 3H), 1.81-1.73 (m, 1H), 1.53-1.43 (m, 1H), 1.15-1.04 
(m, 1H) 0.96-0.84 (m, 6H); 13C NMR (100 MHz, CDCl3) δ 171.54, 171.03, 169.94, 
135.60, 129.19, 128.57, 127.12, 57.53, 53.25, 52.25, 37.83, 37.47, 24.90, 23.11, 15.12, 
11.23; HRMS calculated for C18H27N2O4 (M+H
+) 335.1966 found 335.2163. 
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N-acetyl-L-isoleucyl-L-phenylalanine (II-5b).  
  Synthesized using N-acetyl-L-isoleucyl-L-phenylalanine methyl ester II-5a (220 
mg, 0.658 mmol), acetonitrile (38 mL) and 3% Na2CO3 (57 mL) using method B. White 
solid. Yield: 171.0 mg, 80.7%. 1H NMR (600 MHz, DMSO-d6) δ 7.24-7.15 (m, 5H), 4.40-
4.36 (m, 1H), 4.20-4.16 (m, 1H), 3.02 (dd, J = 13.8, 5.2 Hz, 1H), 2.87 (dd, J = 13.9, 9.1 
Hz, 1H), 1.79 (s, 3H), 1.66-1.61 (m, 1H), 1.37-1.33 (m, 1H), 1.03-0.98 (m, 1H), 0.78-
0.73 (m, 6H); 13C NMR (150 MHz, DMSO-d6) δ 172.75, 171.22, 171.14, 168.98, 168.87, 
137.56, 129.01, 129.11, 126.37, 56.46-56.36, 53.32, 53.23, 36.67-36.54, 24.15, 22.45, 
22.40, 15.22, 10.93; HRMS calculated for C17H25N2O4 (M+H
+) 321.1809 found 
321.2011. 
 
Diethyl N-(N-acetyl-L-isoleucyl-L-phenylalanyl)-1-amino-2-(4-benzyloxyphenyl)ethyl 
phosphonate (II-5c).  
  Synthesized using N-acetyl-L-isoleucyl-L-phenylalanine II-5b (117 mg, 0.365 
mmol), diethyl 1-amino-2-(4-benxyloxyphenyl)ethylphosphonate II-8 (139 mg, 0.384 
mmol), HOBt (58.7 mg, 0.384 mmol), EDC  (73.3mg, 0.384 mmol) and 2,4,6-
trimethylpyridine (95.6 L, 0.73 mmol) in DMF (5 mL) using method A. The product was 
further purified by flash chromatography (4% methanol in DCM, Rf = 0.15) to give a 
mixture of diastereomers. White solid. Yield: 175 mg, 72.1 %. 1H NMR (600 MHz, 
CDCl3) δ 7.38-6.79(m, 14H), 5.05-5.00 (m, 1H), 4.97-4.90 (m, 2H), 4.70-4.62 (m, 1H), 
4.38-4.32 (m, 1H), 4.15-3.91 (m, 4H), 3.18-3.11 (m, 1H), 3.05-3.00 (m, 0.5H), 2.90-2.65 
(m, 2.5H), 2.01 (m, 1.5H), 2.00 (m, 1.5H), 1.76-1.67 (m, 1H), 1.50-1.42 (m, 1H), 1.32-
1.23 (m, 6H), 1.11-0.99 (m, 1H), 0.85-0.78 (m, 4.5H), 0.76-0.70 (m, 1.5H); 13C NMR 
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(150 MHz, CDCl3) δ171.55, 171.20, 170.95-170.81, 170.40, 170.26, 157.97, 157.66, 
137.04, 137.00, 136.44, 136.22, 130.58, 130.14, 129.58, 129.52, 129.36-129.18, 
128.58, 128.39, 128.25, 127.96, 127.48, 127.44, 126.75, 114.95, 114.76, 70.08, 69.87, 
63.14-62.42, 57.91, 57.83, 53.64, 53.45, 47.48, 47.30, 46.45, 46.26, 38.93, 38.83, 
37.58, 37.46, 35.04, 34.83, 25.16, 25.08, 23.09, 23.04, 16.63-16.44, 15.46, 15.34, 
11.43, 11.38; 31P NMR (121 MHz, CDCl3) δ 23.88, 23.68; HRMS calculated for 
C26H49N3O7P (M+H
+) 666.3303 found 666.3700.   
 
Diethyl N-(N-acetyl-L-isoleucyl-L-phenylalanyl)-1-amino-2-(4-hydoxyphenyl)ethyl 
phosphonate (II-5d).   
  Synthesized using diethyl N-(N-acetyl-L-isoleucyl-L-phenylalanyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate II-5c (248 mg, 0.37 mmol), Pd/C (10% Pd, 25 mg) 
in methanol (5 mL) using method C, to yield a mixture of diastereomers. White solid.  
Yield: 169 mg, 79.0%.  1H NMR (600 MHz, MeOD) δ 7.27-7.13 (m, 4H), 7.12-6.98 (m, 
3H), 6.70 (dd, J = 23.8, 8.5 Hz, 2H), 4.68-4.62 (m, 1H), 4.57-4.51 (m, 1H), 4.20-4.05 (m, 
5H), 3.16-3.08 (m, 1H), 3.05 (dd, J = 14.0, 5.2 Hz, 0.5H), 2.84-2.70 (m, 1.5H), 2.54 (dd, 
J = 14.2, 9.5 Hz, 0.5H), 1.95 (s, 1.5H), 1.93 (s, 1.5H), 1.71-1.66 (m, 1H), 1.36-1.29 (m, 
6H), 1.10-1.02 (m, 1H), 0.83 (t, J = 7.3 Hz, 3H), 0.79 (d, J = 6.8 Hz, 1.5H), 0.70 (d, J = 
6.8 Hz, 1.5 H); 13C NMR (150 MHz, MeOD) δ 173.30, 173.25, 173.17, 157.52, 157.31, 
138.21, 138.13, 131.33, 131.00, 130.41, 130.35, 129.39, 129.27, 129.00, 128.90, 
127.68, 127.57, 116.34, 116.29, 64.51, 64.46, 64.23-64.11, 59.52, 59.40, 55.27, 55.03, 
54.80, 48.15, 48.05, 39.29, 39.05, 37.65, 37.61, 35.17, 35.06, 25.84, 25.75, 22.47, 
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16.90-16.73, 15.85, 11.31, 11.25; 31P NMR  (162 MHz, MeOD) δ 26.93, 26.84; HRMS 
calculated for C29H43N3O7P (M+H
+) 576.2834 found 576.3109. 
 
SF2513C: N-(N-acetyl-L-isoleucyl-L-phenylalanyl)-1-amino-2-(4-hydoxyphenyl)ethyl 
phosphonic acid (II-5). 
  Synthesized using diethyl N-(N-acetyl-L-isoleucyl-L-phenylalanyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate II-5d (32.6 mg, 0.057 mmol), acetonitrile (6 mL), 
thioanisole (0.6 mL) and I-TMSi (3.0 mL) using method D.  The phosphonate 
trimethylsilyl ester was hydrolyzed by treatment with 8:2 methanol in water (30 mL). 
Purified by HPLC, using a gradient of 5% acetonitrile in water to 25% acetonitrile in 
water containing ammonium acetate (10 mM) over 30 minutes. White solid.  Yield: 5.15 
mg, 17.5%.  1H NMR (600 MHz, D2O) δ 7.34-7.25 (m, 3H), 7.23 (d, J = 6.9 Hz, 2H), 
7.15 (d, J = 8.5 Hz, 2H), 6.77 (d, J = 8.5 Hz, 2H), 4.64 (dd, J = 10.4, 4.1 Hz, 1H), 4.25-
4.18 (m, 1H), 3.93 (d, J = 8.6 Hz, 1H), 3.19 (dt, J = 14.2, 3.1 Hz, 1H), 3.12 (dd, J = 14.1 
Hz, 4.1 Hz, 1H), 2.76 (dd, J = 14.0, 10.4 Hz, 1H), 2.71-2.65 (m, 1H), 1.94 (s, 3H), 1.61-
1.55 (m, 1H), 1.29-1.22 (m, 1H), 1.02-0.96 (m, 1H), 0.78 (t, J = 7.4 Hz, 3H) 0.58 (d, J = 
6.8 Hz, 3H); 13C NMR (150 MHz, D2O) δ 173.47, 172.35, 171.58, 153.79, 136.52, 
130.26, 130.10-130.00, 129.27, 128.38, 115.05, 58.00, 53.76, 50.59, 49.62, 37.74, 
35.89, 34.75, 24.35, 21.56, 14.42, 9.93; 31P NMR (162 MHz, D2O) δ 18.69; HRMS 
calculated for C25H38N3O7P (M+H
+) 520.2208 found 520.2441.  
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Diethyl N-(N-fluorenylmethyloxycarbonyl-L-glutamyl-5-tert-butyl ester)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (II-7b).  
  Synthesized using N-fluorenylmethyloxycarbonyl-glutamate-5-tert-butyl ester II-
7a (252 mg, 0.593 mmol), diethyl 1-amino-2-(4-benxyloxyphenyl)ethylphosphonate II-8 
(225 mg, 0.620 mmol), HOBt (94.9 mg, 0.620 mmol), EDC  (119 mg, 0.620 mmol) and 
2,4,6-trimethylpyridine (158 L, 1.19 mmol) in DMF (6 mL) using method A.  The 
reaction was dissolved in ethyl acetate and extracted with 1N citric acid, 1N NaHCO3, 
and brine.  The organic layer was then dried over MgSO4, and then the product was 
further purified by flash chromatography (5% methanol in DCM, Rf = 0.21) to give a 
mixture of diastereomers. White solid. Yield: 360 mg, 78.8%. 1H NMR (600 MHz, CDCl3) 
δ 7.41-7.27 (m, 5H), 7.12 (dd, J = 13.2, 8.6 Hz, 2H), 6.87 (d, J = 8.6 Hz, 1H), 6.81 (d, J 
= 8.6 Hz, 1H), 5.00 (s, 1H), 4.95 (s, 1H), 4.70- 4.59 (m, 1.5H), 4.58-4.53 (m, 0.5H), 
4.39- 4.34 (m, 1H), 415-4.02 (m, 4H), 3.22-3.13 (m, 1H), 2.87-2.77 (m, 1H), 2.23 (t, J = 
7.7 Hz, 1H), 2.04 (s, 1.5H), 2.00 (s, 1.5H), 1.96-1.85 (m, 2H), 1.79-1.69 (m, 1.5H), 1.65-
1.58 (m, 0.5H), 1.52-1.43 (m, 1H), 1.39 (s, 9H), 1.31-1.22 (m, 6H), 1.13-1.04 (m, 1H), 
0.89-0.82 (m, 4.5H), 0.77 (d, J = 7.7 Hz, 1H);13C NMR (600 MHz, CDCl3) δ171.91, 
172.80, 171.55, 171.31, 170.90, 170.87, 170.59, 170.34, 158.00, 157.86, 137.32, 
137.24, 130.37, 130.26, 129.39-129.08, 128.74, 128.71, 128.12, 128.08, 127.65, 
127.62, 115.07, 114.94, 80.93, 70.11, 70.06, 63.17-62.71, 57.99, 57.86, 52.42, 52.33, 
47.51, 47.40, 46.48, 46.37, 34.93, 34.82, 31.51, 31.43, 28,67, 28.56, 28.27, 25.43, 
25.37, 23.34, 23.33, 16.71-16.57, 15.61, 15.46,11.68; 31P NMR (162 MHz, D2O) δ 
23.79, 23.61; HRMS calculated for C36H55N3O9P (M+H
+) 704.3671 found 704.3667. 
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Diethyl N-(L-glutamyl-5-tert-butyl ester)-1-amino-2-(4-benzyloxyphenyl)ethyl 
phosphonate (II-7c).  
  Synthesized using diethyl N-(N-fluorenylmethyloxycarbonyl-L-glutamyl-5-tert-
butyl ester)-1-amino-2-(4-benzyloxyphenyl)ethyl phosphonate II-7b (150 mg, 0.194 
mmol) using method E.  Clear oil.  Yield: 65.0 mg, 60.5%.  1H NMR (400 MHz CDCl3) δ 
7.43-7.25 (m, 5H), 7.12 (dd, J = 8.7, 2.4 Hz, 2H), 6.87 (dd, J = 8.5, 6.4 Hz, 2H), 5.01 (d, 
J = 2.1 Hz, 2H), 4.71-4.60 (m, 1H), 4.18-4.04 (m, 4H), 3.32-3.27 (m, 0.5H), 3.25-3.17 
(m, 1.5H), 2.89-2.76 (m, 1H), 2.30-2.15 (m, 1H), 2.07 (t, J = 7.4 Hz, 1H), 1.96-1.86 (m, 
0.5H), 1.86-1.66 (m, 1H), 1.62-1.52 (m, 0.5H), 1.41 (d, J = 3.3 Hz, 9H), 1.33-1.26 (m, 
6H); 13C NMR (100 MHz, CDCl3) δ 173.88-173.78, 172.59, 172.57, 157.58, 157.52, 
136.96, 136.93m 130.08, 130.03, 128.94-128.75, 128.43, 128.40, 1287.81, 127.76, 
127.37, 127.31, 114.66, 80.37, 80.33, 69.82, 62.54-62.35, 54.39, 54.32, 46.58, 46.52, 
45.03, 44.98, 34.75-34.56, 31.47, 31.42, 30.03, 29.88, 27.96, 16.37-16.25; 31P NMR 
(162 MHz, D2O) δ 25.51, 25.43; HRMS calculated for C28H42N2O7P (M+H
+) 549.2725 
found 549.2750. 
 
Diethyl N-(N-acetyl-L-isoleucyl-L-glutamyl-5-tert-butyl ester)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (II-7d).  
  Synthesized using N-acetyl isoleucine II-12 (20.2 mg, 0.118 mmol), diethyl N-(L-
glutamyl-5-tert-butyl ester)-1-amino-2-(4-benzyloxyphenyl)ethyl phosphonate 7c (62.0 
mg, 0.113 mmol), HOBt (18 mg, 0.118 mmol), EDC  (22.6 mg, 0.118 mmol) and 2,4,6-
trimethylpyridine (36 L, 0.23 mmol) in DMF (2 mL) using method A. The reaction was 
dissolved in ethyl acetate and extracted with 1N citric acid, 1N NaHCO3, and brine.  The 
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organic layer was then dried over MgSO4, and then the product was further purified by 
flash chromatography (5% methanol in DCM, Rf = 0.23) to give a mixture of 
diastereomers. White solid. Yield: 60 mg, 75.4%. 1H NMR (600 MHz, CDCl3) δ 7.41-7.27 
(m, 5H), 7.12 (dd, J = 13.2, 8.6 Hz, 2H), 6.87 (d, J = 8.6 Hz, 1H), 6.81 (d, J = 8.6 Hz, 
1H), 5.00 (s, 1H), 4.95 (s, 1H), 4.70- 4.59 (m, 1.5H), 4.58-4.53 (m, 0.5H), 4.39- 4.34 (m, 
1H), 415-4.02 (m, 4H), 3.22-3.13 (m, 1H), 2.87-2.77 (m, 1H), 2.23 (t, J = 7.7 Hz, 1H), 
2.04 (s, 1.5H), 2.00 (s, 1.5H), 1.96-1.85 (m, 2H), 1.79-1.69 (m, 1.5H), 1.65-1.58 (m, 
0.5H), 1.52-1.43 (m, 1H), 1.39 (s, 9H), 1.31-1.22 (m, 6H), 1.13-1.04 (m, 1H), 0.89-0.82 
(m, 4.5H), 0.77 (d, J = 7.7 Hz, 1H);13C NMR (600 MHz, CDCl3) δ171.91, 172.80, 
171.55, 171.31, 170.90, 170.87, 170.59, 170.34, 158.00, 157.86, 137.32, 137.24, 
130.37, 130.26, 129.39-129.08, 128.74, 128.71, 128.12, 128.08, 127.65, 127.62, 
115.07, 114.94, 80.93, 70.11, 70.06, 63.17-62.71, 57.99, 57.86, 52.42, 52.33, 47.51, 
47.40, 46.48, 46.37, 34.93, 34.82, 31.51, 31.43, 28,67, 28.56, 28.27, 25.43, 25.37, 
23.34, 23.33, 16.71-16.57, 15.61, 15.46,11.68; 31P NMR (162 MHz, D2O) δ 23.79, 
23.61; HRMS calculated for C36H55N3O9P (M+H
+) 704.3671 found 704.3667. 
 
Diethyl N-(N-acetyl-L-isoleucyl-L-glutamyl-5-tert-butyl ester)-1-amino-2-(4-
hydroxyphenyl)ethyl phosphonate (II-7e).  
  Synthesized using diethyl N-(N-acetyl-L-isoleucyl-L-glutamyl-5-tert-butyl ester)-1-
amino-2-(4-benzyloxyphenyl) ethyl phosphonate II-7d (54 mg, 0.077 mmol), Pd/C (10% 
Pd, 6 mg) in methanol (2 mL) using method C, to yield a mixture of diastereomers.  
White solid. Yield: 41.4 mg,, 88.0%. 1H NMR (600 MHz, MeOD) δ 7.08 (t, J = 7.4 Hz, 
2H), 6.71 (dd, J = 13.9, 8.4 Hz, 4.62-4.52 (m, 1H), 4.47-4.36 (m, 1H), 4.24-4.13 (m, 4H), 
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3.20-3.10 (m, 1H), 2.86-2.74 (m, 1H), 2.33-2.27 (m, 1H), 2.03 (d, J = 2.60 Hz, 3H), 1.90-
1.72 (m, 2H), 1.64-1.52 (m, 1H), 1.47 (d, J = 3.8 Hz, 9H), 1.39-1.32 (m, 6H), 1.28-1.11 
(m, 1H), 0.98-0.89 (m, 4.5H), 0.81 (d, J = 6.8 Hz, 1.5 H); 13C NMR (150 MHz, MeOD) δ 
173.93, 173.80, 173.44-173.42, 172.94-172-80, 157.55, 157.27, 131.09. 130.92, 
128.94-128.61, 116.28, 116.26, 81.72, 81.66, 64.47-64.04, 59.40, 53.34, 53.30, 47.66, 
47.63, 37.82, 37.80, 35.07, 34.87, 32.28, 32.15, 29.08, 28.73, 28.33, 26.10, 25.99, 
22.46, 22.44, 16.90-16.70, 15.97, 15.88; 31P NMR (162 MHz, MeOD) δ 25.58, 25.51; 
HRMS calculated for C29H49N3O9P (M+H
+) 614.3206 found 614.3263. 
 
Diethyl N-(N-acetyl-L-isoleucyl-L-glutamyl)-1-amino-2-(4-hydroxyphenyl) ethyl 
phosphonate (II-7f).  
  Synthesized using diethyl N-(N-acetyl-L-isoleucyl-L-glutamyl-5-tert-butyl ester)-1-
amino-2-(4-hydroxyphenyl)ethyl phosphonate II-7e (73.0 mg, 0.119 mmol) using method 
F, to yield a mixture of diastereomers. White solid.  Yield: 50.2 mg, 75.8%.  1H NMR 
(600 MHz, MeOD) δ 6.88 (t, J = 8.8 Hz, 2H), 6.51 (dd, J = 19.3, 8.4 Hz, 2H), 4.39-4.32 
(m, 1H), 4.27-4.19 (m, 1H), 4.05-3.93 (m, 5H), 2.99-2.90 (m, 1H), 2.66-2.56 (m, 1H), 
2.23-2.11 (m, 1H), 1.99-1.86 (m, 1H), 1.82 (d, J = 4.7 Hz, 3H), 1.72-1.56 (m, 2H), 1.46-
1.27 (m, 2H), 1.20-1.13 (m, 6H), 1.08-0.94 (m, 1H), 0.76-0.70 (m, 4.5H), 0.61 (d, J = 6.8 
Hz, 1.5H); 13C NMR (150 MHz, MeOD) δ 176.57, 176.47, 173.56-173.49, 173.00, 
172.90, 157.44, 157.27, 131.16, 130.97, 128.98-128.74, 116.35, 116.29, 64.50, 64.15, 
29.54, 53.46, 53.43, 48.08, 48.01, 37.76, 37.74, 35.01, 34.90, 30.83, 30.58, 28.96, 
28.59, 28.11, 28.01, 22.39, 16.88-16.66, 15.96, 15.88, 11.36, 11.33; 31P NMR (162 MHz, 
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MeOD) δ 24.28, 24.13; HRMS calculated for C25H31N3O9P (M+H
+) 558.2575 found 
558.2586. 
 
SF2513 D: N-(N-acetyl-L-isoleucyl-L-glutamyl)-1-amino-2-(4-hydroxyphenyl) 
phosphonic acid (II-7).  
  Synthesized using diethyl N-(N-acetyl-L-isoleucyl-L-glutamyl)-1-amino-2-(4-
hydroxyphenyl) ethyl phosphonate II-7f (15.1 mg, 0.0271 mmol), acetonitrile (2 mL), 
thioanisole (0.2 mL) and I-TMSi (1.0 mL) using method D.  The phosphonate 
trimethylsilyl ester was hydrolyzed by treatment with 8:2 isopropanoll in water (10 mL). 
Purified by HPLC using an isocratic method of 5% acetonitrile in water containing 
ammonium acetate (10 mM) for 10 minutes to yield a mixture of diastereomers. White 
solid.  Yield: 5.15 mg, 17.5%.  1H NMR (600 MHz, D2O) δ 7.19-7.13 (m, 2H), 6.84-6.76 
(m, 2H), 4.39-4.23 (m, 1.5H), 4.22-4.15 (m, 0.5H), 4.13-4.08 (m, 0.5H), 4.03-3.97 (m, 
0.5H), 3.25-3.14 (m, 1H), 2.79-2.63 (m, 1H), 2.43-2.18 (m, 1.5H), 2.04 (s, 3H), 1.86-
1.77 (m, 1H), 1.73-1.62 (m, 1H), 1.58-1.1.50 (m, 0.5H), 1.49-1.35 (m, 1H), 1.24-1.14 (m, 
1H), 1.14-1.06 (m, 0.5H), 0.91-0.82 (m, 4.5H), 0.66-0.62 (m, 1.5H); 13C NMR (150 MHz, 
D2O) δ 179.27, 177.92, 174.39-171.96, 153.96, 153.78, 130.33, 130.24, 130.09-129.86, 
115.24, 115.07, 64.19, 58.51, 58.41, 52.88, 52.52, 36.01, 35.93, 34.64, 34.58, 27.85, 
27.35, 24.67, 24.45, 23.61, 21.55, 21.20, 14.67, 14.48, 10.19, 10.07; 31P NMR (162 
MHz, D2O) δ17.55; HRMS calculated for C21H31N3O9P (M-H
+) 500.1803 found 
500.1755. 
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Co-crystallization of K-26 and ACE 
Overexpression and purification of N-domain and C-domain of ACE constructs 
  Both the N- and C-domain ACE constructs were produced by expression in 
cultured CHO cells and purified as previously described.102, 141 
 
Crystallization and data collection  
  The crystals of the C- and N-domain ACE complexes with K-26 were grown at 
16°C by the hanging drop vapor diffusion method. C-domain ACE (11.5 mg/ml in 50 mM 
HEPES, pH 7.5) was pre-incubated with K-26 (II-1) (2 mM) at room temperature for two 
hours before crystallization. Pre-incubated sample was mixed with the reservoir solution 
consisting of 13.5 % PEG 4000, 50 mM sodium acetate, pH 4.7 and 10 µM ZnSO4, and 
suspended above the well. Diffraction quality of co-crystals appeared after 
approximately 10 days. N-domain ACE (5 mg/ml in 50 mM HEPES, pH 7.5) was pre-
incubated with K-26 (II-1) (2 mM) at room temperature for two hours before 
crystallization. Pre-incubated sample was mixed with the reservoir solution consisting of 
30 % PEG 550MME/PEG 20000, 100 mM TRIS/Bicine pH 8.5 and 0.06M divalent 
cations (Molecular Dimensions Ltd, Suffolk, UK), and suspended above the well. 
Crystals appeared within 3 days. X-ray diffraction data for the C- and N-domain ACE-K-
26 complexes were collected on the PX station IO3 at Diamond Light Source (Oxon, 
UK). A total of 100 and 250 images were collected using a Quantum-315 CCD detector 
(ADSC Systems, CA) for the C- and N- domain structures, respectively. 25% PEG 4000 
was used as a cryoprotectant for C-domain ACE while no cryoprotectant was used for 
the N-domain. Crystal was kept at constant temperature (100K) under the liquid 
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nitrogen jet during data collection. Raw data images were indexed and scaled with 
HKL2000 142 and the CCP4 program SCALA143. Initial phasing for structure solution was 
obtained using the molecular replacement routines of the program PHASER 144 The 
atomic coordinates of C-domain ACE (PDB code 108A)133 and N-domain ACE (PDB 
code 3NXQ)102  were used as a search model respectively. The resultant model was 
refined using REFMAC5145 and adjustment of the model was carried out using COOT146 
Water molecules were added at positions where Fo–Fc electron density peaks 
exceeded 3σ and potential H-bonds could be made. Based on electron density 
interpretation, the inhibitor and sugar moieties were added in the complex structure and 
further refinement was carried out. The coordinate and parameter files for K-26 were 
taken from the AnCE-K-26 complex structure (PDB 2XHM)120  and validated through the 
PRODRG server.147 Validation of the protein structure was conducted with the aid of 
MOLPROBITY. 148 The structures presented 98% and 97% residues within the favored 
Ramachandran region for the C-domain and N-domain complexes, respectively. Figures 
were drawn with PyMOL (DeLano Scientific, San Carlos, CA, USA). Hydrogen bonds 
were verified with the program HBPLUS.149 The detailed refinement statistics can be 
found in Table II-6.  
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   B- factor analysis 
 C-domain ACE N-domain ACE  
C-domain 
ACE 
N-domain 
ACE 
Resolution Å 1.85 2.1 
Whole 
protein 
atom 
22.7 43.2/38.2 
Space group P212121 P1 
Main chain 
atom 
22.2 42.9/37.9 
Cell 
a=56.8, b=84.5, 
c=133.4Å 
α=β=γ=90.0° 
a=73.0, b=77.3, 
c=82.0Å 
α=88.7, β=64.5, 
γ=75.2° 
Side chain 
atom 
23.2 43.5/38.5 
No. of molecule in 
ASU 
1 2 Zinc ion 18.7 35.4/37.0 
Redundancy 4.2 (2.7) 1.8 (1.5) 
Chloride 
ion 
23.2 29.3/27.8 
Total/unique  
number of 
reflection 
939,579/55,751 763,835/90,926 Inhibitor 18.4 30.5/31.7 
Completeness (%) 93.3 (65.4) 84.3 (71.7) 
Glycosylat
ed sugar 
45.5 72.7/60.1 
Rsymm
a 
11.9 (57.6) 8.4 (49.9) Solvent 30.6 34.6 
I/σ(I) 10.2 (1.2) 7.8 (1.7) 
RCSB 
PDB code 
4BZR 4BZS 
Rcryst 
b 
21.4 23.5    
Rfree
c 
25.1 27.7    
Rmsd in bond 
length 
0.006 0.005    
Rmsd in bond 
angle 
1.04 0.91    
 
Table II-6. Refinement statistics for crystal structures of K-26 in both C-domain and N-domain ACE. 
Values in parentheses are for last resolution shell. 
a
Rsymm=ΣhΣi[|Ii(h)- <I(h)>|/ΣhΣi Ii(h)], where Ii is the ith 
measurement and <I(h)> is the weighted mean of all the measurements of I(h). 
b
Rcryst =Σh|Fo-
Fc|/ΣhFo,where Fo and Fc are observed and calculated structure factor amplitudes of reflection h, 
respectively. 
c
Rfree is equal to Rcryst for a randomly selected 5% subset of reflections. 
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Assays for ACE inhibition 
Assay for inhibition of somatic ACE with substrate FAPGG  
  Somatic ACE was extracted from rabbit lung acetone powder. Turnover of the 
substrate FAPGG was monitored in triplicate in a 96-well plate in the presence of 
various concentrations of inhibitor by monitoring the corresponding change in 
absorbance at 340 nm.127-128 IC50 was calculated by plotting the percent activity of the 
enzyme against the log of the concentration of the inhibitor. IC50 curves are available in 
Appendix B.  
 
Assay for inhibition of N- and C- domains of ACE with substrate Z-FHL  
  Z-FHL turnover by purified N- and C- domain ACE constructs  was monitored in 
triplicate with using fluorescence as previously described.129-131 IC50 was calculated by 
plotting the percent activity of the enzyme against the log of the concentration of the 
inhibitor. The Ki value was obtained using a Dixon plot by performing the assay at two 
substrate concentrations (initial concentrations of 1mM and 0.2 mM Z-FHL) and plotting 
1/v against the inhibitor concentration. IC50 curves and Dixon plots are available in 
Appendix B. 
 
Assay for inhibition of bacterial dicarboxypeptidases by K-26 and captopril using 
substrate FAPGG  
  Purified dicarboxypeptidase in 50 mM sodium borate buffer containing 5% 
glycerol, pH = 8.3 (60 uL) was diluted to the appropriate concentration for use in the 
assay, combined with the inhibitor of known concentration (60 uL), and incubated for 5 
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minutes. The substrate FAPGG was added (100 uL of 1 mM FAPGG in 50 mM Tris 
buffer, pH 8.0 with 300 mM sodium chloride), and the turnover was monitored in 
triplicate in a 96-well plate by measuring the corresponding change in absorbance at 
340 nm.127-128 IC50 was calculated by plotting the percent activity of the enzyme against 
the log of the concentration of the inhibitor. IC50 curves are available in Appendix B.   
 
Expression and Purification of Bacterial DCPs 
Preparation of pET28_EcDCP and pET28_MR1DCP  
  The genes encoding EcDCP and MR1DCP were amplified by PCR from purified 
genomic DNA from E.coli and Schwanella oneidensis str. MR- 1 using the appropriate 
forward and reverse primers with restriction enzyme sites (Table II-7).  The PCR product 
was TOPO cloned and transformed into TOP10 cells (Invitrogen TOPO cloning kit) Cells 
were plated (LB agar with kanamycin (5 µg/mL) and spread with Xgal (40 uL, 40 mg/mL 
in DMF)) and colonies confirmed to contain the TOPO vector were selected, grown in 
liquid culture (LB with 5µg/mL kanamycin) and the plasmid DNA was harvested 
(QIAprep Spin Miniprep Kit).  The plasmid DNA was digested using the appropriate 
restriction enzymes (New England Biolabs), purified on 1% agarose gel, extracted 
(Qiagen Gel Extraction Kit), and ligated into pET28a(+) treated with the same restriction 
enzymes to give the resulting vector pET28a_DCP, which codes for the bacterial 
dicarboxypeptidase with a N-terminal hexahistidine tag. All products were verified by 
sequencing.   
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 Strain Used Primer Restriction Enzyme 
EcDCP 
Escherichia coli 
st. K-12 
sbstr. MG1655 
Forward 5’-CATATGACAACAATGAATCCTTTCCTTGTGC-3’ NdeI 
Reverse 5’-GGATCCTTATATGTTCAAGCCACGATGTTGC-3’ BamHI 
MR1DCP 
Schwanella 
oneidensis 
str. MR-1 
Forward 5’-CATATGGCTATTCTATTGAATCGTCCC-3’ NdeI 
Reverse 5’- GTCGACTTACCAGCCGCATTGACG-3’ SalI 
 
Table II-7. PCR primers used for the cloning of EcDCP and MR1DCP from the given strain.  Restriction 
enzyme sites are underlined for the corresponding restriction enzyme. 
 
 
 
Preparation of pET28_K26DCP.  
  The K-26 dicarboxypeptidase gene from Astrosporangium hypotensionis was 
synthesized commercially (Mr. Gene) with NdeI and HindIII restriction enzyme sites in a 
generic kanamycin resistant vector. This vector was transformed into TOP10 E. coli 
cells, which were grown on LB agar supplemented with 50 µg/mL of kanamycin. 
Selected colonies were grown in 5 mL cultures of LB broth (with 50 µg/mL of 
kanamycin). Plasmids were harvested from these cells, digested using the appropriate 
restriction enzymes, and the resulting dicarboxypeptidase gene was ligated into an 
empty pET 28a(+) vector digested with the same restriction enzymes, introducing an N- 
terminal hexahistadine tag.  The product was verified by sequencing. 
 
Transformation, Expression and Purification of bacterial dicarboxypeptidase 
  Electrocompetent BL21DE3 E. coli cells were transformed with the pET28_DCP 
vector.   LB media (1L with 50 mg/mL kanamycin) was inoculated (1%) with an overnight 
culture of BL21(DE3) cells containing the desired plasmid. This culture was shaken at 
37oC until an OD600 = 0.6-0.8 was reached. Dicarboxypeptidase expression was 
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induced by the addition of isopropyl β-D-1-thiogalactopyranoside (IPTG, 1mM final 
concentration) and was carried out at 30oC overnight. Cells were harvested via 
centrifugation and frozen at -80 °C for subsequent purification.  The cell pellet from 1L of 
liquid culture was resuspended in 20 mL of buffer A (10 mM imidazole, 50 mM Tris and 
300 mM NaCl, pH 7.4) with DNAse added. Cells were disrupted with a French press 
(three times), centrifuged (12,000 rpm for 20 min) and the supernatant was applied to a 
5 mL HiTrap nickel affinity column (GE Healthcare) equilibrated with buffer A. The 
column was washed with 10 column volumes of buffer A, then the desired His-tagged 
protein was eluted using a gradient of 100% buffer A to 100% buffer B (buffer A 
containing 500 mM imidazole) over 20 minutes. Gradient fractions having an 
absorbance at 280 nm were pooled and concentrated to 1 mL using an Amicon 
centrifugal filter (MWCO 10 kDa). Concentrated protein was desalted using a 5 mL 
HiTrap desalting column and eluted into 50 mM sodium borate buffer containing 5% 
glycerol (pH = 8.3).  The overexpressed bacterial dicarboxypeptidase was immediately 
tested for FAPGG turnover. 
 
Evolutionary relationships of taxa  
  The evolutionary history was inferred using the Neighbor-Joining method.150 The 
optimal tree with the sum of branch length = 6.39523051 is shown (Figure 3). The 
evolutionary distances were computed using the Poisson correction method 151 and are 
in the units of the number of amino acid substitutions per site. The analysis involved 15 
amino acid sequences. All positions containing gaps and missing data were eliminated. 
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There were a total of 548 positions in the final dataset. Evolutionary analyses were 
conducted in MEGA5. 152. 
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CHAPTER III 
 
ACE INHIBITORY ACTIVITY OF A LIBRARY OF K-26 VARIANTS 
 
Introduction 
 Natural products are a rich source of biologically active molecules and scaffolds 
which have widespread medicinal use.153 One such example of a biologically active 
natural product is the metabolite K-26 (III-1) which is produced by the soil dwelling 
microbe, Astrosporangium hypotensionis (Figure III-1A).7  This natural product has been 
noted for its selectivity for mammalian ACE and comparable activity to the widely 
prescribed antihypertensive drug, captopril, attributes at least partially ascribed to the 
non-proteogenic amino acid, AHEP (III-2). 50, 126   
ACE is a significant target for pharmacological regulation of blood pressure and has 
been discovered to have roles in a wide array of physiological processes from fibrosis to 
fluid balance regulation.2  There are two isoforms of ACE present in humans, somatic 
ACE (sACE) and the tissue specific testicular ACE (tACE).  sACE is comprised of two 
domains, referred to as the N-domain and the C-domain, each with their own HEXXH 
zinc binding sequence, substrate, and pharmacological inhibitor preference. tACE is 
nearly identical to the C-domain of sACE.  Several inhibitors of this enzyme have been 
developed for treatment of hypertension, however, current ACE inhibitors have been 
attributed to side effects such as angioedema and a dry cough, a feature that has been 
associated with the inhibition of both ACE domains and potentially other off target 
enzymes. 
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Co-crystal structures of K-26 (II-1) in both N-domain and C-domain ACE have revealed 
that K-26 adopts a unique binding motif in the active site of ACE.126  The phosphonic 
acid coordinates the zinc while the amino acid sidechains occupy solely the non-prime 
binding pockets.  As all other known ACE inhibitors occupy the prime binding pockets, 
this binding motif is exclusive to K-26 and therefore focusing on the only the prime 
binding pockets is an unexplored realm for potent and selective ACE inhibitor design.92-
93, 101, 103 
As K-26 adopts an unusual binding conformation in the active site of ACE and exhibits 
selectivity for the mammalian enzyme, this natural product family is a relevant starting 
point for exploration for ACE inhibitor design.  However, the current synthetic scheme 
would make obtaining a large library of synthetic variants difficult.  As a result, we chose 
to use computational modeling to predict binding interactions of a set of AHEP (III-2) 
containing K-26 variants with both domains of ACE.   
In this study, we opted to use the computational modeling suite Rosetta for the analysis 
of our set of variants.  This powerful tool has been used in applications from de novo 
proteins structure determination, to studying protein-small molecule interactions, 
performing enzyme design and predicting the structure of biological macromolecules 
and complexes.154-160  Rosetta has furthermore been shown to be an effective method 
of computational inhibitor study having been applied successfully in high-throughput 
library screening and ligand docking.161-162  As the binding site of the K-26 inhibitor is 
known as the crystal structures of this small molecule with the human enzyme are 
available, utilizing Rosetta is an ideal approach to furthering structural activity 
relationship studies to identify inhibitors of interest based on the K-26 scaffold.   
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Using Rosetta, a binding energy will be calculated and used to select a handful of 
variants, with a spectrum of predicted inhibitory activities.  These selected variants will 
be synthesized and experimentally assayed for inhibition of both domains of 
heterologously expressed human ACE.  This analysis provides insight into the specific 
features of K-26 (II-1) and variants, potentially of pharmacological interest, which are 
responsible for the potent inhibition of the two individual domains of this enzyme.    
 
Results 
Rosetta prediction of K-26 variant binding  
Although there are many options for modifications to the K-26 structure to optimize 
inhibitor binding, we chose to approach our study by evaluating the effect of different 
naturally occurring amino acids in two different positions in K-26 (III-1) (Figure III-1B).  
As previous studies have shown the importance of the AHEP (II-2) moiety for the 
pharmacological effect of the small molecule, we chose to leave the side-chain of the 
AHEP (III-2) untouched in our computational modeling experiments.  Furthermore, as 
the N-terminal acetyl is deemed to be important for potent binding of K-26 (III-1) we 
chose to study inhibitors with this N-acetyl functionality.  With our plan to evaluate each 
of the 20 natural amino acids in two different positions, a set of 400 different K-26 based 
in inhibitors would be evaluated for binding in each domain of ACE.  Our approach 
entailed the use of Rosetta to predict the effect of these amino acid modifications by 
generating binding energies for each of the K-26 based inhibitors of interest. 
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Figure III-1: K-26 and modifications for our computational study A. Structure of the ACE inhibitory natural 
product, K-26 (III-1).  AHEP (III-2) is highlighted by a blue box.  B. Amino acids modified in our 
computational study to give our set of 400 computationally studied variants.  The side chains that are 
modified are highlighted in an orange and green box. 
 
 
AHEP (III-2) was generated as a non-canonical amino acid that was utilized as the 
terminal amino acid in all K-26 tripeptide variants studied.  The N-terminal acetyl group 
was appended to the K-26 variants by applying an N-acetyl patch.  The coordinates for 
both the N-acetyl group and the AHEP were derived from the co-crystal structure of K-
26 with tACE.  Partial charges on the phosphonate of the AHEP were established based 
on the partial charges of phosphate.  The initially generated K-26 was docked into the 
computationally relaxed structure with fixed zinc and zinc binding residues.   The 
predicted binding conformation in both N-domain and C-domain ACE was compared to 
the crystal structures of K-26.  As docking the K-26 ligand did not result in a pose that 
emulated the binding of the K-26 inhibitor in the crystal structure, the K-26 backbone 
was restrained as part of the optimization for inhibitor binding.  With the restrained 
backbone, the optimized ligand superimposed with the crystal structure for both the C-
domain and the N-domain of ACE (Figure III-2A,B).   
Each of the 400 different K-26 variants were docked into the N-domain and the C-
domain of ACE and the free energy of binding was calculated for each variant for the 
 
 
 
A B 
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collection of structures generated using the Rosetta energy function.  The function is a 
linear combination of terms which model interaction forces between atoms, solvation 
effects and torsion energies.163  The change in free energy of the inhibitor binding 
(∆∆Gpredicted) predicted by Rosetta is calculated from the difference between the free 
energy of the inhibitor bound (∆Gbound) and not bound (∆Gunbound) in the enzyme.  
     
 
Figure III-2 Comparison of the low binding energy structure predicted by Rosetta (colored) and the crystal 
structure (grey).  A. Low binding predicted by Rosetta for N-domain. ACE is shown in forest. B. Low 
binding energy structure predicted by Rosetta for C-domain. ACE is shown in deep purple.   
 
  
 
Selection of K-26 variants for further study 
For each of the 400 K-26 variants the Rosetta energy function was used to calculate the 
free energy for the inhibitor binding (∆∆Gpredicted) for both the C-domain and the N-
domain of ACE (Figure III-3 A, B).  As domain selectivity is a feature of interest to us in 
inhibitor development, we also compared the ratio of free energy (∆∆Gpredicted) of binding 
for both the C-domain and the N-domain as a means to gain insight as to which variants 
may exhibit domain selective properties (Figure III-3 C).   
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Figure III-3: Heat maps showing the Rosetta predicted ΔΔG of binding for the set of 400 K-26 variants 
analyzed in this study. A. ΔΔGpred for tACE.  B. ΔΔGpred for N-domain ACE. C. Ratio of ΔΔGpred for 
tACE and N-domain ACE to show predicted domain selectivity for tACE (red) or N-domain (blue).   
 
 
 
K-26 (III-1) and ten additional variants were selected for study, which are predicted to 
have a wide range of expected ACE inhibitory properties based on the Rosetta 
predicted ∆∆G values (Figure III-4).  In addition to K-26 (III-1) and the two other 
naturally occurring AHEP containing compounds, SF 2513B (III-3) and SF 2513C (III-4), 
the variant Ac-Ile-Trp-AHEP (III-5) was selected as this inhibitor is predicted to be  one 
of the most potent inhibitors of both domains of ACE.  Comparison of the predicted ∆∆G 
values for tACE and the N-domain of ACE gave us a reason to select  Ac-Ile-Ser-AHEP 
(III-6) as an inhibitor with a preference for the N-domain and Ac-Ile-His-AHEP (III-7), Ac-
His-Trp-AHEP (III-8) and Ac-Leu-Tyr-AHEP (III-9) as inhibitors of tACE (C-domain).  All 
of these potentially domain selective variants were chosen as they were also expected 
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to be reasonably good inhibitors based on the ∆∆Gpredicted values.  Due to less negative 
∆∆Gpredicted values, a middle of the spectrum inhibitor was selected, Ac-Leu-Ile-AHEP 
(III-10) and a poor inhibitor was selected, Ac-Tyr-Ile-AHEP (III-11).  Ac-Tyr-Ile-AHEP is 
predicted to be one of the worst inhibitors of the variant set tested.  Ac-Pro-Tyr-AHEP 
(III-12) was chosen for study as the rigid conformation of proline makes it unexpected 
that this variant would have ∆∆Gpredicted only slightly worse than predicted values for the 
potent analog K-26 (III-1).  The Rosetta predicted binding conformations for each 
variant selected for synthesis were visualized to ensure that the Rosetta energy 
predictions were structurally logical for the binding of the inhibitor in each ACE domain 
(Appendix C).  
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Figure III-4. K-26 variants selected for further study based on Rosetta ∆∆G predictions. 
 
 
Synthesis of K-26 variants 
 The synthesis of all of the K-26 variant tripeptides, with the exception of Ac-Ile-
His-AHEP (III-7), proceeded from the N-terminal to the AHEP phosphonate as 
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previously described (Scheme III-1A).126-127  Ac-Ile-His-AHEP (III-7) was synthesized in 
the direction of the phosphonate towards the N-terminal of the peptide due to the 
commercial availability of the necessary amino acids for synthesis (Scheme III-2B) .  
Both of these schemes proceeded through two peptide coupling steps with HOBt and 
EDC with an intermediate deprotection, followed by global deprotection of the tripeptide.  
The synthesis yielded all K-26 variants as a mixture of two major diasteromers, which 
were separated and purified by preparative C18-HPLC.  K-26 (III-1), SF-2513-B (III-3) 
and SF-2513-C (III-4) had been synthesized and assayed for activity in a prior study.50, 
126  More details about the synthesis is given in the methods section and NMRs of 
structural intermediates can be found in Appendix D.  
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Scheme III-1. Chemical synthesis of K-26 variants.  A. Reagents and conditions: (a) Method A. HOBt, 
EDC, 2,4,6-trimethylpyridine, DMF, 0
o
C for 1 hr, then rt overnight. (b) Method B. 5% NaOH, MeOH, rt, 2 
hours. (c) Method A. 10% Pd/C, H2, MeOH, rt overnight (d) Method F. TFA, DCM, rt, 30 min. (e) Method 
D. I-TMSi, thioanisole, CH3CN, 0
o
C, 3 hours. Ac-Ile-Trp-AHEP (III-5): R1 = Ile, R2 = Trp, R3 = Ile, R4 = Trp. 
Ac-Ile-Ser-AHEP (III-6): R1 = Ile, R2 = Ser(OBzl), R3 = Ile, R4 = Ser. Ac-His-Ile-AHEP (III-7) R1 = His(Trt), 
R2 = Trp, R3 = His, R4 = Trp. Ac-Leu-Tyr-AHEP (III-9): R1 = Leu, R2 = Tyr(OBzl), R3 = Leu, R4 = Tyr. Ac-
Leu-Ile-AHEP (III-10): R1 = Leu, R2 = Ile, R3 = Leu, R4 = Ile. Ac-Tyr-Ile-AHEP: R1 = Tyr(tBu), R2 = Ile, R3 = 
Tyr, R4 = Ile. Ac-Pro-Tyr-AHEP: R1 = Pro, R2 = Tyr(OBzl), R3 = Pro, R4 = Tyr. B. Reagents and conditions 
(a) Method A. HOBt, EDC, 2,4,6-trimethylpyridine, DMF, 0
o
C for 1 hr, then rt overnight. (b) Method E. 
TAEA, DCM, rt, 20 min. (c) Method A, N-Ac-Ile, HOBt, EDC, 2,4,6-trimethylpyridine, DMF, 0
o
C for 1 hr, 
then rt overnight. (d) Method C. 10% Pd/C, H2, MeOH, rt overnight. (e) Method E. TFA, DCM, rt, 30 min. 
(f) Method D. I-TMSi, thioanisole, CH3CN, 0
o
C, 3 hours. 
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Inhibitory activity of K-26 variants       
  Both diastereomers of the chemically synthesized K-26 family 
phosponotripeptides were initially assayed for mammalian ACE inhibition using the 
chromogenic substrate furylacryloyl-phenylalanyl-glycyl-glycine (FAPGG) and rabbit 
lung somatic ACE extract.127-128  As previous studies suggest, diastereomers terminated 
by the naturally occurring (R)-AHEP amino acid are  more potent than those terminated 
by (S)-AHEP, the most potent diastereomer was taken to contain the desired (R)-AHEP 
(Table III-1).126-127 
  
 
K-26 Variant 
IC50 (M) 
(R)-AHEPdiastereomer (S)-AHEP diastereomer 
Ac-Ile-Trp-AHEP (III-5) 6.6 x 10
-8 
2.8 x 10
-7
 
Ac-Ile-Ser-AHEP (III-6) 8.0 x 10
-7 
4.1 x 10
-6 
Ac-Ile-His-AHEP (III-7) 1.1 x 10
-7
 5.2 x 10
-6
 
Ac-His-Trp-AHEP (III-8) 7.4 x 10
-6
 8.2 x 10
-6
 
Ac-Leu-Tyr-AHEP (III-9) 1.3 x 10
-6
 4.9 x 10
-6
 
Ac-Leu-Ile-AHEP (III-10) 4.5 x 10
-5
 8.8 x 10
-6
 
Ac-Tyr-Ile-AHEP (III-11) 5.8 x 10
-5 
1.2 x 10
-4 
Ac-Pro-Tyr-AHEP (III-12) 7.3 x 10
-7
 1.1 x 10
-5
 
 
Table III-1: Somatic ACE inhibition by both isolated diastereomers of the K-26 variants synthesized.   
 
 
 
Correlation between Rosetta predictions and experimental measurements 
 Preliminary analysis was carried out correlating the experimental somatic ACE 
IC50 with the average of the ∆∆Gpredicted for both the C-domain and the N-domain.  The 
binding of the inhibitor to the enzyme can be given by the relationship ∆∆G = ∆Gbound - 
∆Gunbound.   The ∆Gbound can be related to the Ki  through the relationship ∆Gbound = RT ln 
Ki. where Ki is the inhibitory constant of the inhibitor enzyme complex. In our initial 
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analysis, the IC50 was used in place of the Ki as this value generally correlates well with 
the Ki when the enzyme is a potent inhibitor (Table III-2).
164   
 
 
K-26 Variant 
IC50 
Somatic 
ACE (M) 
 ∆∆Gpredicted (kJ) Average 
∆∆Gpredicted 
(kJ) 
∆∆Gmeasured (kJ) C-domain 
ACE 
N-domain 
ACE 
K-26 (III-1) 2.5 x 10
-8 
-43.4 -16.8 -15.9 -16.35 
SF2513B 
(III-3) 1.0 x 10
-7
 -39.9 -13.4 -13.3 -13.35 
SF2513C 
(III-4) 3.5 x 10
-8
 -42.5 -17 -15.2 -16.1 
Ac-Ile-Trp-AHEP 
(III-5) 6.6 x 10
-8 
-41.1 -17.8 -16.5 -17.15 
Ac-Ile-Ser-AHEP 
(III-6) 8.0 x 10
-7 
-34.8 -13.7 -15.3 -14.5 
Ac-Ile-His-AHEP 
(III-7) 1.1 x 10
-7
 -39.7 -18.6 -15 -16.8 
Ac-His-Trp-AHEP 
(III-8) 7.4 x 10
-6
 -29.3 -16.8 -12.9 -14.85 
Ac-Leu-Tyr-AHEP 
(III-9) 1.3 x 10
-6
 -33.6 -16 -13.3 -14.65 
Ac-Leu-Ile-AHEP 
(III-10) 4.5 x 10
-5
 -24.8 -10.4 -9.9 -10.15 
Ac-Tyr-Ile-AHEP 
(III-11) 5.8 x 10
-5 
-24.2 -5.8 -2 -3.9 
Ac-Pro-Tyr-AHEP 
(III-12) 
7.3 x 10
-7
 -35.0 -16.9 -14.7 -15.8 
      
Table III-2. Measured IC50 values for each synthetic K-26 variant with somatic ACE and the 
corresponding ∆∆Gpredicted and ∆∆Gexperimental values. IC50 values for K-26  (III-1), SF 2513B (III-3) and SF 
2513C (III-4) were published in Kramer et al.
126
    
 
 
 
 The average of the ∆∆G value predicted for each domain by Rosetta and the 
∆∆G values calculated from our experimentally measured IC50 values for somatic ACE 
92 
 
inhibition were plotted to visualize a correlation between the data sets.  These data sets 
do have a linear relationship with a R2 = 0.6184 (Figure III-5). 
 
Figure III-5. Correlation plot of ∆∆Gpredicted and ∆∆Gmeasured calculated from the experimental IC50 of each 
variant with somatic ACE. Natural product K-26 variants are shown in blue.  Synthetic predicted variants 
are shown in red. 
  
 
Discussion 
 In this study we describe the application of the computational modeling program 
Rosetta to predict binding affinities of a set of K-26 ACE inhibitor variants. Natural 
products in the K-26 family are among the most potent naturally occurring inhibitors of 
the two domain human enzyme of pharmacological relevance, ACE.  As K-26 (III-1) has 
been shown in previous studies to exhibit an unusual binding mode in the active site of 
ACE, this molecule and variants are of interest in ACE inhibitor design.  The solution 
phase synthesis of K-26 (III-1) and other AHEP (III-2) containing molecules is low 
Ac-Tyr-Ile-AHEP 
Ac-Leu-Ile-AHEP 
Ac-His-Trp-AHEP 
Ac-Ile-Ser-AHEP 
Ac-Leu-Tyr-AHEP 
Ac-Ile-His-AHEP 
K-26 
SF2513 B 
SF2513 C 
Ac-Ile-Trp-AHEP 
Ac-Pro-Tyr-AHEP 
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yielding and the final purification and identification of the resulting diastereomers is 
difficult making AHEP containing peptides a poor candidate for the generation of a large 
library of synthetic variants for structural activity relationship studies.  However, as K-26 
is a modified peptide, generation of an in silico library of variants is reasonable.  As 
crystal structures are available for the natural product K-26 in both domains of ACE, this 
system an ideal candidate for a computational binding study. 
 Generating K-26 in silico was met with challenges.  When docking the inhibitor 
into the active site of ACE it became necessary to fix both the backbone and the zinc in 
order to output a reasonable structure to emulate the crystal structure of this small 
molecule in ACE.  Due to these constraints, all variants studied were generated using 
the fixed K-26 backbone with variation and full flexibility in the sidechains of the amino 
acids. 
 The Rosetta energy function was used to calculate the binding energy for the 400 
variants of interest in both domains of ACE, with a small set of variants being selected 
for synthesis and further study.  When selecting variants, we opted to choose not only 
variants that were predicted to be the most potent binders or particularly domain 
selective, but sampled molecules from across the spectrum of predicted binding 
energies to validate the ability of Rosetta to predict the specific activity of our inhibitors.  
Furthermore, when selecting variants for study, the rational analysis of structure of K-26 
variant in the active site of ACE was important especially as the Rosetta energy function 
has known inaccuracies in the electrostatic portion of the analysis, which manifests itself 
particularly in poor handling of charged amino acids.165  As a result, we also relied on 
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structural information to decide what analogs to select for further study, rather than 
simply using the Rosetta ∆∆Gpredicted. 
 The naturally occurring K-26 (III-1) was returned from our analysis as one of the 
most potent binders of all of the 400 variants studied, an interesting finding as this 
highlights the naturally occurring affinity of this microbially produced molecule for human 
ACE.   However, several other analogs were predicted to have nearly comparable 
binding energies to the K-26 (III-1).  These variants include another natural product from 
the K-26 family, SF2513C (III-4), along with the synthetic variants Ac-Ile-Trp-AHEP (III-
5) and Ac-Ile-His-AHEP (III-7).  Inhibition assays with somatic ACE have placed these 
inhibitors as the most potent of the variants tested suggesting the importance of the 
isoleucine residue in the AA1 position and an aromatic residue present in the AA2 
position of the inhibitor.  The AA1 isoleucine fits comfortably in the binding pocket of the 
enzyme alongside Trp 357 (Trp 335 in N-domain), whereas the aromatic residues in the 
AA2 position may have potential interactions with His 410 (His 388 in N-domain).   
The variants with predicted poor binding, Ac-Leu-Ile-AHEP (III-10) and Ac-Tyr-Ile-AHEP 
(III-11) were also found to be the worst inhibitors based on assays with somatic ACE.  
Interestingly, these poor inhibitors are isomers of the natural products K-26 (III-1) and 
SF 2513BB (III-3) with sidechains of the residues in the AA1 and AA2 position reversed.  
The leucine and tyrosine present in the AA1 position crowds the binding pocket where 
the AA1 sidechain typically resides.  The AA2 isoleucine also crowds the binding pocket 
and has no favorable interactions with the histidine present suggesting that these poor 
steric interactions must be responsible for the lower affinity of these inhibitors (III-10 and 
III-11) compared to the native K-26 (III-1).   
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The variant with the constrained side chain residue in AA1, Ac-Pro-Tyr-AHEP (III-12) 
although an unusual choice for an inhibitor, fits well in the binding pocket of the enzyme.  
The N-acetyl group is able to form important hydrogen bonds with  the backbone of Asp 
358 (Asp 336 in N-domain) while the Pro side chain occupies the binding pocket without 
a negative steric effect.    
Analysis of the experimentally measured IC50 and correlation with the ∆∆Gpredicted 
reveals a trendline describing the relationship between these two terms.  That this 
trendline has an R2 = 0.6148 is promising in that the binding energy function of Rosetta 
is effective at predicting the binding energy that would be measured from inhibition 
assays and therefore the Ki of the variant of interest.  To confirm these results and to 
delve into the domain selective potential of these inhibitors, further analysis will be 
carried out using the inhibition constant (Ki) of each domain of ACE by the synthetic 
variants.  After optimization of the Rosetta energy function for our data set, the validity 
of the Rosetta binding energy predictions for the determination of the binding affinity of 
the K-26 variants specifically in each of the individual domains of ACE will be evaluated. 
 Herein is described an interesting medicinal chemistry application of Rosetta.  
Variants of the K-26 family of natural products, with known potent activity towards the 
human pharmacological target, ACE, are computationally analyzed for binding energy.  
A handful of these peptide variants are synthesized and assayed for ACE inhibitory 
activity.  The Rosetta predicted binding energy is shown to correlate with our 
experimental inhibition measurements showing promise for this type of approach in 
pharmacological inhibitor development.      
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Materials and Methods 
Rosetta prediction of binding energy for K-26 variants 
The coordinates of both tACE and the N-domain of ACE containing K-26 were 
obtained from the Protein Data Bank (PDB ID 4BZR, 4BZS).  A collection of energy 
minimized structures were generated for both domains of ACE in the absence of K-26 
using a protocol analogous to the Rosetta relax protocol. All side chains were repacked 
and minimized with backbone minimization in the immediate vicinity of the k26 binding 
site. Restraints were imposed on the zinc and zinc-coordinating residues to maintain the 
appropriate geometry and positioning of the metal binding site during minimization. The 
top model by score out of 100 models was carried forward.   
A set of 400 K-26 variants were chosen for study.  To model these variants, AHEP was 
generated as a non-canonical amino acid with a corresponding modification to the 
existing Rosetta code to accept non-canonical aminophosphonic acid residues.166 
Idealized internal coordinates for AHEP were established by minimization of N-acetyl, 
phosphonoxymethylated AHEP derived from k26 crystallized in tACE using the 
MMFF94x forcefield. Parameters, such as partial charge, for phosphonate atoms were 
approximated based on parameters for phosphate. All changes to the code and 
database are part of the current Rosetta repository. Experiments reported here were 
performed with revision 55456. 
Coordinates for backbone and AHEP atoms of the co-crystallized k26 were transferred 
into the minimized enzyme to form the backbone of each tripeptide variant. First and 
second-shell side chains were repacked and minimized along with backbone atoms in 
the immediate vicinity of the tripeptide, as with the apo-enzyme. Models were scored 
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with the talaris2013 scoring function163 and binding energies were calculated as the 
difference in energy between the tripeptide bound and unbound models  
(ΔΔG=ΔGbound−ΔGunbound). Reported values are the average of the top ten binding 
energies from 25-50 models for each variant. 
 
Chemical synthesis of variants 
General synthesis. 
  Reactions were carried out in oven or flame dried glassware.  All solvents were 
reagent grade.  Amino acids and peptide coupling agents were purchased from EMD or 
Bachem.  All reagents were commercially available and used without purification unless 
specified otherwise.  AHEP (III-2) was synthesized as previously described.127 HPLC 
purification was carried out using a Phenomonex C18 semi-preparative HPLC column on 
a Waters instrument using a flow rate of 5 mL/min.  The purified analogs were tested for 
somatic ACE inhibitory activity using the substrate FAPGG using the described method. 
The most potent inhibitor was taken to be the desired (R)-diastereomer. All analogs 
were characterized by NMR and HRMS and quantitated, prior to inhibition studies, using 
an attenuated time delay proton NMR experiment (relaxation d1 = 15 s) with dioxane or 
dimethylformamide added as an internal standard.  NMR spectra were acquired on a 
Brucker AV-400, or AV-II-600 instrument.  NMR spectra of synthetic intermediates and 
analogs are available in Appendix D.  
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Method A: Peptide Coupling125, 127, 137  
  The corresponding amino acids or peptides were dissolved in dimethylformamide 
(DMF) with N-hydroxybenzotriazole (HOBt) and the reaction mixture was cooled to 0 oC.  
Under inert atmosphere, 1-ethyl-3(3’-dimethylaminopropyl)carbodiimide hydrochloride 
(EDC) and 2,4,6-trimethylpyridine were added and the reaction was allowed to proceed 
for 1 hour at 0 oC and then overnight at room temperature.  The reaction was dissolved 
in ethyl acetate and extracted with citric acid solution, 1N NaHCO3, and brine.  The 
organic layer was then dried over MgSO4, and concentrated to give the desired product.   
 
Method B: Saponification167  
  The corresponding dipeptide methyl ester was dissolved in methanol.  Sodium 
hydroxide solution was added (5% w/v) and the reaction was stirred at room 
temperature for 2 hours.  After evaporation of the solution, the residue was dissolved in 
ethyl acetate and washed with citric acid (2 x 20 mL), water (1 x 20 mL) and brine (1 x 
20 mL).  The organic layer was dried over MgSO4 and concentrated to give the desired 
product.    
 
Method C: Hydrogenation.125  
  The corresponding tripeptide and palladium on activated carbon (Pd/C) were 
combined in anhydrous methanol and allowed to stir overnight under 1atm hydrogen 
gas.  After filtering through Celite, the filtrate was evaporated to give the product.   
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Method D: Phosphonate Deprotection.127, 138  
  The corresponding ethyl phosphonate was dissolved in anhydrous acetonitrile 
and thioanisole at 0 oC.  Iodotrimethyl silane (I-TMSi) was added dropwise, and the 
reaction was allowed to proceed for 3 hours at 0 oC, after which the solvent was 
removed under vacuum to give a brown oily residue of the phosphonate trimethylsilyl 
ester.  After hydrolysis of the trimethylsilyl ester, the solvent was evaporated and residue 
was redissolved in methanol ant the product was purified via preparative HPLC. 
 
Method E: Fmoc Deprotection.139  
  The corresponding Fmoc protected dipeptide was dissolved in anhydrous DCM 
(5 mL) and under inert atmosphere tris(2-aminoethyl)amine (TAEA) (3.5 mL) was added 
dropwise.  The reaction was allowed to stir for 30 minutes at room temperature then 
was dissolved in additional DCM, washed with brine and phosphate buffer (pH 5.5).  
The aqueous portion was collected and back extracted with additional DCM.  The 
organic layers were pooled, dried over MgSO4 and concentrated to give the product.   
 
Method F: Acid Labile Protecting Group Deprotection.140  
  The corresponding protected peptide was dissolved in DCM (5 mL) and 
trifluoroacetic acid (TFA) (5 mL).  The reaction was stirred for 30 minutes at room 
temperature and the solvent was removed in vaccuo to give the product. 
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N-acetyl-L-isoleucyl- L-tryptophan methyl ester (III-5a). 
  Synthesized using N-Ac-L-isoleucine-OH, III-13 (112 mg, 0.65 mmol), L-
tryptophan methyl ester hydrochloride, III-18 (135 mg, 0.62 mmol), HOBt (104 mg, 0.68 
mmol), EDC  (130 mg, 0.68mmol) and 2,4,6-trimethylpyridine (172 L, 1.3 mmol) in 
DMF (6 mL) using method A. White solid. Yield:  175 mg, 76%. Rotamers. 1H NMR (400 
MHz, CDCl3) δ8.31 (s, 1H), 7.55-7.50 (m, 1H), 7.37-7.32 (m, 1H), 7.21-7.09 (m, 2H), 
7.01 (d, J = 1.9Hz, 1H), 6.51 (s, 1H), 6.23 (s, 0.7H), 6.04 (s 0.3H), 4.94-4.87 (m, 1H), 
4.43 (dd, J = 8.8, 5.5 Hz, 0.3 H), 4.30 (t, J = 7.8 Hz. 0.7 H), 3.68 (s, 3H), 3.31 (t, J = 5.3 
Hz, 2H), 1.95 (s, 2H), 1.93 (s, 1H), 1.83-1.73 (m, 1H), 1.51-1.40 (m, 1H), 1.31-1.25 (m, 
1H), 0.93-0.71 (m, 6H); 13C NMR (100 MHz, CDCl3) δ171.88, 170.99, 170.11, 136.12, 
127.36, 123.24, 122.20, 119.65, 118.39, 111.33, 109.36, 57.60, 52.66, 52.37, 37.46, 
27.48, 24.89, 23.14, 15.16, 11.26. 
 
N-acetyl-L-isoleucyl- L-tryptophan (III-5b). 
  Synthesized using N-acetyl-L-isoleucyl- L-tryptophan methyl ester III-5a (170 mg, 
0.46 mmol), methanol (16 mL) and 5% NaOH (4 mL) using method B. White solid. Yield: 
108 mg, 65%. Rotamers. 1H NMR (400 MHz, CDCl3) δ7.54 (d, J = 7.9 Hz, 1H), 7.29 (d, 
J = 8.1 Hz, 1H), 7.09-6.96 (m, 3H), 4.70 (dd, J = 7.9, 5.1 Hz, 1H), 4.34 (d, J = 5.6 Hz, 
0.2H), 4.19 (d, J = 8.0 Hz, 0.8H), 3.35-3.27 (m, 1H), 3.19-3.12 (m, 1H), 1.90 (s, 2.4H), 
1.89 (s, 0.6H), 1.79-1.67 (m, 1H), 1.51-1.38 (m, 1H), 1.14-1.01 (m, 1H), 0.89-0.78 (m, 
6H); 13C NMR (100 MHz, CDCl3) δ174.96, 173.58, 173.20, 137.93, 128.76, 124.60, 
122.32, 119.81, 119.20, 112.19, 110.72, 59.16, 54.42, 37.93, 28.45, 25.77, 22.41, 15.73, 
11.29.  
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Diethyl N-(N-acetyl-L-isoleucyl-L-tryptophanyl)-1-amino-2-(4-benzyloxyphenyl)ethyl 
phosphonate (III-5c)  
  Synthesized using N-acetyl-L-isoleucyl- L-tryptophan III-5b (200 mg, 0.56 mmol), 
AHEP III-2 (188 mg, 0.52 mmol), HOBt (90 mg, 0.59 mmol), EDC  (113 mg, 0.59 mmol) 
and 2,4,6-trimethylpyridine (146 L, 1.1 mmol) in DMF (6 mL) using method A to give a 
mixture of diastereomers. Tan foam. Yield:  190 mg, 48%.   1H NMR (400 MHz, CDCl3) 
δ7.46-7.19 (m, 7H), 7.18-6.47 (m, 3H), 6.48-6.76 (m, 2H), 6.78-6.68 (m, 2H), 5.04-4.98 
(m, 1H), 4.86-4.84 (m, 1H), 4.83-4.57 (m, 2H), 4.55-4.47 (m, 1H), 4.21-4.03 (m, 4H), 
3.85-3.71 (m, 0.5H), 3.30-3.05 (m, 1.5H), 3.02-2.73 (m, 2H), 2.06-1.93 (m, 3H), 1.83-
1.62 (m, 1H), 1.44-1.24 (m, 7H), 1.13-0.67 (m, 7H); 13C NMR (400 MHz, CDCl3) 
δ172.41-171.76, 171.60-171.12, 170.89-170.60, 157.72-157.40, 137.05-136.91, 136.04-
135.97, 130.36, 130.16-130.03, 129.42-129.29, 128.79-128.65, 128.48-128.34, 127.85-
127.73, 127.41-127.31, 123.61, 121.28, 118.84, 117.98, 115.04-114.59, 111.19, 109.78-
109.42, 69.88-69.72, 63.37-62.19, 57.77-57.62, 53.62-52.94, 47.78-44.06, 37.54-37.35, 
34.96-34.41, 28.17-27.92, 25.08, 22.70-22.64, 16.35-16.17, 15.25-15.15, 11.25-11.12; 
31P NMR (162 MHz, D2O) δ25.25, 25.11.  
 
Diethyl N-(N-acetyl-L-isoleucyl-L-tryptophanyl)-1-amino-2-(4-hydoxyphenyl)ethyl 
phosphonate (III-5d) 
  Synthesized using diethyl N-(N-acetyl-L-isoleucyl-L-tryptophanyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate III-5c (150 mg, 0.26 mmol), Pd/C (10% Pd, 15 mg) 
in methanol (5 mL) using method C, to yield a mixture of diastereomers. Yellowish oil.  
Yield: 126 mg, 81.0%. 1H NMR (600 MHz, MeOD) δ 7.87 (dd, J = 19.6, 8.5 Hz, 1H), 
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7.56 (dd, J = 34.2, 7.7, 1H), 7.33 (dd, J = 13.6, 8.2 Hz, 1H), 7.14-7.04 (m, 3H), 6.93-
6.89 (m, 1H), 6.76-6.70 (m, 2H), 4.79-4.71 (m, 1H), 4.63-4.52 (m, 1H), 4.21-3.99 (m, 
5H), 3.23-3.19 (m, 0.5H), 3.15-3.06 (m, 1H), 3.01-2.96 (m, 0.5H), 2.94-2.88 (m, 0.5H), 
2.84-2.72 (m, 1.5H), 2.01-1.92 (m, 3H), 1.74-1.67 (m, 0.5H), 1.59-1.50 (m, 0.5H), 1.40-
1.25 (m, 7H), 1.10-1.02 (0.5H), 0.97-0.88 (m, 0.5H), 0.86-0.70 (m, 6H); 13C NMR (150 
MHz, MeOD) δ173.99-173.50, 173.43-173.31, 173.25-173.18, 157.36-157.21, 138.07-
137.82, 131.31, 131.12-130.95, 128.99-128.66, 124.73-124.37, 122.37-122.26, 119.80-
119.72, 119.32-119.21, 116.27-116.19, 112.23-112.11, 110.78-110.62, 64.20-64.03, 
59.52, 59.44, 54.93, 54.83, 48.11, 47.84,  37.71-37.64, 35.20-35.04, 29.20-28.76, 
25.81-25.71, 22.46, 22.42, 16.83-16.68, 15.80, 11.39; 31P NMR (162 MHz, MeOD) 
δ25.13, 24.55. 
 
Ac-Ile-Trp-AHEP: N-(N-acetyl-L-isoleucyl-L-tryptophanyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonic acid (III-5)  
Synthesized using diethyl N-(N-acetyl-L-isoleucyl-L-tryptophanyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate III-5d (32mg, 0.052 mmol), acetonitrile (6 mL), 
thioanisole (0.6 mL) and I-TMSi (3.0 mL) using method D.  The phosphonate 
trimethylsilyl ester was hydrolyzed by treatment with 8:2 methanol in water (30 mL). 
Purified by HPLC, using a gradient of 5% acetonitrile in water to 25% acetonitrile in 
water containing ammonium acetate (10 mM) over 30 minutes. White solid.  Yield: 2.1 
mg, 7.2%. 1H NMR (600 MHz, D2O) δ7.67 (d, J = 8.0 Hz, 1H), 7.48 (d, J = 8.2 Hz, 1H), 
7.24 (t, 7.5 Hz, 1H), 7.16 (s, 2H), 7.14 (d, J = 8.5 Hz, 2H), 6.78 (d, J = 8.46 Hz, 2H), 
4.70 (dd, J = 9.8, 4.5 Hz, 1H), 4.28-4.22 (m, 1H), 3.92 (d, J = 7.9 Hz, 1H), 3.42 (dd, J = 
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14.9, 4.5 Hz, 1H), 3.22-3.17 (m, 1H), 2.95 (dd, J = 14.9, 9.8 Hz, 1H), 2.69 (dt, J = 12.7, 
6.5 Hz, 1H), 1.90 (s, 3H), 1.58-1.50 (m, 1H),  1.16-1.09 (m, 1H), 0.94-0.85 (m, 1H), 0.73 
(t, J = 7.3 Hz, 3H), 0.56 (d, J = 6.78 Hz, 3H); 13C NMR (150 MHz, D2O) δ173.53, 
172.32, 171.92, 153.70, 135.84, 130.17, 130.00-129.90, 126.71, 124.28, 121.57, 
119.03, 118.17, 114.93, 111.53, 109.02, 58.10, 53.39, 50.42, 49.45, 35.91, 34.64, 
27.35, 24.02, 21.42, 14.21, 9.99; 31P NMR (162 MHz, D2O) δ18.65. 
 
N-acetyl-L-isoleucyl-O-benzyl-L-serine methyl ester (III-6a) 
  Synthesized using N-Ac-L-isoleucine-OH III-13 (112 mg, 0.65 mmol), L-serine-O-
benzyl methyl ester hydrochloride III-19 (152 mg, 0.62 mmol), HOBt (104.1 mg, 0.68 
mmol), EDC (130.4 mg, 0.68 mmol) and 2,4,6-trimethylpyridine (172 µL, 1.30 mmol) in 
DMF (6 mL) using method A. White solid. Yield: 177 mg, 78.4%.   1H NMR (400 MHz, 
CDCl3) δ 7.35-7.24 (m, 5H),  6.81 (d, J = 8.2 Hz, 1H), 6.41 (d, J = 8.7 Hz, 1H), 4.75-4.70 
(m, 1H), 4.55-4.40 (m, 3H), 3.90-3.84 (m, 1H), 3.73 (s, 3H), 3.67-3.61 (m, 1H), 1.99 (s, 
3H), 1.88-1.78 (m, 1H), 1.56-1.49 (m, 1H), 1.27-1.06 (m, 1H), 0.96-0.85 (m, 6H); 13C 
NMR (100 MHz, CDCl3) δ 171.19, 170,26, 169.86, 137.28, 128.40, 127.85, 127.61, 
73.20, 69.26, 57.39, 52.46, 52.43, 37.88, 24.89, 23.10, 15.06, 11.33. 
 
N-acetyl-L-isoleucyl- O-benzyl-L-serine (III-6b) 
  Synthesized using N-acetyl-L-isoleucyl- O-benzyl-L-serine methyl ester III-6a 
(150 mg, 0.41 mmol), methanol (16 mL) and 5% NaOH (4 mL) using method B. White 
solid. Yield: 105mg, 70%. 1H NMR (400 MHz, MeOD) δ 8.65 (d, J = 7.7 Hz, 1H) 8.30 (d, 
J = 9.1 Hz, 1H), 7.78-7.67 (m, 5H), 4.93-4.85 (m, 3H), 4.72 (dd, J = 9.0, 7.5 Hz, 1H), 
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4.15 (dd, J = 9.8, 5.8 Hz, 1H), 4.06 (dd, J 9.8, 4.2 Hz, 1H), 2.26 (s, 3H), 2.16-2.07 (m, 
1H), 1.89-1.78 (m, 1H), 1.56-1.43 (m, 1H), 1.29-1.78 (m, 6H); 13C NMR (100 MHz, 
MeOD) δ 171.37, 171.33, 169.02, 138.01, 128.19, 127.52, 127.46, 72.13, 69.31, 56.42, 
52.25, 36.84, 24.22, 22.47, 15.24, 11.04. 
 
Diethyl N-(N-acetyl-L-isoleucyl-O-benzyl-L-serinyl)-1-amino-2-(4-benzyloxyphenyl)ethyl 
phosphonate (III-6c) 
  Synthesized using N-acetyl-L-isoleucyl-O-benzyl-L-serine III-6b (80 mg, 0.23 
mmol), AHEP III-2 (80 mg, 0.22 mmol), HOBt (37 mg, 0.24 mmol), EDC (45 mg, 0.24 
mmol) and 2,4,6-trimethylpyridine (64 L, 0.48 mmol) in DMF (3 mL) using method A to 
give a mixture of diastereomers. Clear oil. Yield:  117 mg, 74%. 1H NMR (600 MHz, 
CDCl3) δ7.45-7.18 (m, 1H), 7.16-7.01 (m, 2H), 6.90-6.72 (m, 2H), 5.97-4.89 (m, 2H), 
4.80-4.71 (m, 0.5H), 4.71-4.58 (m, 1.5H), 4.45-4.24 (m, 2.5H), 4.23-3.94 (m, 4.5H), 
3.81-3.74 (m, 0.5H), 3.73-3.65 (m, 0.5H), 3.59-3.47 (m, 1H), 3.22-3.07 (m, 1H), 2.96-
2.73 (m, 1H), 2.09-1.97 (m, 3H), 1.89-1.73 (m, 1H), 1.59-1.39 (m, 1H), 1.37-1.04 (m, 
8.5H), 0.97-0.79 (m, 4.5H); 13C NMR (150 MHz, CDCl3) δ 171.48-171.19, 170.36, 
169.20-169.04, 157.52, 137.36, 137.35, 136.99, 136.91, 130.11, 130.03, 129.20-129.06, 
128.97, 128.84, 128.44, 128.42, 128.36, 127.82-127.68, 127.49, 127.39, 127.37, 
127.33, 114.63, 114.57, 73.17, 73.02, 69.79, 69.74, 69.09, 63.10-62.21, 58.31, 57.74, 
52.83, 52.40, 47.91, 47.44, 46.36, 45.89, 37.49, 36.52, 34.68-34.37, 25.05, 22.94, 
22.92, 16.42-16.25, 15.31, 15.22, 11.27, 11.05; 31P NMR (162 MHz, CDCl3) δ 24.88, 
24.80, 23.69. 
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Diethyl N-(N-acetyl-L-isoleucyl-L-serinyl)-1-amino-2-(4-hydoxyphenyl)ethyl phosphonate 
(III-6d)  
  Synthesized using diethyl N-(N-acetyl-L-isoleucyl-L-serinyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate III-6c (110 mg, 0.16 mmol), Pd/C (10% Pd, 13 mg) 
in methanol (4 mL) using method C, to yield a mixture of diastereomers. Clear oil.  Yield: 
69 mg, 81.0%. 1H NMR (600 MHz, MeOD) δ7.08-7.00 (m, 2H), 6.71-6.65 (m, 2H), 4.59-
4.35 (m, 2H), 4.20-4.06 (m, 5H), 3.71-3.40 (m, 2H), 3.15-3.02 (m, 1H), 2.92-2.74 (m, 
1H), 2.05-1.96 (m, 3H), 1.91-1.72 (m, 1H), 1.62-1.42 (m, 1H), 1.35-1.26 (m, 6H), 1.26-
1.11 (m, 1H), 0.96-0.80 (m, 6H). 13C NMR (150 MHz, MeOD) δ174.06, 173.51, 171.59, 
157.20, 131.11, 130.98, 129.08-128.74, 116.15, 64.52-64.15, 63.28-62.81, 59.86-59.58, 
56.65-56.31, 38.09-37.28, 35.12-34.99, 27.10-27.05, 26.15-25.91, 24.18, 22.49, 16.84-
16.66, 15.92-15.73, 11.48-11.27;  31P NMR (162 MHz, MeOD) δ 25.36.  
 
Ac-Ile-Ser-AHEP: N-(N-acetyl-L-isoleucyl-L-serinyl)-1-amino-2-(4-hydoxyphenyl)ethyl 
phosphonic acid (III-6) 
  Synthesized using diethyl N-(N-acetyl-L-isoleucyl-L-serinyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate III-6d (25 mg, 0.049 mmol), acetonitrile (6 mL), 
thioanisole (0.6 mL) and I-TMSi (3.0 mL) using method D.  The phosphonate 
trimethylsilyl ester was hydrolyzed by treatment with 8:2 methanol in water (30 mL). 
Purified by HPLC, using a gradient of 5% acetonitrile in water to 25% acetonitrile in 
water containing ammonium acetate (10 mM) over 30 minutes. White solid. Yield: 2.8 
mg, 12%. 1H NMR (600 MHz, D2O) δ7.14 (d, J = 8.5 Hz, 2H), 6.77 (d, J = 8.5 Hz, 2H), 
4.48 (t, J = 5.5 Hz, 1H), 4.22-4.16 (m, 1H). 4.08 (d, J = 7.9 Hz, 1H), 3.78-3.70 (m, 2H), 
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2.66 (dt, J = 13.8, 6.3 Hz 1H), 2.30 (s, 3H) 1.73-1.68 (m, 1H), 1.42-1.37 (m, 1H), 1.13-
1.06 (m, 1H), 0.84 (t, J = 7.4, 3H), 0.68 (d, J = 6.8 Hz, 3H); 13C NMR (150 MHz, D2O) δ 
173.94, 172.75, 169.78, 153.63, 130.10, 114.88, 61.58, 58.13, 54.50, 50.70, 49.72, 
36.08, 34.62, 24.43, 21, 37, 14.32, 9.97; 31P NMR (162 MHz, D2O) δ18.64. 
 
Diethyl N-(N-fluorenylmethyloxycarbonyl-τ-trityl-L-histadyl-)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (III-7a) 
  Synthesized using N-(N- N-fluorenylmethyloxycarbonyl-τ-trityl-L-histadine) III-21 
(150 mg, 0.27 mmol), AHEP III-2 (100 mg, 0.28 mmol), HOBt (44 mg, 0.28 mmol), EDC 
(55 mg, 0.28 mmol) and 2,4,6-trimethylpyridine (71 L, 0.53 mmol) in DMF (3 mL) using 
method A to give a mixture of diastereomers. Tan foam. Yield:  117 mg, 85%. 1H NMR 
(600 MHz, CDCl3) δ7.76 (d, J = 7.6 Hz, 2H), 7.62-7.58 (m, 2H), 7.44-7.26 (m, 19H), 
7.19-7.07 (m, 8H), 6.88-6.84 (m, 1H), 6.78 (d, J = 8.2 Hz, 1H), 6.72 (s, 1H), 4.94 (s, 2H), 
4.75-4.69 (m, 1H), 4.55-4.48 (m, 1H), 4.35-4.25 (m, 1H), 4.20-4.02 (m, 5H), 3.27-3.15 
(m, 1H), 3.07-3.01 (m, 0.5H), 2.95-2.86 (m, 1.5H), 2.77-2.67 (m, 1H), 1.32-1.26 (m, 6H); 
13C NMR (150 MHz, CDCl3) δ171.23-171.11, 157.64-157.52, 143.96-143.92, 142.24-
142.11, 138.18-138.02, 137.09, 137.00-136.89, 130.37, 129.74, 128.59, 128.13-128.11, 
127.93, 127.72-127.71, 127.49-127.39, 127.15-127.12, 125.29, 119.96, 119.52-119.36, 
114.73-114.67, 75.49-75.48, 69.99-69.83, 67.18-67.04, 62.96-62.48, 55.46-54.57, 
47.35-46.32, 34.04-33.75, 31.30-30.66, 16.54-16.40; 31P NMR (162 MHz, CDCl3) 
δ25.25, 25.11.  
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Diethyl N-(τ-trityl-L-histadyl-)-1-amino-2-(4-benzyloxyphenyl)ethyl phosphonate (III-7b)  
Synthesized using diethyl N-(N-fluorenylmethyloxycarbonyl- τ-trityl-L-histadyl-)-1-
amino-2-(4-benzyloxyphenyl)ethyl phosphonate III-7a (170 mg, 0.18 mmol) using 
method E to yield a mixture of diastereomers.  Yellowish foam.  Yield: 104 mg, 62%. 1H 
NMR (600 MHz, CDCl3) δ7.76-7.73 (m, 1H), 7.70-7.60 (m, 1H), 7.33-7.19 (m, 14H), 
7.05-7.02 (m, 7H), 6.77 (d, J = 3.3 Hz, 2H), 6.52 (d, J = 6.3 Hz, 1H), 4.92-4.87 (m, 2H), 
4.62-4.53 (m, 1H), 4.06-3.96 (m, 5H), 3.47-3.35 (m, 0.5H), 3.18-3.05 (m, 1H), 2.80-2.71 
(m, 1H), 2.57-2.53 (m, 0.5H), 2.43-2.32 (m, 1H), 1.22-1.17 (m, 6H); 13C NMR (150 MHz, 
CDCl3) δ174.18-174.20, 157.68-157.65, 142.44, 138.70, 138.45, 137.15, 130.41, 
130.30, 129.80, 129.31-129.03, 128.82-128.69, 128.62-128.61, 128.16, 127.99-127.96, 
127.59-127.47, 127.14-127.13, 119.35-119.34, 114.85-114.79, 75.36-75.35, 70.06-
70.03, 62.70-62.54, 55.89, 48.23-47.88, 46.74-46.52, 45.71-45.49, 35.10-34.89, 33.29-
32.98, 16.62-16.47; 31P NMR (162 MHz, CDCl3) δ25.59, 25.50.  
 
Diethyl N-(N-acetyl-L-isoleucyl-τ-trityl-L-histadyl)-1-amino-2-(4-benzyloxyphenyl)ethyl 
phosphonate (III-7c) 
Synthesized using N-Ac-L-isoleucine-OH III-13 (41 mg, 0.23 mmol), diethyl N-(τ-
trityl-L-histadyl-)-1-amino-2-(4-benzyloxyphenyl)ethyl phosphonate III-7b (190 mg, 0.26 
mmol), HOBt (42 mg, 0.27 mmol), EDC (53 mg, 0.27 mmol) and 2,4,6-trimethylpyridine 
(71 µL, 0.53 mmol) in DMF (3 mL) using method A to yield a mixture of diastereomers.. 
White solid. Yield: 144 mg, 62%. 1H NMR (600 MHz, CDCl3) δ7.64-7.59 (m, 2H), 7.29-
7.18 (m, 14H), 7.04-6.97 (m, 7H), 6.93 (d, J = 8.6 Hz, 1H), 6.74 (d, J = 8.5 Hz, 1H), 6.65 
(d, J = 6.66, 1H), 4.87-4.84 (m, 2H), 4.57-4.49 (m, 2H), 4.29-4.25 (m, 1H), 4.05-3.96 (m, 
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4H), 3.09-2.99 (m, 1H), 2.85-2.65 (m, 2H), 2.59-2.42 (m, 1H), 1.86-1.85 (m, 3H), 1.80-
1.70 (m, 1H), 1.38-1.26 (m, 1H), 1.19-1.11 (m, 6H), 1.07-0.97 (m, 1H), 0.77-0.73 (m, 
6H); 13C NMR (150 MHz, CDCl3) δ171.26, 170.87-170.56, 170.47-170.17, 157.57-
157.53, 142.23-142.16, 138.04-137.83, 137.13-137.10, 136.81-136.70, 130.38-130.28, 
129.77-129.76, 129.44-129.26, 128.77, 128.61-128.53, 128.21-128.17, 127.89-127.87, 
127.51-127.42, 127.09, 119.77-119.36, 114.66, 107.81, 75.54-75.50, 69.97-69.88, 
62.87-62.43, 58.21-57.83, 53.69-52.87, 47.70-46.47, 37.73-37.37, 34.97-34.68, 30.59-
29.39, 25.04-24.67, 23.21-23.18, 16.50-16.36, 15.56-15.34, 11.64-11.59.31P NMR (162 
MHz, CDCl3) δ25.21, 24.94. 
 
Diethyl N-(N-acetyl-L-isoleucyl-τ-trityl-L-histadyl)-1-amino-2-(4-hydoxyphenyl)ethyl 
phosphonate (III-7d) 
Synthesized using diethyl N-(N-acetyl-L-isoleucyl-τ-trityl-L-histadyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate III-7c (120 mg, 0.13 mmol), Pd/C (10% Pd, 13 mg) 
in methanol (4 mL) using method C, to yield a mixture of diastereomers. White solid.  
Yield: 81 mg, 75%.1H NMR (600 MHz, MeOD) δ7.73 (d, J = 7.3 Hz, 1H), 7.49-6.89 (m, 
17H), 6.75-6.66 (m, 1H), 6.48-6.45 (m, 1H), 4.80-4.70 (m, 1H), 4.56-4.35 (m, 1H), 4.23-
3.98 (m, 5H), 3.23-3.01 (m, 1.5H), 3.01-2.92 (m, 1H), 2.86-2.70 (m, 1.5H), 2.02-1.86 (m, 
3H), 1.79-1.70 (m, 1H), 1.59-1.42 (m, 1H), 1.36-1.13 (m, 7H), 0.92-0.88 (m, 6H);  13C 
NMR (150 MHz, MeOD) δ171.13-171.04, 170.86-170.84, 170.30, 157.38-157.25, 
140.31-141.26, 137.31-137.23, 134.85-134.69, 131.39-131.35, 131.04-130.94, 130.89-
130.79, 130.37, 130.11, 129.87-129.71, 129.19, 128.70, 128.50, 127.96-127.88, 
127.23, 124.99, 120.67, 116.32-116.04, 80.01, 64.41-64.23, 60.11-59.78, 57.92, 53.17-
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52.80, 48.19, 37.32-37.02, 35.20-34.82, 29.27-29.01, 26.37-26.12, 22.50-22.43, 16.89-
16.75, 15.86-15.78, 11.33-11.25; 31P NMR (162 MHz, MeOD) δ24.26, 23.93, 23.82.  
 
Ac-Ile-His-AHEP: N-(N-acetyl-L-isoleucyl-L-histadyl)-1-amino-2-(4-hydoxyphenyl)ethyl 
phosphonic acid (III-7) 
Synthesized by first treating diethyl N-(N-acetyl-L-isoleucyl-τ-trityl-L-histadyl)-1-
amino-2-(4-hydoxyphenyl)ethyl phosphonate III-7d (57mg, 0.071 mmol) with method F.  
The resulting residue was concentrated in vaccuo and without further purification or 
characterization was treated with acetonitrile (6 mL), thioanisole (0.6 mL) and I-TMSi 
(3.0 mL) using method D.  The resulting phosphonate trimethylsilyl ester was 
hydrolyzed by treatment with 8:2 isopropanol in water (30 mL). Purified by HPLC, using 
a gradient of 5% acetonitrile in water to 25% acetonitrile in water containing formic acid 
(0.1%) over 30 minutes. White solid.  Yield: 2.9 mg, 8.1%.1H NMR (600 MHz, D2O) 
δ7.62 (s, 1H), 7.12 (d, J= 8.3 Hz, 2H), 6.83 (s, 1H), 6.73 (d, J = 8.3 Hz, 2H), 4.61-4.59 
(m, 1H), 4.09-4.00 (m, 2H), 3.18 (d, J = 14.3 Hz, 1H), 3.09 (dd, J = 15.1, 4.1 Hz, 1H), 
2.99-2.55 (m, 1H), 2.62-2.55 (m, 2H), 2.01 (s, 3H), 1.72-1.67 (m, 1H), 1.32-1.26 (m, 
1H), 1.08-1.01 (m, 1H), 0.81 (t, J = 7.4 Hz, 3H), 0.69 (d, J = 6.3 Hz, 3H); 13C NMR (150 
MHz, D2O) δ173.94, 127.58, 171.01, 154.46, 136.33, 131.03-130.94, 130.52-130.44, 
130.30, 115.54-115.30, 115.24, 58.50-58.34, 52.45, 52.05, 51.13, 36.01, 35.96, 30.20, 
24.38, 21.59, 14.60, 10.15; 31P NMR (162 MHz, D2O) δ16.70. 
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N-acetyl-(τ-trityl-L-histadyl)-L-tryptophan methyl ester (III-8a) 
Synthesized using N-acetyl-(τ-trityl-L-histadyl)-OH III-14 (285 mg, 0.65 mmol), L-
tryptophan methyl ester hydrochloride III-18 (135 mg, 0.62 mmol), HOBt (104.1 mg, 
0.68 mmol), EDC (130.4 mg, 0.68 mmol) and 2,4,6-trimethylpyridine (172 µL, 1.30 
mmol) in DMF (6 mL) using method A. White solid. Yield: 287 mg, 73%.   1H NMR (600 
MHz, CDCl3) δ7.46 (dd, J = 19.6, 7.8 Hz, 2H), 7.34-7.24 (m, 12H), 7.10-7.07 (m, 7H), 
7.03 (t, J = 7.6 Hz, 1H) 6.95 (s, 1H), 6.63 (s, 1H), 4.84-4.81 (m, 1H), 4.73-4.70 (m, 1H), 
3.51 (s, 3H), 3.27 (dd, J = 14.8, 5.6 Hz, 1H), 3.19 (dd, J = 14.8, 5.3 Hz, 1H), 2.98 (dd, J 
= 14.9, 5.9 Hz, 1H), 2.91 (dd, J = 14.7, 5.5 Hz, 1H), 1.76 (s, 3H); 13C NMR (150 MHz, 
CDCl3) δ172.17, 171.15, 170.45, 142.32, 138.28, 136.85, 136.17, 129.80, 128.12, 
127.52, 123.55, 121.88, 119.85, 119.36, 118.52, 111.39, 109.47, 75.45, 53.26, 53.11, 
52.25, 30.18, 27.52, 23.03. 
 
N-acetyl-(τ-trityl-L-histadyl) -L-tryptophan (III-8b) 
  Synthesized using N-acetyl-(τ-trityl-L-histadyl)-L-tryptophan methyl ester III-8a 
(170 mg, 0.27 mmol), methanol (16 mL) and 5% NaOH (4 mL) using method B. White 
solid. Yield: 95 mg, 57%. Rotamers. 1H NMR (600 MHz, MeOD) δ8.42 (s, 1H), 8.02 (dd, 
J = 22.5, 7.9 Hz, 0.5 H), 7.77 (dd, J = 22.4, 7.5 Hz, 0.5 H), 7.56 (d, J = 7.9 Hz, 1H), 
7.45-7.30 (m, 12H), 7.18-6.99 (m, 9H), 4.74-4.66 (m, 2H), 3.40-3.35 (m, 1H), 3.24-3.10 
(m, 2H), 2.96-2.90 (m, 1H), 1.85 (s, 3H); 13C NMR (150 MHz, MeOD) δ175.57-175.22, 
173.71-173.17, 171.77-171.69, 141.63, 137.99-137.62, 132.34, 130.64, 130.02, 129.85, 
129.71, 129.16, 128.73, 128.69-128.61, 128.17-128.03, 124.79-124.64, 122.92-121.99, 
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120.62-119.19, 112.35-112.29, 110.63-110.58, 79.45, 54.86-54.78, 53.41-53.32, 30.75, 
28.86-28.25, 22.61-22.57. 
 
Diethyl N-(N-acetyl-(τ-trityl-L-histadyl) -L-tryptophanyl)-1-amino-2-(4- 
benzyloxyphenyl)ethyl phosphonate (III-8c) 
  Synthesized using N-acetyl-(τ-trityl-L-histadyl) -L-tryptophan III-8b (40 mg, 0.064 
mmol), AHEP III-2 (22 mg, 0.062 mmol), HOBt (10 mg, 0.068 mmol), EDC  (13 mg, 
0.068 mmol) and 2,4,6-trimethylpyridine (17 L, 0.13 mmol) in DMF (1 mL) using 
method A to give a mixture of diastereomers. Tan foam. Yield:  40 mg, 64%. 1H NMR 
(600 MHz, CDCl3) δ7.64-7.58 (m, 0.5H), 7.54-7.43 (m, 0.5H), 7.40-7.17 (m, 16H), 7.15-
7.07 (m, 1H), 7.06-6.99 (m, 6H), 6.95-6.84 (m, 2H), 6.80-6.69 (m, 4H), 6.68-6.54 (m, 
1H), 4.98 -4.83 (m, 2H), 4.70-4.59 (m, 1.5H), 4.36-4.24 (m, 0.5H), 4.06-3.89 (m, 5H), 
3.20-3.16 (m, 1H), 3.10-2.92 (m, 2H), 2.88-2.61 (m, 3H), 1.78 (s, 1.5H), 1.40 (s, 1.5H), 
1.23-1.11 (m, 6H); 13C NMR (150 MHz, CDCl3) δ712.93-172.70, 172.31, 171.80-171.76, 
159.73-159.62, 159.13, 144.13, 140.53, 139.03-139.00, 138.33-137.68, 132.19-123.07, 
131.66, 130.72-130.71, 130.54-130.50, 130.21-130.14, 129.90-129.74, 129.47, 129.09-
129.05, 128.89, 126.13-125.72, 123.89-123.73, 122.99, 122.12-121.36, 120.36-120.11, 
116.81-116.75, 113.33-113.27, 110.68, 109.79, 77.51, 72.18-71.94, 65.08-64.39, 62.39, 
56.32-55.87, 49.63-47.70, 36.71-35.59, 31.67-31.08, 28.12, 24.79-23.03, 18.51-18.39; 
31P NMR (162 MHz, CDCl3) δ25.74, 25.33, 24.92, 24.82. 
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Ac-His-Trp-AHEP: N-(N-acetyl-L-histadyl-L-tryptophanyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonic acid (III-8)   
Synthesized by first treating diethyl N-(N-acetyl-(τ-trityl-L-histadyl) -L-
tryptophanyl)-1-amino-2-(4-benzyloxyphenyl)ethyl phosphonate (III-8c) (35mg, 0.036 
mmol) with Pd/C (10% Pd, 13 mg) in methanol (4 mL) using method C followed by 
method F without purification of characterization of the intermediates.  The resulting 
residue was treated with acetonitrile (2 mL), thioanisole (0.2 mL) and I-TMSi (1.0 mL) 
using method D.  The phosphonate trimethylsilyl ester was hydrolyzed by treatment with 
8:2 isopropanol in water (30 mL). Purified by HPLC, using a gradient of 5% acetonitrile 
in water to 25% acetonitrile in water containing formic acid (0.1%) over 30 minutes. 
White solid.  Yield: 0.77 mg, 2.6%. 1H NMR (600 MHz,D2O) δ8.46 (s, 2H), 7.59 (d, J = 
8.0 Hz, 1H), 7.48 (d, J = 8.2 Hz, 1H), 7.24 (t, J = 7.3 Hz, 1H), 7.15 (t, J = 7.4 Hz, 1H), 
7.11-7.09 (m, 3H), 6.75 (d, J = 8.1 Hz, 2H), 4.64-4.57 (m, 1H), 4.44-4.4qw20 (m, 1H), 
4.16-4.11 (m, 1H), 3.22-3.17 (m, 2H), 2.87-2.80 (m, 2H), 2.75-2.70 (m, 1H), 2.64-2.58 
(m, 1H), 1.74 (s, 3H); 13C NMR (150 MHz,D2O) δ173.43, 172.22, 171.02, 154.35, 
136.00, 131.00, 130.51, 126.89, 124.26, 121.76, 119.20, 118.30, 115.24, 111.74, 
109.32, 53.86, 53.14, 36.41, 28.34, 26.96, 23.24; 31P NMR (162 MHz, D2O) δ16.49.  
 
N-acetyl-L-leucyl-O-benzyl-L-tyrosine methyl ester (III-9a) 
  Synthesized using N-Ac-L-leucine-OH III-15 (112 mg, 0.65 mmol), O-benzyl-L-
tyrosine methyl ester hydrochloride III-20 (200 mg, 0.62 mmol), HOBt (104 mg, 0.68 
mmol), EDC (130 mg, 0.68mmol) and 2,4,6-trimethylpyridine (172 L, 1.3 mmol) in DMF 
(6 mL) using method A. White solid. Yield 185 mg, 68%. 1H NMR (600 MHz, CDCl3) 
113 
 
δ7.41 (d, J = 7.6 Hz, 2H), 7.37 (t, J = 7.3 Hz, 2H), 7.32 (t, J = 7.4 Hz, 1H), 7.03 (d, J = 
8.5 Hz, 2H), 6.89 (d,  J = 8.6 Hz, 2H), 6.73 (d,  J = 7.8 Hz, 1H), 6.21 (d,  J = 8.3 Hz, 1H), 
5.02 (s, 3H), 4.79 (dd, J = 13.9, 6.2 Hz, 1H), 4.49-4.36 (m, 1H), 3.70 (s, 3H), 3.07 (dd, J 
= 14.0, 5.7 Hz, 1H), 3.00 (dd, J = 14.0, 6.5 Hz, 1H), 1.95 (s, 3H), 1.66-1.58 (m, 2H), 
1.52-1.48 (m, 1H), 0.91 (t, J = 7.3 Hz, 6H);   13C NMR (150 MHz, CDCl3) δ171.05, 
171.83, 170.25, 158.01, 137.08, 130.44, 128.68, 127.59, 115.02, 70.04, 52.53, 52.42, 
51.68, 41.17, 37.15, 24.80, 23.15, 22.91, 22.31.  
 
N-acetyl-L-leucyl-O-benzyl-L-tyrosine (III-9b) 
  Synthesized using N-acetyl-L-leucyl-O-benzyl-L-tyrosine methyl ester III-9a (178 
mg, 0.40 mmol), methanol (16 mL) and 5% NaOH (4 mL) using method B. White solid. 
Yield: 153 mg, 90%.1H NMR (400 MHz, MeOD) δ7.34 (d, J = 7.3 Hz, 2H), 7.28 (t, J = 
7.1 Hz, 2H), 7.22 (t, J = 7.2 Hz, 1H), 7.05 (d, J = 8.6 Hz, 2H), 6.82 (d, J = 8.6 Hz, 2H), 
4.96 (s, 2H), 4.54 (dd, J = 8.1, 5.2 Hz, 1H), 4.33 (dd, J = 9.3, 5.8 Hz, 1H), 3.06 (dd, J = 
14.0, 5.2 Hz, 1H), 2.86 (dd, J = 13.6, 8.2 Hz, 1H), 1.94 (s, 3H), 1.60-1.49 (m, 1H), 1.48-
1.37 (m, 2H), 0.84 (dd, J = 16.8, 6.5 Hz, 6H); 13C NMR (100 MHz, MeOD) δ174.47-
174.40, 173.46, 173.140173.03, 159.14, 138.77, 131.46, 130.39, 129.49, 115.32, 70.94, 
54.95, 52.98, 41.69, 37.45, 25.82, 23.33, 22.42, 22.03.  
 
Diethyl N-(N-acetyl-L-leucyl-O-benzyl-L-tyrosyl)-1-amino-2-(4-benzyloxyphenyl)ethyl 
phosphonate (III-9c) 
  Synthesized using N-acetyl-L-leucyl-O-benzyl-L-tyrosine III-9b (140 mg, 0.32 
mmol), AHEP III-2 (109 mg, 0.30 mmol), HOBt (52 mg, 0.34 mmol), EDC (65 mg, 0.34 
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mmol) and 2,4,6-trimethylpyridine (84 L, 0.63 mmol) in DMF (3 mL) using method A to 
give a mixture of diastereomers. Clear oil. Yield:  134 mg, 53%. 1H NMR (600 MHz, 
CDCl3) δ7.37-7.26 (m, 10H), 7.18-6.99 (m, 4H), 6.93-6.74 (m, 4H), 4.98-4.87 (m, 4H), 
4.87-4.75 (m, 1H), 4.68-4.60 (m, 1H), 4.49-4.44 (m, 1H), 4.15-4.00 (m, 4H), 3.15-3.08 
(m, 1H), 3.00-2.93 (m, 1H), 2.89-2.75 (m, 2H), 1.97-1.92 (m, 3H), 1.60-1.53 (m, 1H), 
1.53-1.45 (m, 1H), 1.32-1.19 (m, 7H), 0.91-0.81 (m, 6H); 13C NMR (150 MHz, CDCl3) 
δ172.40-172.18, 171.26-170.87, 170.56-170.44, 157.95-157.68, 137.20-136.97, 130.65-
130.42, 130.21, 129.13-129.05, 128.73-128.62, 128.61-128.55, 127.96-127.93, 127.54-
127.49, 70.04-69.88, 63.76-62.53, 54.08-53.75, 51.83-51.70, 47.35-46.22, 41.45-40.93, 
37.64-37.57, 35.07-34.70, 24.78, 22.96-22.87, 22.35-22.24, 22.07, 16.57-16.40; 31P 
NMR (162 MHz, CDCl3) δ25.09, 25.02.  
 
Diethyl N-(N-acetyl-L-leucyl-O-benzyl-L-tyrosyl)-1-amino-2-(4-hydoxyphenyl)ethyl 
phosphonate (III-9d) 
  Synthesized using diethyl N-(N-acetyl-L-leucyl-O-benzyl-L-tyrosyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate III-9c (120 mg, 0.15 mmol), Pd/C (10% Pd, 15 mg) 
in methanol (3 mL) using method C, to yield a mixture of diastereomers. Clear oil.  Yield: 
45 mg, 51%. 1H NMR (600 MHz, MeOD) δ7.10-6.99 (m, 4H), 6.75-6.61 (m, 4H), 4.57-
4.50 (m, 2H), 4.33-4.27 (m, 1H), 4.20-4.06 (m, 4H), 3.16-3.08 (m, 1H), 2.98-2.93 (m, 
1H), 2.84-2.76 (m, 1H), 2.74-2.67 (m, 1H), 1.98-1.94 (m, 4H), 1.58-1.51 (m, 1H), 1.45-
1.38 (m, 1H), 1.37-1.29 (m, 6H), 0.97-0.85 (m, 6H); 13C NMR (150 MHz, D2O) δ174.56-
174.15, 173.36, 173.18-173.09, 157.43-157.07, 131.35-131.28, 131.15-131.08, 128.98-
128.88, 128.67-128.51, 116.31-115.99, 64.50-64.17, 55.68-55.18, 53.29-53.15, 48.33-
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48.06, 41.69-48.06, 41.69-41.37, 38.22-38.12, 35.25-34.95, 25.76, 23.31-23.27, 22.43, 
21.92, 16.85-16.71; 31P NMR (162 MHz, MeOD) δ25.49.  
 
Ac-Leu-Tyr-AHEP: N-(N-acetyl-L-leucyl-L-tyrosyl)-1-amino-2-(4-hydoxyphenyl)ethyl 
phosphonic acid (III-9) 
  Synthesized using diethyl N-(N-acetyl-L-leucyl-O-benzyl-L-tyrosyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate III-9d (21 mg, 0.036 mmol), acetonitrile (4 mL), 
thioanisole (0.4 mL) and I-TMSi (2.0 mL) using method D.  The phosphonate 
trimethylsilyl ester was hydrolyzed by treatment with 8:2 methanol in water (20 mL). 
Purified by HPLC, using a gradient of 5% acetonitrile in water to 25% acetonitrile in 
water containing ammonium acetate (10 mM) over 30 minutes. White solid.  Yield: 1.8 
mg, 8.4%. 1H NMR (600 MHz, D2O) δ7.14 (d, J = 8.3 Hz, 2H), 7.07 (d, J = 8.3Hz, 2H), 
6.79 (dd, J = 8.2, 4.6 Hz, 4H), 4.57 (dd, J = 10.3, 3.8 Hz, 1H), 4.25-4.15 (m, 2H), 3.19 
(d, J = 13.9 Hz, 1H), 3.05 (dd, J = 14.1, 3.7 Hz, 1H), 2.69-2.63 (m, 2H), 1.94 (s, 3H), 
1.46-1.39 (m, 1H), 1.38-1.33 (m, 1H), 1.24-1.19 (m, 1H), 0.86 (d, J = 6.6 Hz, 3H), 0.81 
(d, J = 6.5 Hz, 3H);  13C NMR (150 MHz, D2O) δ 173.66, 173.57, 171.85, 157.09, 
153.81, 130.62, 130.38, 128.49, 115.18, 115.07, 54.08, 52.03, 50.93, 49.99, 39.61, 
36.60, 35.09, 24.15, 21.96, 21.58, 20.70; 31P NMR (162 MHz,D2O) δ18.02.  
 
N-acetyl-L-leucyl-L-isoleucine methyl ester (III-10a) 
  Synthesized using N-Ac-L-leucine-OH III-15 (112 mg, 0.65 mmol), L-isoleucine 
methyl ester hydrochloride III-20 (99 mg, 0.62 mmol), HOBt (104 mg, 0.68 mmol), EDC 
(130 mg, 0.68mmol) and 2,4,6-trimethylpyridine (172 L, 1.3 mmol) in DMF (6 mL) 
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using method A. White solid. Yield 150 mg, 81%. 1H NMR (600 MHz, CDCl3) δ7.73 (d, J 
= 8.1 Hz, 1H), 7.63 (d, J = 8.4 Hz, 1H), 4.72 (dd, J = 14.8, 8.6 Hz, 1H), 4.48 (dd, J = 8.1, 
5.2 Hz, 1H), 3.74 (s, 3H), 1.95 (s, 3H), 1.89-1.84 (m, 1H), 1.71-1.65 (m, 1H), 1.63-1.58 
(m, 1H), 1.57-1.52 (m, 1H), 1.44-1.37 (m, 1H), 1.24-1.16 (m, 1H), 0.92-0.84 (m, 12H); 
13C NMR (150 MHz, CDCl3) δ173.27, 172.04, 170.40, 56.65, 51.87, 51.45, 41.21, 37.17, 
24.97, 24.50, 22.70, 22.63, 22.12, 15.34, 11.52.  
 
N-acetyl-L-leucyl-L-isoleucine (III-10b) 
  Synthesized using N-acetyl-L-leucyl-L-isoleucine methyl ester III-10a (138 mg, 
0.46 mmol), methanol (16 mL) and 5% NaOH (4 mL) using method B. White solid. Yield: 
108 mg, 82%.1H NMR (400 MHz, MeOD) δ4.45 (dd, J = 9.0, 6.2 Hz, 1H), 4.37-4.33 (m, 
1H), 1.97 (s, 3H), 1.94-1.85 (m, 1H), 1.73-1.63 (m, 1H), 1.60-1.47 (m, 3H), 1.30-1.20 
(m, 1H), 0.98-0.90 (m, 12H); 13C NMR (101 MHz, MeOD) δ174.89, 174.62, 173.27, 
58.06, 53.14, 41.68, 38.38, 26.15, 25.85, 23.36, 22.33, 22.07, 15.98, 11.84.  
 
Diethyl N-(N-acetyl-L-leucyl-L-isoleucyl)-1-amino-2-(4-benzyloxyphenyl)ethyl 
phosphonate (III-10c) 
  Synthesized using N-acetyl-L-leucyl-L-isoleucine III-10b (87 mg, 0.30 mmol), 
AHEP III-2 (104 mg, 0.29 mmol), HOBt (48 mg, 0.31 mmol), EDC (60 mg, 0.31 mmol) 
and 2,4,6-trimethylpyridine (80 L, 0.60 mmol) in DMF (3 mL) using method A to give a 
mixture of diastereomers. Tan foam. Yield:  130 mg, 67%.1H NMR (600 MHz, CDCl3) 
δ7.41-7.27 (m, 5H), 7.16-7.11 (m, 2H), 6.89-6.80 (m, 2H), 5.01-4.90 (m, 2H), 4.71-4.48 
(m, 2H), 4.13-4.01 (m, 5H), 3.21-3.02 (m, 1H), 2.91-2.79 (m, 1H), 2.03-1.98 (m, 3H), 
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1.78-1.69 (m, 0.5H), 1.67-1.58 (m, 1.5H), 1.58-1.51 (m, 1H), 1.51-1.42 (m, 1H), 1.40-
1.19 (m, 7H), 1.12-0.99 (m, 1H), 0.98-0.77 (m, 6H); 13C NMR (151 MHz, CDCl3) 
δ172.55-172.33, 171.04-170.96, 170.45-170.32, 157.76-157.60, 137.14-137.00, 130.22-
130.17, 130.10, 129.33-129.03, 128.58-128.50, 127.94-127.88, 127.48-127.40, 114.89-
114.72, 70.03-69.83, 63.01-62.37, 57.61-56.63, 52.08-51.63, 47.37-45.90, 41.76-41.09, 
37.98-37.19, 34.95-34.47, 24.85-24.70, 23.09-23.00, 22.89-22.82, 22.28-22.22, 16.61-
16.36, 15.01-14.75, 11.77-11.55; 31P NMR (162 MHz, CDCl3) δ25.26, 25.16.  
 
Diethyl N-(N-acetyl-L-leucyl-L-isoleucyl)-1-amino-2-(4-hydoxyphenyl)ethyl phosphonate 
(III-10d) 
  Synthesized using N-(N-acetyl-L-leucyl-L-isoleucyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate III-10c (113 mg, 0.18 mmol), Pd/C (10% Pd, 15 mg) 
in methanol (3 mL) using method C, to yield a mixture of diastereomers. Clear oil.  Yield: 
56 mg, 58%. 1H NMR (600 MHz, MeOD) δ7.08-7.02 (m, 2H), 6.69-6.66 (m, 2H), 4.61-
4.49 (m, 1H), 4.40-4.34 (m, 1H), 4.20 (d, J = 7.5 Hz, 1H), 4.16-4.12 (m, 4H), 3.17-3.06 
(m, 1H), 2.80-2.72 (m, 1H), 2.10-1.97 (m, 3H), 1.89-1.80 (m, 0.5H), 1.77-1.70 (m, 0.5H), 
1.69-1.50 (m, 3H), 1.45-1.39 (m, 1H), 1.37-1.28 (m, 6H), 1.21-1.14 (m, 0.5H), 1,14-1.04 
(m, 0.5H), 0.98-0.83 (m, 6H); 13C NMR (150 MHz, MeOD) δ174.41-174.30, 173.39-
173.31, 173.06, 157.37-157.21, 131.10-130.99, 128.98-128.83, 116.31-116.19, 64.28-
64.03, 58.83-58.65, 53.19, 47.89-47.80, 41.71-41.35, 38.53-37.99, 34.90-34.65, 25.94-
25.52, 23.48-23.13, 22.38-22.29, 21.84-21.79, 16.96-16.67, 15.64-15.44, 11.39-11.29; 
31P NMR (162 MHz, MeOD) δ25.72, 25.48.  
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Ac-Leu-Ile-AHEP: N-(N-acetyl-L-leucyl-L-isoleucine)-1-amino-2-(4-hydoxyphenyl)ethyl 
phosphonic acid  (III-10) 
  Synthesized using diethyl N-(N-acetyl-L-leucyl-L-isoleucyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate III-10d (24 mg, 0.044 mmol), acetonitrile (4 mL), 
thioanisole (0.4 mL) and I-TMSi (2.0 mL) using method D.  The phosphonate 
trimethylsilyl ester was hydrolyzed by treatment with 8:2 methanol in water (20 mL). 
Purified by HPLC, using a gradient of 5% acetonitrile in water to 25% acetonitrile in 
water containing ammonium acetate (10 mM) over 30 minutes. White solid. Yield: 1.9 
mg, 8.9%. 1H NMR (600 MHz, D2O) δ7.22 (d, J= 8.5 Hz, 2H), 6.86 (d, J= 8.5 Hz, 2H), 
4.32 (dd, J = 10.6, 4.4 Hz, 1H), 4.29-4.00 (m, 1H), 4.20 (d, J = 8.5 Hz, 1H), 3.25 (d, J = 
14.1 Hz, 1H), 2.74 (t, J = 12.6 Hz, 1H), 2.10 (s, 3H), 1.84-1.76 (m, 1H), 1.70-1.59 (m, 
2H), 1.41-1.33 (m, 2H), 1.16-1.09 (m, 1H), 1.01 (d, J = 6.5 Hz, 3H), 0.94 (d, J = 6.5 Hz, 
3H), 0.92 (d, J = 6.9 Hz, 3H), 0.88 (t, J = 7.4 Hz, 3H);  13C NMR (151 MHz, D2O) 
δ174.05, 173.86, 172.19, 153.72, 130.30, 130.11, 115.06, 57.75, 52.28, 50.58, 49.60, 
39.37, 36.56, 34.67, 24.27, 23.99, 22.13, 21.44, 20.46, 14.55, 9.78; 31P NMR (162 
MHz,D2O) δ18.68.  
 
N-acetyl-O-tert-butyl-L-tyrosyl-L-isoleucine methyl ester (III-11a)  
  Synthesized using N-acetyl-O-tert-butyl-L-tyrosine III-16 (182 mg, 0.65 mmol), L-
isoleucine methyl ester hydrochloride III-20 (90 mg, 0.62 mmol), HOBt (104 mg, 0.68 
mmol), EDC (130 mg, 0.68mmol) and 2,4,6-trimethylpyridine (172 L, 1.3 mmol) in DMF 
(6 mL) using method A. Clear oil. Yield:  223 mg, 89%.   1H NMR (400 MHz, CDCl3) δ 
7.08 (d, J = 8.2 Hz, 2H), 6.86 (dd, J = 8.3, 1.1 Hz, 2H), 4.82-4.68 (m, 1H), 4.44 (dd, J = 
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8.3, 5.1 Hz, 1H), 3.68 (s, 3H), 2.97 (d, J = 7.2 Hz, 2H), 1.93 (s, 3H), 1.86-1.68 (m, 1H), 
1.41-1.24 (m, 1H), 1.29 (s, 9H), 1.15-0.96 (m, 1H), 0.88-0.71 (m, 6H); 13C NMR (100 
MHz, CDCl3) δ 171.72, 171.51, 170.06, 154.18, 131.23, 129.56, 124.07, 78.20, 56.58, 
54.42, 51.91, 37.53, 28.70, 25.00, 22.88, 15.25, 11.41. 
 
N-acetyl-O-tert-butyl-L-tyrosyl-L-isoleucine (III-11b) 
  Synthesized using of N-acetyl-O-tert-butyl-L-tyrosyl-L-isoleucine methyl ester III-
11a (205 mg, 0.51 mmol), methanol (20 mL) and 5% NaOH (5 mL) using method B. 
Clear oil. Yield: 184 mg, 52%. 1H NMR (400 MHz, MeOD) δ 7.08 (d, J = 8.4 Hz, 2H), 
6.81 (dd, J = 8.5, 2.1 Hz, 2H), 4.67-4.59 (m, 1H), 4.30 (d, J = 5.5 Hz, 0.7H). 4.23 (d, J = 
5.4 Hz, 0.3H), 3.04-2.92 (m, 2H), 2.81-2.70 (m, 2H), 1.83 (s, 0.7H), 1.81 (s, 2.3 H), 
1.85-1.64 (m, 1H), 1.49-1.37 (m, 1H), 1.22 (s, 9H), 1.33-1.11 (m, 0.5H), 1.06-0.93 (m, 
0.5H), 0.86-0.71 (m, 6H);   13C NMR (100 MHz, MeOD) δ174.40, 173.69, 173.19-
172.90, 155.24-155.08, 133.53, 130.82, 130.79, 125.12, 79.50-79.42, 58.06-57.97, 
55.99-55.90, 38.23-38.12, 38.58, 29.16, 26.12, 22.41-22.34, 15.97, 11.86. 
 
Diethyl N-(N-acetyl-O-tert-butyl-L-tyrosyl-L-isoleucyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (III-11c)  
  Synthesized using N-acetyl-O-tert-butyl-L-tyrosyl-L-isoleucine III-11b (184 mg, 
0.47 mmol), AHEP III-2 (163 mg, 0.45 mmol), HOBt (75 mg, 0.49 mmol), EDC (95 mg, 
0.49 mmol) and 2,4,6-trimethylpyridine (130 L, 0.99 mmol) in DMF (5 mL) using 
method A to give a mixture of diastereomers. Yellowish foam. Yield:  172 mg, 52%.  1H 
NMR (400 MHz, CDCl3) δ7.43-7.19 (m, 5H), 7.18-7.06 (m, 4H), 6.90-6.78 (m, 4H), 5.02-
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4.91 (m, 2H), 4.83-4.66 (m, 1H), 4.65-4.51 (m, 1H), 4.20-3.98 (m, 5H), 3.24-3.00 (m, 
2H), 3.00-2.79 (m, 2H), 2.00-1.85 (m, 3H), 1.81-1.49 (m, 1H), 1.48-1.33 (m, 0.5H), 1.34-
1.20 (m, 15H), 1.21-0.93 (1.5H), 0.91-0.30 (6H); 13C NMR (100 MHz, CDCl3) δ171.68, 
171.41-170.64, 170.36-169.98, 157.79-157.46, 154.28-153.95, 137.09-136.82, 131.92-
131.27, 130.11, 129.80-129.60, 129.52-128.64, 128.56-128.34, 127.91-127.69, 127.48-
127.26, 124.12-123.85, 114.84-114.58, 78.26-78.04, 69.91, 63.66-63.08, 62.90-62.10, 
57.79-56.44, 55.39-54.30, 47.75-47.00, 45.90-45.45, 44.21-43.96, 38.06-36.91, 34.97-
34.22, 28.72, 25.92-24.23, 22.88-22.58, 16.58-16.28, 14.19-14.09, 11.74-11.34;  31P 
NMR (162 MHz, CDCl3) δ 25.37-24.79. 
 
Diethyl N-(N-acetyl-O-tert-butyl-L-tyrosyl-L-isoleucyl)-1-amino-2-(4-hydoxyphenyl)ethyl 
phosphonate (III-11d)  
  Synthesized using diethyl N-(N-acetyl-O-tert-butyl-L-tyrosyl-L-isoleucyl)-1-amino-
2-(4-benzyloxyphenyl)ethyl phosphonate III-11c (165 mg, 0.22 mmol), Pd/C (10% Pd, 
20 mg) in methanol (5 mL) using method C, to yield a mixture of diastereomers. 
Yellowish oil.  Yield: 77 mg, 76%. 1H NMR (400 MHz, MeOD) δ 7.21-7.13 (m, 2H), 7.11-
7.05 (m, 2H), 6.96-6.89 (m, 2H), 6.75-6.67 (m, 2H), 4.68-4.43 (m, 2H), 4.28-4.11 (m, 
5H), 3.20-3.00 (m, 2H) 2.99-2.70 (m, 2H), 2.02-1.80 (m, 3H), 1.83-1.68 (m, 1H), 1.68-
1.51 (m, 0.5H), 1.40 -1.29 (m, 15H), 1.24-1.03 (m, 1.5H), 1.00-0.84 (m, 2H), 0.84-0.68 
(m, 2H), 0.68-0.45 (m, 2H); 13C NMR (100 MHz, MeOD) δ174.02-173.42, 173.41-
173.06, 171.05-172.51, 157.46-157.05, 155.35-154.99, 133.83-133.73, 131.42-130.95, 
130.78-130.59, 129.23-128.51, 125.15, 116.44-116.01, 79.34-79.32, 65.20-65.04, 
64.33-64.06, 59.27-58.56, 56.86-55.86, 49.46-47.44, 38.39-37.63, 35.14-34.48, 29.15, 
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27.19-24.89, 22.45-22.32, 16.78-16.67, 15.77-15.45, 11.99-11.30;  31P NMR (162 MHz, 
MeOD) δ 25.77-25.15. 
 
Diethyl N-(N-acetyl-L-tyrosyl-L-isoleucyl)-1-amino-2-(4-hydoxyphenyl)ethyl phosphonate 
(III-11e)  
  Synthesized using diethyl N-(N-acetyl-O-tert-butyl-L-tyrosyl-L-isoleucyl)-1-amino-
2-(4-hydoxyphenyl)ethyl phosphonate III-11d (80 mg, 0.12 mmol) using method F, to 
yield a mixture of diastereomers. Yellowish oil.  Yield: 47 mg, 64%.  1H NMR (600 MHz, 
MeOD) δ 6.92-6.87 (m, 4H), 6.55-6.49 (m, 4H), 4.46-4.30 (m, 2H), 4.08-3.94 (m, 5H), 
2.96-2.88 (m, 1H), 2.85-2.71 (m, 1H)2.68-2.50 (m, 2H), 1.84-1.70 (m, 3H), 1.62-1.52 (m, 
0.5H), 1.52-1.44 (m, 0.25H), 1.42-1.34 (m, 0.25H), 1.28-1.05 (m, 7H), 1.05-0.94 (m, 
0.5H), 0.93-0.83 (m, 0.5H), 0.76-0.25 (m, 6H); 13C NMR (150 MHz, MeOD) 174.14-
173.57, 173.35, 173.35-173.06, 160.55-159.64, 157.40-157.12, 131.32-131.21, 131.17-
131.08, 129.30-128.50, 116.31-116.17, 65.20-65.04, 64.51-64.02, 59.29-57.79, 57.11-
56.20, 48.32-46.49, 38.49-36.98, 35.34-34.50, 27.01-24.95, 22.51-22.31, 16.87-16.59, 
15.81-15.46, 12.02-11.26;  31P NMR (162 MHz, MeOD) δ 25.67, 25.45, 25.17. 
 
Ac-Tyr-Ile-AHEP: N-(N-acetyl-L-tyrosyl-L-isoleucyl)-1-amino-2-(4-hydoxyphenyl)ethyl 
phosphonic acid (III-11) 
  Synthesized using diethyl N-(N-acetyl-L-tyrosyl-L-isoleucyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate III-11e (23 mg, 0.039 mmol), acetonitrile (4 mL), 
thioanisole (0.4 mL) and I-TMSi (2.0 mL) using method D.  The phosphonate 
trimethylsilyl ester was hydrolyzed by treatment with 8:2 methanol in water (20 mL). 
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Purified by HPLC, using a gradient of 5% acetonitrile in water to 25% acetonitrile in 
water containing ammonium acetate (10 mM) over 30 minutes. White solid.  Yield: 2.5 
mg, 12%. 1H NMR (600 MHz, D2O) δ7.16 (d, J = 8.4 Hz, 2H), 7.07 (d, J = 8.5 Hz, 2H), 
6.83 (d, J = 8.5 Hz, 2H), 6.78 (d, J = 8.5 Hz, 2H), 4.43 (dd, J = 9.8, 5.2 Hz, 1H), 4.28-
4.22 (m, 1H), 4.11 (d, J = 8.8 Hz, 1H), 3.19 (d, J = 14.2 Hz, 1H), 2.84 (dd, J = 14.3, 5.1 
Hz, 1H), 2.75-2.65 (m, 1H), 1.91 (s, 3H), 1.72-1.66 (m, 1H), 1.27-1.21 (m, 1H), 1.04-
0.96 (m, 1H), 0.82 (d, J = 6.8, 3H), 0.78 (t, J = 7.32 Hz, 3H); 13C NMR (150, D2O) 
173.91, 172.62, 172.03, 154.23, 153.89, 130.41, 128.60, 115.37, 115.12, 57.99, 55.09, 
50.65, 49.63, 26.43, 26.14, 24.67, 24.04, 21.46, 14.54, 9.82;  31P NMR (162 MHz, D2O) 
δ 18.67. 
 
N-acetyl-L-prolinyl-O-benzyl-L-tyrosine methyl ester (III-12a) 
  Synthesized using N-acetyl-L-proline III-17 (102 mg, 0.65 mmol), O-benzyl-L-
tyrosine methyl ester hydrochloride III-20 (200 mg, 0.62 mmol), HOBt (104 mg, 0.68 
mmol), EDC (130 mg, 0.68 mmol) and 2,4,6-trimethylpyridine (172 L, 1.3 mmol) in 
DMF (6 mL) using method A. Clear oil. Yield:  191 mg, 73%. Rotamers. 1H NMR (400 
MHz, CDCl3) δ7.37-7.26 (m, 5H), 7.06-6.99 (m, 2H), 6.89-6.81 (m, 2H), 4.99 (s, 0.6H), 
4.97 (s, 1.4H), 4.79-4.75 (m, 0.3H), 4.75-4.70 (m, 0.7H), 4.49 (dd, J = 8.0, 1.7 Hz, 0.7 
H), 4.18 (dd, J  = 8.7, 2.2 Hz, 0.3H), 3.68 (s, 0.7H), 3.65 (s, 2.3 H), 3.45-3.41 (m, 0.5H), 
3.24 (dd, J = 8.0, 5.4 Hz, 1.5H), 3.17-3.05 (m, 1H), 2.95-2.85 (m, 1H), 2.30-2.24 (m, 
1H), 1.95 (s, 0.7H), 1.93 (s, 2.3H), 1.91-1.81 (m, 2H), 1.75-1.67 (m, 1H);  13C NMR (100 
MHz, CDCl3) δ171.78, 170.80, 170.62, 157.56, 136.95, 130.21, 129.92, 128.44, 127.81, 
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127.29, 114.86, 114.59, 69.80, 69.76. 59.20, 53.20, 53.06, 52.24, 52.12, 47.92, 36.88, 
27.08, 24.69, 22.29-22.13. 
 
N-acetyl-L-prolinyl-O-benzyl-L-tyrosine (III-12b) 
  Synthesized using N-acetyl-L-prolinyl-O-benzyl-L-tyrosine methyl ester III-12a 
(220 mg, 0.52 mmol), methanol (12 mL) and 5% NaOH (3 mL) using method B. White 
solid. Yield: 134 mg, 63%. 1H NMR (600 MHz, MeOD) δ7.42-7.39 (m, 2H), 7.34 (t, J = 
7.4 Hz, 2H), 7.28 (t, J = 7.3 Hz, 1H), 7.14 (t, J = 8.76 Hz, 2H), 6.89 (dd, J = 8.5, 6.6 Hz, 
2H), 5.04 (s, 2H), 4.71 (dd, J = 10.9, 4.4 Hz, 0.5H), 4.61 (dd, J = 7.5, 5.5 Hz, 0.5H), 4.42 
(dd, J = 8.8, 3.4 Hz, 0.5H), 4.26 (dd, J = 8.8, 2.8 Hz, 0.5H), 3.54-3.46 (m, 1H), 3.42-3.37 
(m, 1H), 3.25 (dd, J = 14.2, 4.5 Hz, 0.5H), 3.11 (dd, J = 14.1, 5.4 Hz, 0.5H), 2.96 (dd, J 
= 14.1, 7.6 Hz, 0.5H), 2.89-2.85 (m, 0.5H), 2.23-2.18 (m, 0.5H), 2.09-2.02 (m, 0.5H), 
2.04 (s, 1.5H), 2.00 (s, 1.5H), 1.99-1.93 (m, 0.5H), 1.92-1.85 (m, 1.5H), 1.78-1.72 (m, 
0.5H), 1.71-1.66 (m, 0.5H); 13C NMR (100 MHz, MeOD) δ176.77, 174.40-174.13, 
173.48, 159.13-159.11, 138.85-138.77, 131.49, 131.18, 130.84, 130.38, 129.49-129.48, 
128.83-128.81, 128.49-128.47, 115.96, 115.84, 74.14, 70.91-70.90, 62.56, 60.99, 55.03, 
54.67, 47.90, 37.39, 37.22, 23.92, 30.43, 25.50, 23.62, 22.19, 22.07.  
 
Diethyl N-(N-acetyl-L-prolinyl-O-benzyl-L-tyrosyl)-1-amino-2-(4-benzyloxyphenyl)ethyl 
phosphonate (III-12c) 
  Synthesized using N-acetyl-L-prolinyl-O-benzyl-L-tyrosine III-12b (134 mg, 0.33 
mmol), AHEP III-2 (112 mg, 0.31 mmol), HOBt (52 mg, 0.34 mmol), EDC  (65 mg, 0.34 
mmol) and 2,4,6-trimethylpyridine (90 L, 0.68 mmol) in DMF (4 mL) using method A to 
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give a mixture of diastereomers. Clear oil. Yield:  126 mg, 50%.   1H NMR (400 MHz, 
CDCl3) δ7.40-7.26 (m, 10H), 7.18-7.12 (m, 2H), 7.05-6.93 (m, 2H), 6.91-6.83 (m, 2H), 
6.83-6.73 (m, 2H), 5.02-4.94 (m, 4H), 4.82-4.67 (m, 1H), 4.67-4.55 (m, 1H), 4.43-4.32 
(m, 0.5H), 4.18-4.02 (m, 4.5H), 3.43-3.36 (m, 0.5H), 3.27-3.07 (m, 2.5H), 3.03-2.96 (m, 
0.5H), 2.93-2.77 (m, 1.5H), 2.76-2.67 (m, 1H), 2.19-2.12 (m, 0.5H), 2.12-1.97 (m, 2H), 
1.92 (s, 0.5H), 1.88-1.83 (m, 1.5H), 1.83-1.67 (m, 2.5H), 1.36-1.22 (m, 6H); 13C NMR 
(100 MHz, CDCl3) δ171.15-171.12, 170.92-170.87, 170.69-170.65, 157.73-157.46, 
137.09-137.03, 130.35, 130.21, 130.17, 129.25, 129.14-129.06, 128.57-128.50, 127.96-
127.83, 127.47-127.39, 114.80-114.50, 39.95-69.87, 63.23-62.46, 59.88-59.68, 53.56, 
48.00, 47.23-45.69, 36.57-36.00, 34.51-34.39, 27.95, 27.47, 24.73-24.69, 22.33-22.30, 
16.51-16.37; 31P NMR (162 MHz, CDCl3) δ25.19, 24.84. 
 
Diethyl N-(N-acetyl-L-prolinyl-O-benzyl-L-tyrosyl)-1-amino-2-(4-hydoxyphenyl)ethyl 
phosphonate (III-12d) 
Synthesized using diethyl N-(N-acetyl-L-prolinyl-O-benzyl-L-tyrosyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate III-12c (110 mg, 0.14 mmol), Pd/C (10% Pd, 15 
mg) in methanol (3 mL) using method C, to yield a mixture of diastereomers. Clear oil.  
Yield: 52 mg, 65%.1H NMR (400 MHz, MeOD) δ7.12-7.01 (m, 3H), 6.96-6.82 (m, 1H), 
6.76-6.65 (m, 4H), 4.62-4.53 (m, 1.5H), 4.38-4.32 (m, 0.5H), 4.24-4.05 (m, 5H), 3.59-
3.46 (1.5H), 3.39-3.35 (m, 0.5H), 3.20-3.10 (m, 1.5H), 3.05-2.97 (m, 0.5H), 2.88-2.68 
(m, 2H), 2.14-1.96 (m, 4H), 1.96-1.70 (m, 3H), 1.4-1.31 (m, 6H); 13 CNMR (600 MHz, 
MeOD) δ 173.94-173.84, 173.35-173.11, 172.80, 157.38-157.10, 131.29-131.02, 
129.98-128.60, 116.30-116.04, 64.36-64.22, 62.10, 61.54-61.45, 55.71-55.21, 47.94, 
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38.84-37.70, 35.20-37.93, 33.02, 30.46-30.41, 35.56-25.48, 23.73-23.60, 22.36-21.99, 
16.88-16.65; 1P NMR (400 MHz, MeOD) δ25.35 (broad). 
 
Ac-Pro-Tyr-AHEP: N-(N-acetyl-L-prolinyl-L-tyrosyl)-1-amino-2-(4-hydoxyphenyl)ethyl 
phosphonic acid (III-12) 
Synthesized using diethyl N-(N-acetyl-L-prolinyl-O-benzyl-L-tyrosyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate III-12d (21 mg, 0.036 mmol), acetonitrile (4 mL), 
thioanisole (0.4 mL) and I-TMSi (2.0 mL) using method D.  The phosphonate 
trimethylsilyl ester was hydrolyzed by treatment with 8:2 methanol in water (20 mL). 
Purified by HPLC, using a gradient of 5% acetonitrile in water to 25% acetonitrile in 
water containing ammonium acetate (10 mM) over 30 minutes. White solid.  Yield: 1.8 
mg, 9.7%. 1H NMR (600 MHz, D2O) δ7.16-7.12 (m, 3H), 7.05 (d, J = 8.5Hz, 1H), 6.82-
6.80 (m, 3H), 6.76 (d, J = 8.7 Hz, 1H), 4.65 (dd, J = 11.7, 3.7 Hz, 0.5H), 4.54 (dd, J = 
9.5, 4.9 Hz, 0.5H), 4.28 (dd, J = 8.5, 4.1 Hz, 1H), 4.22-4.20 (m, 1H), 3.54-3.46 (m, 1H), 
3.40-3.35 (m, 1H), 3.20 (d, J = 13.7Hz, 1H), 3.12 (dd, J = 14.1, 3.6 Hz, 0.5H), 2.99 (dd, 
J = 14.3, 4.8 Hz, 0.5H), 2.68-2.64 (m, 2H), 2.18-2.12 (m, 0.5H), 2.08 (s, 1.5H), 2.08-
2.00 (m, 0.5H), 2.00 (s, 1.5H), 1.91-1.86 (m, 0.5H), 1.85-1.79 (m, 0.5H), 1.76-1.58 (m, 
2H); 13C NMR (150 MHz, D2O) δ173.56-173.52, 172.81, 172.08-171.85, 154.18, 154.14, 
153.88, 153.78, 130.47, 130.42, 130.28, 130.18, 128.67, 128.48, 115.38, 115.30, 
115.09, 114.94, 61.17, 59.81, 54.17, 54.04, 48.51, 46.96, 36.70, 36.10, 35.08, 34.91, 
31.51, 29.20, 24.04, 22.41, 21.37, 20.64; 31P NMR (162 MHz, D2O) δ18.71. 
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Assay for ACE inhibition 
Assay for inhibition of somatic ACE with substrate FAPGG  
  Somatic ACE was extracted from rabbit lung acetone powder. Turnover of the 
substrate FAPGG was monitored in triplicate in a 96-well plate in the presence of 
various concentrations of inhibitor by monitoring the corresponding change in 
absorbance at 340 nm.127-128 IC50 was calculated by plotting the percent activity of the 
enzyme against the log of the concentration of the inhibitor. IC50 curves are available in 
Appendix E.  
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CHAPTER IV 
 
K-26 CHEMICAL PROBE DEVELOPMENT 
 
Introduction 
 Affinity chromatography is one of the most widely used methods for small 
molecule target-identification.168-170 In this classic approach, structural activity 
relationship studies are used to determine which functional groups are expendable 
while still retaining activity of the small molecule of interest.  These dispensable 
functional groups are then used as points for modification of the drug for attachment to 
a solid matrix or linker.  This chemical probe is then able to interact directly with the 
protein target, which can subsequently be identified.  This method has successfully 
been applied for discovery of potential drug targets and small molecule enzymatic 
interactions, with a possible role in giving insight into the biosynthesis and discovery of 
mechanism of action of a small molecule.170   
 Our small molecule of interest, K-26, has an unknown target and mechanism of 
biosynthesis. Although ACE is a central enzyme in blood pressure and fluid balance 
regulation in mammals and a target of pharmaceutical treatment of cardiovascular 
disease, it is unlikely that mammalian ACE would be the environmental target of the 
microbially produced tripeptide, K-26 (IV-1).126  Furthermore, the unique terminal 
phosphonic acid, a structural feature of the non-proteogenic amino acid, (R)-1-amino-2-
(4-hydroxyphenyl) ethylphosphonic acid (R)-AHEP (II-2) is interesting from a 
biosynthetic perspective as the unique carbon-phosphorus bond must be synthesized 
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by unprecedented mechanism.49, 59  Although phosphonate containing natural products 
are common, all examples with known biosynthesis utilize a phosphoenol pyruvate 
(PEP) mutase which catalyzes the  intramolecular rearrangement of 
phosphoenolpyruvate to phosphonopyruvate, a precursor in carbon-phosphorus bond 
formation in all known examples.59  Furthermore, it is not clear how the appropriate 
intermediate necessary in carbon-phosphorus bond formation could result from a 
precursor of AHEP in a PEP mutase catalyzed process.49  Lastly, there is no PEP 
mutase identifiable in the annotated genome of the K-26 producing organism, leading 
us to believe that the biosynthesis of this natural product must proceed through an 
alternate and novel mechanism. 
K-26 is an ideal candidate for development of a chemical probe as there have been 
previous structural activity relationship studies of this small molecule with ACE.  These 
studies of K-26 revealed that both (R)-AHEP and the N-acetyl tail are imperative for 
potent ACE inhibitory activity (Figure II-1).50  If (R)-AHEP is replaced with (S)-AHEP the 
inhibition of ACE drops 10 fold (IV-4), removing AHEP in favor of a tyrosine residue 
results in a 1500 fold decrease in ACE inhibition (IV-5), and protecting the AHEP 
phosphonate with ethyl esters results in a 25000 fold drop in activity (IV-6). Additionally 
removal of the N-acetyl tail results in a 15 fold decrease in activity (IV-3, IV-7). 
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Figure IV-1: Important structural features of K-26 and analogs for ACE inhibition.  Both the S-AHEP and 
N-acetyl functionalities are important for potent ACE inhibition by this small molecule.  AHEP (IV-2) is 
shown in blue. Modifications of from the original K-26 (IV-1) structure are highlighted in red.    
 
 
 
 Based on those prior SAR studies, a chemical probe design must leave (R)-
AHEP untouched and would build off the N-terminal end of the peptide.  The linker 
would be attached to the N-terminal end of dAcK-26 (IV-3), a K-26 derivative without the 
N-acetyl tail.  The linker was designed to restore the amide functionality of the N-acetyl 
group of K-26, when coupled to dAcK-26 (IV-3). Thus we were able to obtain probes 
with the essential (R)-AHEP and an extended derivative of the N-acetyl functionality 
intact.  This would presumably give a chemical probe with the highest degree of ACE 
inhibitory activity possible giving ACE a utility as an enzymatic target in probe 
development experiments.  Also, the unmodified (R)-AHEP would be left free to target 
the enzymatic machinery responsible for the biosynthesis of this unique amino acid and 
natural product. 
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Results 
Probe design and synthesis 
 In the design of a K-26 affinity probe, we initially chose to pursue a probe with a 
PEG linker and a biotin tag to be used as a handle for affinity purification with 
streptavidin, systems both widely used in affinity chromatography (IV-8, Figure IV-2).171-
174  A probe of this type has the advantage of being un-tethered until the addition of 
solid phase avidin, which has a strong affinity interaction with the biotin.  As a result, this 
probe can be purified, quantified and the inhibitory activity can be tested allowing 
verification that potent inhibitory activity remains even after the addition of the linker.  
Furthermore, biotin has been used with the ACE inhibitor lisinopril (IV-9) to develop a 
chemical probe.175  The second system chosen was a linker bound directly to 
sepharose (IV-10), which has been used with the ACE inhibitor lisinopril as a standard 
method for affinity purification of ACE (IV-11).176 
 K-26 functionality was imparted on both probes by linking the free amino terminal 
of the K-26 derivative, dAcK-26 (IV-3) to the respective linkers through an aqueous 
coupling with an N-hydroxysuccinimide ester (NHS, IV-12) (SchemeIV-1).176-177 
Coupling of the primary amine in dAcK-26 (IV-3) to the commercially available NHS-
PEG12-biotin linker yielded free biotin-K-26 (IV-8) which was purified by LC-MS, and 
characterized then quantitated by NMR prior to use.  The sepharose-K-26 probe (IV-10) 
was synthesized in a fashion similar to the affinity resin used in the well precedented 
and common ACE affinity purification method,  which uses the potent ACE inhibitor 
lisinopril (IV-9) tethered to a sepharose bead by a 6-(4-aminobenzamido)hexanoic acid 
linker (IV-11).  Here, we coupled a 6-(4-aminobenzamino)hexanoic acid linker to epoxy 
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activated Sepharose 6B.  After the linker was functionalized with N-hydroxysuccinimide 
(IV-12), we coupled dAcK-26 (IV-3) to the linker under aqueous conditions to yield 
Sepharose-K-26 (IV-10).     
 
 
Figure IV-2: Inhibitors and probes of interest in this study. 
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Scheme IV-1: Aqueous coupling of dAcK-26 to linker bound N-hydroxysuccinimide to yield K-26 affinity 
resin. 
 
 
 
Biotin-K-26 probe evaluation 
 After synthesis, the free biotin-K-26 (IV-8) was evaluated for the ability to potently 
inhibit ACE using both the substrate FAPGG to assay for inhibition of somatic ACE and 
the substrate Z-FHL to assay for inhibition of purified N-domain and C-domain ACE 
constructs.127-128 The biotin-K-26 probe was determined to still be a mid-nanomolar 
inhibitor of somatic ACE (IC50 = 93.5 nM) (Figure IV-3A). The relative long linker 
resulted in approximately a 7-fold drop in activity compared to free K-26 (IC50 = 12.5 
nM), but restored some of the potency compared to dAcK-26 (IC50 = 234 nM),
127 with 
the biotin-K-26 probe having about 3 times the activity of dAcK-26. We did expect the 
bulky linker to have an effect on the ACE inhibition compared to free K-26. Furthermore, 
the biotin-K-26 probe was tested as an inhibitor of the individual C- and N- domains of 
ACE using overexpressed and purified ACE constructs with the substrate Z-FHL (Figure 
IV-3B,C).102, 129-131, 141 The biotin-K-26 (IV-8) was found to be a potent mid-nanomolar 
inhibitor of both domains of ACE, with a very slight preference for the N- domain. 
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Figure IV-3. IC50 curves for inhibition of ACE by the biotin-K-26 probe. A. Inhibition of rabbit lung somatic 
ACE by free biotin-K-26 using the substrate FAPGG. B. Inhibition of purified N-domain ACE by free biotin-
K-26 using the substrate Z-FHL. C. Inhibition of purified C-domain ACE by free biotin-K-26 using the 
substrate Z-FHL.     
   
 
 Next, to determine if biotin retained the ability to bind to avidin in the biotin-K-26 
probe, we used a colorimetric assay with 4'-hydroxyazobenzene-2-carboxylic acid 
(HABA).178  HABA is displaced from the biotin binding sites on avidin in when increasing 
amounts of a biotinylated probe or free biotin is added, a process which can be 
monitored by a decrease in absorbance at 500 nm.  This titration experiment with HABA 
indicated that the probe effectively binds to avidin, although it appears to be 
approximately two-fold less efficient than biotin alone (Figure IV-4). The results of the 
HABA assay confirmed that adding the K-26 to the biotin-PEG linker did not interfere 
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with the affinity interaction between the biotin and the avidin and biotin-K-26 is indeed 
able to bind to NeutrAvidin. 
 
 
Figure IV-4. HABA colorimetric assay evaluating the ability of biotin and biotin-K-26 to bind to soluble 
avidin. 
 
 
General pull-down schematic 
The ability of K-26 probe conjugates to bind and purify ACE was first assessed via 
competition experiments using authentic K-26 (IV-1). Two tACE containing samples 
were prepared by spiking in 5 µg/mL of the heterologous enzyme into cell culture media 
(Figure IV-5).  An excess of K-26 (IV-1) was added to one of these sample replicates as 
a preblocked control sample, denoted as K-26 (+), while an equal volume of buffer was 
added to the other sample, denoted K-26 (-). The K-26 concentration in the control 
replicate was 5 µM in solution, a concentration high enough to entirely abolish ACE 
activity and prevent ACE, or any other proteins with a high specific affinity to the 
chemical probe, from binding.  After a brief incubation period, the K-26 probe conjugate 
(IV-8, IV-10) was added. The supernatant was removed and retained for activity testing 
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and the beads were thoroughly washed with buffer to remove non-specifically binding 
proteins. A portion of denaturing SDS-page loading buffer was added to the beads, and 
boiled to denature bound proteins.  These bound proteins were analyzed via gel 
chromatography, western blotting or by a spectral counting proteomics method. 
 
Figure IV-5. General pull-down experimental design. Free K-26 is added to block the binding of the target 
proteins in the K-26 (+) sample. Non-specific proteins bind to the probe in both cases with (+) and without 
(-) free K-26. 
 
 
 
Mutually exclusive binding of biotin-K-26 
 Although our free biotin-K-26 probe (IV-8) was found to be a mid-nanomolar 
inhibitor of both domains of ACE and was shown to retain the high affinity interaction 
between the biotin and the avidin, when the probe was bound to the solid phase, no 
binding of tACE was observed and only a slight depletion in ACE activity was noted 
upon addition of the probe to ACE containing media. The pull-down with the biotin-K-26 
chemical probe (IV-8) remained ineffective under a variety of incubation conditions, 
(ranging from 1 hour to 48 hours at 0 oC and at room temperature) and buffer ionic 
strengths.  Furthermore, the pull-down efficacy was not increased when the biotin-K-26 
chemical probe (IV-8) was incubated with ACE in solution prior to adding the 
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NeutrAvidin to pullout the chemical probe.  In light of that unexpected result, we 
explored the possibility of an unfavorable NeutrAvidin/K-26 interaction, we evaluated the 
ability of the biotin-K-26 probe to inhibit ACE in the presence of soluble avidin (Figure 
IV-6). 
 
 
Figure IV-6. ACE activity when incubated with biotin-K-26 (IV-8) and avidin, biotin-K-26, K-26 (IV-1) and 
avidin or K-26 alone.  ACE activity decreases in the presence of the inhibitor K-26, K-26 with avidin and 
biotin-K-26 alone, however biotin-K-26 (IV-8) in the presence of avidin does not inhibit ACE. 
     
 
Both free biotin-K-26 (IV-8) and K-26 (IV-1) were shown to inhibit ACE potently, with 
increasing concentrations of both molecules causing a decrease in ACE activity, as 
expected. When soluble avidin was added to the system, K-26 (IV-1) was still capable 
of potently inhibiting ACE as shown by the decrease in ACE activity with the increase in 
K-26 (IV-1) concentration. However, adding avidin to the system rendered the biotin-K-
26 (IV-8) incapable of inhibiting ACE. Surprisingly, ACE showed no degree of inhibition 
when incubated with 100 nM of biotin-K-26 (IV-8) in the presence of avidin. In the 
absence of avidin, 100 nM of biotin-K-26 (IV-8) was shown to nearly abolish ACE 
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activity, confirming that our biotin-K-26 (IV-8) probe is only able to bind the avidin and 
the target ACE in a mutually exclusive fashion.  
 
Pull-downs of heterologously expressed ACE with sepharose-K-26 (IV-10) 
The poor performance of the biotinylated probe (IV-8) prompted us to investigate the 
use of alternative affinity probes, particularly ones where the K-26 (IV-1) would be linked 
directly linked to a solid phase, abrogating the mutually exclusive binding interactions of 
avidin and ACE. We investigated the use of a Sepharose resin probe based on a 
previously developed lisinopril resin (IV-11), which is used as a standard method for the 
purification of heterologously expressed ACE.176  Initial characterization of K-26-
sepharose (IV-10) using activity assays and western blots revealed a much lower ACE 
affinity than the corresponding lisinopril resin (Figure IV-7A,B).    
As our K-26 chemical probe (IV-10) is unique with respect to the lisinopril probe (IV-11) 
due to the K-26 phosphonate moiety which is negatively charged at neutral pH, the ionic 
strength of the enzyme containing solution was an important aspect to consider in these 
pull-down experiments. We rationalized that increasing the ionic strength of the media 
or buffer by adding sodium chloride would reduce the ability of the K-26 functionality to 
non-specifically bind with other charged species and in turn increase the ability that the 
probe to specifically bind with the target enzymes.  Modifying the ionic strength of the 
solution by increasing the NaCl concentration was successful in dramatically increasing 
the affinity of the K-26 probe (IV-10) of ACE and in turn the pull-down efficiency (Figure 
IV-7C). Importantly, affinity pull-down of ACE spiked culture media supplemented with 1 
M NaCl, was shown to be significantly more effective with K-26-sepharose (IV-10) than 
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with the corresponding biotin-K-26 (IV-8) resin (Figure IV-7D). Additionally, the 
observation that an excess of authentic K-26 (IV-1) is able to block binding to 
sepharose-K-26 (IV-10) suggests that the interaction is specific. 
 
 
Figure IV-7. Western blots of preliminary pull downs with tACE A. Western blot of pull-down with biotin-K-
26 (IV-8) from media with 5µg/mL of tACE.  B. Western blot of pull-down with sepharose-lisinopril (IV-11) 
from media with 5µg/mL of tACE. C. Western blot of pull-down with K-26 functionalized sepharose (IV-10) 
in media with 5µg/mL of tACE and different ionic strengths. D. Western blot of pull-down with K-26 (IV-1) 
with either K-26 functionalized sepharose (IV-10) or biotin-K-26 (IV-8) from media with 1000 mM of NaCl 
and 5 µg/mL of tACE. Western blots were imaged for ACE using a polyclonal anti C-domain antibody.  K-
26 (+) samples have had the inhibitor K-26 (IV-1) added prior to the addition of the probe.  Lanes with the 
notation B contain the protein which was denatured off of the affinity resin (bead) after the pull-down. 
Lanes with the designation S correspond to the analysis of the proteins remaining in solution after 
incubation with the affinity resin. 
 
 
 Using tACE spiked into buffer, the amount of enzyme the probe was able to bind 
was evaluated (Figure IV-8A).  When 25 µg/mL of tACE was spiked into buffer, a visible 
amount of tACE was pulled out with the probe, however a significant amount of tACE 
remained in solution.  With 10 µg/mL of tACE spiked into buffer, the amount of tACE 
remaining in solution was less than the sample of tACE bound to the beads, showing 
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tACE enrichment on the beads.  With the samples containing 5 µg/mL and 1 µg/mL of 
ACE, only a small amount of ACE was detected suggesting that 10 µg/mL of tACE was 
optimal for visualization of tACE on the coomasie gel.  K-26 was then shown to 
effectively compete for tACE and prevent the enzyme from binding to the probe when 
10 µg/mL of tACE was spiked in to the buffer (Figure IV-8B). 
 
 
Figure IV-8. Western blots of pull downs of tACE with sepharose-K-26 probe A. Coomasie stained gel of 
pull-down using sepharose-K-26 (IV-10) with various concentrations of tACE spiked into buffer.  
Remaining tACE in the buffer after incubation is shown in the S lanes.  B. Coomasie stained gel of pull-
down using sepharose-K-26 (IV-10) with 10 µg/mL of tACE spiked into buffer showing that binding of 
tACE can be blocked through the addition of the competitive inhibitor K-26 (IV-1).  Lanes with the notation 
B contain the protein which was denatured off of the affinity resin (bead) after the pull-down. Lanes with 
the designation S correspond to the analysis of the proteins remaining in solution after incubation with the 
affinity resin. 
 
 
 
 These results were further confirmed using a spectral counting proteomics 
method to analyze proteins pulled out of cell media spiked with 5 µg/mL of tACE.179-180 
The data was analyzed using fold change between the number of normalized spectral 
counts between the K-26 (+) and K-26 (-) samples. A protein was defined as a hit if 
there was at least a 2 fold difference between the K-26 (-) and K-26 (+) samples and the 
140 
 
K-26 (-) sample had at least 5 spectral counts. As a point of comparison we conducted 
the same experiment using the Pantoliano sepharose-lisinopril affinity resin (IV-11) in 
which pre-blocking with lisinopril (IV-9) was used as a control. As expected, both probes 
were found to only specifically bind tACE, The sepharose-K-26 probe (IV-10) exhibited 
a 3.5 fold difference in spectral counts between the K-26 (+) and K-26 (-) samples. 
whereas, the sepharose-lisinopril (IV-11) resin had 5.22 fold more spectral counts in the 
lisinopril (-) sample, when compared to the lisinopril pre-blocked control (+) (Table IV-1). 
 
Probe 
Used 
Protein 
Accession 
Number 
MW 
kDa 
Normalized Spectral 
Counts Binding 
Ratio Competitive 
Inhibitor (-) 
Competitive 
Inhibitor (+) 
L
is
in
o
p
ri
l 
tACE 
2IUL:A| 
PDBID 
tACE 
68 141 27 5.22 
Angiotensin-converting 
enzyme Heterocephalus 
glaber 
tr|G5BDK0|G5BD
K0_HETGA 
150 49 14 3.5 
Uncharacterized protein  
Spermophilus 
tridecemlineatus 
tr|I3MDG2|I3MDG
2_SPETR 
151 47 14 3.36 
Angiotensin-converting 
enzyme Mus musculus 
sp|P09470|ACE_
MOUSE (+5) 
151 21 0 - 
K
-2
6
 
tACE 
2IUL:A|PDBID 
tACE 
68 49 16 3.06 
 
Table IV-1: Summary of Proteomics Hits for K-26 (IV-10) and Lisinopril (IV-11) probe with overexpressed 
ACE in media.  Binding to the lisinopril probe was blocked by the competitive inhibitor, lisinopril.  Binding 
to the K-26 probe was blocked by the competitive inhibitor K-26.  
 
 
 As a next step in probe validation, we decided to examine if the sepharose-K-26 
probe (IV-10) was able to pull low levels of ACE out of a complex sample mixture.  We 
spiked ACE into bacterial cell free extracts at level which we would expect to be a closer 
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representation the physiological expression levels of a possible target enzyme. As 
degradation of ACE by proteases present in the bacterial extracts is a possibility, we 
added PMSF to the cell free extracts and examined the time course necessary to 
achieve a depletion of ACE activity after the addition of the probe. Using the substrate 
FAPGG, we assayed for ACE activity and compared the ACE activity to a sample 
without the probe added, which had been incubated under the same conditions. We 
examined the ability of the probe to deplete the spiked in ACE activity in cell free 
extracts of both E. coli and the producing actinomycete in comparison to ACE spiked 
into buffer (Figure IV-9).  Addition of the probe depleted the ACE activity to one third of 
the levels seen in the sample without beads added.  When ACE was spiked into 
bacterial cell free extracts, the ACE activity was not depleted as drastically as the 
respective sample without beads added. However there was a significant decrease in 
ACE activity suggesting that the enzyme is indeed binding to the probe. Despite the 
decrease in measured ACE activity in the samples, when the bound proteins were 
eluted off of the beads, a corresponding protein band was not visible on a coomassie 
stained gel and proteomics analysis of the elutant from the beads did not return ACE as 
a hit. This likely is the result of low abundance of ACE in the bacterial extract or due to 
ACE degradation by proteases present in the bacterial cell free extracts despite the 
addition of PMSF and the short time course of the incubation. 
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Figure IV-9. Depletion of activity of ACE spiked into buffer, E.coli or actinomycete K-26 cell free extract by 
the addition of the sepharose-K-26 probe (beads). ACE activity was monitored using the substrate 
FAPGG in samples in which the probe (IV-10) had been added (beads) and compared to a control 
sample where a volume of buffer had been added in place of the beads (no beads). All samples were 
incubated under identical conditions before ACE activity was measured. Activity of the no beads control 
was set to 100%.   
 
 
 
Application of sepharose-K-26 (IV-10) in preliminary target ID experiments 
 The sepharose-K-26 probe (IV-10) was then applied in a preliminary target 
identification experiment using cell free extract from both E. coli and the K-26 producing 
organism.   Our first attempt of a pull-down of was using cell free extract from E. coli 
with the goal of determining if the K-26 probe (IV-10) was able to target any enzymes in 
this cell free extract, particularly the E. coli dicarboxypeptidase (EcDCP) which has 
been characterized as a bacterial ACE-like enzyme126 and to use these results as a 
possible control to eliminate non-specific enzymatic hits from future pull-down 
experiments.  The experiment did not return results suggesting that EcDCP is a target 
for K-26, which is not surprising given the known low affinity of K-26 for EcDCP and 
furthermore did not reveal any potential K-26 target (Table IV-2). 
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Protein Accession Number MW kDa 
Normalized 
Spectral Counts Binding 
Ratio 
K-26 (-) K-26 (+) 
30S ribosomal protein S1 RS1_ECOLI 61 26 17 1.53 
DNA-directed RNA polymerase subunit 
beta 
RPOB_ECOLI 151 17 11 1.55 
Translation initiation factor IF-2 IF2_ECOLI 97 12 8 1.50 
Pyruvate dehydrogenase E1 component ODP1_ECOLI 100 11 7 1.57 
DNA-directed RNA polymerase subunit 
beta 
RPOC_ECOLI 155 11 6 1.83 
Glycerophosphoryl diester 
phosphodiesterase 
GLPQ_ECOLI 41 8 2 4.00 
Uracil phosphoribosyltransferase UPP_ECOLI 23 8 1 8.00 
50S ribosomal protein L1 RL1_ECOLI 25 7 4 1.75 
Chaperone protein htpG HTPG_ECOLI 71 7 2 3.50 
50S ribosomal protein L6 RL6_ECOLI 19 6 4 1.50 
Transcription elongation protein nusA NUSA_ECOLI 55 5 3 1.67 
Enolase ENO_ECOLI 46 5 1 5.00 
 
Table IV-2: Hits from pull-down with sepharose-K-26 (IV-10) in E.coli cell free extract. 
 
 
 
Next we carried out a pull-down experiment with actinomycete K-26 cell free extract, 
with the goal of determining the endogenous target of K-26 (IV-1), if any, and to glean 
information about the biosynthetic pathway of this small molecule.  In the target ID 
experiments with actinomycete K-26 extract, to increase the probability of successfully 
targeting a protein of interest, we first determined that the actinomycete was indeed 
producing the small molecule K-26 (IV-1) using mass spectrometry.49 The presence of 
K-26 (IV-1) in the liquid culture of the actinomycete would ensure that the enzymes 
responsible for the biosynthesis of this small molecule were being produced. Cell free 
extract from the actinomycete culture determined to produce K-26 (IV-1) was used in 
the target identification experiment.  Despite the fact that K-26 was in known production 
by the actinomycete and 11 protein hits were identified in the experiment, no enzymes 
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were identified which have a discernible role in the biosynthesis of K-26 (IV-1) or an 
explainable role as a target (Table IV-3).   
 
 
Table IV-3: Summary of proteomics hits for K-26 probe (IV-10) applied for target identification with 
actinomycete K-26 cell free extract. 
 
 
Discussion 
  Target identification with a chemical probe based on the microbial natural product 
K-26 (IV-1) has presented several challenges.  The development of the biotin-K-26 
probe (IV-8) appeared to progress as expected as our untethered probe still retained 
Protein Accession Number 
MW 
kDa 
Normalized 
Spectral Counts 
Binding 
Ratio 
K-26 (-) K-26 (+) 
Cytosol aminopeptidase family, 
catalytic domain protein 
pak26.polypeptide.98805.1 
(+1) 
49 7 3 2.33 
response regulator 
pak26.polypeptide.97571.2 
(+1) 
23 6 3 2 
glutamine synthetase, type I 
pak26.polypeptide.102241.
1 (+1) 
51 
 
6 2 3 
Xylose isomerase-like TIM barrel 
family protein 
pak26.polypeptide.102749.
1 (+1) 
37 6 1 6 
3-deoxy-7-phosphoheptulonate 
synthase 
pak26.polypeptide.102496.
1 (+1) 
49 6 1 6 
RibD C-terminal domain protein 
pak26.polypeptide.98395.1 
(+1) 
21 5 2 2.5 
hypothetical protein 
pak26.polypeptide.99216.1 
(+1) 
116 5 2 2.5 
isoleucyl-tRNA synthetase 
pak26.polypeptide.100171.
1 (+1) 
116 5 1 5 
pyruvate dehydrogenase e1 
component, beta subunit (ec 
1.2.4.1). 
pak26.polypeptide.103166.
1 (+1) 
35 5 1 5 
valyl-tRNA synthetase 
pak26.polypeptide.101480.
1 (+1) 
95 5 1 5 
amidotransferase) (gmp 
synthetase). 
pak26.polypeptide.102625.
1 (+1) 
56 5 1 5 
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low nanomolar affinity for ACE.  However, this probe was unexpectedly unable to pull 
ACE out of media even under a variety of incubation conditions and solution ionic 
strengths.  Troubleshooting the system allowed us to come to the conclusion that the 
biotin-K-26 probe (IV-8) retains its ability to independently bind avidin and inhibit ACE; 
however this interaction is mutually exclusive.   
  As avidin does not affect the inhibitory effect of free K-26 (IV-1) on ACE, the 
mutually exclusive interaction of biotin-K-26 (IV-8) binding must not be due to potential 
charge-charge interactions between the K-26 (IV-1) and avidin.  A literature search 
reveals an ACE affinity resin consisting of an avidin tethered biotinylated-lisinopril, which 
has been shown to similarly be unable to bind to ACE despite the high affinity of the 
biotin-lisinopril alone for ACE.175  The shortcomings of this previously described 
biotinylated-lisinopril affinity resin are attributed to a linker of insufficient length.  This 20 
angstrom long linker is presumed to be too short to accommodate both of the deeply 
recessed binding sites which are located in a cleft on both avidin and in ACE.  Our 
biotin-K-26 probe (IV-8), in contrast, contains 12 PEG units, giving the probe spacer 
arm an overall length of 56.0 angstroms, a length more than sufficient to reach the 
active sites of both ACE and avidin simultaneously when the probe is extended.   
A computational modeling study does, however, suggest that PEG chains may 
hydrogen bond with water and form a helical structure.181  If this is indeed the case, it 
would greatly reduce the overall length of the linker.  If the linker length were reduced, it 
could perhaps be too short to extend into the recessed ACE active site after the biotin is 
bound to the avidin or streptavidin and potentially explain the obtained results. 
Regardless, as the biotin-PEG linker system used on this probe is a widely employed 
146 
 
system for small molecule target identification experiments the ineffectiveness of the 
biotin-K-26 probe to pull the ACE out of solution is unexpected given the mid-nanomolar 
inhibition by the free biotin-K-26 probe (IV-8), and inevitably led us to choose to develop 
an alternate affinity sepharose-K-26 probe (IV-10).   
    This sepharose-K-26 probe (IV-10) was found to be significantly more effective 
than the corresponding biotin-K-26 probe (IV-8) at targeting ACE spiked into buffer and 
media.  However, this probe was not able to definitively pullout low abundance ACE 
spiked into a complex protein mixture of a cell free extract.  As there are many other 
enzymes present it is possible that ACE was outcompeted for the binding sites on the 
probe.  Also, it is presumed that ACE is degraded quickly as an unnaturally occurring 
enzyme in the cell free extract and with only a low abundance of the ACE spiked in 
initially, perhaps it is possible that only a small amount, less than the limits of detection 
of the spectral counting mass spectrometry experiment, was pulled out. 
Target identification experiments using the sepharose-K-26 probe (IV-10) in the 
actinomycete K-26 extract also did not return any obvious hits for the small molecule 
target or biosynthetic enzymes.  Interestingly, the isoleucyl tRNA synthetase 100171 is a 
shared hit from a previously carried out pyrophosphate exchange assay to identify 
biosynthetic enzymes in K-26.182  Although recent literature has pointed to a role of 
tRNA synthetases in peptide bond formation of a phosphonate containing natural 
product, it is unclear at this time why this isoleucyl tRNA synthetase, would have an 
affinity for the phosphonate moiety of K-26.183  Possibilities include that the isoleucyl 
tRNA synthetase may be a high abundance protein co-purifying with a lower abundance 
biosynthetic target, however previous experiments examining the gene cluster 
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containing the isoleucyl tRNA synthetase have all but eliminated those enzymes has 
having a role in K-26 biosynthesis.182  Regardless, the endogenous target and 
biosynthesis of the fascinating metabolite, K-26 (IV-1), specifically of the biosynthetically 
unprecedented carbon-phosphorus linkage in the AHEP moiety remains elusive.   
 
Materials and Methods 
Chemical Synthesis 
General Probe Synthesis  
Reactions were carried out in oven or flame dried glassware. All solvents were 
reagent grade.  Amino acids and peptide coupling agents were purchased from EMD or 
Bachem. All reagents were commercially available and used without purification unless 
specified otherwise. Purification was carried out using a Phenomonex C18 semi-
preparative HPLC column on a Waters HPLC or a Thermo HPLC-MS instrument using 
a flow rate of 5 mL/min. Where possible, characterization was completed by NMR and 
HRMS.  Quantitation of synthetic products were carried out using an attenuated time 
delay proton experiment (d1=15s) with dioxane or DMF added as an internal standard.  
NMR spectra were acquired on a Brucker DRX-400, AV-400, DRX-500, or AV-II-600 
instrument.  High resolution mass spectral data were acquired at Vanderbilt University 
by Cody Goodwin.  
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Synthesis of N-(N-acetyl-L-isoleucyl-L-tyrosyl)-1-(R)-amino-2-(4-hydroxyphenyl)ethyl 
phosphonic acid (K-26, IV-1) 
  Synthesis and HPLC purification was carried out as previously described.50 The 
synthetic product was verified and quantitated by NMR.   
 
Synthesis of N-(L-isoleucyl-L-tyrosyl)-1-(R)-amino-2-(4-hydroxyphenyl)ethyl phosphonic 
acid (dAcK-26, IV-3)   
 Synthesis and HPLC purification was carried out as previously described.50 The 
synthetic product was verified and quantitated by NMR.   
 
Synthesis of Biotin-PEG12-K26 (IV-8)  
 N-(L-isoleucyl-L-tyrosyl)-1-(R)-amino-2-(4-hydroxyphenyl)ethyl phosphonic acid 
(dAcK-26 (IV-3), 939 g,1.9 mol) was dissolved in 3.6 mL of 100 mM phosphate 
buffer, pH=8.0. Under argon atmosphere, 45 L of a biotin-PEG12-NHS (250 mM, 
Pierce) dissolved in DMF was added. The reaction was stirred for 5 hours at room 
temperature. After reducing the volume in vaccuo the product was purified by HPLC-MS 
using a linear gradient of water to acetonitrile (ranging from 95:5 to 70:30 over 30 
minutes) containing 10 mM ammonium acetate. Evaporation of the HPLC solvents 
yielded the product (31%, 776 g). 1H NMR spectra is included in Appendix F. 1H NMR 
(600 MHz, D2O) δ7.13 (dd, J = 13.3, 8.5 Hz, 4H), 6.76 (dd, J = 17.8, 8.5 Hz, 4H), 4.62-
4.59 (m, 1H), 4.59-4.56 (m, 1H), 4.43-4.41 (m, 1H), 4.09-4.03 (m, 1H), 4.03 (d J = 8.6 
Hz, 1H), 3.84-3.74 (m, 2H), 3.74-3.66 (m, 42 H), 3.66-3.61 (m, 5H), 3.42-3.39 (m, 2H), 
3.35-3.31 (m, 1H), 3.24-3.18 (m, 1H), 3.16-3.11 (m, 1H), 3.01-2.98 (m, 1H), 2.67-2.60 
149 
 
(m, 2H), 2.56-2.44 (m, 2H), 2.30-2.67 (m, 2H), 1.77-1.70 (m, 1H), 1.70-1.55 (m, 4H), 
1.47-1.40 (m, 2H), 1.23-1.18 (m, 1H), 1.01-0.94 (m, 1H), 0.79 (t, J = 7.3 Hz, 3H), 0.63 
(d, J = 6.8 Hz, 3H); HRMS calculated for C60H101N6O22PS (M + 2H
+) 660.3208, found 
660.3320.  
 
Functionalization of NeutrAvidin with biotin-PEG12-K26 probe (IV-8)   
A solution of Biotin-PEG12-K-26 (IV-8) (0.758 mM, 100 µL) in  10 mM HEPES 
buffer (pH=7.5 with 30 mM KCl and 100 µM ZnCl2) was incubated with 250 µL of 
Neutravidin beads and an additional 150 µL of HEPES buffer overnight at 4oC with 
gentle mixing on a lab rotator.  After the incubation, the beads were allowed to settle out 
of solution and the supernatant was removed.  The beads were washed 5 times with 
cold HEPES buffer (750 µL) to remove any unbound probe, then stored at 4oC in 250 µL 
of HEPES buffer as a 50% slurry.   
 
Preparation of Sepharose-K26 (IV-10)  
Preparation of sepharose-K-26 (IV-10) was carried out similarly to that of 
sepharose bound lisinopril, using free dAcK-26 (IV-3) in place of free lisinopril (IV-9),176, 
184-185 (Scheme IV-2). Specifically, epoxy activated sepharose 6B (0.5 g) was first 
washed with water (75 mL) in a sintered glass funnel.  The swollen gel was mixed with 
N-(p-aminobenzoyl)-6-aminocaproic acid (90 mM) in 0.1 M NaOH (pH = 12.9, 2.5 mL) 
overnight at 45oC.  After blocking unreacted sites through a 4 hour incubation with 
ethanolamine (1M final concentration), the resin was washed with HCl (10 mM, 75 mL), 
dioxane (35 mL), and DMF (14 mL).  The linker was then functionalized with an N-
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hydrozysuccinimide through a 4 hour room temperature incubation with NHS (0.2 M 
final concentration) and diisopropylcarbodiimide (DIPCl, 0.2 M final conc) in DMF (2.5 
mL).  After washing the NHS activated sepharose (IV-15) with dioxane (35 mL),   dAcK-
26 (IV-3) (0.067 M) in 7.5 mL of sodium bicarbonate (0.1 M, pH = 10.2) was loaded onto 
sepharose by incubating the functionalized sepharose with the dAcK-26 (IV-3) for 16 
hours at 4oC under gentle agitation.  After the incubation, the beads were washed with 
150 mL of Tris (100 mM, pH = 7.5) buffer in a fritted funnel to ensure that all unbound 
dAcK-26 (IV-3) was removed.  Washes were collected and the amount of dAcK-26 (IV-
3) remaining was quantitated by NMR using an attenuated time delay proton experiment 
(d1=15s) with dioxane added as an internal standard to ensure that dAcK-26 (IV-3) was 
indeed coupling to the linker.  Sepharose-K-26 (IV-10) was stored at 4oC in 100 mM Tris 
buffer, which would aid in blocking unreacted  N-hydroxysuccinimide sites on the linker.     
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Scheme IV-2. Synthesis of sepharose K-26 (IV-10).  a.1 M NaOH, pH 12.9, 45
o
C 16 hours. Unreacted 
sites blocked with ethanolamine then resin washed with HCl, water, dioxane and DMF. b. DMF, NHS, 
DIPCl, 2 hours, RT. c. dAcK-26, 100 mM NaHCO3 pH 10.2, 4
o
C 16 hours.   
 
    
Analysis of Biotin-PEG12-K-26 Probe (IV-8) 
Determining IC50 of biotin-PEG12-K-26 with somatic ACE with substrate FAPGG  
Somatic ACE was extracted from rabbit lung acetone powder. Turnover of the 
substrate FAPGG was monitored in a 96-well plate in the presence of various 
concentrations of  biotin-K-26 (IV-8) inhibitor by monitoring the corresponding change in 
absorbance at 340 nm as previously described.127-128   IC50 was calculated by plotting 
the percent activity of the enzyme against the log of the concentration of the inhibitor. 
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Determining IC50 of biotin-PEG12-K-26 with N- and C- domains of ACE with substrate Z-
FHL  
Z-FHL turnover by heterologously expressed N-domain and tACE in the 
presence of various concentrations of biotin-K-26 (IV-8) was monitored using 
fluorescence as previously described.129-131 IC50 was calculated by plotting the percent 
activity of the enzyme against the log of the concentration of the inhibitor.  
 
Evaluation of biotinylated probe affinity to avidin  
 The ability of the biotinylated probe to bind to avidin was performed essentially as 
previously described.178 Briefly, the dye 4-Hydroxybenzene-2’-carboxylic acid (HABA) 
binds to avidin with a low dissociation constant, and its stoichiometric displacement by 
biotin can be followed by a change in absorbance at 450 nm. The binding experiments 
were performed in a total volume of 150 μL with a final concentration of 0.25 mg/mL 
Avidin and 1 mM HABA, with a range of different biotin concentrations. 
 
Evaluation of the simultaneous binding of K-26 and avidin to the biotin-K-26 probe  
 The ability of the biotinylated probe to bind both avidin and heterologously 
expressed tACE G13 simultaneously was evaluated by pre-incubating various 
concentrations of either the biotin-K-26 probe or free K-26 with a 15-fold excess of 
avidin, followed by incubation with tACE G13.  After the incubation, the catalytic activity 
of the tACE was evaluated using a fluorogenic assay with Z-FHL as substrate.186 
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Pull-downs with chemical probes 
General pull-down procedure  
 The pull-downs were conducted using a batch method.  To the two samples 
containing the desired proteins to be evaluated (1 mL, each) was added either K-26 (IV-
1) (5 µM final concentration) or an equal volume of buffer.  These samples were 
designated K-26 (+) and K-26 (-), respectively.  An additional portion of the protein 
sample was retained for catalytic activity testing.  These samples were allowed to 
incubate for 5 minutes on ice and then 50 µL of either the solid phase bound biotin-K-26 
or streptavidin-K-26, or free biotin-K-26 (10 µL of 1 mg/mL probe, 0.758 mM) was added 
to both the K-26 (+) and the K-26 (-) sample.  In the case where free biotin-K-26 was 
added, 50 µL of Neutravidin beads were added after an additional 5 minute incubation.  
The samples were incubated at 4oC with gentle agitation, after which point the 
supernatant above the beads was removed and retained for catalytic activity testing and 
other analysis.  The beads were washed three times with 500 µL portions of cold 
HEPES buffer (10 mM, pH=7.5 with 30 mM KCl and 100 µM ZnCl2) to remove 
specifically bound proteins, centrifuging briefly (10 sec at 300 rpm) between each wash 
to hasten the settling of the beads in solution.  After the last wash, residual solution was 
removed from the beads and then the beads were boiled in a portion of SDS-page 
loading buffer to denature bound proteins, which were analyzed by a coomassie stained 
gel, a western blot using polyclonal anti-C-domain antibodies, or through a mass 
spectrometry based spectral counting proteomics method.  Retained solution samples 
were analyzed for ACE catalytic activity, with the rationale that the lower the catalytic 
activity, the less ACE that remained in the solution, by monitoring the turnover of either 
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the substrate Z-FHL or FAPGG using one of the previously described assays.  
  
Pull-down of recombinanatly expressed tACE in media   
 General pull-down procedure was followed using samples of tissue culture media, 
spiked with approximately 5 µg/mL of tACE G13, a minimally glycosylated recombinant 
human ACE variant (tACE G13) with wild-type activity (expressed and purified as 
previously described.187  After addition of the K-26 (IV-1) to block binding, the probe was 
added and the samples were incubated overnight at 4oC.  The pull-down was run in 
parallel with the previously described lisinopril-sepharose,176 which was blocked with 
free lisinopril (IV-9) (5 µM total concentration) to give lisinopril (+) and lisinopril (-) 
samples.  Supernatant samples were analyzed for ACE catalytic activity and both 
denatured bead samples and supernatant samples were analyzed via western blot.    
 
Pull-down of recombinanatly expressed tACE under various ionic strengths   
 General pull-down procedure was followed using samples of tissue culture media 
containing NaCl (0 mM 300 mM, 600 mM or 1000 mM), spiked with approximately 5 
µg/mL of tACE G13.  Pull-down was conducted using both the sepharose K-26 probe 
(IV-10), with which K-26 (IV-1) was used to block binding, or lisinopril-sepharose (IV-
11), which was blocked with free lisinopril (IV-9) (5 µM) as a control.  Supernatant 
samples were analyzed for ACE catalytic activity and both the supernatant and the 
denatured bead samples were analyzed via a western blot. 
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Pull-down of recombinanatly expressed tACE with 1000 mM salt by both biotin-K-26 (IV-
8) and sepharose-K-26 (IV-10)   
 General pull-down procedure was followed using samples of tissue culture media 
containing 1000 mM NaCl spiked with approximately 5 µg/mL of tACE G13. Pull-down 
was conducted using both the sepharose K-26 probe and biotin-K-26 functionalized 
Neutravidin, blocked with K-26 as a control (5 µM total concentration).  Supernatant 
samples were analyzed for ACE catalytic activity and both the supernatant and 
denatured bead samples were analyzed via a western blot.  The sepharose (+) and 
sepharose (-) samples were submitted to the Vanderbilt Proteomics core for analysis  
by a mass spectrometry spectral counting method.   
 
Preparation of Astrosporangium hypotensionis extracts  
 The actinomycete K-26 was grown as previously described.7  The K-26 production 
cultures were tested for K-26 production after 48, 60, 72, 84 and 96 hours of growth, to 
determine when the K-26 producing enzymes would be at their maximum levels. 
Relative K-26 levels were determined via mass spectrometry using Ile-Tyr-Tyr as an 
internal standard.188 As K-26 production seemed to peak at 84 hours, 2 g of cells from 
that time point were used to prepare the lysate for the target identification experiment. 
The given mass of cells were resuspended in 20 mL of cold Tris buffer (50 mM, pH = 
7.5, 100 mM NaCl) and lysed by French press with 1 mM PMSF.   
 
Application of probe with bacterial extracts  
 Prepared bacterial extracts (1 mL), with spiked in tACE (2.5 ng/mL) either spiked 
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with free K-26 (IV-1) (5 µM) or buffer (50 mM Tris buffer, pH = 7.5 with 300 mM NaCl). 
An additional portion of the protein sample was retained for catalytic activity testing.  
After mixing and incubating on ice for 5 minutes, sepharose-K-26 (IV-10) was added (50 
µL). The bead slurry was mixed with the extract on an end over end lab rotator at 4oC 
for 30 minutes, to reduce non-specific binding, after which point the supernatant was 
removed.  After briefly centrifuging, the supernatant was removed and retained for 
analysis. The beads were washed with 3 x 500 µL of cold HEPES buffer (10 mM, 
pH=7.5 with 30 mM KCl and 100 µM ZnCl2) buffer, centrifuging between washes. The 
beads were denatured by boiling in SDS loading buffer and the resulting denatured 
proteins were run on a 10% SDS- page gel.  Retained protein samples and 
supernatants were analyzed for catalytic ACE activity using FAPGG as a substrate in a 
previously described assay.  Bead samples were submitted to the Vanderbilt proteomics 
core for analysis via a mass spectroscopy based spectral counting method to identify 
specific proteins bound under the project ID 3230 and 3632    
 
Quantitative Proteomics Analysis  
Shotgun proteomic analysis of filtrate was performed by first resolving eluted 
proteins approximately 1cm using a 10% Novex precast gel, and then performing in-gel 
tryptic digestion to recover peptides.  Resulting peptides were analyzed by a 70 minute 
data dependent LC-MS/MS analysis.  Briefly, peptides were autosampled onto a 200 
mm by 0.1 mm (Jupiter 3 micron, 300A), self-packed analytical column coupled directly 
to an LTQ (ThermoFisher) using a nanoelectrospray source and resolved using an 
aqueous to organic gradient.  A series of a full scan mass spectrum followed by 5 data-
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dependent tandem mass spectra (MS/MS) was collected throughout the run and 
dynamic exclusion was enabled to minimize acquisition of redundant spectra.  MS/MS 
spectra were searched via SEQUEST against either an E .coli or Astrosporangium 
hypotensionis database that also contained reversed version for each of the entries. 
(http://www.ncbi.nlm.nih.gov/pubmed/7741214).  Identifications were filtered and 
collated into spectral count numbers at the protein level using Scaffold (Proteome 
Software) 
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CHAPTER V 
 
FUTURE DIRECTIONS 
   
Natural products are a rich source of pharmaceutically active molecules.  The K-26 
family of microbial metabolites is a class of natural products which are among the most 
potent natural product inhibitors of human ACE.  This pharmacologically relevant 
enzyme consists of two tissue specific isoforms, the single domain testicular ACE and 
somatic ACE which is comprised of two domains, each with differing physiological roles 
in processes including blood pressure, fluid balance and fibrosis regulation.  In the 
previous chapters of this dissertation, research centered around the K-26 family of 
potent ACE-inhibitors has been described.  
Structural activity studies of K-26 and related tripeptides were facilitated by the crystal 
structures of K-26 in both domains of a heterologously expressed mammalian ACE 
construct.  These structures reveal that K-26 adopts an unusual binding motif in the 
active site of the enzyme, occupying only the non-prime binding pockets, making this 
metabolite a unique and interesting subject for ACE inhibitor design and study.  
Naturally occurring members of the K-26 family and a set of selected AHEP containing 
tripeptides from a computational modeling experiment of 400 of these tripeptides have 
been synthesized and evaluated for somatic ACE inhibition.  Of all analogs evaluated, 
K-26 is still taken to be the most potent AHEP containing ACE inhibitor.  Imminent 
studies on the ACE inhibitory properties will give more relevant data pertaining to the 
domain selectivity of these variants.  
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Interestingly, K-26 has been established to exhibit selectivity for mammalian ACE.  This 
microbial natural product is not a potent inhibitor of closely related ACE-like enzymes 
that have been studied from bacterial sources, an unexpected result given the high 
sequence similarity between mammalian and bacterial ACE-like enzymes.  The widely 
prescribed and pharmacologically relevant ACE inhibitor captopril, however, is a potent 
inhibitor of these bacterial ACE-like enzymes. 
Furthermore two chemical probes have been developed using K-26 by using 
heterologously expressed ACE to validate the probes.  The first of these affinity probes, 
a biotin based probe, was determined to be a potent nanomolar inhibitor ACE.  This 
probe, however, was ineffective at pulling ACE out of solution as there seems to be a 
mutually exclusive relationship between binding the solid phase streptavidin and the 
target ACE.  A K-26 affinity probe tethered directly to a solid phase sepharose was 
deemed to be more effective through validation with overexpressed mammalian ACE.  
This chemical probe was applied in a preliminary pull-down experiment to glean 
information about a possible endogenous target or biosynthetic enzymes responsible for 
assembly of the AHEP moiety with inconclusive results.   
Despite these and previous studies on K-26, many questions remain about this 
fascinating small molecule.  These questions, along with potential approaches for 
furthering research on this small molecule, will be discussed in the following 
paragraphs.   
The structural activity studies conducted in this dissertation have only begun to examine 
the potential structural modifications to K-26 that could aid in the design of inhibitors 
with increased potency and domain selectivity to human ACE.  As K-26 only occupies 
160 
 
the S1, S2 and S3 binding pockets, one approach would be to design inhibitors that 
build off of the tripeptidic K-26 scaffold.  This could be accomplished by building off of 
either the N-terminus of K-26 or the phosphonate in AHEP.  This extended inhibitor 
would utilize additional binding pockets within the active site of ACE.  Also, as only 
naturally occurring amino acids were used in this study, incorporating non-proteogenic 
amino acids into the tripeptidic structure of K-26 may be a fruitful outlet for more potent 
and selective inhibitor design.   
The synthesis and purification of K-26 and other AHEP containing tripeptides has been 
a challenge of this research.  Due to the limitations of the current synthetic approach, 
the development of a method for the enantoselective synthesis of AHEP or for the 
attachment of AHEP onto the solid phase for solid phase peptide synthesis would 
undoubtedly simply the process.  Additionally, discovery of the biosynthetic process for 
AHEP and K-26 may allow for biosynthetic methods to be adopted.  Any study which 
would rely on the synthesis of K-26 and variants would be expedited and this would 
make larger and more diverse libraries of these AHEP based molecules obtainable.   
Aside from the pharmacological applications of this ACE inhibitory peptide, two 
interesting, but large, questions remain unanswered about K-26: How this small 
molecule made and what is its function in nature?  The chemical probe developed in 
this study was applied in preliminary experiments with cell free extract of the 
actinomycete, with the goal of beginning to shed light on some of these important 
questions.  Despite the high affinity of K-26 for mammalian ACE and the probe 
validation with ACE, no enzymes were unambiguously identified from the actinomycete 
that would logically have a role in either the biosynthesis of AHEP or as an endogenous 
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target.  It would be reasonable to conclude that our possible target of interest is 
expressed at low levels by the actinomycete, especially given the low production levels 
of the small molecule K-26 by the actinomycete.  This may render the affinity probe 
ineffective as it is not capable of capturing enough of the target enzyme for proteomics 
analysis.  This could be remedied in two ways:  the abundance of the target can be 
increased or the probe can be made more effective.   
One approach would be to modify the actinomycete culture conditions to increase the 
production levels of K-26.  This increase in K-26 would likely be associated with a 
corresponding increase in the levels of relevant biosynthetic enzymes, raising the 
likelihood that our probe will bind these enzymes in high enough abundance to return a 
proteomics hit.   Furthermore, to aid in the identification of lower abundance proteins, 
the knowledge gained from the development of our current affinity probe could be 
applied to generate a similar covalently binding chemical probe.  A probe of this type 
could make use of an aryl azide, diazarine or benzophenone functionality. 189 In 
particular, an aliphatic diazarine may be a favorable option to consider for incorporation 
in place of the isoleucine in K-26.190-191 When exposed to UV light, the generated radical 
would form a covalent linkage with a functionality present in the active site of the 
enzyme, irreversibly tethering the enzyme target to the probe.  This would allow for the 
capture and identification of low abundance proteins or protein targets with lower affinity 
for the chemical probe.   
  Due to this covalent linkage, the enzymatic target of the K-26 probe could be 
denatured before pulling out of solution.  This would possibly be an effective method to 
eliminate the mutually exclusive binding relationship which was apparent with the biotin 
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K-26 affinity probe.  Therefore, biotin may remain a suitable choice in covalent binding 
K-26 probe design.  The use of biotin in chemical probe design has associated benefits, 
such as the potential for cell permeability of the probe and the ability to utilize the 
streptavidin-biotin relationship for identification and purification of the target. 170 
Undoubtedly, this would increase the likelihood of an unambiguous proteomics hit, 
raising the chance of success of these experiments.192-193 
In this study, the N-acetyl portion of the molecule was chosen for the placement of the 
handle in chemical probe development.  This would allow the AHEP portion and 
phosphonic acid to be unhindered and to presumably interact with the biosynthetic 
machinery responsible for its assembly.  Attachment of the handle to a different portion 
of K-26 may render the probe capable of capturing biosynthetic enzymes and enzymatic 
targets that interact with other regions of this natural product.       
Furthermore, any chemical probe based on K-26 could be broadly applied to a wide 
range of organisms in environmental target identification experiments.  However, a 
study of this sort may be challenging without additional information about potential 
organisms that the actinomycete K-26 commonly co-inhabits with in the environment. 
  
163 
 
REFERENCES 
 
1.  Newman, D. J.; Cragg, G. M., Natural products as sources of new drugs over the 30 
years from 1981 to 2010. J Nat Prod 2012, 75, 311-35. 
 
2.  Shen, X. Z.; Ong, F. S.; Bernstein, E. A.; Janjulia, T.; Blackwell, W. L.; Shah, K. H.; 
Taylor, B. L.; Gonzalez-Villalobos, R. A.; Fuchs, S.; Bernstein, K. E., Nontraditional 
roles of angiotensin-converting enzyme. Hypertension 2012, 59, 763-8. 
 
3. CDC High blood pressure facts. http://www.cdc.gov/bloodpressure/facts.htm 
(accessed June 15, 2014). 
 
4. WHO A global brief on hypertension: Silent killer, global public health crisis. 
http://www.who.int/cardiovascular_diseases/publications/global_brief_hypertension/en/ 
(accessed July 1, 2014). 
 
5.  Morimoto, T.; Gandhi, T. K.; Fiskio, J. M.; Seger, A. C.; So, J. W.; Cook, E. F.; Fukui, 
T.; Bates, D. W., An evaluation of risk factors for adverse drug events associated with 
angiotensin-converting enzyme inhibitors. J Eval Clin Pract 2004, 10, 499-509. 
 
6.  Dictionary of Natural Products. http://dnp.chemnetbase.com. 
 
7. Yamato, M.; Koguchi, T.; Okachi, R.; Yamada, K.; Nakayama, K.; Kase, H.; 
Karasawa, A.; Shuto, K., K-26, a novel inhibitor of angiotensin I converting enzyme 
produced by an actinomycete K-26. J Antibiot (Tokyo) 1986, 39, 44-52. 
 
8. Nakagomi, K.; Ebisu, H.; Sadakane, Y.; Fujii, N.; Akizawa, T.; Tanimura, T., 
Properties and human origin of two angiotensin-I-converting enzyme inhibitory peptides 
isolated from a tryptic hydrolysate of human serum albumin. Biol Pharm Bull 2000, 23, 
879-83. 
 
9.  Nakagomi, K.; Fujimura, A.; Ebisu, H.; Sakai, T.; Sadakane, Y.; Fujii, N.; Tanimura, 
T., Acein-1, a novel angiotensin-I-converting enzyme inhibitory peptide isolated from 
tryptic hydrolysate of human plasma. FEBS Lett 1998, 438, 255-7. 
 
10.  Nakagomi, K.; Yamada, R.; Ebisu, H.; Sadakane, Y.; Akizawa, T.; Tanimura, T., 
Isolation of acein-2, a novel angiotensin-I-converting enzyme inhibitory peptide derived 
from a tryptic hydrolysate of human plasma. FEBS Lett 2000, 467, 235-8. 
 
11.  Kohama, Y.; Matsumoto, S.; Oka, H.; Teramoto, T.; Okabe, M.; Mimura, T., 
Isolation of angiotensin-converting enzyme inhibitor from tuna muscle. Biochem Biophys 
Res Commun 1988, 155, 332-7. 
 
164 
 
12.  Kohama, Y.; Oka, H.; Matsumoto, S.; Nakagawa, T.; Miyamoto, T.; Mimura, T.; 
Nagase, Y.; Satake, M.; Takane, T.; Fujita, T., Biological properties of angiotensin-
converting enzyme inhibitor derived from tuna muscle. J Pharmacobiodyn 1989, 12, 
566-71. 
 
13.  Matsumura, N.; Fujii, M.; Takeda, Y.; Shimizu, T., Isolation and characterization of 
angiotensin I-converting enzyme inhibitory peptides derived from bonito bowels. Biosci 
Biotechnol Biochem 1993, 57, 1743-4. 
 
14.  Matsumura, N.; Fujii, M.; Takeda, Y.; Sugita, K.; Shimizu, T., Angiotensin I-
converting enzyme inhibitory peptides derived from bonito bowels autolysate. Biosci 
Biotechnol Biochem 1993, 57, 695-7. 
 
15.  Ferreira, L. A.; Henriques, O. B.; Lebrun, I.; Batista, M. B.; Prezoto, B. C.; Andreoni, 
A. S.; Zelnik, R.; Habermehl, G., A new bradykinin-potentiating peptide (peptide P) 
isolated from the venom of Bothrops jararacussu (jararacucu tapete, urutu dourado). 
Toxicon 1992, 30, 33-40. 
 
16.  Kato, H.; Suzuki, T., Bradykinin-potentiating peptides from the venom of 
Agkistrodon halys blomhoffi. Isolation of five bradykinin potentiators and the amino acid 
sequences of two of them, potentiators B and C. Biochemistry 1971, 10, 972-80. 
 
17.  Komori, Y.; Sugihara, H., Purification and physiological study of a hypotensive 
factor from the venom of Vipera aspis aspis (aspic viper). Toxicon 1990, 28, 359-69. 
 
18.  Hyoung Lee, D.; Ho Kim, J.; Sik Park, J.; Jun Choi, Y.; Soo Lee, J., Isolation and 
characterization of a novel angiotensin I-converting enzyme inhibitory peptide derived 
from the edible mushroom Tricholoma giganteum. Peptides 2004, 25, 621-7. 
 
19.  Jang, J. H.; Jeong, S. C.; Kim, J. H.; Lee, Y. H.; Ju, Y. C.; Lee, J. S., 
Characterisation of a new antihypertensive angiotensin I-converting enzyme inhibitory 
peptide from Pleurotus cornucopiae. Food Chem 2011, 127, 412-8. 
 
20.  Huang, W. Y.; Davidge, S. T.; Wu, J., Bioactive natural constituents from food 
sources-potential use in hypertension prevention and treatment. Crit Rev Food Sci Nutr 
2013, 53, 615-30. 
 
21.  Murray, B. A.; Fitzgerald, R. J., Angiotensin converting enzyme inhibitory peptides 
derived from food proteins: biochemistry, bioactivity and production. Curr Pharm Des 
2007, 13, 773-91. 
 
22.  Morigiwa, A.; Kitabatake, K.; Fujimoto, Y.; Ikekawa, N., Angiotensin converting 
enzyme-inhibitory triterpenes from Ganoderma lucidum. Chem Pharm Bull (Tokyo) 
1986, 34, 3025-8. 
 
165 
 
23.  Boh, B.; Berovic, M.; Zhang, J.; Zhi-Bin, L., Ganoderma lucidum and its 
pharmaceutically active compounds. Biotechnol Annu Rev 2007, 13, 265-301. 
 
24.  Somanadhan, B.; Smitt, U. W.; George, V.; Pushpangadan, P.; Rajasekharan, S.; 
Duus, J. O.; Nyman, U.; Olsen, C. E.; Jaroszewski, J. W., Angiotensin converting 
enzyme (ACE) inhibitors from Jasminum azoricum and Jasminum grandiflorum. Planta 
Med 1998, 64, 246-50. 
 
25.  Hansen, K.; Adsersen, A.; Christensen, S. B.; Jensen, S. R.; Nyman, U.; Smitt, U. 
W., Isolation of an angiotensin converting enzyme (ACE) inhibitor from Olea europaea 
and Olea lancea. Phytomedicine 1996, 2, 319-25. 
 
26.  Ando, T.; Okada, S.; Uchida, I.; Hemmi, K.; Nishikawa, M.; Tsurumi, Y.; Fujie, A.; 
Yoshida, K.; Okuhara, M., WF-10129, a novel angiotensin converting enzyme inhibitor 
produced by a fungus, Doratomyces putredinis. J Antibiot (Tokyo) 1987, 40, 468-75. 
 
27.  Baldwin, J. E., Adlington, R. M., Andrew, R. T., Smith M. L., Carbon based 
mucleophilic ring opening of activated monocyclic B-lactams; Synthesis and 
sterochemical assignment of the ACE inhibitor WF-10129. Tetrahedron 1995, 51, 4733-
4762. 
 
28.  Bush, K.; Henry, P. R.; Souser-Woehleke, M.; Trejo, W. H.; Slusarchyk, D. S., 
Phenacein--an angiotensin-converting enzyme inhibitor produced by a streptomycete. I. 
Taxonomy, fermentation and biological properties. J Antibiot (Tokyo) 1984, 37, 1308-12. 
 
29.  Liu, W. C.; Parker, W. L.; Brandt, S. S.; Atwal, K. S.; Ruby, E. P., Phenacein--an 
angiotensin-converting enzyme inhibitor produced by a streptomycete. II. Isolation, 
structure determination and synthesis. J Antibiot (Tokyo) 1984, 37, 1313-9. 
 
30.  Nakatsukasa, W. M.; Wilgus, R. M.; Thomas, D. N.; Mertz, F. P.; Boeck, L. D., 
Angiotensin converting enzyme inhibitors produced by Streptomyces chromofuscus. 
Discovery, taxonomy and fermentation. J Antibiot (Tokyo) 1985, 38, 997-1002. 
 
31.  Mynderse, J. S.; Samlaska, S. K.; Fukuda, D. S.; Du Bus, R. H.; Baker, P. J., 
Isolation of A58365A and A58365B, angiotensin converting enzyme inhibitors produced 
by Streptomyces chromofuscus. J Antibiot (Tokyo) 1985, 38, 1003-7. 
 
32.  Umezawa, H.; Aoyagi, T.; Ogawa, K.; Obata, T.; Iinuma, H.; Naganawa, H.; 
Hamada, M.; Takeuchi, T., Foroxymithine, a new inhibitor of angiotensin-converting 
enzyme, produced by actinomycetes. J Antibiot (Tokyo) 1985, 38, 1813-5. 
 
33.  Huang, L.; Albers-Schonberg, G.; Monaghan, R. L.; Jakubas, K.; Pong, S. S.; 
Hensens, O. D.; Burg, R. W.; Ostlind, D. A.; Conroy, J.; Stapley, E. O., Discovery, 
production and purification of the Na+, K+ activated ATPase inhibitor, L-681,110 from 
the fermentation broth of Streptomyces sp. MA-5038. J Antibiot (Tokyo) 1984, 37, 970-
5. 
166 
 
 
34.  Hensens, O. D.; Liesch, J. M., Structure elucidation of angiotensin converting 
enzyme inhibitor L-681,176 from Streptomyces sp. MA 5143a. J Antibiot (Tokyo) 1984, 
37, 466-8. 
 
35.  Kodani, S.; Ohnishi-Kameyama, M.; Yoshida, M.; Ochi, K., A New Siderophore 
Isolated from Streptomyces sp TM-34 with Potent Inhibitory Activity Against 
Angiotensin-Converting Enzyme. Euro J Org Chem 2011, 3191-3196. 
 
36.  Kido, Y.; Hamakado, T.; Yoshida, T.; Anno, M.; Motoki, Y.; Wakamiya, T.; Shiba, T., 
Isolation and characterization of ancovenin, a new inhibitor of angiotensin I converting 
enzyme, produced by actinomycetes. J Antibiot (Tokyo) 1983, 36, 1295-9. 
 
37.  Wakamiya, T.; Ueki, Y.; Shiba, T.; Kido, Y.; Motoki, Y., The Structure of Ancovenin, 
a New Peptide Inhibitor of Angiotensin-I Converting Enzyme. Tetrahedron Lett 1985, 26, 
665-668. 
 
38.  Singh, P. D.; Johnson, J. H., Muraceins--muramyl peptides produced by Nocardia 
orientalis as angiotensin-converting enzyme inhibitors. II. Isolation and structure 
determination. J Antibiot (Tokyo) 1984, 37, 336-43. 
 
39.  Bush, K.; Henry, P. R.; Slusarchyk, D. S., Muraceins--muramyl peptides produced 
by Nocardia orientalis as angiotensin-converting enzyme inhibitors. I. Taxonomy, 
fermentation and biological properties. J Antibiot (Tokyo) 1984, 37, 330-5. 
 
40.  Ishida, K.; Kato, T.; Murakami, M.; Watanabe, M.; Watanabe, M. F., Microginins, 
zinc metalloproteases inhibitors from the cyanobacterium Microcystis aeruginosa. 
Tetrahedron 2000, 56, 8643-8656. 
 
41.  Kodani, S.; Suzuki, S.; Ishida, K.; Murakami, M., Five new cyanobacterial peptides 
from water bloom materials of lake Teganuma (Japan). FEMS Microbiology Letters 
1999, 178, 343-348. 
 
42.  Kraft, M.; Schleberger, C.; Weckesser, J.; Schulz, G. E., Binding structure of the 
leucine aminopeptidase inhibitor microginin FR1. FEBS Letters 2006, 580, 6943-6947. 
 
43.  Matsuura, F.; Hamada, Y.; Shioiri, T., Total Synthesis of Microginin, an 
Angiotensin-Converting Enzyme-Inhibitory Pentapeptide from the Blue-Green-Alga 
Microcystis-Aeruginosa. Tetrahedron 1994, 50, 11303-11314. 
 
44.  Neumann, U.; Forchert, A.; Flury, T.; Weckesser, J., Microginin FR1, a linear 
peptide from a water bloom of Microcystis species. FEMS Microbiology Letters 1997, 
153, 475-478. 
 
167 
 
45.  Okino, T.; Matsuda, H.; Murakami, M.; Yamaguchi, K., Microginin, an Angiotensin-
Converting Enzyme-Inhibitor from the Blue-Green-Alga Microcystis-Aeruginosa. 
Tetrahedron Lett 1993, 34, 501-504. 
 
46.  Kase, H.; Kaneko, M.; Yamada, K., K-13, a novel inhibitor of angiotensin I 
converting enzyme produced by Micromonospora halophytica subsp. exilisia. I. 
Fermentation, isolation and biological properties. J Antibiot (Tokyo) 1987, 40, 450-4. 
 
47.  Yasuzawa, T.; Shirahata, K.; Sano, H., K-13, a novel inhibitor of angiotensin I 
converting enzyme produced by Micromonospora halophytica subsp. exilisia. II. 
Structure determination. J Antibiot (Tokyo) 1987, 40, 455-8. 
 
48.  Hirayama, N.; Kasai, M.; Shirahata, K., Structure and conformation of a novel 
inhibitor of angiotensin I converting enzyme--a tripeptide containing phosphonic acid. Int 
J Pept Protein Res 1991, 38, 20-4. 
 
49.  Ntai, I.; Manier, M. L.; Hachey, D. L.; Bachmann, B. O., Biosynthetic origins of C-P 
bond containing tripeptide K-26. Org Lett 2005, 7, 2763-5. 
 
50.  Ntai, I.; Bachmann, B. O., Identification of ACE pharmacophore in the 
phosphonopeptide metabolite K-26. Bioorg Med Chem Lett 2008, 18, 3068-71. 
 
51.  Ohuchi, I.; Kurihara, K.; Shinohara, A.; Takei, T.; Yoshida, J.; Amano, S.; Miyadoh, 
S.; Matsuhashi, Y.; Shomure, T.; Sezaki, M., Studies on new angiotensin converting 
enzyme inhibitors, SF2513 A, B and C, Produced by Streptosporangium 
nondiastaticum. Sci. Reports of Meiji Seiki Kaisha 1988, 27, 46-54. 
 
52.  Koguchi, T.; Yamada, K.; Yamato, M.; Okachi, R.; Nakayama, K.; Kase, H., K-4, a 
novel inhibitor of angiotensin I converting enzyme produced by Actinomadura 
spiculosospora. J Antibiot (Tokyo) 1986, 39, 364-71. 
 
53.  Kido, Y.; Hamakado, T.; Anno, M.; Miyagawa, E.; Motoki, Y.; Wakamiya, T.; Shiba, 
T., Isolation and characterization of I5B2, a new phosphorus containing inhibitor of 
angiotensin I converting enzyme produced by Actinomadura sp. J Antibiot (Tokyo) 
1984, 37, 965-9. 
 
54.  Hidaka, T.; Shimotohno, K. W.; Morishita, T.; Seto, H., Studies on the biosynthesis 
of bialaphos (SF-1293). 18. 2-phosphinomethylmalic acid synthase: a descendant of 
(R)-citrate synthase? J Antibiot (Tokyo) 1999, 52, 925-31. 
 
55.  Mirakhur, A.; Gallagher, M. J.; Ledson, M. J.; Hart, C. A.; Walshaw, M. J., 
Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis. J Cyst 
Fibros 2003, 2, 19-24. 
 
168 
 
56.  Morikawa, K.; Nonaka, M.; Yoshikawa, Y.; Torii, I., Synergistic effect of fosfomycin 
and arbekacin on a methicillin-resistant Staphylococcus aureus-induced biofilm in a rat 
model. Int J Antimicrob Agents 2005, 25, 44-50. 
 
57.  Tempera, G.; Mirabile, M.; Mangiafico, A.; Caccamo, M.; Bonfiglio, G., Fosfomycin 
tromethamine in uncomplicated urinary tract infections: an epidemiological survey. J 
Chemother 2004, 16, 216-7. 
 
58.  Wiesner, J.; Borrmann, S.; Jomaa, H., Fosmidomycin for the treatment of malaria. 
Parasitol Res 2003, 90 Suppl 2, S71-6. 
 
59.  Metcalf, W. W.; Van Der Donk, W. A., Biosynthesis of phosphonic and phosphinic 
acid natural products. Annu Rev Biochem 2009, 78, 65-94. 
 
60.  Freeman, S.; Seidel, H. M.; Schwalbe, C. H.; Knowles, J. R., Phosphonate 
Biosynthesis - the Stereochemical Course of Phosphoenolpyruvate Phosphomutase. 
Journal of the American Chemical Society 1989, 111, 9233-9234. 
 
61.  Mcqueney, M. S.; Lee, S. L.; Swartz, W. H.; Ammon, H. L.; Mariano, P. S.; 
Dunawaymariano, D., Evidence for an Intramolecular, Stepwise Reaction Pathway for 
Pep Phosphomutase Catalyzed P-C Bond Formation. Journal of Organic Chemistry 
1991, 56, 7121-7130. 
 
62.  Liu, S. J.; Lu, Z. B.; Jia, Y.; Dunaway-Mariano, D.; Herzberg, O., Dissociative 
phosphoryl transfer in PEP mutase catalysis: Structure of the enzyme/sulfopyruvate 
complex and kinetic properties of mutants. Biochemistry 2002, 41, 10270-10276. 
 
63.  Ntai, I.; Phelan, V. V.; Bachmann, B. O., Phosphonopeptide K-26 biosynthetic 
intermediates in Astrosporangium hypotensionis. Chem Commun (Camb) 2006, 4518-
20. 
 
64.  Skeggs, L. T., Jr., Discovery of the two angiotensin peptides and the angiotensin 
converting enzyme. Hypertension 1993, 21, 259-60. 
 
65.  Skeggs, L. T., Jr.; Kahn, J. R.; Shumway, N. P., The preparation and function of the 
hypertensin-converting enzyme. J Exp Med 1956, 103, 295-9. 
 
66.  Bernstein, K. E.; Martin, B. M.; Edwards, A. S.; Bernstein, E. A., Mouse 
angiotensin-converting enzyme is a protein composed of two homologous domains. J 
Biol Chem 1989, 264, 11945-51. 
 
67.  Soubrier, F.; Alhenc-Gelas, F.; Hubert, C.; Allegrini, J.; John, M.; Tregear, G.; 
Corvol, P., Two putative active centers in human angiotensin I-converting enzyme 
revealed by molecular cloning. Proc Natl Acad Sci U S A 1988, 85, 9386-90. 
 
169 
 
68.  Cushman, D. W.; Cheung, H. S., Concentrations of angiotensin-converting enzyme 
in tissues of the rat. Biochim Biophys Acta 1971, 250, 261-5. 
 
69.  El-Dorry, H. A.; Bull, H. G.; Iwata, K.; Thornberry, N. A.; Cordes, E. H.; Soffer, R. L., 
Molecular and catalytic properties of rabbit testicular dipeptidyl carboxypeptidase. J Biol 
Chem 1982, 257, 14128-33. 
 
70.  Das, M.; Hartley, J. L.; Soffers, R. L., Serum angiotensin-converting enzyme. 
Isolation and relationship to the pulmonary enzyme. J Biol Chem 1977, 252, 1316-9. 
 
71.  Wei, L.; Alhenc-Gelas, F.; Soubrier, F.; Michaud, A.; Corvol, P.; Clauser, E., 
Expression and characterization of recombinant human angiotensin I-converting 
enzyme. Evidence for a C-terminal transmembrane anchor and for a proteolytic 
processing of the secreted recombinant and plasma enzymes. J Biol Chem 1991, 266, 
5540-6. 
 
72.  Naim, H. Y., Angiotensin-converting enzyme of the human small intestine. Subunit 
and quaternary structure, biosynthesis and membrane association. Biochem J 1992, 
286 (Pt 2), 451-7. 
 
73.  Allinson, T. M.; Parkin, E. T.; Condon, T. P.; Schwager, S. L.; Sturrock, E. D.; 
Turner, A. J.; Hooper, N. M., The role of ADAM10 and ADAM17 in the ectodomain 
shedding of angiotensin converting enzyme and the amyloid precursor protein. Eur J 
Biochem 2004, 271, 2539-47. 
 
74.  Oppong, S. Y.; Hooper, N. M., Characterization of a secretase activity which 
releases angiotensin-converting enzyme from the membrane. Biochem J 1993, 292 ( Pt 
2), 597-603. 
 
75.  Parkin, E. T.; Turner, A. J.; Hooper, N. M., Secretase-mediated cell surface 
shedding of the angiotensin-converting enzyme. Protein Pept Lett 2004, 11, 423-32. 
 
76.  Bernstein, K. E.; Ong, F. S.; Blackwell, W. L.; Shah, K. H.; Giani, J. F.; Gonzalez-
Villalobos, R. A.; Shen, X. Z.; Fuchs, S.; Touyz, R. M., A modern understanding of the 
traditional and nontraditional biological functions of angiotensin-converting enzyme. 
Pharmacol Rev 2013, 65, 1-46. 
 
77.  Bernstein, K. E.; Shen, X. Z.; Gonzalez-Villalobos, R. A.; Billet, S.; Okwan-Duodu, 
D.; Ong, F. S.; Fuchs, S., Different in vivo functions of the two catalytic domains of 
angiotensin-converting enzyme (ACE). Curr Opin Pharmacol 2011, 11, 105-11. 
 
78.  Gonzalez-Villalobos, R. A.; Shen, X. Z.; Bernstein, E. A.; Janjulia, T.; Taylor, B.; 
Giani, J. F.; Blackwell, W. L.; Shah, K. H.; Shi, P. D.; Fuchs, S.; Bernstein, K. E., 
Rediscovering ACE: novel insights into the many roles of the angiotensin-converting 
enzyme. J Mol Med (Berl) 2013, 91, 1143-54. 
 
170 
 
79.  Zou, K.; Maeda, T.; Watanabe, A.; Liu, J.; Liu, S.; Oba, R.; Satoh, Y.; Komano, H.; 
Michikawa, M., Abeta42-to-Abeta40- and angiotensin-converting activities in different 
domains of angiotensin-converting enzyme. J Biol Chem 2009, 284, 31914-20. 
 
80.  Eckman, E. A.; Adams, S. K.; Troendle, F. J.; Stodola, B. A.; Kahn, M. A.; Fauq, A. 
H.; Xiao, H. D.; Bernstein, K. E.; Eckman, C. B., Regulation of steady-state beta-
amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not 
angiotensin-converting enzyme. J Biol Chem 2006, 281, 30471-8. 
 
81.  Wolozin, B.; Bednar, M. M., Interventions for heart disease and their effects on 
Alzheimer's disease. Neurol Res 2006, 28, 630-6. 
 
82.  Rousseau, A.; Michaud, A.; Chauvet, M. T.; Lenfant, M.; Corvol, P., The 
hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of 
the N-terminal active site of human angiotensin-converting enzyme. J Biol Chem 1995, 
270, 3656-61. 
 
83.  Bonnet, D.; Lemoine, F. M.; Khoury, E.; Pradelles, P.; Najman, A.; Guigon, M., 
Reversible inhibitory effects and absence of toxicity of the tetrapeptide acetyl-N-Ser-
Asp-Lys-Pro (AcSDKP) in human long-term bone marrow culture. Exp Hematol 1992, 
20, 1165-9. 
 
84.  Liao, T. D.; Yang, X. P.; D'ambrosio, M.; Zhang, Y.; Rhaleb, N. E.; Carretero, O. A., 
N-acetyl-seryl-aspartyl-lysyl-proline attenuates renal injury and dysfunction in 
hypertensive rats with reduced renal mass: council for high blood pressure research. 
Hypertension 2010, 55, 459-67. 
 
85.  Lin, C. X.; Rhaleb, N. E.; Yang, X. P.; Liao, T. D.; D'ambrosio, M. A.; Carretero, O. 
A., Prevention of aortic fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in angiotensin II-
induced hypertension. Am J Physiol Heart Circ Physiol 2008, 295, H1253-H1261. 
 
86.  Peng, H.; Carretero, O. A.; Brigstock, D. R.; Oja-Tebbe, N.; Rhaleb, N. E., Ac-
SDKP reverses cardiac fibrosis in rats with renovascular hypertension. Hypertension 
2003, 42, 1164-70. 
 
87.  Wei, L.; Alhenc-Gelas, F.; Corvol, P.; Clauser, E., The two homologous domains of 
human angiotensin I-converting enzyme are both catalytically active. J Biol Chem 1991, 
266, 9002-8. 
 
88.  Fuchs, S.; Frenzel, K.; Hubert, C.; Lyng, R.; Muller, L.; Michaud, A.; Xiao, H. D.; 
Adams, J. W.; Capecchi, M. R.; Corvol, P.; Shur, B. D.; Bernstein, K. E., Male fertility is 
dependent on dipeptidase activity of testis ACE. Nat Med 2005, 11, 1140-2; author reply 
1142-3. 
 
89.  Yu, X. C.; Sturrock, E. D.; Wu, Z.; Biemann, K.; Ehlers, M. R.; Riordan, J. F., 
Identification of N-linked glycosylation sites in human testis angiotensin-converting 
171 
 
enzyme and expression of an active deglycosylated form. J Biol Chem 1997, 272, 3511-
9. 
 
90.  O'neill, H. G.; Redelinghuys, P.; Schwager, S. L.; Sturrock, E. D., The role of 
glycosylation and domain interactions in the thermal stability of human angiotensin-
converting enzyme. Biol Chem 2008, 389, 1153-61. 
 
91.  Voronov, S.; Zueva, N.; Orlov, V.; Arutyunyan, A.; Kost, O., Temperature-induced 
selective death of the C-domain within angiotensin-converting enzyme molecule. FEBS 
Lett 2002, 522, 77-82. 
 
92.  Corradi, H. R.; Schwager, S. L.; Nchinda, A. T.; Sturrock, E. D.; Acharya, K. R., 
Crystal structure of the N domain of human somatic angiotensin I-converting enzyme 
provides a structural basis for domain-specific inhibitor design. J Mol Biol 2006, 357, 
964-74. 
 
93.  Natesh, R.; Schwager, S. L.; Sturrock, E. D.; Acharya, K. R., Crystal structure of the 
human angiotensin-converting enzyme-lisinopril complex. Nature 2003, 421, 551-4. 
 
94.  Erdos, E. G., The ACE and I: how ACE inhibitors came to be. FASEB J 2006, 20, 
1034-1038. 
 
95.  Smith, C. G.; Vane, J. R., The discovery of captopril. FASEB J 2003, 17, 788-789. 
 
96.  Koh, C. Y.; Kini, M., From snake venom toxins to therapeutics - Cardiovascular 
examples. Toxicon 2012, 59, 497-506. 
 
97.  Natesh, R.; Schwager, S. L.; Evans, H. R.; Sturrock, E. D.; Acharya, K. R., 
Structural details on the binding of antihypertensive drugs captopril and enalaprilat to 
human testicular angiotensin I-converting enzyme. Biochemistry 2004, 43, 8718-24. 
 
98.  Akif, M.; Masuyer, G.; Schwager, S. L.; Bhuyan, B. J.; Mugesh, G.; Isaac, R. E.; 
Sturrock, E. D.; Acharya, K. R., Structural characterization of angiotensin I-converting 
enzyme in complex with a selenium analogue of captopril. FEBS J 2011, 278, 3644-50. 
 
99.  Dive, V.; Cotton, J.; Yiotakis, A.; Michaud, A.; Vassiliou, S.; Jiracek, J.; Vazeux, G.; 
Chauvet, M. T.; Cuniasse, P.; Corvol, P., RXP 407, a phosphinic peptide, is a potent 
inhibitor of angiotensin I converting enzyme able to differentiate between its two active 
sites. Proc Natl Acad Sci U S A 1999, 96, 4330-5. 
 
100.  Georgiadis, D.; Cuniasse, P.; Cotton, J.; Yiotakis, A.; Dive, V., Structural 
determinants of RXPA380, a potent and highly selective inhibitor of the angiotensin-
converting enzyme C-domain. Biochemistry 2004, 43, 8048-54. 
 
172 
 
101.  Kroger, W. L.; Douglas, R. G.; O'neill, H. G.; Dive, V.; Sturrock, E. D., Investigating 
the domain specificity of phosphinic inhibitors RXPA380 and RXP407 in angiotensin-
converting enzyme. Biochemistry 2009, 48, 8405-12. 
 
102.  Anthony, C. S.; Corradi, H. R.; Schwager, S. L.; Redelinghuys, P.; Georgiadis, D.; 
Dive, V.; Acharya, K. R.; Sturrock, E. D., The N domain of human angiotensin-I-
converting enzyme: the role of N-glycosylation and the crystal structure in complex with 
an N domain-specific phosphinic inhibitor, RXP407. J Biol Chem 2010, 285, 35685-93. 
 
103.  Corradi, H. R.; Chitapi, I.; Sewell, B. T.; Georgiadis, D.; Dive, V.; Sturrock, E. D.; 
Acharya, K. R., The structure of testis angiotensin-converting enzyme in complex with 
the C domain-specific inhibitor RXPA380. Biochemistry 2007, 46, 5473-8. 
 
104.  Macours, N.; Poels, J.; Hens, K.; Francis, C.; Huybrechts, R., Structure, 
evolutionary conservation, and functions of angiotensin- and endothelin-converting 
enzymes. Int Rev Cytol 2004, 239, 47-97. 
 
105.  Baig, M. S.; Kumar, A.; Siddiqi, M. I.; Goyal, N., Characterization of 
dipeptidylcarboxypeptidase of Leishmania donovani: a molecular model for structure 
based design of antileishmanials. J Comput Aided Mol Des 2010, 24, 77-87. 
 
106.  Cunha, C. E.; Magliarelli Hde, F.; Paschoalin, T.; Nchinda, A. T.; Lima, J. C.; 
Juliano, M. A.; Paiva, P. B.; Sturrock, E. D.; Travassos, L. R.; Carmona, A. K., Catalytic 
properties of recombinant dipeptidyl carboxypeptidase from Escherichia coli: a 
comparative study with angiotensin I-converting enzyme. Biol Chem 2009, 390, 931-40. 
 
107.  Riviere, G.; Michaud, A.; Corradi, H. R.; Sturrock, E. D.; Ravi Acharya, K.; Cogez, 
V.; Bohin, J. P.; Vieau, D.; Corvol, P., Characterization of the first angiotensin-
converting like enzyme in bacteria: Ancestor ACE is already active. Gene 2007, 399, 
81-90. 
 
108.  Cornell, M. J.; Williams, T. A.; Lamango, N. S.; Coates, D.; Corvol, P.; Soubrier, 
F.; Hoheisel, J.; Lehrach, H.; Isaac, R. E., Cloning and expression of an evolutionary 
conserved single-domain angiotensin converting enzyme from Drosophila 
melanogaster. J Biol Chem 1995, 270, 13613-9. 
 
109.  Taylor, C. A.; Coates, D.; Shirras, A. D., The Acer gene of Drosophila codes for an 
angiotensin-converting enzyme homologue. Gene 1996, 181, 191-7. 
 
110.  Williams, T. A.; Michaud, A.; Houard, X.; Chauvet, M. T.; Soubrier, F.; Corvol, P., 
Drosophila melanogaster angiotensin I-converting enzyme expressed in Pichia pastoris 
resembles the C domain of the mammalian homologue and does not require 
glycosylation for secretion and enzymic activity. Biochem J 1996, 318 ( Pt 1), 125-31. 
 
111.  Riviere, G.; Michaud, A.; Deloffre, L.; Vandenbulcke, F.; Levoye, A.; Breton, C.; 
Corvol, P.; Salzet, M.; Vieau, D., Characterization of the first non-insect invertebrate 
173 
 
functional angiotensin-converting enzyme (ACE): leech TtACE resembles the N-domain 
of mammalian ACE. Biochem J 2004, 382, 565-73. 
 
112.  Laurent, V.; Salzet, M., Biochemical properties of the angiotensin-converting-like 
enzyme from the leech Theromyzon tessulatum. Peptides 1996, 17, 737-45. 
 
113.  Hooper, N. M., Families of zinc metalloproteases. FEBS Lett 1994, 354, 1-6. 
 
114.  Miyoshi, S.; Shinoda, S., Microbial metalloproteases and pathogenesis. Microbes 
Infect 2000, 2, 91-8. 
 
115.  Donoghue, M.; Hsieh, F.; Baronas, E.; Godbout, K.; Gosselin, M.; Stagliano, N.; 
Donovan, M.; Woolf, B.; Robison, K.; Jeyaseelan, R.; Breitbart, R. E.; Acton, S., A novel 
angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I 
to angiotensin 1-9. Circ Res 2000, 87, E1-9. 
 
116. BLAST: Basic Local Sequence Alignment Search Tool. 
http://blast.ncbi.nlm.nih.gov/Blast.cgi. 
 
117. Multiple Sequence Alignment by CLUSTALW. 
http://www.genome.jp/tools/clustalw/. 
 
118.  Kim, H. M.; Shin, D. R.; Yoo, O. J.; Lee, H.; Lee, J. O., Crystal structure of 
Drosophila angiotensin I-converting enzyme bound to captopril and lisinopril. FEBS Lett 
2003, 538, 65-70. 
 
119.  Akif, M.; Georgiadis, D.; Mahajan, A.; Dive, V.; Sturrock, E. D.; Isaac, R. E.; 
Acharya, K. R., High-resolution crystal structures of Drosophila melanogaster 
angiotensin-converting enzyme in complex with novel inhibitors and antihypertensive 
drugs. J Mol Biol 2010, 400, 502-17. 
 
120.  Akif, M.; Ntai, I.; Sturrock, E. D.; Isaac, R. E.; Bachmann, B. O.; Acharya, K. R., 
Crystal structure of a phosphonotripeptide K-26 in complex with angiotensin converting 
enzyme homologue (AnCE) from Drosophila melanogaster. Biochem Biophys Res 
Commun 2010, 398, 532-6. 
 
121.  Newman, D. J.; Cragg, G. M., Natural products as sources of new drugs over the 
30 years from 1981 to 2010. J. Nat. Prod. 2012, 75, 311-335. 
 
122.  Crawford, J. M.; Clardy, J., Bacterial symbionts and natural products. Chem. 
Commun. (Camb) 2011, 47, 7559-7566. 
 
123.  Koguchi, T.; Yamada, K.; Yamato, M.; Okachi, R.; Nakayama, K.; Kase, H., K-4, a 
novel inhibitor of angiotensin I converting enzyme produced by Actinomadura 
spiculosospora. J. Antibiot. (Tokyo) 1986, 39, 364-371. 
 
174 
 
124.  Yamato, M.; Koguchi, T.; Okachi, R.; Yamada, K.; Nakayama, K.; Kase, H.; 
Karasawa, A.; Shuto, K., K-26, a novel inhibitor of angiotensin I converting enzyme 
produced by an actinomycete K-26. J. Antibiot. (Tokyo) 1986, 39, 44-52. 
 
125.  Kido, Y.; Hamakado, T.; Anno, M.; Miyagawa, E.; Motoki, Y.; Wakamiya, T.; 
Shiba, T., Isolation and characterization of I5B2, a new phosphorus containing inhibitor 
of angiotensin I converting enzyme produced by Actinomadura sp. J. Antibiot. (Tokyo) 
1984, 37, 965-969. 
 
126.  Kramer, G. J.; Mohd, A.; Schwager, S. L.; Masuyer, G.; Acharya, K. R.; Sturrock, 
E. D.; Bachmann, B. O., Interkingdom pharmacology of Angiotensin-I converting 
enzyme inhibitor phosphonates produced by actinomycetes. ACS Med Chem Lett 2014, 
5, 346-51. 
 
127.  Ntai, I.; Bachmann, B. O., Identification of ACE pharmacophore in the 
phosphonopeptide metabolite K-26. Bioorg Med Chem Lett 2008, 18, 3068-3071. 
 
128.  Holmquist, B.; Bunning, P.; Riordan, J. F., A continuous spectrophotometric assay 
for angiotensin converting enzyme. Anal Biochem 1979, 95, 540-548. 
 
129.  Friedland, J.; Silverstein, E., A sensitive fluorimetric assay for serum angiotensin-
converting enzyme. Am\. J Clin Path 1976, 66, 416-424. 
 
130.  Nchinda, A. T.; Chibale, K.; Redelinghuys, P.; Sturrock, E. D., Synthesis of novel 
keto-ACE analogues as domain-selective angiotensin I-converting enzyme inhibitors. 
Bioorg Med Chem Lett 2006, 16, 4612-4615. 
 
131.  Schwager, S. L.; Carmona, A. K.; Sturrock, E. D., A high-throughput fluorimetric 
assay for angiotensin I-converting enzyme. Nat Protoc 2006, 1, 1961-1964. 
 
132.  Natesh, R.; Schwager, S. L.; Evans, H. R.; Sturrock, E. D.; Acharya, K. R., 
Structural details on the binding of antihypertensive drugs captopril and enalaprilat to 
human testicular angiotensin I-converting enzyme. Biochemistry 2004, 43, 8718-8724. 
 
133.  Natesh, R.; Schwager, S. L.; Sturrock, E. D.; Acharya, K. R., Crystal structure of 
the human angiotensin-converting enzyme-lisinopril complex. Nature 2003, 421, 551-
554. 
 
134.  Cunha, C. E.; Magliarelli Hde, F.; Paschoalin, T.; Nchinda, A. T.; Lima, J. C.; 
Juliano, M. A.; Paiva, P. B.; Sturrock, E. D.; Travassos, L. R.; Carmona, A. K., Catalytic 
properties of recombinant dipeptidyl carboxypeptidase from Escherichia coli: a 
comparative study with angiotensin I-converting enzyme. Biol Chem 2009, 390, 931-
940. 
 
135.  Miyoshi, S.; Shinoda, S., Microbial metalloproteases and pathogenesis. Microbes 
Infect 2000, 2, 91-98. 
175 
 
 
136.  Williams, T. A.; Michaud, A.; Houard, X.; Chauvet, M. T.; Soubrier, F.; Corvol, P., 
Drosophila melanogaster angiotensin I-converting enzyme expressed in Pichia pastoris 
resembles the C domain of the mammalian homologue and does not require 
glycosylation for secretion and enzymic activity. Biochem J 1996, 318 ( Pt 1), 125-131. 
 
137.  Carpino, L. A.; El-Faham, A.; Albericio, F., Efficiency in peptide coupling: 1-
Hydroxy-7-azabenzotriazole vs 3,4-Dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine. J Org 
Chem 1995, 60, 3561-3564. 
 
138.  Oishi, S.; Karki, R. G.; Kang, S. U.; Wang, X.; Worthy, K. M.; Bindu, L. K.; 
Nicklaus, M. C.; Fisher, R. J.; Burke, T. R., Jr., Design and synthesis of conformationally 
constrained Grb2 SH2 domain binding peptides employing alpha-methylphenylalanyl 
based phosphotyrosyl mimetics. J Med Chem 2005, 48, 764-772. 
 
139.  Carpino, L. A.; Sadat-Aalaee, D.; Beyermann, M., Tris(2-aminoethy1)amine as a 
substitute for 4-(Aminomethy1)piperidine in the FMOC/polyamine approach to rapid 
peptide synthesis. J Org Chem 1990, 55, 1673-1675. 
 
140.  Boger, D. L. Y., D., Total synthesis of deoxybouvardin and RA-VII: 
Macrocyclization via an intramolecular Ullmann reaction J Am Chem Soc 1991, 113, 
1427-1429. 
 
141.  Gordon, K.; Redelinghuys, P.; Schwager, S. L.; Ehlers, M. R.; Papageorgiou, A. 
C.; Natesh, R.; Acharya, K. R.; Sturrock, E. D., Deglycosylation, processing and 
crystallization of human testis angiotensin-converting enzyme. Biochem J 2003, 371, 
437-442. 
 
142.  Otwinowski, W.; Minor, W., Processing of X-ray diffraction data collected in 
oscillation mode. In Macromolecular Crystallography, part A, Carter Jr., C. W.; Sweet, 
R. M., Eds. Academic Press: New York, 1997; pp 307-326. 
 
143.  CCP4, The CCP4 Suite: Programs for protein crystallography. Acta. Crystallogr., 
Sect.  D: Biol. Crystallogr. 1994, 50, 760-763. 
 
144.  Mccoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; 
Read, R. J., Phaser Crystallographic Software. J Appl Crystallogr 2007, 40, 658-674. 
 
145.  Murshudov, G. N.; Vagin, A. A.; Dodson, E. J., Refinement of macromolecular 
structures by the maximum-likelihood method. Acta Crystallogr, Sect D: Biol Crystallogr 
1997, 53, 240-255. 
 
146.  Emsley, P.; Cowtan, K., COOT: Model-building tools for molecular graphics. Acta 
Crystallogr, Sect D: Biol Crystallogr 2004, 60, 2126-2132. 
 
176 
 
147.  Schuttelkopf, A. W.; Van Aalten, D. M., PRODRG: a tool for high-throughput 
crystallography of protein-ligand complexes. Acta Crystallogr, Sect D: Biol Crystallogr 
2004, 60, 1355-1363. 
 
148.  Davis, I. W.; Leaver-Fay, A.; Chen, V. B.; Block, J. N.; Kapral, G. J.; Wang, X.; 
Murray, L. W.; Arendall, W. B., 3rd; Snoeyink, J.; Richardson, J. S.; Richardson, D. C., 
MolProbity: All-atom contacts and structure validation for proteins and nucleic acids. 
Nucleic Acids Res. 2007, 35, W375-W383. 
 
149.  Mcdonald, I. K.; Thornton, J. M., Satisfying hydrogen bonding potential in proteins. 
J Mol Biol 1994, 238, 777-793. 
 
150.  Saitou, N.; Nei, M., The neighbor-joining method: a new method for reconstructing 
phylogenetic trees. Mol Biol Evol 1987, 4, 406-425. 
 
151.  Bryson, V.; Vogel, H. J., Evolutionary divergence and convergence in proteins. In 
Evolving Genes and Proteins, Zuckerkandl, E.; Pauling, L., Eds. Academic Press: New 
York, 1965; pp 97-166. 
 
152.  Tamura, K.; Peterson, D.; Peterson, N.; Stecher, G.; Nei, M.; Kumar, S., MEGA5: 
molecular evolutionary genetics analysis using maximum likelihood, evolutionary 
distance, and maximum parsimony methods. Mol Biol Evol 2011, 28, 2731-2739. 
 
153.  Li, J. W.; Vederas, J. C., Drug discovery and natural products: end of an era or an 
endless frontier? Science 2009, 325, 161-5. 
 
154.  Rohl, C. A.; Strauss, C. E.; Misura, K. M.; Baker, D., Protein structure prediction 
using Rosetta. Methods Enzymol 2004, 383, 66-93. 
 
155.  Siegel, J. B.; Zanghellini, A.; Lovick, H. M.; Kiss, G.; Lambert, A. R.; St Clair, J. L.; 
Gallaher, J. L.; Hilvert, D.; Gelb, M. H.; Stoddard, B. L.; Houk, K. N.; Michael, F. E.; 
Baker, D., Computational design of an enzyme catalyst for a stereoselective bimolecular 
Diels-Alder reaction. Science 2010, 329, 309-13. 
 
156.  Kuhlman, B.; Dantas, G.; Ireton, G. C.; Varani, G.; Stoddard, B. L.; Baker, D., 
Design of a novel globular protein fold with atomic-level accuracy. Science 2003, 302, 
1364-8. 
 
157.  Davis, I. W.; Raha, K.; Head, M. S.; Baker, D., Blind docking of pharmaceutically 
relevant compounds using RosettaLigand. Protein Sci 2009, 18, 1998-2002. 
 
158.  Davis, I. W.; Baker, D., RosettaLigand docking with full ligand and receptor 
flexibility. J Mol Biol 2009, 385, 381-92. 
 
177 
 
159.  Misura, K. M.; Chivian, D.; Rohl, C. A.; Kim, D. E.; Baker, D., Physically realistic 
homology models built with ROSETTA can be more accurate than their templates. Proc 
Natl Acad Sci U S A 2006, 103, 5361-6. 
 
160.  Das, R.; Baker, D., Macromolecular modeling with rosetta. Annu Rev Biochem 
2008, 77, 363-82. 
 
161.  Ballester, P. J.; Westwood, I.; Laurieri, N.; Sim, E.; Richards, W. G., Prospective 
virtual screening with Ultrafast Shape Recognition: the identification of novel inhibitors 
of arylamine N-acetyltransferases. J R Soc Interface 2010, 7, 335-42. 
 
162.  Perola, E.; Walters, W. P.; Charifson, P. S., A detailed comparison of current 
docking and scoring methods on systems of pharmaceutical relevance. Proteins 2004, 
56, 235-49. 
 
163.  Leaver-Fay, A.; O'meara, M. J.; Tyka, M.; Jacak, R.; Song, Y.; Kellogg, E. H.; 
Thompson, J.; Davis, I. W.; Pache, R. A.; Lyskov, S.; Gray, J. J.; Kortemme, T.; 
Richardson, J. S.; Havranek, J. J.; Snoeyink, J.; Baker, D.; Kuhlman, B., Scientific 
benchmarks for guiding macromolecular energy function improvement. Methods 
Enzymol 2013, 523, 109-43. 
 
164.  Cheng, Y.; Prusoff, W. H., Relationship between the inhibition constant (K1) and 
the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic 
reaction. Biochem Pharmacol 1973, 22, 3099-108. 
 
165.  Nannemann, D. P.; Kaufmann, K. W.; Meiler, J.; Bachmann, B. O., Design and 
directed evolution of a dideoxy purine nucleoside phosphorylase. Protein Eng Des Sel 
2010, 23, 607-16. 
 
166.  Renfrew, P. D.; Campbell, G.; Strauss, C. E.; Bonneau, R., The 2010 Rosetta 
developers meeting: macromolecular prediction and design meets reproducible 
publishing. PLoS One 2011, 6, e22431. 
 
167.  Katukojvala, S.; Barlett, K. N.; Lotesta, S. D.; Williams, L. J., Spirodiepoxides in 
total synthesis: epoxomicin. J Am Chem Soc 2004, 126, 15348-9. 
 
168.  Kawatani, M.; Osada, H., Affinity-based target identification for bioactive small 
molecules. Medchemcomm 2014, 5, 277-287. 
 
169.  Leslie, B. J.; Hergenrother, P. J., Identification of the cellular targets of bioactive 
small organic molecules using affinity reagents. Chem Soc Rev 2008, 37, 1347-60. 
 
170.  Ziegler, S.; Pries, V.; Hedberg, C.; Waldmann, H., Target identification for small 
bioactive molecules: finding the needle in the haystack. Angew Chem Int Ed Engl 2013, 
52, 2744-92. 
 
178 
 
171.  Wulff, J. E.; Siegrist, R.; Myers, A. G., The natural product avrainvillamide binds to 
the oncoprotein nucleophosmin. J Am Chem Soc 2007, 129, 14444-51. 
 
172.  Wang, G.; Shang, L.; Burgett, A. W.; Harran, P. G.; Wang, X., Diazonamide toxins 
reveal an unexpected function for ornithine delta-amino transferase in mitotic cell 
division. Proc Natl Acad Sci U S A 2007, 104, 2068-73. 
 
173.  Emami, K. H.; Nguyen, C.; Ma, H.; Kim, D. H.; Jeong, K. W.; Eguchi, M.; Moon, R. 
T.; Teo, J. L.; Kim, H. Y.; Moon, S. H.; Ha, J. R.; Kahn, M., A small molecule inhibitor of 
beta-catenin/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci U S A 
2004, 101, 12682-7. 
 
174.  Statsuk, A. V.; Bai, R.; Baryza, J. L.; Verma, V. A.; Hamel, E.; Wender, P. A.; 
Kozmin, S. A., Actin is the primary cellular receptor of bistramide A. Nat Chem Biol 
2005, 1, 383-8. 
 
175.  Bernstein, K. E.; Welsh, S. L.; Inman, J. K., A deeply recessed active site in 
angiotensin-converting enzyme is indicated from the binding characteristics of biotin-
spacer-inhibitor reagents. Biochem Biophys Res Commun 1990, 167, 310-6. 
 
176.  Pantoliano, M. W.; Holmquist, B.; Riordan, J. F., Affinity chromatographic 
purification of angiotensin converting enzyme. Biochemistry 1984, 23, 1037-42. 
 
177.  Zhu, J.; Wan, Q.; Danishefsky, S. J., Synthesis of Biotinylated Tumor-Associated 
Carbohydrate Antigens for Immunological Studies. Tetrahedron Lett 2009, 50, 712-714. 
 
178.  Green, N. M., Spectrophotometric determination of avidin and biotin. In Methods in 
Enzymol., Academic Press: New York, 1970; Vol. XVIII, p 418. 
 
179.  Li, M.; Gray, W.; Zhang, H.; Chung, C. H.; Billheimer, D.; Yarbrough, W. G.; 
Liebler, D. C.; Shyr, Y.; Slebos, R. J., Comparative shotgun proteomics using spectral 
count data and quasi-likelihood modeling. J Proteome Res 2010, 9, 4295-305. 
 
180.  Choi, H.; Fermin, D.; Nesvizhskii, A. I., Significance analysis of spectral count data 
in label-free shotgun proteomics. Mol Cell Proteomics 2008, 7, 2373-85. 
 
181.  Xue, Y.; O'mara, M. L.; Surawski, P. P.; Trau, M.; Mark, A. E., Effect of 
poly(ethylene glycol) (PEG) spacers on the conformational properties of small peptides: 
a molecular dynamics study. Langmuir 2011, 27, 296-303. 
 
182.  Phelan, V. V., Biosynthetic Investigations of the Peptide Natural Products K-26 
and Anthramycin. 2011. 
 
183.  Bougioukou, D. J.; Mukherjee, S.; Van Der Donk, W. A., Revisiting the 
biosynthesis of dehydrophos reveals a tRNA-dependent pathway. Proc Natl Acad Sci U 
S A 2013, 110, 10952-7. 
179 
 
 
184.  Cuatrecasas, P.; Parikh, I., Adsorbents for affinity chromatography. Use of N-
hydroxysuccinimide esters of agarose. Biochemistry 1972, 11, 2291-9. 
 
185.  Cuatrecasas, P., Affinity chromatography of macromolecules. Adv Enzymol Relat 
Areas Mol Biol 1972, 36, 29-89. 
 
186.  Schwager, S. L.; Carmona, A. K.; Sturrock, E. D., A high-throughput fluorimetric 
assay for angiotensin I-converting enzyme. Nat Protoc 2006, 1, 1961-4. 
 
187.  Gordon, K.; Redelinghuys, P.; Schwager, S. L.; Ehlers, M. R.; Papageorgiou, A. 
C.; Natesh, R.; Acharya, K. R.; Sturrock, E. D., Deglycosylation, processing and 
crystallization of human testis angiotensin-converting enzyme. Biochem J 2003, 371, 
437-42. 
 
188.  Ntai, I.; Manier, M. L.; Hachey, D. L.; Bachmann, B. O., Biosynthetic origins of C-P 
bond containing tripeptide K-26. Org Lett 2005, 7, 2763-2765. 
 
189.  Geurink, P. P.; Prely, L. M.; Van Der Marel, G. A.; Bischoff, R.; Overkleeft, H. S., 
Photoaffinity labeling in activity-based protein profiling. Top Curr Chem 2012, 324, 85-
113. 
 
190.  Shi, H.; Zhang, C. J.; Chen, G. Y.; Yao, S. Q., Cell-based proteome profiling of 
potential dasatinib targets by use of affinity-based probes. J Am Chem Soc 2012, 134, 
3001-14. 
 
191.  Das, J., Aliphatic diazirines as photoaffinity probes for proteins: recent 
developments. Chem Rev 2011, 111, 4405-17. 
 
192.  Wang, R. E.; Hunt, C. R.; Chen, J.; Taylor, J. S., Biotinylated quercetin as an 
intrinsic photoaffinity proteomics probe for the identification of quercetin target proteins. 
Bioorg Med Chem 2011, 19, 4710-20. 
 
193.  Ishikawa, F.; Kakeya, H., Specific enrichment of nonribosomal peptide synthetase 
module by an affinity probe for adenylation domains. Bioorg Med Chem Lett 2014, 24, 
865-9. 
 
 
 
 
 
 
180 
 
APPENDIX A 
 
NMR SPECTRA  
OF SYNTHETIC INTERMEDIATES  
FROM CHAPTER II 
  
181 
 
NMR spectra of K-4 (II-2) and synthetic intermediates (II-2a - II-2d) 
 
1
HNMR Spectrum (600 MHz) of N-benzyloxycarbonyl-N-methyl-L-valyl-L-phenylalanine methyl ester (II-
2a) in CDCl3 
 
 
 
 
13
CNMR Spectrum (150 MHz) of N-benzyloxycarbonyl-N-methyl-L-valyl-L-phenylalanine methyl ester (II-
2a) in CDCl3 
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1
HNMR Spectrum (600 MHz) of N-benzyloxycarbonyl-N-methyl-L-valyl-L-phenylalanine (II-2b) in CDCl3 
 
 
 
 
 
 
 
 
 
13
CNMR Spectrum (150 MHz) of N-benzyloxycarbonyl-N-methyl-L-valyl-L-phenylalanine (II-2b) in CDCl3 
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1
HNMR Spectrum (400 MHz) of N-(N-benzyloxycarbonyl-N-methyl-L-valyl-L-phenylalanyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (II-2c) in CDCl3 
 
 
 
 
 
 
 
 
13
CNMR Spectrum (150 MHz) of N-(N-benzyloxycarbonyl-N-methyl-L-valyl-L-phenylalanyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (II-2c) in CDCl3 
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31
PNMR Spectrum (162 MHz) of N-(N-benzyloxycarbonyl-N-methyl-L-valyl-L-phenylalanyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (II-2c) in CDCl3 
 
 
 
 
 
 
 
 
 
 
 
1
HNMR Spectrum (600 MHz) of diethyl N-(N-methyl-L-valyl-L-phenylalanyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate (II-2d) in CDCl3 
185 
 
 
13
CNMR Spectrum (150 MHz) of diethyl N-(N-methyl-L-valyl-L-phenylalanyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate (II-2d) in CDCl3 
 
 
 
 
31
PNMR Spectrum (162 MHz) of diethyl N-(N-methyl-L-valyl-L-phenylalanyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate (II-2d) in CDCl3 
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1
HNMR Spectrum (600 MHz) of K-4: N-(N-methyl-L-isoleucyl-L-phenylalanyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonic acid (II-2) in D2O, pD = 11.9 
 
 
13
CNMR Spectrum (150 MHz) of K-4: N-(N-methyl-L-isoleucyl-L-phenylalanyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonic acid  (II-2) in D2O, pD = 11.9 
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31
PNMR Spectrum (162 MHz) of K-4: N-(N-methyl-L-isoleucyl-L-phenylalanyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonic acid (II-2) in D2O, pD = 11.9 
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NMR spectra of 15-B-2 (II-3) and synthetic intermediates (II-3a - II-3d) 
 
 
 
 
 
1
HNMR Spectrum (600 MHz) of N-benzyloxycarbonyl-N-methyl-L-valyl-O-benzyl-L-tyrosine methyl ester  
(II-3a) in CDCl3 
 
 
 
 
 
 
 
13
CNMR Spectrum (150 MHz) of N-benzyloxycarbonyl-N-methyl-L-valyl-O-benzyl-L-tyrosine methyl ester 
(II-3a) in CDCl3 
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1
HNMR Spectrum (400 MHz) of N-benzyloxycarbonyl-N-methyl-L-valyl-O-benzyl-L-tyrosine (II-3b) in 
CDCl3 
 
 
 
 
 
 
 
 
13
CNMR Spectrum (150 MHz) of N-benzyloxycarbonyl-N-methyl-L-valyl-O-benzyl-L-tyrosine (II-3b) in 
CDCl3 
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1
HNMR Spectrum (600 MHz) of diethyl N-(N-benzyloxycarbonyl-N-methyl-L-valyl-O-benzyl-L-tyrosyl)-1-
amino-2-(4-benzyloxyphenyl)ethyl phosphonate (II-3c) in CDCl3 
 
 
 
13
CNMR Spectrum (150 MHz) diethyl N-(N-benzyloxycarbonyl-N-methyl-L-valyl-O-benzyl-L-tyrosyl)-1-
amino-2-(4-benzyloxyphenyl)ethyl phosphonate (II-3c) in CDCl3 
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31
PNMR Spectrum (162 MHz) of diethyl N-(N-benzyloxycarbonyl-N-methyl-L-valyl-O-benzyl-L-tyrosyl)-1-
amino-2-(4-benzyloxyphenyl)ethyl phosphonate (II-3c) in CDCl3 
 
 
 
1
HNMR Spectrum (600 MHz) of diethyl N-(N-methyl-L-valyl-L-tyrosyl)-1-amino-2-(4-hydoxyphenyl)ethyl 
phosphonate (II-3d) in MeOD 
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13
CNMR Spectrum (150 MHz) diethyl N-(N-methyl-L-valyl-L-tyrosyl)-1-amino-2-(4-hydoxyphenyl)ethyl 
phosphonate (II-3d) in MeOD 
 
 
 
 
 
 
 
 
 
31
PNMR Spectrum (162 MHz) of diethyl N-(N-methyl-L-valyl-L-tyrosyl)-1-amino-2-(4-hydoxyphenyl)ethyl 
phosphonate (II-3d) in MeOD 
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1
HNMR Spectrum (600 MHz) of 15-B-2: N-(N-methyl-L-valyl-L-tyrosyl)-1-amino-2-(4-hydoxyphenyl)ethyl 
phosphonic acid (II-3) in D2O, pD = 11.9 
 
 
13
CNMR Spectrum (150 MHz) of 15-B-2: N-(N-methyl-L-valyl-L-tyrosyl)-1-amino-2-(4-hydoxyphenyl)ethyl 
phosphonic acid (II-3) in D2O, pD = 11.9 
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31
PNMR Spectrum (162 MHz) of 15-B-2:  N-(N-methyl-L-valyl-L-tyrosyl)-1-amino-2-(4-hydoxyphenyl)ethyl 
phosphonic acid (II-3) in D2O, pD = 11.9 
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NMR spectra of SF2513 B (II-4) and synthetic intermediates (II-4a - II-4d) 
 
1
HNMR Spectrum (600 MHz) of N-acetyl-L-isoleucyl-L-leucine methyl ester (II-4a) in CDCl3 
 
 
 
 
13
CNMR Spectrum (150 MHz) of N-acetyl-L-isoleucyl-L-leucine methyl ester (II-4a) in CDCl3 
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1
HNMR Spectrum (600 MHz) of N-acetyl-L-isoleucyl-L-leucine (II-4b) in DMSO-d
6 
 
 
 
13
CNMR Spectrum (150 MHz) of N-acetyl-L-isoleucyl-L-leucine (II-4b) in DMSO-d
6 
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1
HNMR Spectrum (600 MHz) of diethyl N-(N-acetyl-L-isoleucyl-L-leucyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (II-4c) in CDCl3 
 
 
13
CNMR Spectrum (150 MHz) of diethyl N-(N-acetyl-L-isoleucyl-L-leucyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (II-4c) in CDCl3 
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31
PNMR Spectrum (121 MHz) diethyl N-(N-acetyl-L-isoleucyl-L-leucyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (II-4c) in CDCl3 
 
 
 
 
1
HNMR Spectrum (600 MHz) of diethyl N-(N-acetyl-L-isoleucyl-L-leucyl)-1-amino-2-(4-hydoxyphenyl)ethyl 
phosphonate (II-4d) in MeOD 
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13
CNMR Spectrum (150 MHz) of diethyl N-(N-acetyl-L-isoleucyl-L-leucyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate (II-4d) in MeOD 
 
 
 
 
 
 
 
 
31
PNMR Spectrum (121 MHz) diethyl N-(N-acetyl-L-isoleucyl-L-leucyl)-1-amino-2-(4-hydoxyphenyl)ethyl 
phosphonate (II-4d) in MeOD 
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1
HNMR Spectrum (600 MHz) of SF2513 B: N-(N-acetyl-L-isoleucyl-L-leucyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonic acid (II-4) in D2O 
 
 
 
 
 
 
 
13
CNMR Spectrum (150 MHz) of SF2513 B: N-(N-acetyl-L-isoleucyl-L-leucyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonic acid  (II-4) in D2O 
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31
PNMR Spectrum (162 MHz) of SF2513 B: N-(N-acetyl-L-isoleucyl-L-leucyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonic acid (II-4) in D2O 
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NMR spectra of SF2513 C (II-5) and synthetic intermediates (II-5a - II-5d) 
 
 
1
HNMR Spectrum (400 MHz) of N-acetyl-L-isoleucyl-L-phenylalanine methyl ester (II-5a) in CDCl3 
 
 
 
 
 
13
CNMR Spectrum (100 MHz) of N-acetyl-L-isoleucyl-L-phenylalanine methyl ester (II-5a) in CDCl3 
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1
HNMR Spectrum (600 MHz) of N-acetyl-L-isoleucyl-L-phenylalanine (II-5b) in DMSO-d
6 
 
 
13
CNMR Spectrum (1II-50 MHz) of N-acetyl-L-isoleucyl-L-phenylalanine (II-5b) in DMSO-d
6 
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1
HNMR Spectrum (600 MHz) of diethyl N-(N-acetyl-L-isoleucyl-L-phenylalanyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (II-5c) in CDCl3 
 
 
13
CNMR Spectrum (150 MHz) of diethyl N-(N-acetyl-L-isoleucyl-L-phenylalanyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (II-5c) in CDCl3 
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31
PNMR Spectrum (121 MHz) of diethyl N-(N-acetyl-L-isoleucyl-L-phenylalanyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (II-5c) in CDCl3 
 
 
 
1
HNMR Spectrum (600 MHz) of diethyl N-(N-acetyl-L-isoleucyl-L-phenylalanyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate (II-5d) in MeOD 
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13
CNMR Spectrum (150 MHz) of diethyl N-(N-acetyl-L-isoleucyl-L-phenylalanyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate (II-5d) in MeOD 
 
 
 
 
 
 
 
31
PNMR Spectrum (162 MHz) of diethyl N-(N-acetyl-L-isoleucyl-L-phenylalanyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate (II-5d) in MeOD 
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1
HNMR Spectrum (600 MHz) of SF2513 C: N-(N-acetyl-L-isoleucyl-L-phenylalanyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonic acid (II-5) in D2O 
 
 
 
 
 
 
13
CNMR Spectrum (150 MHz) of SF2513 C: N-(N-acetyl-L-isoleucyl-L-phenylalanyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonic acid (II-5)  in D2O 
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31
PNMR Spectrum (162 MHz) of SF2513 C: N-(N-acetyl-L-isoleucyl-L-phenylalanyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonic acid  (II-5) in D2O 
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NMR spectra of SF2513 D (II-7) and synthetic intermediates (II-7b – II-7e) 
 
 
1
HNMR Spectrum (400 MHz) of diethyl N-(N-fluorenylmethyloxycarbonyl-L-glutamyl-5-tert-butyl ester)-1-
amino-2-(4-benzyloxyphenyl)ethyl phosphonate (II-7b) in CDCl3 
 
 
 
13
CNMR Spectrum (100 MHz) of diethyl N-(N-fluorenylmethyloxycarbonyl-L-glutamyl-5-tert-butyl ester)-1-
amino-2-(4-benzyloxyphenyl)ethyl phosphonate (II-7b) in CDCl3 
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31
PNMR Spectrum (162 MHz) of diethyl N-(N-fluorenylmethyloxycarbonyl-L-glutamyl-5-tert-butyl ester)-1-
amino-2-(4-benzyloxyphenyl)ethyl phosphonate (II-7b) in CDCl3 
 
 
1
HNMR Spectrum (400 MHz) of diethyl N-(L-glutamyl-5-tert-butyl ester)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (II-7c) in CDCl3 
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13
CNMR Spectrum (100 MHz) of diethyl N-(L-glutamyl-5-tert-butyl ester)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (II-7c) in CDCl3 
 
 
 
 
 
 
 
 
 
 
31
PNMR Spectrum (162 MHz) of diethyl N-(L-glutamyl-5-tert-butyl ester)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (II-7c) in CDCl3 
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1
HNMR Spectrum (600 MHz) diethyl N-(N-acetyl-L-isoleucyl-L-glutamyl-5-tert-butyl ester)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (II-7d) in CDCl3 
 
 
 
 
13
CNMR Spectrum (150 MHz) of diethyl N-(N-acetyl-L-isoleucyl-L-glutamyl-5-tert-butyl ester)-1-amino-2-
(4-benzyloxyphenyl)ethyl phosphonate (II-7d) in CDCl3 
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31
PNMR Spectrum (162 MHz) of diethyl N-(N-acetyl-L-isoleucyl-L-glutamyl-5-tert-butyl ester)-1-amino-2-
(4-benzyloxyphenyl)ethyl phosphonate (II-7d) in CDCl3 
 
 
 
 
1
HNMR Spectrum (600 MHz) of diethyl N-(N-acetyl-L-isoleucyl-L-glutamyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (II-7e) in MeOD 
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13
CNMR Spectrum (150 MHz) of diethyl N-(N-acetyl-L-isoleucyl-L-glutamyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (II-7e) in MeOD 
 
 
 
 
 
 
 
31
PNMR Spectrum (162 MHz) of diethyl N-(N-acetyl-L-isoleucyl-L-glutamyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (II-7e) in MeOD 
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1
HNMR Spectrum (600 MHz) of diethyl N-(N-acetyl-L-isoleucyl-L-glutamyl)-1-amino-2-(4-hydroxyphenyl) 
ethyl phosphonate (II-7f) in MeOD 
 
13
CNMR Spectrum (150 MHz) of diethyl N-(N-acetyl-L-isoleucyl-L-glutamyl)-1-amino-2-(4-hydroxyphenyl) 
ethyl phosphonate (II-7f) in MeOD 
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31
PNMR Spectrum (162 MHz) of diethyl N-(N-acetyl-L-isoleucyl-L-glutamyl)-1-amino-2-(4-hydroxyphenyl) 
ethyl phosphonate (II-7f) in MeOD 
 
 
 
 
 
1
HNMR Spectrum (600 MHz) of SF2513 D: N-(N-acetyl-L-isoleucyl-L-glutamyl)-1-amino-2-(4-
hydroxyphenyl) phosphonic acid (II-7) in D2O 
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13
CNMR Spectrum (150 MHz) of SF2513 D: N-(N-acetyl-L-isoleucyl-L-glutamyl)-1-amino-2-(4-
hydroxyphenyl) phosphonic acid (II-7) in D2O 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31
PNMR Spectrum (162 MHz) of SF2513 D: N-(N-acetyl-L-isoleucyl-L-glutamyl)-1-amino-2-(4-
hydroxyphenyl) phosphonic acid (II-7) in D2O 
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APPENDIX B 
 
GRAPHS USED IN IC50 AND KI CALCULATIONS 
FROM CHAPTER II 
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IC50 curves for inhibition of somatic ACE by the K-26 analog 
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IC50 curves for the inhibition of C-domain ACE by the K-26 analog 
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IC50 curves for the inhibition of N-domain ACE by the K-26 analog 
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Dixon plot to determine Ki the inhibition of C-domain ACE by the K-26 analog 
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Dixon plot to determine Ki the inhibition of N-domain ACE by the K-26 analog 
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IC50 curves for the inhibition of bacterial DCPs by K-26 and captopril 
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APPENDIX C 
 
ROSETTA PREDICTED BINDING CONFORMATIONS OF K-26 VARIANTS  
FROM CHAPTER III 
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Rosetta predicted SF 2513B (III-3) conformation in tACE (green) and N-ACE (purple) 
 
 
Rosetta predicted SF 2513C (III-4) conformation in tACE (green) and N-ACE (purple) 
 
 
 
Rosetta predicted Ac-Ile-Trp-AHEP (III-5) conformation in tACE (green) and N-ACE (purple) 
 
 
 
Rosetta predicted Ac-Ile-Ser-AHEP (III-6) conformation in tACE (green) and N-ACE (purple) 
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Rosetta predicted Ac-Ile-His-AHEP (III-7) conformation in tACE (green) and N-ACE (purple) 
 
 
 
Rosetta predicted Ac-His-Trp-AHEP (III-9) conformation in tACE (green) and N-ACE (purple) 
 
 
 
Rosetta predicted Ac-Leu-Tyr-AHEP (III-9) conformation in tACE (green) and N-ACE (purple) 
 
 
 
Rosetta predicted Ac-Leu-Ile-AHEP (III-10) conformation in tACE (green) and N-ACE (purple) 
228 
 
 
Rosetta predicted Ac-Tyr-Ile-AHEP (III-11) conformation in tACE (green) and N-ACE (purple) 
 
 
 
Rosetta predicted Ac-Pro-Tyr-AHEP (III-12) conformation in tACE (green) and N-ACE (purple) 
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APPENDIX D 
 
NMR SPECTRA  
OF SYNTHETIC INTERMEDIATES  
FROM CHAPTER III 
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NMR spectra of Ac-Ile-Trp-AHEP (III-3) and synthetic intermediates (III-3a - III-3d) 
 
1
HNMR Spectrum (400 MHz) of N-acetyl-L-isoleucyl-L-tryptophan methyl ester (III-3a) in CDCl3 
 
13
CNMR Spectrum (100 MHz) of N-acetyl-L-isoleucyl-L-tryptophan methyl ester (III-3a) in CDCl3 
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1
HNMR Spectrum (400 MHz) of N-acetyl-L-isoleucyl-L-tryptophan (III-3b) in MeOD 
 
 
 
13
CNMR Spectrum (100 MHz) of N-acetyl-L-isoleucyl-L-tryptophan (III-3b) in MeOD 
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1
HNMR Spectrum (600 MHz) of diethyl N-(N-acetyl-L-isoleucyl-L-tryptophanyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (III-3c) in CDCl3 
 
 
 
13
CNMR Spectrum (150 MHz) of diethyl N-(N-acetyl-L-isoleucyl-L-tryptophanyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (III-3c) in CDCl3 
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31
PNMR Spectrum (162 MHz) of diethyl N-(N-acetyl-L-isoleucyl-L-tryptophanyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (III-3c) in CDCl3 
 
 
1
HNMR Spectrum (600 MHz) of diethyl N-(N-acetyl-L-isoleucyl-L-leucyl)-1-amino-2-(4-hydoxyphenyl)ethyl 
phosphonate (III-3d) in MeOD 
234 
 
 
 
13
CNMR Spectrum (150 MHz) of diethyl N-(N-acetyl-L-isoleucyl-L-tryptophanyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate (III-3d) in MeOD 
 
 
 
31
PNMR Spectrum (121 MHz) diethyl N-(N-acetyl-L-isoleucyl-L-tryptophanyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate (III-3d) in MeOD 
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1
HNMR Spectrum (600 MHz) of Ac-Ile-Trp-AHEP: N-(N-acetyl-L-isoleucyl-L-tryptophanyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonic acid (III-3) in D2O 
 
 
 
 
 
 
 
 
 
 
 
13
CNMR Spectrum (150 MHz) of Ac-Ile-Trp-AHEP: N-(N-acetyl-L-isoleucyl-L-tryptophanyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonic acid  (III-3) in D2O 
236 
 
 
 
 
 
 
31
PNMR Spectrum (162 MHz) of Ac-Ile-Trp-AHEP: N-(N-acetyl-L-isoleucyl-L-tryptophanyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonic acid (III-3) in D2O 
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NMR spectra of Ac-Ile-Ser-AHEP (III-4) and synthetic intermediates (III-4a - III-4d) 
 
1
HNMR Spectrum (400 MHz) of N-acetyl-L-isoleucyl-O-benzyl-L-serine methyl ester (III-4a) in CDCl3 
 
 
13
CNMR Spectrum (100 MHz) of N-acetyl-L-isoleucyl- O-benzyl-L-serine methyl ester (III-4a) in CDCl3 
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1
HNMR Spectrum (400 MHz) of N-acetyl-L-isoleucyl- O-benzyl-L-serine (III-4b) in MeOD 
 
 
 
13
CNMR Spectrum (100 MHz) of N-acetyl-L-isoleucyl- O-benzyl-L-serine (III-4b) in MeOD 
239 
 
 
 
1
HNMR Spectrum (600 MHz) of diethyl N-(N-acetyl-L-isoleucyl-O-benzyl-L-serinyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (III-4c) in CDCl3 
 
 
 
13
CNMR Spectrum (150 MHz) of diethyl N-(N-acetyl-L-isoleucyl-O-benzyl-L-serinyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (III-4c) in CDCl3 
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31
PNMR Spectrum (162 MHz) of diethyl N-(N-acetyl-L-isoleucyl-O-benzyl-L-serinyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (III-4c) in CDCl3 
 
 
1
HNMR Spectrum (600 MHz) of diethyl N-(N-acetyl-L-isoleucyl-L-serinyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate (III-4d) in MeOD 
241 
 
 
 
13
CNMR Spectrum (150 MHz) of diethyl N-(N-acetyl-L-isoleucyl-L-serinyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate (III-4d) in MeOD 
 
 
 
31
PNMR Spectrum (121 MHz) diethyl N-(N-acetyl-L-isoleucyl-L-serinyl)-1-amino-2-(4-hydoxyphenyl)ethyl 
phosphonate (III-4d) in MeOD 
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1
HNMR Spectrum (600 MHz) of Ac-Ile-Ser-AHEP: N-(N-acetyl-L-isoleucyl-L-serinyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonic acid (III-4) in D2O 
 
 
 
 
 
 
 
 
 
13
CNMR Spectrum (150 MHz) of Ac-Ile-Ser-AHEP: N-(N-acetyl-L-isoleucyl-L-serinyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonic acid  (III-4) in D2O 
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31
PNMR Spectrum (162 MHz) of Ac-Ile-Ser-AHEP: N-(N-acetyl-L-isoleucyl-L-serinyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonic acid (III-4) in D2O 
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NMR spectra of Ac-Ile-His-AHEP (III-5) and synthetic intermediates (III-5a - III-5d) 
 
1
HNMR Spectrum (400 MHz) of diethyl N-(N-fluorenylmethyloxycarbonyl-Ƭ-trityl-L-histadyl-)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (III-5a) in CDCl3 
 
 
 
13
CNMR Spectrum (100 MHz) of diethyl N-(N-fluorenylmethyloxycarbonyl-Ƭ-trityl-L-histadyl-)-1-amino-2-
(4-benzyloxyphenyl)ethyl phosphonate (III-5a) in CDCl3 
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31
PNMR Spectrum (162 MHz) of diethyl N-(N-fluorenylmethyloxycarbonyl-Ƭ-trityl-L-histadyl-)-1-amino-2-
(4-benzyloxyphenyl)ethyl phosphonate (III-5a) in CDCl3 
 
 
  
1
HNMR Spectrum (400 MHz) of diethyl N-(Ƭ-trityl-L-histadyl-)-1-amino-2-(4-benzyloxyphenyl)ethyl 
phosphonate (III-3b) in CDCl3 
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13
CNMR Spectrum (100 MHz) of diethyl N-(Ƭ-trityl-L-histadyl-)-1-amino-2-(4-benzyloxyphenyl)ethyl 
phosphonate (III-3b) in CDCl3 
 
 
 
 
31
PNMR Spectrum (162 MHz) of diethyl N-(Ƭ-trityl-L-histadyl-)-1-amino-2-(4-benzyloxyphenyl)ethyl 
phosphonate (III-5b) in CDCl3 
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1
HNMR Spectrum (600 MHz) of diethyl N-(N-acetyl-L-isoleucyl- Ƭ-trityl-L-histadyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (III-5c) in CDCl3 
 
 
 
 
13
CNMR Spectrum (150 MHz) of diethyl N-(N-acetyl-L-isoleucyl- Ƭ-trityl-L-histadyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (III-5c) in CDCl3 
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31
PNMR Spectrum (162 MHz) of diethyl N-( N-acetyl-L-isoleucyl- Ƭ-trityl-L-histadyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (III-5c) in CDCl3 
 
 
 
 
1
HNMR Spectrum (600 MHz) of diethyl N-( N-acetyl-L-isoleucyl- Ƭ-trityl-L-histadyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate (III-5d) in MeOD 
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13
CNMR Spectrum (150 MHz) of diethyl N-( N-acetyl-L-isoleucyl- Ƭ-trityl-L-histadyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate (III-5d) in MeOD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31
PNMR Spectrum (162 MHz) diethyl N-( N-acetyl-L-isoleucyl- Ƭ-trityl-L-histadyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate (III-5d) in MeOD 
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1
HNMR Spectrum (600 MHz) of Ac-Ile-His-AHEP: N-(N-acetyl-L-isoleucyl-L-histadyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonic acid (III-5) in D2O 
 
 
 
 
13
CNMR Spectrum (150 MHz) of Ac-Ile-His-AHEP: N-(N-acetyl-L-isoleucyl-L-histadyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonic acid (III-5) in D2O 
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31
PNMR Spectrum (162 MHz) of Ac-Ile-His-AHEP: N-(N-acetyl-L-isoleucyl-L-histadyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonic acid (III-5) in D2O 
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NMR spectra of Ac-His-Trp-AHEP (III-6) and synthetic intermediates (III-6a - III-6c) 
 
1
HNMR Spectrum (400 MHz) of N-acetyl-(Ƭ-trityl-L-histady)l-L-tryptophan methyl ester (III-6a) in CDCl3 
 
 
 
 
13
CNMR Spectrum (100 MHz) of N-(Ƭ-trityl-L-histadyl)-L-tryptophan methyl ester (III-6a) in CDCl3 
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1
HNMR Spectrum (400 MHz) of N-acetyl-(Ƭ-trityl-L-histady)l-L-tryptophan (III-6b) in MeOD 
 
 
 
 
 
13
CNMR Spectrum (100 MHz) of N-acetyl-(Ƭ-trityl-L-histadyl) -L-tryptophan (III-6b) in MeOD 
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1
HNMR Spectrum (600 MHz) of diethyl N-(N-acetyl-(Ƭ-trityl-L-histadyl) -L-tryptophanyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (III-6c) in CDCl3 
 
 
 
 
13
CNMR Spectrum (150 MHz) of diethyl N-(N-acetyl-(Ƭ-trityl-L-histadyl)-L-tryptophanyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (III-6c) in CDCl3 
255 
 
 
 
31
PNMR Spectrum (162 MHz) of diethyl N-(N-acetyl-(Ƭ-trityl-L-histadyl)-L-tryptophanyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (III-6c) in CDCl3 
 
 
 
 
1
HNMR Spectrum (600 MHz) of Ac-His-Trp-AHEP: N-(N-acetyl-L-histadyl-L-tryptophanyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonic acid (III-6) in D2O 
256 
 
 
 
13
CNMR Spectrum (150 MHz) of Ac-His-Trp-AHEP: N-(N-acetyl-L-histadyl-L-tryptophanyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonic acid  (III-6) in D2O 
 
 
 
 
 
 
 
 
 
 
 
 
31
PNMR Spectrum (162 MHz) of Ac-His-Trp-AHEP: N-(N-acetyl-L-histadyl-L-tryptophanyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonic acid (III-6) in D2O  
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NMR spectra of Ac-Leu-Tyr-AHEP (III-7) and synthetic intermediates (III-7a - III-7d) 
 
1
HNMR Spectrum (400 MHz) of N-acetyl-L-leucyl-O-benzyl-L-tyrosine methyl ester (III-7a) in CDCl3 
 
 
 
 
13
CNMR Spectrum (100 MHz) of N-acetyl-L-leucyl-O-benzyl-L-tyrosine methyl ester (III-7a) in CDCl3 
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1
HNMR Spectrum (400 MHz) of N-acetyl-L-leucyl-O-benzyl-L-tyrosine (III-7b) in MeOD 
 
 
 
 
 
 
13
CNMR Spectrum (100 MHz) of N-acetyl-L-leucyl-O-benzyl-L-tyrosine (III-7b) in MeOD 
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1
HNMR Spectrum (600 MHz) of diethyl N-(N-acetyl-L-leucyl-O-benzyl-L-tyrosyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (III-7c) in CDCl3 
 
 
 
 
 
13
CNMR Spectrum (150 MHz) of diethyl N-(N-acetyl-L-leucyl-O-benzyl-L-tyrosyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (III-7c) in CDCl3 
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31
PNMR Spectrum (162 MHz) of diethyl N-(N-acetyl-L-leucyl-O-benzyl-L-tyrosyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (III-7c) in CDCl3 
 
 
 
 
1
HNMR Spectrum (600 MHz) of diethyl N-(N-acetyl-L-leucyl-O-benzyl-L-tyrosyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate (III-7d) in MeOD 
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13
CNMR Spectrum (150 MHz) of diethyl N-(N-acetyl-L-leucyl-O-benzyl-L-tyrosyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate (III-7d) in MeOD 
 
 
 
 
 
 
 
 
 
31
PNMR Spectrum (121 MHz) diethyl N-(N-acetyl-L-leucyl-O-benzyl-L-tyrosyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate (III-7d) in MeOD 
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1
HNMR Spectrum (600 MHz) of Ac-Leu-Tyr-AHEP: N-(N-acetyl-L-leucyl-L-tyrosyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonic acid (III-7) in D2O 
 
 
 
 
 
13
CNMR Spectrum (150 MHz) of Ac-Leu-Tyr-AHEP: N-(N-acetyl-L-leucyl-L-tyrosyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonic acid  (III-7) in D2O 
263 
 
 
 
 
 
 
 
 
 
31
PNMR Spectrum (162 MHz) of Ac-Leu-Tyr-AHEP: N-(N-acetyl-L-leucyl-L-tyrosyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonic acid (III-7) in D2O 
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NMR spectra of Ac-Leu-Ile-AHEP (III-8) and synthetic intermediates (III-8a - III-8d) 
 
1
HNMR Spectrum (400 MHz) of N-acetyl-L-leucyl-L-isoleucine methyl ester (III-8a) in CDCl3 
 
 
 
 
 
 
 
13
CNMR Spectrum (100 MHz) of N-acetyl-L-leucyl-L-isoleucine methyl ester (III-8a) in CDCl3 
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1
HNMR Spectrum (400 MHz) of N-acetyl-L-leucyl-L-isoleucine (III-8b) in MeOD 
 
 
 
13
CNMR Spectrum (100 MHz) of N-acetyl-L-leucyl-L-isoleucine (III-8b) in MeOD 
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1
HNMR Spectrum (600 MHz) of diethyl N-(N-acetyl-L-leucyl-L-isoleucyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (III-8c) in CDCl3 
 
 
 
 
 
13
CNMR Spectrum (150 MHz) of diethyl N-(N-acetyl-L-leucyl-L-isoleucyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (III-8c) in CDCl3 
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31
PNMR Spectrum (162 MHz) of diethyl N-(N-acetyl-L-leucyl-L-isoleucyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (III-8c) in CDCl3 
 
 
 
 
 
1
HNMR Spectrum (600 MHz) of diethyl N-(N-acetyl-L-leucyl-L-isoleucyl)-1-amino-2-(4-hydoxyphenyl)ethyl 
phosphonate (III-8d) in MeOD 
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13
CNMR Spectrum (150 MHz) of diethyl N-(N-acetyl-L-leucyl-L-isoleucyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate (III-8d) in MeOD 
 
 
 
 
 
 
 
31
PNMR Spectrum (121 MHz) diethyl N-(N-acetyl-L-leucyl-L-isoleucyl)-1-amino-2-(4-hydoxyphenyl)ethyl 
phosphonate (III-8d) in MeOD 
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1
HNMR Spectrum (600 MHz) of Ac-Leu-Ile-AHEP: N-(N-acetyl-L-leucyl-L-isoleucine)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonic acid (III-8) in D2O 
 
 
 
 
 
13
CNMR Spectrum (150 MHz) of Ac-Leu-Ile-AHEP: N-(N-acetyl-L-leucyl-L-isoleucine)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonic acid  (III-8) in D2O 
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31
PNMR Spectrum (162 MHz) of Ac-Leu-Ile-AHEP: N-(N-acetyl-L-leucyl-L-isoleucine)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonic acid (III-8) in D2O 
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NMR spectra of Ac-Tyr-Ile-AHEP (III-9) and synthetic intermediates (III-9a - III-9e) 
 
1
HNMR Spectrum (400 MHz) of N-acetyl-O-tert-butyl-L-tyrosyl-L-isoleucine methyl ester (III-9a) in CDCl3 
 
 
 
13
CNMR Spectrum (100 MHz) of N-acetyl-O-tert-butyl-L-tyrosyl-L-isoleucine methyl ester (III-9a) in CDCl3 
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1
HNMR Spectrum (400 MHz) of N-acetyl-O-tert-butyl-L-tyrosyl-L-isoleucine (III-9b) in MeOD 
 
 
 
13
CNMR Spectrum (100 MHz) of N-acetyl-O-tert-butyl-L-tyrosyl-L-isoleucine (III-9b) in MeOD 
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1
HNMR Spectrum (600 MHz) of diethyl N-(N-acetyl-O-tert-butyl-L-tyrosyl-L-isoleucyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (III-9c) in CDCl3 
 
 
 
13
CNMR Spectrum (150 MHz) of diethyl N-(N-acetyl-O-tert-butyl-L-tyrosyl-L-isoleucyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (III-9c) in CDCl3 
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31
PNMR Spectrum (162 MHz) of diethyl N-(N-acetyl-O-tert-butyl-L-tyrosyl-L-isoleucyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (III-9c) in CDCl3 
 
 1
HNMR Spectrum (600 MHz) of diethyl N-(N-acetyl-O-tert-butyl-L-tyrosyl-L-isoleucyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate (III-9d) in MeOD 
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13
CNMR Spectrum (150 MHz) of diethyl N-(N-acetyl-O-tert-butyl-L-tyrosyl-L-isoleucyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate (III-9d) in MeOD 
 
 
 
31
PNMR Spectrum (162 MHz) of diethyl N-(N-acetyl-O-tert-butyl-L-tyrosyl-L-isoleucyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate (III-9d) in MeOD 
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1
HNMR Spectrum (600 MHz) of diethyl N-(N-acetyl-L-tyrosyl-L-isoleucyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate (III-9e) in MeOD 
 
 
13
CNMR Spectrum (150 MHz) of diethyl N-(N-acetyl-L-tyrosyl-L-isoleucyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate (III-9e) in MeOD 
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31
PNMR Spectrum (162 MHz) of diethyl N-(N-acetyl-L-tyrosyl-L-isoleucyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate (III-9e) in MeOD 
 
 
 
1
HNMR Spectrum (600 MHz) of Ac-Tyr-Ile-AHEP: N-(N-acetyl-L-tyrosyl-L-isoleucyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonic acid (III-9) in D2O 
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13
CNMR Spectrum (150 MHz) of Ac-Tyr-Ile-AHEP: N-(N-acetyl-L-tyrosyl-L-isoleucyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonic acid (III-9) in D2O 
 
 
 
31
PNMR Spectrum (162 MHz) of Ac-Ile-Trp-AHEP of Ac-Tyr-Ile-AHEP: N-(N-acetyl-L-tyrosyl-L-isoleucyl)-
1-amino-2-(4-hydoxyphenyl)ethyl phosphonic acid (III-9) in D2O 
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NMR spectra of Ac-Pro-Tyr-AHEP (III-10) and synthetic intermediates (III-10a - III-
10d) 
 
1
HNMR Spectrum (400 MHz) of N-acetyl-L-prolinyl-O-benzyl-L-tyrosine methyl ester (III-10a) in CDCl3 
 
 
 
 
 
 
13
CNMR Spectrum (100 MHz) of N-acetyl-L-prolinyl-O-benzyl-L-tyrosine methyl ester (III-10a) in CDCl3 
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1
HNMR Spectrum (400 MHz) of N-acetyl-L-prolinyl-O-benzyl-L-tyrosine (III-10b) in MeOD 
 
 
 
13
CNMR Spectrum (100 MHz) of N-acetyl-L-prolinyl-O-benzyl-L-tyrosine (III-10b) in MeOD 
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1
HNMR Spectrum (600 MHz) of diethyl N-(N-acetyl-L-prolinyl-O-benzyl-L-tyrosyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (III-10c) in CDCl3 
 
 
 
  
13
CNMR Spectrum (150 MHz) of diethyl N-(N-acetyl-L-prolinyl-O-benzyl-L-tyrosyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (III-10c) in CDCl3 
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31
PNMR Spectrum (162 MHz) of diethyl N-(N-acetyl-L-prolinyl-O-benzyl-L-tyrosyl)-1-amino-2-(4-
benzyloxyphenyl)ethyl phosphonate (III-10c) in CDCl3 
 
 
1
HNMR Spectrum (600 MHz) of diethyl N-(N-acetyl-L-prolinyl-O-benzyl-L-tyrosyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate (III-10d) in MeOD 
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13
CNMR Spectrum (150 MHz) of diethyl N-(N-acetyl-L-prolinyl-O-benzyl-L-tyrosyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate (III-10d) in MeOD 
 
 
31
PNMR Spectrum (121 MHz) diethyl N-(N-acetyl-L-prolinyl-O-benzyl-L-tyrosyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonate (III-10d) in MeOD 
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1
HNMR Spectrum (600 MHz) of Ac-Leu-Tyr-AHEP: N-(N-acetyl-L-prolinyl-L-tyrosyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonic acid (III-10) in D2O 
 
 
13
CNMR Spectrum (150 MHz) of Ac-Leu-Tyr-AHEP: N-(N-acetyl-L-prolinyl-L-tyrosyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonic acid  (III-10) in D2O 
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31
PNMR Spectrum (162 MHz) of Ac-Leu-Tyr-AHEP: N-(N-acetyl-L-prolinyl-L-tyrosyl)-1-amino-2-(4-
hydoxyphenyl)ethyl phosphonic acid (III-10) in D2O 
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APPENDIX E 
 
GRAPHS USED IN IC50 CALCULATIONS 
FROM CHAPTER III 
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IC50 curves for inhibition of somatic ACE by K-26 variant
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APPENDIX F 
 
NMR SPECTRA  
OF BIOTIN PROBE 
FROM CHAPTER IV 
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1H NMR of Biotin-PEG12-K-26 (IV-8) 
 
 
